{"3a8f3c3b8c4be0144795e7dc34472a9a7dd35cc5": [["BackgroundCampylobacter jejuni is a leading cause of bacterial gastroenteritis in humans, resulting in diarrhea and abdominal pain.", [["abdominal", "ANATOMY", 116, 125], ["BackgroundCampylobacter jejuni", "DISEASE", 0, 30], ["bacterial gastroenteritis", "DISEASE", 53, 78], ["diarrhea", "DISEASE", 103, 111], ["abdominal pain", "DISEASE", 116, 130], ["BackgroundCampylobacter jejuni", "ORGANISM", 0, 30], ["humans", "ORGANISM", 82, 88], ["abdominal", "ORGANISM_SUBDIVISION", 116, 125], ["BackgroundCampylobacter jejuni", "SPECIES", 0, 30], ["humans", "SPECIES", 82, 88], ["BackgroundCampylobacter jejuni", "SPECIES", 0, 30], ["humans", "SPECIES", 82, 88], ["BackgroundCampylobacter jejuni", "PROBLEM", 0, 30], ["bacterial gastroenteritis in humans", "PROBLEM", 53, 88], ["diarrhea", "PROBLEM", 103, 111], ["abdominal pain", "PROBLEM", 116, 130], ["jejuni", "OBSERVATION", 24, 30], ["bacterial", "OBSERVATION_MODIFIER", 53, 62], ["gastroenteritis", "OBSERVATION", 63, 78], ["diarrhea", "OBSERVATION", 103, 111], ["abdominal", "ANATOMY", 116, 125], ["pain", "OBSERVATION", 126, 130]]], ["C. jejuni is commonly found in the intestinal tract of many food-producing animals, such as poultry, cattle, and sheep [1] .", [["intestinal tract", "ANATOMY", 35, 51], ["C. jejuni", "DISEASE", 0, 9], ["C. jejuni", "ORGANISM", 0, 9], ["intestinal tract", "ORGANISM_SUBDIVISION", 35, 51], ["C. jejuni", "SPECIES", 0, 9], ["cattle", "SPECIES", 101, 107], ["sheep", "SPECIES", 113, 118], ["C. jejuni", "SPECIES", 0, 9], ["poultry", "SPECIES", 92, 99], ["cattle", "SPECIES", 101, 107], ["sheep", "SPECIES", 113, 118], ["C. jejuni", "PROBLEM", 0, 9], ["jejuni", "OBSERVATION", 3, 9], ["intestinal tract", "ANATOMY", 35, 51]]], ["In these hosts, C. jejuni generally persists without causing visible clinical symptoms of disease.", [["C. jejuni", "ORGANISM", 16, 25], ["C. jejuni", "SPECIES", 16, 25], ["C. jejuni", "SPECIES", 16, 25], ["C. jejuni", "PROBLEM", 16, 25], ["visible clinical symptoms of disease", "PROBLEM", 61, 97], ["jejuni", "OBSERVATION", 19, 25], ["without causing", "UNCERTAINTY", 45, 60], ["disease", "OBSERVATION", 90, 97]]], ["Although it has been historically known that C. fetus subsp fetus (vibriosis) is the main cause of ovine abortion, recently C. jejuni has been increasingly implicated in ovine abortion cases worldwide [2] [3] [4] [5] .", [["fetus", "ANATOMY", 60, 65], ["ovine abortion", "DISEASE", 99, 113], ["C. jejuni", "DISEASE", 124, 133], ["ovine abortion", "DISEASE", 170, 184], ["C. fetus", "ORGANISM", 45, 53], ["subsp fetus", "ORGANISM", 54, 65], ["vibriosis", "CANCER", 67, 76], ["ovine", "ORGANISM", 99, 104], ["C. jejuni", "ORGANISM", 124, 133], ["ovine", "ORGANISM", 170, 175], ["[2] [3] [4", "SIMPLE_CHEMICAL", 201, 211], ["C. fetus subsp", "SPECIES", 45, 59], ["C. jejuni", "SPECIES", 124, 133], ["C. fetus subsp fetus", "SPECIES", 45, 65], ["ovine", "SPECIES", 99, 104], ["C. jejuni", "SPECIES", 124, 133], ["C. fetus subsp fetus (vibriosis", "PROBLEM", 45, 76], ["ovine abortion", "PROBLEM", 99, 113], ["recently C. jejuni", "PROBLEM", 115, 133], ["ovine abortion", "OBSERVATION", 99, 113]]], ["Campylobacter-induced ovine abortion rates usually range from 5% to 50% in infected flocks [4, 6] .", [["ovine abortion", "DISEASE", 22, 36], ["ovine", "ORGANISM", 22, 27], ["Campylobacter", "PROBLEM", 0, 13], ["induced ovine abortion", "TREATMENT", 14, 36]]], ["C. jejuni has been identified in aborted lambs during multiple lambing seasons on different farms in Iowa, Idaho, South Dakota, and California [5] .", [["C. jejuni", "ORGANISM", 0, 9], ["lambs", "ORGANISM", 41, 46], ["C. jejuni", "SPECIES", 0, 9], ["lambs", "SPECIES", 41, 46], ["C. jejuni", "SPECIES", 0, 9], ["C. jejuni", "PROBLEM", 0, 9], ["jejuni", "OBSERVATION", 3, 9]]], ["A specific tetracycline-resistant C. jejuni clone (SA) has emerged as the major cause of C. jejuniassociated sheep abortion in the USA [5] .", [["tetracycline", "CHEMICAL", 11, 23], ["SA", "CHEMICAL", 51, 53], ["sheep abortion", "DISEASE", 109, 123], ["tetracycline", "CHEMICAL", 11, 23], ["tetracycline", "SIMPLE_CHEMICAL", 11, 23], ["C. jejuni clone", "ORGANISM", 34, 49], ["SA", "CANCER", 51, 53], ["sheep", "ORGANISM", 109, 114], ["C. jejuni", "SPECIES", 34, 43], ["C. jejuniassociated sheep", "SPECIES", 89, 114], ["C. jejuni", "SPECIES", 34, 43], ["C. jejuniassociated sheep", "SPECIES", 89, 114], ["A specific tetracycline", "TREATMENT", 0, 23], ["resistant C. jejuni clone", "PROBLEM", 24, 49], ["C. jejuniassociated sheep abortion", "PROBLEM", 89, 123], ["jejuni clone", "OBSERVATION", 37, 49], ["jejuniassociated sheep abortion", "OBSERVATION", 92, 123]]], ["In addition, clone SA has been also detected in abortion cases in cows and goats [7] .BackgroundThe pathogenesis of ovine campylobacteriosis is thought to include bacteremia, placentitis and uterine and fetal infection, which may ultimately lead to abortion that typically occurs in the third trimester of pregnancy [4, 8] .", [["uterine", "ANATOMY", 191, 198], ["fetal", "ANATOMY", 203, 208], ["SA", "CHEMICAL", 19, 21], ["ovine campylobacteriosis", "DISEASE", 116, 140], ["bacteremia", "DISEASE", 163, 173], ["placentitis", "DISEASE", 175, 186], ["uterine and fetal infection", "DISEASE", 191, 218], ["abortion", "DISEASE", 249, 257], ["SA", "GENE_OR_GENE_PRODUCT", 19, 21], ["cows", "ORGANISM_SUBDIVISION", 66, 70], ["ovine", "ORGANISM", 116, 121], ["uterine", "CANCER", 191, 198], ["fetal", "ORGAN", 203, 208], ["cows", "SPECIES", 66, 70], ["goats", "SPECIES", 75, 80], ["goats", "SPECIES", 75, 80], ["ovine", "SPECIES", 116, 121], ["ovine campylobacteriosis", "PROBLEM", 116, 140], ["bacteremia", "PROBLEM", 163, 173], ["placentitis", "PROBLEM", 175, 186], ["uterine and fetal infection", "PROBLEM", 191, 218], ["abortion", "PROBLEM", 249, 257], ["ovine campylobacteriosis", "OBSERVATION", 116, 140], ["thought to include", "UNCERTAINTY", 144, 162], ["bacteremia", "OBSERVATION", 163, 173], ["uterine", "ANATOMY", 191, 198], ["fetal", "ANATOMY", 203, 208], ["infection", "OBSERVATION", 209, 218]]], ["Furthermore, infection can occasionally result in the retention of dead fetus in the uterus which may cause death of pregnant ewes due to septicemia and uterine sepsis; however, no clinical signs can be seen at the beginning of infection [4] .", [["fetus", "ANATOMY", 72, 77], ["uterus", "ANATOMY", 85, 91], ["uterine", "ANATOMY", 153, 160], ["infection", "DISEASE", 13, 22], ["death", "DISEASE", 108, 113], ["septicemia", "DISEASE", 138, 148], ["uterine sepsis", "DISEASE", 153, 167], ["infection", "DISEASE", 228, 237], ["fetus", "ORGAN", 72, 77], ["uterus", "ORGAN", 85, 91], ["uterine", "ORGAN", 153, 160], ["infection", "PROBLEM", 13, 22], ["dead fetus in the uterus", "PROBLEM", 67, 91], ["death", "PROBLEM", 108, 113], ["pregnant ewes", "PROBLEM", 117, 130], ["septicemia", "PROBLEM", 138, 148], ["uterine sepsis", "PROBLEM", 153, 167], ["clinical signs", "PROBLEM", 181, 195], ["infection", "PROBLEM", 228, 237], ["infection", "OBSERVATION", 13, 22], ["dead fetus", "OBSERVATION", 67, 77], ["uterus", "ANATOMY", 85, 91], ["may cause", "UNCERTAINTY", 98, 107], ["septicemia", "OBSERVATION", 138, 148], ["uterine", "ANATOMY", 153, 160], ["sepsis", "OBSERVATION", 161, 167], ["infection", "OBSERVATION", 228, 237]]], ["The mechanisms by which the gut commensal C. jejuni is able to establish systemic infection and lead to an acute abortion in sheep are still not completely defined.", [["gut", "ANATOMY", 28, 31], ["infection", "DISEASE", 82, 91], ["gut commensal", "ORGANISM", 28, 41], ["C. jejuni", "ORGANISM", 42, 51], ["sheep", "ORGANISM", 125, 130], ["C. jejuni", "SPECIES", 42, 51], ["sheep", "SPECIES", 125, 130], ["C. jejuni", "SPECIES", 42, 51], ["sheep", "SPECIES", 125, 130], ["the gut commensal C. jejuni", "PROBLEM", 24, 51], ["systemic infection", "PROBLEM", 73, 91], ["an acute abortion in sheep", "PROBLEM", 104, 130], ["jejuni", "OBSERVATION", 45, 51], ["infection", "OBSERVATION", 82, 91], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["abortion", "OBSERVATION", 113, 121]]], ["Furthermore, in a recent study, PFGE analysis of C. jejuni SA isolates revealed a high similarity to human gastroenteritis-associated C. jejuni isolates [7] .", [["gastroenteritis", "DISEASE", 107, 122], ["C. jejuni", "ORGANISM", 49, 58], ["SA isolates", "ORGANISM", 59, 70], ["human", "ORGANISM", 101, 106], ["C. jejuni", "ORGANISM", 134, 143], ["C. jejuni", "SPECIES", 49, 58], ["human", "SPECIES", 101, 106], ["C. jejuni", "SPECIES", 134, 143], ["C. jejuni", "SPECIES", 49, 58], ["human", "SPECIES", 101, 106], ["C. jejuni", "SPECIES", 134, 143], ["a recent study", "TEST", 16, 30], ["PFGE analysis", "TEST", 32, 45], ["C. jejuni SA isolates", "TEST", 49, 70], ["human gastroenteritis", "PROBLEM", 101, 122], ["C. jejuni isolates", "PROBLEM", 134, 152], ["gastroenteritis", "OBSERVATION", 107, 122], ["jejuni isolates", "OBSERVATION", 137, 152]]], ["This suggested a potential relevance of these ovine abortion isolates to human health.", [["ovine", "ORGANISM", 46, 51], ["human", "ORGANISM", 73, 78], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["these ovine abortion", "TREATMENT", 40, 60]]], ["Therefore, there is a critical need for understanding the pathogenesis of C. jejuni induced abortion.BackgroundUsing guinea pigs, abortion was effectively induced in pregnant animals intra-peritoneally or orally inoculated with C. jejuni clone SA, and the bacteria were recovered from fetuses and placental tissues [9] .", [["fetuses", "ANATOMY", 285, 292], ["placental tissues", "ANATOMY", 297, 314], ["C. jejuni induced abortion", "DISEASE", 74, 100], ["C. jejuni", "ORGANISM", 74, 83], ["guinea pigs", "ORGANISM", 117, 128], ["C. jejuni clone SA", "ORGANISM", 228, 246], ["fetuses", "DEVELOPING_ANATOMICAL_STRUCTURE", 285, 292], ["placental tissues", "TISSUE", 297, 314], ["C. jejuni", "SPECIES", 74, 83], ["guinea pigs", "SPECIES", 117, 128], ["C. jejuni", "SPECIES", 228, 237], ["C. jejuni", "SPECIES", 74, 83], ["C. jejuni", "SPECIES", 228, 237], ["C. jejuni induced abortion", "PROBLEM", 74, 100], ["BackgroundUsing guinea pigs", "TREATMENT", 101, 128], ["abortion", "PROBLEM", 130, 138], ["C. jejuni clone SA", "PROBLEM", 228, 246], ["the bacteria", "PROBLEM", 252, 264], ["fetuses and placental tissues", "PROBLEM", 285, 314], ["jejuni induced abortion", "OBSERVATION", 77, 100], ["guinea pigs", "OBSERVATION", 117, 128], ["placental tissues", "ANATOMY", 297, 314]]], ["These findings have indicated that ovine abortion-associated C. jejuni is highly abortificient and guinea pigs are a useful model to understand the pathogenesis of abortion.", [["ovine abortion", "DISEASE", 35, 49], ["C. jejuni", "DISEASE", 61, 70], ["abortion", "DISEASE", 164, 172], ["ovine", "ORGANISM", 35, 40], ["C. jejuni", "ORGANISM", 61, 70], ["guinea pigs", "ORGANISM", 99, 110], ["C. jejuni", "SPECIES", 61, 70], ["guinea pigs", "SPECIES", 99, 110], ["C. jejuni", "SPECIES", 61, 70], ["guinea", "SPECIES", 99, 105], ["ovine abortion", "PROBLEM", 35, 49], ["C. jejuni", "PROBLEM", 61, 70], ["abortion", "PROBLEM", 164, 172], ["jejuni", "OBSERVATION", 64, 70]]], ["However, further in vivo studies in a natural host (sheep) are needed to better characterize the virulence potential and pathogenesis of the abortion-associated C. jejuni.", [["abortion", "DISEASE", 141, 149], ["C. jejuni", "DISEASE", 161, 170], ["sheep", "ORGANISM", 52, 57], ["C. jejuni", "ORGANISM", 161, 170], ["sheep", "SPECIES", 52, 57], ["C. jejuni", "SPECIES", 161, 170], ["sheep", "SPECIES", 52, 57], ["C. jejuni", "SPECIES", 161, 170], ["further in vivo studies", "TEST", 9, 32], ["the abortion", "PROBLEM", 137, 149], ["C. jejuni", "PROBLEM", 161, 170], ["jejuni", "OBSERVATION", 164, 170]]], ["These studies would aid in the development of effective control or prevention strategies.BackgroundIn order to gain more insights into the pathogenesis of C. jejuni induced abortion in sheep, in vivo pathogenesis studies of ovine abortion were conducted using pregnant ewes and host gene expression profiles were compared between infected and uninfected ewes using microarray analysis.", [["C. jejuni", "DISEASE", 155, 164], ["abortion", "DISEASE", 173, 181], ["ovine abortion", "DISEASE", 224, 238], ["C. jejuni", "ORGANISM", 155, 164], ["sheep", "ORGANISM", 185, 190], ["ovine", "ORGANISM", 224, 229], ["ewes", "ORGANISM", 269, 273], ["C. jejuni", "SPECIES", 155, 164], ["sheep", "SPECIES", 185, 190], ["C. jejuni", "SPECIES", 155, 164], ["sheep", "SPECIES", 185, 190], ["ovine", "SPECIES", 224, 229], ["These studies", "TEST", 0, 13], ["effective control", "TREATMENT", 46, 63], ["prevention strategies", "TREATMENT", 67, 88], ["C. jejuni", "PROBLEM", 155, 164], ["ovine abortion", "PROBLEM", 224, 238], ["pregnant ewes", "TREATMENT", 260, 273], ["host gene expression profiles", "PROBLEM", 278, 307], ["microarray analysis", "TEST", 365, 384]]], ["Overall, the results suggested that bovine and ovine C. jejuni clone SA can induce abortion in pregnant ewes by causing necrotizing suppurative placentitis and endometritis, which was also supported by increased expressions of host genes related to cellular necrosis and suppurative inflammation (pro-inflammatory cytokines).Ethics statementAnimal experiments were conducted according to the guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).", [["cellular", "ANATOMY", 249, 257], ["suppurative", "ANATOMY", 271, 282], ["SA", "CHEMICAL", 69, 71], ["abortion", "DISEASE", 83, 91], ["placentitis", "DISEASE", 144, 155], ["endometritis", "DISEASE", 160, 172], ["necrosis", "DISEASE", 258, 266], ["inflammation", "DISEASE", 283, 295], ["bovine", "ORGANISM", 36, 42], ["ovine", "ORGANISM", 47, 52], ["C. jejuni", "ORGANISM", 53, 62], ["clone SA", "ORGANISM", 63, 71], ["ewes", "ORGANISM", 104, 108], ["cellular", "CELL", 249, 257], ["host genes", "DNA", 227, 237], ["pro-inflammatory cytokines", "PROTEIN", 297, 323], ["bovine", "SPECIES", 36, 42], ["C. jejuni", "SPECIES", 53, 62], ["bovine", "SPECIES", 36, 42], ["C. jejuni", "SPECIES", 53, 62], ["bovine and ovine C. jejuni clone SA", "TREATMENT", 36, 71], ["necrotizing suppurative placentitis", "PROBLEM", 120, 155], ["endometritis", "PROBLEM", 160, 172], ["host genes", "PROBLEM", 227, 237], ["cellular necrosis", "PROBLEM", 249, 266], ["suppurative inflammation", "PROBLEM", 271, 295], ["pro-inflammatory cytokines", "PROBLEM", 297, 323], ["Assessment", "TEST", 426, 436], ["necrotizing", "OBSERVATION_MODIFIER", 120, 131], ["suppurative", "OBSERVATION_MODIFIER", 132, 143], ["placentitis", "OBSERVATION", 144, 155], ["endometritis", "OBSERVATION", 160, 172], ["increased", "OBSERVATION_MODIFIER", 202, 211], ["host genes", "OBSERVATION_MODIFIER", 227, 237], ["cellular", "OBSERVATION_MODIFIER", 249, 257], ["necrosis", "OBSERVATION", 258, 266], ["suppurative", "OBSERVATION_MODIFIER", 271, 282], ["inflammation", "OBSERVATION", 283, 295], ["inflammatory", "OBSERVATION_MODIFIER", 301, 313]]], ["The animal studies were approved by the Agricultural Animal Care and Use Committee (AgACUC), OARDC, The Ohio State University (OSU) under the protocol number 2011A00000028.", [["The animal studies", "TEST", 0, 18]]], ["By necessity, microbial pathogenesis studies are heavily focused on the use of in vivo models, because the host immune responses interplay with pathogen evasion constitute a complex response that cannot yet be accurately replicated in vitro.", [["microbial pathogenesis studies", "TEST", 14, 44], ["pathogen evasion", "TREATMENT", 144, 160]]], ["Specifically, based on the C. jejuni associated abortion rates reported in the literature (50%) and preliminary studies, using 4 animals per group yielded a power of 0.85 (\u03b1 =0.05).", [["C. jejuni", "ORGANISM", 27, 36], ["C. jejuni", "SPECIES", 27, 36], ["C. jejuni", "SPECIES", 27, 36], ["the C. jejuni associated abortion rates", "PROBLEM", 23, 62], ["preliminary studies", "TEST", 100, 119]]], ["Since the objective of this study was to understand the complex host-pathogen interactions, the use of laboratory animals was unavoidable and justifiable.Ethics statementPregnant ewes were housed at the Food Animal Health Research Program Animal Care Facility which is fully accredited by AAALAC.", [["ewes", "ORGANISM", 179, 183], ["this study", "TEST", 23, 33], ["laboratory animals", "TEST", 103, 121]]], ["Infectious agents were administered using manual restraint for less than one minute to minimize distress.", [["Infectious agents", "TREATMENT", 0, 17], ["manual restraint", "TREATMENT", 42, 58], ["distress", "PROBLEM", 96, 104]]], ["Sheep were euthanized using phenobarbital injection i/v consistent with the recommendations of the panel on euthanasia of the American Veterinary Medical Association and by the Ohio State University Institutional Laboratory Animal Care and Use Committee.Abortion associated C. jejuni isolatesThree Campylobacter isolates were obtained from the Ohio Department of Agriculture (ODA, Columbus, OH).", [["phenobarbital", "CHEMICAL", 28, 41], ["phenobarbital", "CHEMICAL", 28, 41], ["Sheep", "ORGANISM", 0, 5], ["phenobarbital", "SIMPLE_CHEMICAL", 28, 41], ["C. jejuni", "ORGANISM", 274, 283], ["Sheep", "SPECIES", 0, 5], ["C. jejuni", "SPECIES", 274, 283], ["Sheep", "SPECIES", 0, 5], ["C. jejuni", "SPECIES", 274, 283], ["phenobarbital injection", "TREATMENT", 28, 51], ["Abortion", "TREATMENT", 254, 262], ["C. jejuni isolates", "PROBLEM", 274, 292], ["Three Campylobacter isolates", "PROBLEM", 292, 320], ["jejuni isolates", "OBSERVATION", 277, 292], ["Campylobacter isolates", "OBSERVATION", 298, 320]]], ["Two C. jejuni isolates (Ovine abortion-I and Ovine abortion-II) were retrieved from aborted Suffolk sheep fetuses from ewes in their third trimester of pregnancy in 2008, and one C. jejuni isolate (Bovine abortion) was isolated from an aborted cow in 2009.", [["fetuses", "ANATOMY", 106, 113], ["Bovine abortion", "DISEASE", 198, 213], ["C. jejuni", "ORGANISM", 4, 13], ["Ovine", "ORGANISM", 24, 29], ["sheep", "ORGANISM", 100, 105], ["fetuses", "DEVELOPING_ANATOMICAL_STRUCTURE", 106, 113], ["C. jejuni", "ORGANISM", 179, 188], ["Bovine", "ORGANISM", 198, 204], ["cow", "ORGANISM_SUBDIVISION", 244, 247], ["C. jejuni", "SPECIES", 4, 13], ["sheep", "SPECIES", 100, 105], ["C. jejuni", "SPECIES", 179, 188], ["Bovine", "SPECIES", 198, 204], ["cow", "SPECIES", 244, 247], ["C. jejuni", "SPECIES", 4, 13], ["sheep", "SPECIES", 100, 105], ["C. jejuni", "SPECIES", 179, 188], ["Bovine", "SPECIES", 198, 204], ["cow", "SPECIES", 244, 247], ["Two C. jejuni isolates", "TREATMENT", 0, 22], ["Ovine abortion", "TREATMENT", 24, 38], ["Bovine abortion", "PROBLEM", 198, 213], ["jejuni isolates", "OBSERVATION", 7, 22], ["jejuni isolate", "OBSERVATION", 182, 196]]], ["These isolates (Ovine abortion-I, Ovine abortion-II, and Bovine abortion) were confirmed as C. jejuni using a genus as well as a species specific PCR [10, 11] .", [["Ovine abortion", "DISEASE", 16, 30], ["Bovine abortion", "DISEASE", 57, 72], ["Ovine", "ORGANISM", 16, 21], ["Ovine", "ORGANISM", 34, 39], ["Bovine", "ORGANISM", 57, 63], ["C. jejuni", "ORGANISM", 92, 101], ["Bovine", "SPECIES", 57, 63], ["C. jejuni", "SPECIES", 92, 101], ["Bovine", "SPECIES", 57, 63], ["C. jejuni", "SPECIES", 92, 101], ["These isolates (Ovine abortion", "TREATMENT", 0, 30], ["Ovine abortion-II, and Bovine abortion", "TREATMENT", 34, 72], ["C. jejuni", "PROBLEM", 92, 101], ["a species specific PCR", "TEST", 127, 149]]], ["Furthermore, PFGE analysis [11] [12] [13] showed that the ovine and bovine abortion isolates possessed identical profiles.", [["ovine", "ORGANISM", 58, 63], ["bovine", "ORGANISM", 68, 74], ["bovine", "SPECIES", 68, 74], ["bovine", "SPECIES", 68, 74], ["PFGE analysis", "TEST", 13, 26], ["the ovine and bovine abortion", "TREATMENT", 54, 83]]], ["In addition, MLST analysis confirmed that these abortion-associated C. jejuni belonged to the same previously described abortion associated tetracycline resistant clone SA [sequence type (ST) 8; clonal complex (CC) 21] [5, 11, 13, 14] (Additional file 1: Figure S1 ).Abortion associated C. jejuni isolatesInoculation of pregnant ewes with the ovine and bovine abortion C. jejuni isolates Four groups of ewes in the third trimester of pregnancy were used.", [["tetracycline", "CHEMICAL", 140, 152], ["tetracycline", "CHEMICAL", 140, 152], ["C. jejuni", "ORGANISM", 68, 77], ["tetracycline", "SIMPLE_CHEMICAL", 140, 152], ["C. jejuni", "ORGANISM", 287, 296], ["ewes", "ORGANISM", 329, 333], ["ovine", "ORGANISM", 343, 348], ["bovine", "ORGANISM", 353, 359], ["C. jejuni", "ORGANISM", 369, 378], ["ewes", "ORGANISM", 403, 407], ["C. jejuni", "SPECIES", 68, 77], ["C. jejuni", "SPECIES", 287, 296], ["ovine", "SPECIES", 343, 348], ["bovine", "SPECIES", 353, 359], ["C. jejuni", "SPECIES", 369, 378], ["C. jejuni", "SPECIES", 68, 77], ["C. jejuni", "SPECIES", 287, 296], ["ovine", "SPECIES", 343, 348], ["bovine", "SPECIES", 353, 359], ["C. jejuni", "SPECIES", 369, 378], ["MLST analysis", "TEST", 13, 26], ["these abortion", "PROBLEM", 42, 56], ["C. jejuni", "PROBLEM", 68, 77], ["tetracycline resistant clone SA", "PROBLEM", 140, 171], ["clonal complex (CC)", "TEST", 195, 214], ["Abortion", "TREATMENT", 267, 275], ["C. jejuni isolates", "TREATMENT", 287, 305], ["the ovine and bovine abortion C. jejuni isolates", "TREATMENT", 339, 387], ["jejuni isolates", "OBSERVATION", 290, 305]]], ["These ewes were obtained from the OSU sheep facility herd which had no history of abortions and was vaccinated only against Chlamydia and Toxoplasma.", [["abortions", "DISEASE", 82, 91], ["Chlamydia and Toxoplasma", "DISEASE", 124, 148], ["ewes", "ORGANISM", 6, 10], ["sheep", "ORGANISM", 38, 43], ["Toxoplasma", "ORGANISM", 138, 148], ["sheep", "SPECIES", 38, 43], ["sheep", "SPECIES", 38, 43], ["abortions", "PROBLEM", 82, 91], ["Chlamydia", "PROBLEM", 124, 133], ["Toxoplasma", "PROBLEM", 138, 148]]], ["Ewes were tested for pregnancy with ultrasound at approximately 8-9 weeks after insemination and then pregnant ewes (14-15 weeks) were inoculated with C. jejuni strains.", [["Ewes", "ANATOMY", 0, 4], ["ewes", "ORGANISM", 111, 115], ["C. jejuni", "ORGANISM", 151, 160], ["C. jejuni", "SPECIES", 151, 160], ["C. jejuni", "SPECIES", 151, 160], ["pregnancy", "PROBLEM", 21, 30], ["ultrasound", "TEST", 36, 46], ["insemination", "TREATMENT", 80, 92], ["C. jejuni strains", "PROBLEM", 151, 168], ["jejuni strains", "OBSERVATION", 154, 168]]], ["Fecal samples were collected from all ewes one week before inoculation and examined for the presence of Campylobacter.", [["Fecal samples", "ANATOMY", 0, 13], ["Campylobacter", "CHEMICAL", 104, 117], ["Fecal samples", "ORGANISM_SUBSTANCE", 0, 13], ["Fecal samples", "TEST", 0, 13], ["Campylobacter", "PROBLEM", 104, 117], ["Campylobacter", "OBSERVATION", 104, 117]]], ["The first group was inoculated with a common laboratory strain, C. jejuni 81-176, (G1).", [["C. jejuni", "ORGANISM", 64, 73], ["C. jejuni", "SPECIES", 64, 73], ["C. jejuni 81-176", "SPECIES", 64, 80], ["a common laboratory strain", "PROBLEM", 36, 62], ["C. jejuni", "TEST", 64, 73]]], ["The second and third groups were inoculated with (Bovine abortion: G2) and (Ovine abortion-II: G3) isolates, respectively.", [["Bovine", "ORGANISM", 50, 56], ["Bovine", "SPECIES", 50, 56]]], ["In each group, two ewes were inoculated with C. jejuni via oral route and the other two were inoculated i/v. Oral inoculation simulated the natural route of C. jejuni infection in sheep; however, to insure that the infection will occur, sheep were also inoculated i/v. The fourth group, which consisted of two ewes, was used as a non-inoculated control.", [["oral", "ANATOMY", 59, 63], ["Oral", "ANATOMY", 109, 113], ["C. jejuni infection", "DISEASE", 157, 176], ["infection", "DISEASE", 215, 224], ["ewes", "ORGANISM", 19, 23], ["C. jejuni", "ORGANISM", 45, 54], ["oral", "ORGANISM_SUBDIVISION", 59, 63], ["C. jejuni", "ORGANISM", 157, 166], ["sheep", "ORGANISM", 180, 185], ["sheep", "ORGANISM", 237, 242], ["ewes", "ORGANISM", 310, 314], ["C. jejuni", "SPECIES", 45, 54], ["C. jejuni", "SPECIES", 157, 166], ["sheep", "SPECIES", 180, 185], ["sheep", "SPECIES", 237, 242], ["C. jejuni", "SPECIES", 45, 54], ["C. jejuni", "SPECIES", 157, 166], ["sheep", "SPECIES", 180, 185], ["sheep", "SPECIES", 237, 242], ["C. jejuni", "TREATMENT", 45, 54], ["oral route", "TREATMENT", 59, 69], ["Oral inoculation", "TREATMENT", 109, 125], ["C. jejuni infection", "PROBLEM", 157, 176], ["the infection", "PROBLEM", 211, 224], ["a non-inoculated control", "TREATMENT", 328, 352], ["jejuni infection", "OBSERVATION", 160, 176], ["infection", "OBSERVATION", 215, 224]]], ["Ewes were either drench inoculated orally with 50 ml sterile PBS containing 10 10 CFU ml -1 or via i/v using a syringe with 1.5 ml sterile PBS containing 10 9 CFU.", [["Ewes", "ANATOMY", 0, 4], ["orally", "ANATOMY", 35, 41], ["a syringe", "TREATMENT", 109, 118], ["1.5 ml sterile PBS", "TREATMENT", 124, 142]]], ["These doses were selected based on previous studies [8, 15] .", [["previous studies", "TEST", 35, 51]]], ["The ewes were monitored after infection until abortion or the end of pregnancy.Necropsy of ewes and bacteriological examinationEwes and fetuses were necropsied immediately following abortion or normal delivery.", [["fetuses", "ANATOMY", 136, 143], ["infection", "DISEASE", 30, 39], ["ewes", "ORGANISM", 4, 8], ["fetuses", "ORGANISM", 136, 143], ["infection", "PROBLEM", 30, 39], ["abortion", "TREATMENT", 46, 54], ["bacteriological examination", "TEST", 100, 127], ["fetuses", "PROBLEM", 136, 143]]], ["Maternal tissues: caruncles and placenta, liver, kidney, spleen, lungs, uterus, small intestine, blood, colostrum, placental fluids, and feces; and fetal tissues: small intestine, lung, liver, meconium, cecal contents, fetal fluids (abdominal fluids and blood) were collected and processed for microbiological examination individually.", [["tissues", "ANATOMY", 9, 16], ["caruncles", "ANATOMY", 18, 27], ["placenta", "ANATOMY", 32, 40], ["liver", "ANATOMY", 42, 47], ["kidney", "ANATOMY", 49, 55], ["spleen", "ANATOMY", 57, 63], ["lungs", "ANATOMY", 65, 70], ["uterus", "ANATOMY", 72, 78], ["small intestine", "ANATOMY", 80, 95], ["blood", "ANATOMY", 97, 102], ["colostrum", "ANATOMY", 104, 113], ["placental fluids", "ANATOMY", 115, 131], ["feces", "ANATOMY", 137, 142], ["fetal tissues", "ANATOMY", 148, 161], ["small intestine", "ANATOMY", 163, 178], ["lung", "ANATOMY", 180, 184], ["liver", "ANATOMY", 186, 191], ["meconium", "ANATOMY", 193, 201], ["cecal", "ANATOMY", 203, 208], ["fetal fluids", "ANATOMY", 219, 231], ["abdominal fluids", "ANATOMY", 233, 249], ["blood", "ANATOMY", 254, 259], ["Maternal", "TISSUE", 0, 8], ["tissues", "TISSUE", 9, 16], ["caruncles", "TISSUE", 18, 27], ["placenta", "TISSUE", 32, 40], ["liver", "ORGAN", 42, 47], ["kidney", "ORGAN", 49, 55], ["spleen", "ORGAN", 57, 63], ["lungs", "ORGAN", 65, 70], ["uterus", "ORGAN", 72, 78], ["small intestine", "MULTI-TISSUE_STRUCTURE", 80, 95], ["blood", "ORGANISM_SUBSTANCE", 97, 102], ["colostrum", "ORGANISM_SUBSTANCE", 104, 113], ["placental fluids", "TISSUE", 115, 131], ["feces", "ORGANISM_SUBDIVISION", 137, 142], ["fetal tissues", "TISSUE", 148, 161], ["small intestine", "MULTI-TISSUE_STRUCTURE", 163, 178], ["lung", "ORGAN", 180, 184], ["liver", "ORGAN", 186, 191], ["meconium", "ORGANISM_SUBSTANCE", 193, 201], ["cecal", "ORGANISM_SUBDIVISION", 203, 208], ["fetal fluids", "ORGANISM_SUBSTANCE", 219, 231], ["abdominal fluids", "ORGANISM_SUBSTANCE", 233, 249], ["blood", "ORGANISM_SUBSTANCE", 254, 259], ["blood, colostrum, placental fluids, and feces", "TEST", 97, 142], ["microbiological examination", "TEST", 294, 321], ["placenta", "ANATOMY", 32, 40], ["liver", "ANATOMY", 42, 47], ["kidney", "ANATOMY", 49, 55], ["spleen", "ANATOMY", 57, 63], ["lungs", "ANATOMY", 65, 70], ["uterus", "ANATOMY", 72, 78], ["small intestine", "ANATOMY", 80, 95], ["blood", "ANATOMY", 97, 102], ["placental", "ANATOMY", 115, 124], ["fluids", "OBSERVATION", 125, 131], ["feces", "OBSERVATION", 137, 142], ["fetal tissues", "ANATOMY", 148, 161], ["small intestine", "ANATOMY", 163, 178], ["lung", "ANATOMY", 180, 184], ["liver", "ANATOMY", 186, 191], ["meconium", "OBSERVATION", 193, 201], ["cecal", "ANATOMY", 203, 208], ["contents", "OBSERVATION", 209, 217], ["abdominal", "ANATOMY", 233, 242]]], ["The tissues were aseptically collected using separate sterilized sets of necropsy tools for each organ.", [["tissues", "ANATOMY", 4, 11], ["organ", "ANATOMY", 97, 102], ["tissues", "TISSUE", 4, 11], ["organ", "ORGAN", 97, 102], ["necropsy tools", "TEST", 73, 87], ["tissues", "ANATOMY", 4, 11]]], ["To detect C. jejuni, 1 g of each tissue was enriched in Preston broth for 48 h at 42\u00b0C under microaerobic conditions.", [["tissue", "ANATOMY", 33, 39], ["C. jejuni", "ORGANISM", 10, 19], ["tissue", "TISSUE", 33, 39], ["C", "SIMPLE_CHEMICAL", 85, 86], ["C. jejuni", "SPECIES", 10, 19], ["C. jejuni", "SPECIES", 10, 19], ["C. jejuni", "PROBLEM", 10, 19], ["jejuni", "ANATOMY", 13, 19], ["microaerobic conditions", "OBSERVATION", 93, 116]]], ["An (100 \u03bcl) inoculum from the enrichments was spread onto modified Cefoperazone Charcoal Deoxycholate Agar (mCCDA) plates, which were then incubated for an additional 48 h at 42\u00b0C under microaerobic conditions [16] .", [["Cefoperazone Charcoal Deoxycholate", "CHEMICAL", 67, 101], ["Deoxycholate", "CHEMICAL", 89, 101], ["Charcoal Deoxycholate Agar", "SIMPLE_CHEMICAL", 80, 106], ["mCCDA", "SIMPLE_CHEMICAL", 108, 113], ["C", "SIMPLE_CHEMICAL", 178, 179], ["An (100 \u03bcl) inoculum", "TREATMENT", 0, 20], ["the enrichments", "PROBLEM", 26, 41], ["modified Cefoperazone Charcoal Deoxycholate Agar (mCCDA) plates", "TREATMENT", 58, 121], ["microaerobic conditions", "OBSERVATION", 186, 209]]], ["Furthermore, an inoculum (100 \u03bcl) from placental and uterine tissues of each animal was plated directly onto mCCDA plates, respectively.", [["placental", "ANATOMY", 39, 48], ["uterine tissues", "ANATOMY", 53, 68], ["placental", "TISSUE", 39, 48], ["uterine tissues", "TISSUE", 53, 68], ["an inoculum", "TREATMENT", 13, 24], ["placental and uterine tissues", "TREATMENT", 39, 68], ["inoculum", "OBSERVATION", 16, 24], ["uterine tissues", "ANATOMY", 53, 68]]], ["The plates were then incubated as described previously and the CFU were counted.", [["the CFU", "TEST", 59, 66], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["The growth was categorized as + = (mild growth: less than 100 CFU), ++ = (moderate growth: less than 300 CFU), +++ = (heavy growth: too many to count), -= (no growth).Histopathological studiesA histopathological examination [17] was conducted to determine the pathological changes in infected and control ewes and fetal tissues.", [["fetal tissues", "ANATOMY", 314, 327], ["fetal tissues", "TISSUE", 314, 327], ["mild growth", "PROBLEM", 35, 46], ["Histopathological studiesA", "TEST", 167, 193], ["histopathological examination", "TEST", 194, 223], ["the pathological changes in infected and control ewes and fetal tissues", "PROBLEM", 256, 327], ["mild", "OBSERVATION_MODIFIER", 35, 39], ["growth", "OBSERVATION_MODIFIER", 40, 46], ["moderate", "OBSERVATION_MODIFIER", 74, 82], ["growth", "OBSERVATION_MODIFIER", 83, 89], ["no", "UNCERTAINTY", 156, 158], ["infected", "OBSERVATION", 284, 292], ["fetal tissues", "ANATOMY", 314, 327]]], ["Samples collected from the intestine, liver, kidney, spleen, placenta, and uterus as well as tissue samples collected from lambs (lung and small intestine) after normal delivery or from aborted and/or stillbirth fetuses were examined for histological changes.", [["Samples", "ANATOMY", 0, 7], ["intestine", "ANATOMY", 27, 36], ["liver", "ANATOMY", 38, 43], ["kidney", "ANATOMY", 45, 51], ["spleen", "ANATOMY", 53, 59], ["placenta", "ANATOMY", 61, 69], ["uterus", "ANATOMY", 75, 81], ["tissue samples", "ANATOMY", 93, 107], ["lambs", "ANATOMY", 123, 128], ["lung", "ANATOMY", 130, 134], ["small intestine", "ANATOMY", 139, 154], ["fetuses", "ANATOMY", 212, 219], ["intestine", "ORGAN", 27, 36], ["liver", "ORGAN", 38, 43], ["kidney", "ORGAN", 45, 51], ["spleen", "ORGAN", 53, 59], ["placenta", "ORGAN", 61, 69], ["uterus", "ORGAN", 75, 81], ["tissue samples", "TISSUE", 93, 107], ["lambs", "ORGANISM", 123, 128], ["lung", "ORGAN", 130, 134], ["small intestine", "ORGAN", 139, 154], ["fetuses", "ORGANISM", 212, 219], ["lambs", "SPECIES", 123, 128], ["Samples collected from the intestine", "TEST", 0, 36], ["tissue samples", "TEST", 93, 107], ["stillbirth fetuses", "PROBLEM", 201, 219], ["histological changes", "PROBLEM", 238, 258], ["intestine", "ANATOMY", 27, 36], ["liver", "ANATOMY", 38, 43], ["kidney", "ANATOMY", 45, 51], ["spleen", "ANATOMY", 53, 59], ["placenta", "ANATOMY", 61, 69], ["uterus", "ANATOMY", 75, 81], ["lung", "ANATOMY", 130, 134], ["small intestine", "ANATOMY", 139, 154]]], ["Tissues were placed in 10% phosphate buffered formaldehyde (pH 7.0), dehydrated in graded alcohol, embedded in paraffin, and cut in 3-\u03bcm sections onto microscope slides.", [["Tissues", "ANATOMY", 0, 7], ["sections", "ANATOMY", 137, 145], ["phosphate", "CHEMICAL", 27, 36], ["formaldehyde", "CHEMICAL", 46, 58], ["alcohol", "CHEMICAL", 90, 97], ["phosphate", "CHEMICAL", 27, 36], ["formaldehyde", "CHEMICAL", 46, 58], ["alcohol", "CHEMICAL", 90, 97], ["paraffin", "CHEMICAL", 111, 119], ["Tissues", "CANCER", 0, 7], ["phosphate buffered formaldehyde", "SIMPLE_CHEMICAL", 27, 58], ["alcohol", "SIMPLE_CHEMICAL", 90, 97], ["pH", "TEST", 60, 62], ["microscope slides", "TEST", 151, 168]]], ["The slides were fixed and stained with hematoxylin and eosin (H&E) and samples were blinded prior to analysis for histopathological changes by a pathologist.Immunohistochemistry (IHC)Monoclonal mouse anti-C. jejuni antibody clone B082M (Acris Antibodies, Inc., San Diego, CA) was used for the detection of C. jejuni antigens in formalin-fixed, paraffinembedded tissues.", [["samples", "ANATOMY", 71, 78], ["tissues", "ANATOMY", 361, 368], ["hematoxylin", "CHEMICAL", 39, 50], ["eosin", "CHEMICAL", 55, 60], ["formalin", "CHEMICAL", 328, 336], ["hematoxylin", "SIMPLE_CHEMICAL", 39, 50], ["eosin", "SIMPLE_CHEMICAL", 55, 60], ["mouse", "ORGANISM", 194, 199], ["C. jejuni antigens", "GENE_OR_GENE_PRODUCT", 306, 324], ["tissues", "TISSUE", 361, 368], ["B082M", "PROTEIN", 230, 235], ["Acris Antibodies", "PROTEIN", 237, 253], ["C. jejuni antigens", "PROTEIN", 306, 324], ["mouse", "SPECIES", 194, 199], ["anti-C. jejuni", "SPECIES", 200, 214], ["C. jejuni", "SPECIES", 306, 315], ["mouse anti-C. jejuni", "SPECIES", 194, 214], ["C. jejuni", "SPECIES", 306, 315], ["hematoxylin", "TREATMENT", 39, 50], ["eosin", "TREATMENT", 55, 60], ["samples", "TEST", 71, 78], ["analysis", "TEST", 101, 109], ["histopathological changes", "PROBLEM", 114, 139], ["Immunohistochemistry", "TEST", 157, 177], ["IHC", "TEST", 179, 182], ["Monoclonal mouse anti-C. jejuni antibody", "TEST", 183, 223], ["clone B082M", "TEST", 224, 235], ["Acris Antibodies", "TEST", 237, 253], ["the detection", "TEST", 289, 302], ["C. jejuni antigens", "PROBLEM", 306, 324], ["jejuni antigens", "OBSERVATION", 309, 324], ["paraffinembedded tissues", "ANATOMY", 344, 368]]], ["The antibody was diluted 1 in 200 in PBST [phosphate-buffered saline (PBS) containing 0.1% Tween 20] .", [["phosphate", "CHEMICAL", 43, 52], ["phosphate", "CHEMICAL", 43, 52], ["Tween 20", "CHEMICAL", 91, 99], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 43, 68], ["The antibody", "TEST", 0, 12], ["phosphate", "TEST", 43, 52], ["buffered saline (PBS)", "TREATMENT", 53, 74]]], ["IHC was carried out using an in house protocol that was developed for pig tissues as described previously [17] .", [["tissues", "ANATOMY", 74, 81], ["pig", "ORGANISM", 70, 73], ["tissues", "TISSUE", 74, 81], ["pig", "SPECIES", 70, 73], ["pig", "SPECIES", 70, 73], ["IHC", "TEST", 0, 3], ["an in house protocol", "TREATMENT", 26, 46], ["pig tissues", "PROBLEM", 70, 81]]], ["Paraffin-embedded tissues were sectioned at 3 \u03bcm thickness and collected on positively charged slides (Fisher Scientific, PA).", [["tissues", "ANATOMY", 18, 25], ["tissues", "TISSUE", 18, 25], ["embedded tissues", "OBSERVATION", 9, 25]]], ["The slides were kept at 60\u00b0C for 20 min, deparaffinized in xylene twice for 5 min each, and rehydrated through a graded ethanol series (100% to 50%).", [["xylene", "CHEMICAL", 59, 65], ["ethanol", "CHEMICAL", 120, 127], ["xylene", "CHEMICAL", 59, 65], ["ethanol", "CHEMICAL", 120, 127], ["xylene", "SIMPLE_CHEMICAL", 59, 65], ["ethanol", "SIMPLE_CHEMICAL", 120, 127], ["The slides", "TREATMENT", 0, 10], ["a graded ethanol series", "TREATMENT", 111, 134]]], ["Endogenous alkaline phosphatase was quenched with glacial acetic acid (20%) for 2 min at 4\u00b0C. Antigen retrieval was performed using 100 \u03bcg ml -1 of proteinase K (Invitrogen, Carlsbad, CA).", [["glacial acetic acid", "CHEMICAL", 50, 69], ["glacial acetic acid", "CHEMICAL", 50, 69], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 11, 31], ["glacial acetic acid", "SIMPLE_CHEMICAL", 50, 69], ["proteinase K", "GENE_OR_GENE_PRODUCT", 148, 160], ["CA", "GENE_OR_GENE_PRODUCT", 184, 186], ["alkaline phosphatase", "PROTEIN", 11, 31], ["proteinase K", "PROTEIN", 148, 160], ["Endogenous alkaline phosphatase", "TEST", 0, 31], ["glacial acetic acid", "TEST", 50, 69], ["Antigen retrieval", "TREATMENT", 94, 111], ["proteinase K (Invitrogen", "TREATMENT", 148, 172], ["alkaline phosphatase", "OBSERVATION", 11, 31]]], ["The tissue slides were then washed in PBST three times and blocked with 1\u00d7 buffered solution of casein (Universal Blocking Reagent; Biogenex, Fremont, CA) in distilled water for 30 min at room temperature to saturate nonspecific protein-binding sites.", [["tissue", "ANATOMY", 4, 10], ["tissue slides", "CANCER", 4, 17], ["casein", "SIMPLE_CHEMICAL", 96, 102], ["protein-binding sites", "PROTEIN", 229, 250], ["The tissue slides", "TREATMENT", 0, 17], ["PBST", "TREATMENT", 38, 42], ["casein", "TREATMENT", 96, 102], ["Universal Blocking Reagent", "TREATMENT", 104, 130], ["Biogenex", "TREATMENT", 132, 140], ["nonspecific protein-binding sites", "PROBLEM", 217, 250], ["tissue", "ANATOMY", 4, 10], ["slides", "OBSERVATION", 11, 17], ["binding sites", "OBSERVATION", 237, 250]]], ["Sections were coated with monoclonal antibodies and incubated overnight at 4\u00b0C in a humid chamber.", [["monoclonal antibodies", "PROTEIN", 26, 47], ["monoclonal antibodies", "TEST", 26, 47], ["a humid chamber", "TREATMENT", 82, 97], ["humid chamber", "OBSERVATION", 84, 97]]], ["After three washes with PBST, the sections were flooded and incubated for 1 h at 37\u00b0C with goat anti-mouse IgG labeled with alkaline phosphatase (Dako, Glostrup, Denmark) diluted 1 in 200 in PBST.", [["sections", "ANATOMY", 34, 42], ["goat", "ORGANISM", 91, 95], ["goat anti-mouse IgG", "PROTEIN", 91, 110], ["alkaline phosphatase", "PROTEIN", 124, 144], ["goat", "SPECIES", 91, 95], ["anti-mouse", "SPECIES", 96, 106], ["goat", "SPECIES", 91, 95], ["PBST", "TREATMENT", 24, 28], ["goat anti-mouse IgG", "TEST", 91, 110], ["alkaline phosphatase", "TEST", 124, 144]]], ["After three washes with PBST, the final reaction was generated by immersing the tissue sections in a staining solution [1 tablet of Fast Red in 2 ml of 0.1 M Tris-buffer (pH 8.2); Roche Applied Science, Mannheim, Germany] for 10 min at room temperature.", [["tissue sections", "ANATOMY", 80, 95], ["Tris", "CHEMICAL", 158, 162], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 80, 95], ["PBST", "TREATMENT", 24, 28], ["the final reaction", "PROBLEM", 30, 48], ["a staining solution", "TREATMENT", 99, 118], ["Fast Red", "TREATMENT", 132, 140], ["pH", "TEST", 171, 173]]], ["Sections were lightly counterstained with Mayer's hematoxylin.Immunohistochemistry (IHC)In situ terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) assay Paraffin-embedded placental tissues were prepared as described above and evaluated by an in situ TUNEL assay kit (Roche Applied Science) for apoptosis [18] according to the manufacturer's instructions.", [["placental tissues", "ANATOMY", 199, 216], ["dUTP", "CHEMICAL", 143, 147], ["hematoxylin", "CHEMICAL", 50, 61], ["dUTP", "CHEMICAL", 143, 147], ["hematoxylin", "SIMPLE_CHEMICAL", 50, 61], ["terminal deoxynucleotidyl transferase", "GENE_OR_GENE_PRODUCT", 96, 133], ["dUTP", "SIMPLE_CHEMICAL", 143, 147], ["placental tissues", "TISSUE", 199, 216], ["Mayer's hematoxylin", "TREATMENT", 42, 61], ["Immunohistochemistry", "TEST", 62, 82], ["IHC", "TEST", 84, 87], ["terminal deoxynucleotidyl transferase", "TEST", 96, 133], ["dUTP nick end labelling (TUNEL) assay Paraffin-embedded placental tissues", "TREATMENT", 143, 216], ["apoptosis", "PROBLEM", 322, 331], ["deoxynucleotidyl transferase", "OBSERVATION", 105, 133], ["dUTP nick", "OBSERVATION", 143, 152], ["placental tissues", "ANATOMY", 199, 216]]], ["The severity of apoptosis was qualitatively estimated based on the distribution and number of in situ TUNEL-positive cells in the placenta per microscopic area at \u00d7 200 magnification.", [["cells", "ANATOMY", 117, 122], ["placenta", "ANATOMY", 130, 138], ["area", "ANATOMY", 155, 159], ["cells", "CELL", 117, 122], ["placenta", "ORGAN", 130, 138], ["in situ TUNEL-positive cells", "CELL_LINE", 94, 122], ["apoptosis", "PROBLEM", 16, 25], ["positive cells", "PROBLEM", 108, 122], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["apoptosis", "OBSERVATION", 16, 25], ["positive cells", "OBSERVATION", 108, 122], ["placenta", "ANATOMY", 130, 138]]], ["TUNEL-positive cells (red staining) were then randomly compared between infected and negative control animals.Immunohistochemistry (IHC)Total RNA extraction from uterus RNA was extracted from uterine tissues of two animals from each group of ewes that undergone abortion or delivered a stillbirth.", [["TUNEL-positive cells", "ANATOMY", 0, 20], ["uterus", "ANATOMY", 162, 168], ["uterine tissues", "ANATOMY", 192, 207], ["stillbirth", "DISEASE", 286, 296], ["uterus", "ORGAN", 162, 168], ["uterine tissues", "TISSUE", 192, 207], ["ewes", "ORGANISM", 242, 246], ["TUNEL-positive cells", "CELL_LINE", 0, 20], ["uterus RNA", "RNA", 162, 172], ["TUNEL", "TEST", 0, 5], ["red staining", "TEST", 22, 34], ["Immunohistochemistry", "TEST", 110, 130], ["Total RNA extraction", "TREATMENT", 136, 156], ["uterus RNA", "PROBLEM", 162, 172], ["abortion", "TREATMENT", 262, 270], ["positive cells", "OBSERVATION", 6, 20], ["negative", "OBSERVATION", 85, 93], ["uterus", "ANATOMY", 162, 168], ["uterine tissues", "ANATOMY", 192, 207]]], ["Similarly, uterine tissues from two control non-inoculated and two 81-176 inoculated sheep were used for RNA extraction.", [["uterine tissues", "ANATOMY", 11, 26], ["uterine tissues", "TISSUE", 11, 26], ["sheep", "ORGANISM", 85, 90], ["sheep", "SPECIES", 85, 90], ["sheep", "SPECIES", 85, 90], ["RNA extraction", "TREATMENT", 105, 119], ["uterine tissues", "ANATOMY", 11, 26], ["two", "OBSERVATION_MODIFIER", 32, 35]]], ["Uterus samples were collected aseptically during necropsy and immediately flash frozen in liquid nitrogen.", [["Uterus samples", "ANATOMY", 0, 14], ["nitrogen", "CHEMICAL", 97, 105], ["Uterus samples", "CANCER", 0, 14], ["Uterus samples", "TEST", 0, 14], ["necropsy", "TREATMENT", 49, 57], ["flash frozen in liquid nitrogen", "TREATMENT", 74, 105], ["liquid nitrogen", "OBSERVATION", 90, 105]]], ["The samples were then immediately transferred to -70\u00b0C until further analysis.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11], ["further analysis", "TEST", 61, 77]]], ["At the completion of the experiment, RNA extraction from the frozen tissues was performed using Qiagen RNeasy\u00ae Mini Columns following the manufacturer protocol.", [["tissues", "ANATOMY", 68, 75], ["tissues", "TISSUE", 68, 75], ["RNA extraction", "TREATMENT", 37, 51], ["the frozen tissues", "PROBLEM", 57, 75], ["the manufacturer protocol", "TREATMENT", 134, 159], ["frozen tissues", "OBSERVATION", 61, 75]]], ["Briefly, 30 mg of tissue was lysed in 1 ml TRIzol (Invitrogen) with homogenization (Cole-Parmer, lab Gen 125).", [["tissue", "ANATOMY", 18, 24], ["tissue", "TISSUE", 18, 24], ["tissue", "TREATMENT", 18, 24], ["TRIzol", "TREATMENT", 43, 49]]], ["Chloroform (0.2 ml) was added, the samples were mixed vigorously and incubated at room temperature for 2-3 min.", [["samples", "ANATOMY", 35, 42], ["Chloroform", "CHEMICAL", 0, 10], ["Chloroform", "CHEMICAL", 0, 10], ["Chloroform", "SIMPLE_CHEMICAL", 0, 10], ["Chloroform", "TREATMENT", 0, 10]]], ["Samples were centrifuged at 12,000 \u00d7 g at 4\u00b0C for 5 min.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7]]], ["The aqueous phase was separated and used for RNA extraction using Qiagen RNeasy\u00ae Mini Columns.", [["RNA extraction", "TREATMENT", 45, 59], ["Columns", "ANATOMY_MODIFIER", 86, 93]]], ["The RNA was stored at -70\u00b0C until further use.Microarray analysisThe RNA concentration was determined using the Nano-Drop spectrophotometer (NanoDrop products, Wilmington, DE), and the integrity of the RNA was confirmed by gel electrophoresis as well as by using an Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara CA).", [["The RNA", "TEST", 0, 7], ["Microarray analysis", "TEST", 46, 65], ["The RNA concentration", "TREATMENT", 65, 86], ["the Nano-Drop spectrophotometer (NanoDrop products", "TREATMENT", 108, 158], ["gel electrophoresis", "TEST", 223, 242], ["an Agilent 2100 bioanalyzer (Agilent Technologies", "TREATMENT", 263, 312]]], ["The samples with ratio closer to 2 were used for microarray analyses.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11], ["ratio", "TEST", 17, 22], ["microarray analyses", "TEST", 49, 68]]], ["Microarray expression analysis was performed using Ovis aries Sureprint 8 \u00d7 15K arrays (Agilent Technologies, Santa Clara CA).", [["Ovis", "SPECIES", 51, 55], ["Microarray expression analysis", "TEST", 0, 30]]], ["The Sureprint sheep array has 60mer oligos representing 15,208 probes.Microarray analysisMicroarray hybridizations were performed according to manufacturer's instructions at the Research Institute at Nationwide Children's Hospital, Biomedical Genomics Core Facility, (Columbus, OH).", [["sheep", "ORGANISM", 14, 19], ["60mer oligos", "DNA", 30, 42], ["sheep", "SPECIES", 14, 19], ["sheep", "SPECIES", 14, 19], ["The Sureprint sheep array", "TREATMENT", 0, 25], ["Microarray analysisMicroarray hybridizations", "TEST", 70, 114]]], ["In brief, samples were labeled with Cy3, purified using Qiagen columns, and checked for labeling efficiency using the Nanodrop.", [["samples", "ANATOMY", 10, 17], ["Cy3", "SIMPLE_CHEMICAL", 36, 39], ["Cy3", "TEST", 36, 39], ["Qiagen columns", "TREATMENT", 56, 70], ["labeling efficiency", "PROBLEM", 88, 107], ["the Nanodrop", "TREATMENT", 114, 126]]], ["The labeled samples were fragmented and hybridized to the array overnight.", [["samples", "ANATOMY", 12, 19], ["The labeled samples", "TEST", 0, 19], ["fragmented", "OBSERVATION_MODIFIER", 25, 35]]], ["Microarray slides were then washed and scanned with Agilent G2505C Microarray Scanner at 2 \u03bcM resolution.", [["Microarray slides", "TEST", 0, 17]]], ["Images were analyzed with Feature Extraction 10.10 (Agilent Technologies, CA).Microarray analysisFor analysis, the intensity data were background corrected and summarized with quantile normalization method [19, 20] .", [["Images", "TEST", 0, 6], ["Feature Extraction", "TEST", 26, 44], ["Microarray analysis", "TEST", 78, 97], ["analysis", "TEST", 101, 109], ["the intensity data", "TEST", 111, 129]]], ["A filtering method was applied if more than 80% of arrays showed that the expression levels of a gene were at or below the noise cutoff.", [["A filtering method", "TREATMENT", 0, 18]]], ["The data from 2 samples were averaged for further analysis.", [["samples", "ANATOMY", 16, 23], ["The data from 2 samples", "TEST", 0, 23], ["further analysis", "TEST", 42, 58]]], ["Ingenuity Pathway Analysis (IPA; http://www.ingenuity.com) was used to identify signaling pathways and networks involving genes of interest.Statistical analysisData describing C. jejuni counts and in vitro assays were analyzed using one-way ANOVA followed by Tukey's Multiple Comparison adjustment.", [["C. jejuni", "ORGANISM", 176, 185], ["C. jejuni", "SPECIES", 176, 185], ["C. jejuni", "SPECIES", 176, 185], ["Ingenuity Pathway Analysis", "TEST", 0, 26], ["Statistical analysisData", "TEST", 140, 164], ["C. jejuni counts", "TEST", 176, 192], ["vitro assays", "TEST", 200, 212], ["jejuni counts", "OBSERVATION", 179, 192]]], ["A value of P < 0.05 was considered statistically significant for all experiments.", [["A value", "TEST", 0, 7]]], ["Measurements were expressed as mean \u00b1 SE (standard error) and represent averages of three replicates.", [["Measurements", "TEST", 0, 12]]], ["For microarray data analysis, linear regression models were used for comparisons among different treatment groups.Statistical analysisDue to the small sample size per treatment group, the P-values were not adjusted for multiple gene testing within each treatment group comparisons.", [["microarray data analysis", "TEST", 4, 28], ["linear regression models", "TEST", 30, 54], ["different treatment groups", "TREATMENT", 87, 113], ["the P-values", "TEST", 184, 196], ["multiple gene testing", "TEST", 219, 240], ["small", "OBSERVATION_MODIFIER", 145, 150], ["size", "OBSERVATION_MODIFIER", 158, 162]]], ["However, the overall type I error at 0.05 for the multiple group comparisons (4 treatment groups and 6 comparisons) was strongly controlled.", [["4 treatment groups", "TREATMENT", 78, 96]]], ["Therefore, based on the Bonferroni correction for multiple comparisons test [21] , a P-value =0.05/6 = 0.008 was used as cutoff to determine if a gene was differentially expressed within a comparison group.", [["multiple comparisons test", "TEST", 50, 75], ["a P-value", "TEST", 83, 92]]], ["Subsequently, the tests were ordered by fold change and P-values.", [["the tests", "TEST", 14, 23], ["P-values", "TEST", 56, 64]]], ["As a 2-fold difference is a widely accepted cutoff for biological differences, genes with at least a 2-fold change and a P-value < 0.008 were considered differentially expressed.Clinical observations of pregnant ewes after infectionThe ovine and bovine abortion-associated C. jejuni strains induced abortion or stillbirth.", [["infection", "DISEASE", 223, 232], ["abortion", "DISEASE", 299, 307], ["stillbirth", "DISEASE", 311, 321], ["ewes", "ORGANISM", 212, 216], ["ovine", "ORGANISM", 236, 241], ["bovine", "ORGANISM", 246, 252], ["C. jejuni", "ORGANISM", 273, 282], ["bovine", "SPECIES", 246, 252], ["C. jejuni", "SPECIES", 273, 282], ["C. jejuni", "SPECIES", 273, 282], ["a 2-fold difference", "PROBLEM", 3, 22], ["a 2-fold change", "PROBLEM", 99, 114], ["a P-value", "TEST", 119, 128], ["infection", "PROBLEM", 223, 232], ["The ovine and bovine abortion", "TREATMENT", 232, 261], ["C. jejuni strains", "PROBLEM", 273, 290], ["stillbirth", "PROBLEM", 311, 321], ["bovine abortion", "OBSERVATION", 246, 261], ["jejuni strains", "OBSERVATION", 276, 290]]], ["One of the ewes orally inoculated with the ovine isolate (G3-O-2) aborted at PID 15 ( Figure 1A) .", [["ewes", "ORGANISM", 11, 15], ["ovine", "ORGANISM", 43, 48], ["G3-O-2", "CELL", 58, 64], ["the ovine isolate", "TREATMENT", 39, 56]]], ["A month later, another ewe (G3-O-1) from the same group delivered a dead fetus.", [["fetus", "ANATOMY", 73, 78], ["fetus", "ORGAN", 73, 78], ["a dead fetus", "PROBLEM", 66, 78]]], ["Furthermore, one ewe (G3-V-1) i/v inoculated with the ovine isolate died 20 h after inoculation (Table 1) .", [["ovine", "ORGANISM", 54, 59], ["ovine", "SPECIES", 54, 59], ["the ovine isolate", "TREATMENT", 50, 67]]], ["Rectal temperatures of inoculated ewes were elevated (105-105.5\u00b0F) 3 to 4 days post i/v inoculation and at PIDs 10-12 in orally inoculated ewes.", [["Rectal", "ANATOMY", 0, 6], ["PIDs 10-12", "CHEMICAL", 107, 117], ["Rectal", "ORGAN", 0, 6], ["ewes", "ORGANISM", 34, 38], ["Rectal temperatures", "TEST", 0, 19], ["elevated", "PROBLEM", 44, 52], ["i/v inoculation", "PROBLEM", 84, 99], ["PIDs", "TEST", 107, 111]]], ["Stillbirths were observed in 2 cases in G2 (G2-V-1 and G2-V-2), which were inoculated i/v with the bovine isolate (Table 1) , whereas the two ewes orally inoculated in G2 group delivered normally.", [["Stillbirths", "DISEASE", 0, 11], ["G2-V-2", "CELL", 55, 61], ["bovine", "ORGANISM", 99, 105], ["ewes", "ORGANISM", 142, 146], ["bovine", "SPECIES", 99, 105], ["Stillbirths", "PROBLEM", 0, 11], ["the bovine isolate", "TEST", 95, 113]]], ["No clinical signs were observed in the G1 ewes orally or i/v inoculated with 81-176 strain, and they delivered normally.", [["clinical signs", "PROBLEM", 3, 17], ["i/v", "TEST", 57, 60]]], ["Feces changed from pasty to diarrheic in most of the inoculated ewes, which was profoundly seen in the G2 and G3 groups.", [["Feces", "ANATOMY", 0, 5], ["diarrheic", "DISEASE", 28, 37], ["Feces", "PROBLEM", 0, 5], ["diarrheic", "PROBLEM", 28, 37], ["diarrheic", "OBSERVATION", 28, 37]]], ["No abortions or clinical signs were observed in control non-inoculated ewes (Table 1) .Pathological studiesMajor macroscopic lesions of abortion-associated C. jejuni-inoculated ewes included placentitis and endometritis, regardless of the ovine or bovine strains used.", [["lesions", "ANATOMY", 125, 132], ["abortions", "DISEASE", 3, 12], ["abortion", "DISEASE", 136, 144], ["placentitis", "DISEASE", 191, 202], ["endometritis", "DISEASE", 207, 219], ["lesions", "PATHOLOGICAL_FORMATION", 125, 132], ["ovine", "ORGANISM", 239, 244], ["bovine", "ORGANISM", 248, 254], ["bovine", "SPECIES", 248, 254], ["ovine", "SPECIES", 239, 244], ["bovine", "SPECIES", 248, 254], ["abortions", "PROBLEM", 3, 12], ["clinical signs", "TEST", 16, 30], ["Pathological studies", "TEST", 87, 107], ["Major macroscopic lesions of abortion", "PROBLEM", 107, 144], ["C. jejuni-inoculated ewes", "PROBLEM", 156, 181], ["placentitis", "PROBLEM", 191, 202], ["endometritis", "PROBLEM", 207, 219], ["the ovine", "PROBLEM", 235, 244], ["bovine strains", "TREATMENT", 248, 262], ["abortions", "OBSERVATION", 3, 12], ["macroscopic", "OBSERVATION_MODIFIER", 113, 124], ["lesions", "OBSERVATION", 125, 132], ["abortion", "OBSERVATION", 136, 144], ["jejuni-inoculated ewes", "OBSERVATION", 159, 181], ["endometritis", "OBSERVATION", 207, 219]]], ["The affected placentomes and uterus appeared edematous, hemorrhagic, and fibrinopurulent ( Figure 1B) .", [["placentomes", "ANATOMY", 13, 24], ["uterus", "ANATOMY", 29, 35], ["edematous", "ANATOMY", 45, 54], ["hemorrhagic", "DISEASE", 56, 67], ["placentomes", "CANCER", 13, 24], ["uterus", "ORGAN", 29, 35], ["The affected placentomes and uterus", "PROBLEM", 0, 35], ["edematous", "PROBLEM", 45, 54], ["hemorrhagic", "PROBLEM", 56, 67], ["fibrinopurulent ( Figure 1B)", "PROBLEM", 73, 101], ["affected", "OBSERVATION_MODIFIER", 4, 12], ["placentomes", "OBSERVATION", 13, 24], ["uterus", "ANATOMY", 29, 35], ["edematous", "OBSERVATION", 45, 54], ["hemorrhagic", "OBSERVATION_MODIFIER", 56, 67]]], ["Enlarged placentomes were more prominent in the G3 ewes orally or i/v infected with the ovine abortion-II isolate.", [["placentomes", "CANCER", 9, 20], ["ovine", "ORGANISM", 88, 93], ["Enlarged placentomes", "PROBLEM", 0, 20], ["the ovine abortion", "TREATMENT", 84, 102], ["placentomes", "OBSERVATION", 9, 20], ["more prominent", "OBSERVATION_MODIFIER", 26, 40], ["infected", "OBSERVATION", 70, 78]]], ["Liver and spleen also exhibited petechial hemorrhages on their surface in ewes that were i/v inoculated with the bovine abortion strain (G2-V-1) as well as in ewes orally or i/v inoculated with the ovine abortion strain (G3-V-1; G3-O-1; G3-O-2).", [["Liver", "ANATOMY", 0, 5], ["spleen", "ANATOMY", 10, 16], ["petechial", "ANATOMY", 32, 41], ["surface", "ANATOMY", 63, 70], ["hemorrhages", "DISEASE", 42, 53], ["Liver", "ORGAN", 0, 5], ["spleen", "ORGAN", 10, 16], ["petechial hemorrhages", "PATHOLOGICAL_FORMATION", 32, 53], ["bovine", "ORGANISM", 113, 119], ["G2-V-1", "CELL", 137, 143], ["ewes", "ORGANISM", 159, 163], ["ovine", "ORGANISM", 198, 203], ["G3-O-2", "CELL", 237, 243], ["bovine", "SPECIES", 113, 119], ["petechial hemorrhages", "PROBLEM", 32, 53], ["the bovine abortion strain", "PROBLEM", 109, 135], ["i/v", "PROBLEM", 174, 177], ["the ovine abortion strain", "PROBLEM", 194, 219], ["G3", "TEST", 229, 231], ["spleen", "ANATOMY", 10, 16], ["petechial", "OBSERVATION_MODIFIER", 32, 41], ["hemorrhages", "OBSERVATION", 42, 53], ["bovine abortion", "OBSERVATION", 113, 128]]], ["Additionally, hydrothorax and subcutaneous hemorrhage as potential signs of acute septicemia were detected in the dead ewe at 20-24 h after i/v inoculation ( Figure 1C and D); however, pneumonia was not accompanied with the former lesion.", [["subcutaneous", "ANATOMY", 30, 42], ["lesion", "ANATOMY", 231, 237], ["hydrothorax", "DISEASE", 14, 25], ["hemorrhage", "DISEASE", 43, 53], ["septicemia", "DISEASE", 82, 92], ["pneumonia", "DISEASE", 185, 194], ["hydrothorax", "PATHOLOGICAL_FORMATION", 14, 25], ["ewe", "ORGAN", 119, 122], ["hydrothorax", "PROBLEM", 14, 25], ["subcutaneous hemorrhage", "PROBLEM", 30, 53], ["acute septicemia", "PROBLEM", 76, 92], ["i/v inoculation", "PROBLEM", 140, 155], ["pneumonia", "PROBLEM", 185, 194], ["the former lesion", "PROBLEM", 220, 237], ["hydrothorax", "OBSERVATION", 14, 25], ["subcutaneous", "ANATOMY", 30, 42], ["hemorrhage", "OBSERVATION", 43, 53], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["septicemia", "OBSERVATION", 82, 92], ["pneumonia", "OBSERVATION", 185, 194], ["former", "OBSERVATION_MODIFIER", 224, 230], ["lesion", "OBSERVATION", 231, 237]]], ["No gross lesions were noted in G1 or the control ewes.Pathological studiesIn line with macroscopic observations, histological lesions mainly consisted of suppurative placentitis or endometritis or both.", [["gross lesions", "ANATOMY", 3, 16], ["lesions", "ANATOMY", 126, 133], ["placentitis", "DISEASE", 166, 177], ["endometritis", "DISEASE", 181, 193], ["gross lesions", "PATHOLOGICAL_FORMATION", 3, 16], ["lesions", "PATHOLOGICAL_FORMATION", 126, 133], ["gross lesions", "PROBLEM", 3, 16], ["Pathological studies", "TEST", 54, 74], ["macroscopic observations", "TEST", 87, 111], ["histological lesions", "PROBLEM", 113, 133], ["suppurative placentitis", "PROBLEM", 154, 177], ["endometritis", "PROBLEM", 181, 193], ["gross", "OBSERVATION_MODIFIER", 3, 8], ["lesions", "OBSERVATION", 9, 16], ["lesions", "OBSERVATION", 126, 133], ["suppurative", "OBSERVATION_MODIFIER", 154, 165], ["placentitis", "OBSERVATION", 166, 177], ["endometritis", "OBSERVATION", 181, 193], ["both", "OBSERVATION_MODIFIER", 197, 201]]], ["Placentitis was commonly observed widespread throughout placenta, comprising placentomes and chorioallantoic membranes.", [["placenta", "ANATOMY", 56, 64], ["placentomes", "ANATOMY", 77, 88], ["chorioallantoic membranes", "ANATOMY", 93, 118], ["Placentitis", "DISEASE", 0, 11], ["placenta", "ORGAN", 56, 64], ["chorioallantoic membranes", "MULTI-TISSUE_STRUCTURE", 93, 118], ["chorioallantoic membranes", "TREATMENT", 93, 118], ["placenta", "ANATOMY", 56, 64], ["chorioallantoic membranes", "OBSERVATION", 93, 118]]], ["In the placentomes of inoculated ewes (G2 and G3), trophoblasts lining the placental villi were necrotic with extensive neutrophilic infiltration (Figure 2A and B) .", [["placentomes", "ANATOMY", 7, 18], ["ewes", "ANATOMY", 33, 37], ["trophoblasts", "ANATOMY", 51, 63], ["placental villi", "ANATOMY", 75, 90], ["neutrophilic", "ANATOMY", 120, 132], ["necrotic", "DISEASE", 96, 104], ["trophoblasts", "CELL", 51, 63], ["placental villi", "MULTI-TISSUE_STRUCTURE", 75, 90], ["trophoblasts", "CELL_TYPE", 51, 63], ["trophoblasts lining the placental villi", "PROBLEM", 51, 90], ["necrotic", "PROBLEM", 96, 104], ["extensive neutrophilic infiltration", "PROBLEM", 110, 145], ["placental villi", "ANATOMY", 75, 90], ["necrotic", "OBSERVATION_MODIFIER", 96, 104], ["extensive", "OBSERVATION_MODIFIER", 110, 119], ["neutrophilic infiltration", "OBSERVATION", 120, 145]]], ["Occasionally, small bacterial colonies were found within the necrotic lesions ( Figure 2C ).", [["colonies", "ANATOMY", 30, 38], ["necrotic lesions", "ANATOMY", 61, 77], ["necrotic", "DISEASE", 61, 69], ["necrotic lesions", "PATHOLOGICAL_FORMATION", 61, 77], ["small bacterial colonies", "PROBLEM", 14, 38], ["the necrotic lesions", "PROBLEM", 57, 77], ["small", "OBSERVATION_MODIFIER", 14, 19], ["bacterial colonies", "OBSERVATION", 20, 38], ["necrotic", "OBSERVATION_MODIFIER", 61, 69], ["lesions", "OBSERVATION", 70, 77]]], ["Concomitantly, chorioallantoic membranes exhibited moderate to severe necrosis and suppurative inflammation of the epithelium ( Figure 2D ).", [["chorioallantoic membranes", "ANATOMY", 15, 40], ["epithelium", "ANATOMY", 115, 125], ["necrosis", "DISEASE", 70, 78], ["inflammation", "DISEASE", 95, 107], ["chorioallantoic membranes", "MULTI-TISSUE_STRUCTURE", 15, 40], ["epithelium", "TISSUE", 115, 125], ["chorioallantoic membranes", "PROBLEM", 15, 40], ["moderate to severe necrosis", "PROBLEM", 51, 78], ["suppurative inflammation of the epithelium", "PROBLEM", 83, 125], ["chorioallantoic membranes", "ANATOMY", 15, 40], ["moderate", "OBSERVATION_MODIFIER", 51, 59], ["severe", "OBSERVATION_MODIFIER", 63, 69], ["necrosis", "OBSERVATION", 70, 78], ["suppurative", "OBSERVATION_MODIFIER", 83, 94], ["inflammation", "OBSERVATION", 95, 107], ["epithelium", "ANATOMY_MODIFIER", 115, 125]]], ["In IHC analysis, large amounts of C. jejuni antigens were evident in trophoblastic epithelial cells lining the chorioallantoic membrane ( Figure 2E and F); however, it was notable that under the IHC conditions, including the use of a single detection antibody, bacterial antigens were rarely detected in the placentomes and in the stroma of chorioallantoic membranes regardless of the ovine or bovine strains used and the severity of the lesions observed.", [["trophoblastic epithelial cells", "ANATOMY", 69, 99], ["chorioallantoic membrane", "ANATOMY", 111, 135], ["placentomes", "ANATOMY", 308, 319], ["stroma", "ANATOMY", 331, 337], ["chorioallantoic membranes", "ANATOMY", 341, 366], ["lesions", "ANATOMY", 438, 445], ["C. jejuni", "ORGANISM", 34, 43], ["trophoblastic epithelial cells", "CELL", 69, 99], ["chorioallantoic membrane", "MULTI-TISSUE_STRUCTURE", 111, 135], ["placentomes", "CANCER", 308, 319], ["stroma", "TISSUE", 331, 337], ["chorioallantoic membranes", "MULTI-TISSUE_STRUCTURE", 341, 366], ["ovine", "ORGANISM", 385, 390], ["bovine", "ORGANISM", 394, 400], ["lesions", "PATHOLOGICAL_FORMATION", 438, 445], ["C. jejuni antigens", "PROTEIN", 34, 52], ["trophoblastic epithelial cells", "CELL_TYPE", 69, 99], ["bacterial antigens", "PROTEIN", 261, 279], ["C. jejuni", "SPECIES", 34, 43], ["bovine", "SPECIES", 394, 400], ["C. jejuni", "SPECIES", 34, 43], ["bovine", "SPECIES", 394, 400], ["IHC analysis", "TEST", 3, 15], ["C. jejuni antigens", "PROBLEM", 34, 52], ["trophoblastic epithelial cells", "PROBLEM", 69, 99], ["a single detection antibody", "TEST", 232, 259], ["bacterial antigens", "PROBLEM", 261, 279], ["chorioallantoic membranes", "TREATMENT", 341, 366], ["the ovine or bovine strains", "PROBLEM", 381, 408], ["the lesions", "PROBLEM", 434, 445], ["large", "OBSERVATION_MODIFIER", 17, 22], ["amounts", "OBSERVATION_MODIFIER", 23, 30], ["C. jejuni antigens", "OBSERVATION", 34, 52], ["trophoblastic epithelial cells", "OBSERVATION", 69, 99], ["chorioallantoic membrane", "ANATOMY", 111, 135], ["stroma", "ANATOMY_MODIFIER", 331, 337], ["chorioallantoic membranes", "OBSERVATION", 341, 366], ["lesions", "OBSERVATION", 438, 445]]], ["These data indicated a possible tissue tropism of the abortion-associated C. jejuni in the chorioallantoic placenta of sheep.Pathological studiesModerate to severe endometritis observed in abortion associated C. jejuni-inoculated ewes was characterized by suppurative inflammation in the endometrium and in the lumen of uterus ( Figure 3A) , and occasional severe necrosis of endometrium accompanied by severe suppurative inflammation ( Figure 3B ).", [["tissue", "ANATOMY", 32, 38], ["chorioallantoic placenta", "ANATOMY", 91, 115], ["endometrium", "ANATOMY", 288, 299], ["lumen", "ANATOMY", 311, 316], ["uterus", "ANATOMY", 320, 326], ["endometrium", "ANATOMY", 376, 387], ["suppurative", "ANATOMY", 410, 421], ["endometritis", "DISEASE", 164, 176], ["abortion", "DISEASE", 189, 197], ["inflammation", "DISEASE", 268, 280], ["necrosis", "DISEASE", 364, 372], ["suppurative inflammation", "DISEASE", 410, 434], ["tissue", "TISSUE", 32, 38], ["C. jejuni", "ORGANISM", 74, 83], ["chorioallantoic placenta", "MULTI-TISSUE_STRUCTURE", 91, 115], ["sheep", "ORGANISM", 119, 124], ["endometrium", "MULTI-TISSUE_STRUCTURE", 288, 299], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 311, 316], ["uterus", "ORGAN", 320, 326], ["endometrium", "MULTI-TISSUE_STRUCTURE", 376, 387], ["C. jejuni", "SPECIES", 74, 83], ["sheep", "SPECIES", 119, 124], ["C. jejuni", "SPECIES", 74, 83], ["sheep", "SPECIES", 119, 124], ["tissue tropism", "PROBLEM", 32, 46], ["the abortion", "PROBLEM", 50, 62], ["C. jejuni", "PROBLEM", 74, 83], ["Pathological studies", "TEST", 125, 145], ["Moderate to severe endometritis", "PROBLEM", 145, 176], ["C. jejuni-inoculated ewes", "PROBLEM", 209, 234], ["suppurative inflammation in the endometrium", "PROBLEM", 256, 299], ["occasional severe necrosis of endometrium", "PROBLEM", 346, 387], ["severe suppurative inflammation", "PROBLEM", 403, 434], ["jejuni", "OBSERVATION", 77, 83], ["chorioallantoic placenta", "ANATOMY", 91, 115], ["Moderate", "OBSERVATION_MODIFIER", 145, 153], ["severe", "OBSERVATION_MODIFIER", 157, 163], ["endometritis", "OBSERVATION", 164, 176], ["jejuni-inoculated ewes", "OBSERVATION", 212, 234], ["suppurative", "OBSERVATION_MODIFIER", 256, 267], ["inflammation", "OBSERVATION", 268, 280], ["endometrium", "ANATOMY", 288, 299], ["lumen", "ANATOMY_MODIFIER", 311, 316], ["uterus", "ANATOMY", 320, 326], ["occasional", "OBSERVATION_MODIFIER", 346, 356], ["severe", "OBSERVATION_MODIFIER", 357, 363], ["necrosis", "OBSERVATION", 364, 372], ["endometrium", "ANATOMY", 376, 387], ["severe", "OBSERVATION_MODIFIER", 403, 409], ["suppurative", "OBSERVATION_MODIFIER", 410, 421], ["inflammation", "OBSERVATION", 422, 434]]], ["In G2 ewes infected i/v with the bovine abortion isolate, endometrial glands were filled with large numbers of neutrophils ( Figure 3C ).", [["endometrial glands", "ANATOMY", 58, 76], ["neutrophils", "ANATOMY", 111, 122], ["bovine", "ORGANISM", 33, 39], ["endometrial glands", "ORGAN", 58, 76], ["neutrophils", "CELL", 111, 122], ["neutrophils", "CELL_TYPE", 111, 122], ["bovine", "SPECIES", 33, 39], ["bovine", "SPECIES", 33, 39], ["the bovine abortion isolate", "TREATMENT", 29, 56], ["neutrophils", "TEST", 111, 122], ["endometrial glands", "ANATOMY", 58, 76], ["large", "OBSERVATION_MODIFIER", 94, 99], ["numbers", "OBSERVATION_MODIFIER", 100, 107]]], ["In addition, 2 ewes from G2 which were orally inoculated with the bovine isolate showed mild diffuse suppurative lymphadenitis ( Figure 3D ).", [["lymphadenitis", "DISEASE", 113, 126], ["bovine", "ORGANISM", 66, 72], ["bovine", "SPECIES", 66, 72], ["bovine", "SPECIES", 66, 72], ["the bovine isolate", "TEST", 62, 80], ["mild diffuse suppurative lymphadenitis", "PROBLEM", 88, 126], ["mild", "OBSERVATION_MODIFIER", 88, 92], ["diffuse", "OBSERVATION_MODIFIER", 93, 100], ["suppurative", "OBSERVATION_MODIFIER", 101, 112], ["lymphadenitis", "OBSERVATION", 113, 126]]], ["Three ewes from G2 and G3 i/v inoculated with bovine or ovine strains, respectively, exhibited periportal suppurative hepatitis ( Figure 3E ).", [["strains", "ANATOMY", 62, 69], ["periportal suppurative", "ANATOMY", 95, 117], ["periportal suppurative hepatitis", "DISEASE", 95, 127], ["bovine", "ORGANISM", 46, 52], ["ovine", "ORGANISM", 56, 61], ["bovine", "SPECIES", 46, 52], ["bovine", "SPECIES", 46, 52], ["ovine", "SPECIES", 56, 61], ["G3 i/v", "TEST", 23, 29], ["bovine or ovine strains", "PROBLEM", 46, 69], ["periportal suppurative hepatitis", "PROBLEM", 95, 127], ["periportal", "ANATOMY", 95, 105], ["suppurative", "OBSERVATION_MODIFIER", 106, 117], ["hepatitis", "OBSERVATION", 118, 127]]], ["In G1 and the control group, no histological lesions were detected in cotyledons, endometrium, liver, spleen, and other major organs.", [["lesions", "ANATOMY", 45, 52], ["cotyledons", "ANATOMY", 70, 80], ["endometrium", "ANATOMY", 82, 93], ["liver", "ANATOMY", 95, 100], ["spleen", "ANATOMY", 102, 108], ["organs", "ANATOMY", 126, 132], ["lesions", "PATHOLOGICAL_FORMATION", 45, 52], ["cotyledons", "TISSUE", 70, 80], ["endometrium", "MULTI-TISSUE_STRUCTURE", 82, 93], ["liver", "ORGAN", 95, 100], ["spleen", "ORGAN", 102, 108], ["organs", "ORGAN", 126, 132], ["histological lesions", "PROBLEM", 32, 52], ["no", "UNCERTAINTY", 29, 31], ["histological", "OBSERVATION_MODIFIER", 32, 44], ["lesions", "OBSERVATION", 45, 52], ["endometrium", "ANATOMY", 82, 93], ["liver", "ANATOMY", 95, 100], ["spleen", "ANATOMY", 102, 108]]], ["Histological examination of intestinal tissues was not performed as these tissues underwent spontaneous autolysis.Pathological studiesUsing the in situ TUNEL assay, relative to the negative control or 81-176 inoculated ewes, the placentomes of the ewes infected with bovine or ovine abortion C. jejuni strains showed in situ TUNEL-positive cells (red staining) (Figure 4 ).", [["intestinal tissues", "ANATOMY", 28, 46], ["tissues", "ANATOMY", 74, 81], ["placentomes", "ANATOMY", 229, 240], ["cells", "ANATOMY", 340, 345], ["intestinal tissues", "TISSUE", 28, 46], ["tissues", "TISSUE", 74, 81], ["ewes", "ORGANISM", 219, 223], ["placentomes", "CANCER", 229, 240], ["ewes", "ORGANISM", 248, 252], ["bovine", "ORGANISM", 267, 273], ["ovine abortion", "ORGANISM", 277, 291], ["C. jejuni", "ORGANISM", 292, 301], ["cells", "CELL", 340, 345], ["TUNEL-positive cells", "CELL_LINE", 325, 345], ["bovine", "SPECIES", 267, 273], ["C. jejuni", "SPECIES", 292, 301], ["bovine", "SPECIES", 267, 273], ["ovine", "SPECIES", 277, 282], ["C. jejuni", "SPECIES", 292, 301], ["Histological examination", "TEST", 0, 24], ["spontaneous autolysis", "PROBLEM", 92, 113], ["Pathological studies", "TEST", 114, 134], ["the in situ TUNEL assay", "TEST", 140, 163], ["bovine or ovine abortion", "TREATMENT", 267, 291], ["jejuni strains", "TEST", 295, 309], ["positive cells", "PROBLEM", 331, 345], ["red staining", "TEST", 347, 359], ["intestinal tissues", "ANATOMY", 28, 46], ["situ TUNEL", "OBSERVATION", 320, 330], ["positive cells", "OBSERVATION", 331, 345]]], ["Most of TUNEL-positive cells appeared to be trophoblasts exfoliated from placental villi.", [["TUNEL-positive cells", "ANATOMY", 8, 28], ["trophoblasts", "ANATOMY", 44, 56], ["placental villi", "ANATOMY", 73, 88], ["trophoblasts", "CELL", 44, 56], ["placental villi", "MULTI-TISSUE_STRUCTURE", 73, 88], ["TUNEL-positive cells", "CELL_LINE", 8, 28], ["trophoblasts", "CELL_TYPE", 44, 56], ["TUNEL-positive cells", "PROBLEM", 8, 28], ["trophoblasts", "PROBLEM", 44, 56], ["positive cells", "OBSERVATION", 14, 28], ["trophoblasts", "OBSERVATION", 44, 56], ["placental villi", "ANATOMY", 73, 88]]], ["The in situ TUNEL-positive signals were also detected in trophoblasts lining the chorioallantoic membrane of the infected ewes (data not shown).Bacteriological studiesC. jejuni was retrieved from feces of all the inoculated ewes at the time of necropsy except from two ewes ( Table 1) .", [["trophoblasts", "ANATOMY", 57, 69], ["chorioallantoic membrane", "ANATOMY", 81, 105], ["feces", "ANATOMY", 196, 201], ["trophoblasts", "CELL", 57, 69], ["chorioallantoic membrane", "MULTI-TISSUE_STRUCTURE", 81, 105], ["jejuni", "ORGANISM", 170, 176], ["feces", "ORGANISM_SUBSTANCE", 196, 201], ["trophoblasts", "CELL_TYPE", 57, 69], ["jejuni", "SPECIES", 170, 176], ["jejuni", "SPECIES", 170, 176], ["Bacteriological studiesC", "TEST", 144, 168], ["jejuni", "PROBLEM", 170, 176], ["necropsy", "TEST", 244, 252], ["situ", "OBSERVATION_MODIFIER", 7, 11], ["TUNEL", "OBSERVATION", 12, 17], ["positive signals", "OBSERVATION", 18, 34], ["chorioallantoic membrane", "OBSERVATION", 81, 105], ["infected", "OBSERVATION", 113, 121]]], ["C. jejuni was occasionally retrieved from several tissues of euthanized ewes including liver, spleen, uterus, placenta, blood, and small intestine in both G2 and G3 groups.", [["tissues", "ANATOMY", 50, 57], ["ewes", "ANATOMY", 72, 76], ["liver", "ANATOMY", 87, 92], ["spleen", "ANATOMY", 94, 100], ["uterus", "ANATOMY", 102, 108], ["placenta", "ANATOMY", 110, 118], ["blood", "ANATOMY", 120, 125], ["small intestine", "ANATOMY", 131, 146], ["C. jejuni", "ORGANISM", 0, 9], ["tissues", "TISSUE", 50, 57], ["ewes", "ORGANISM_SUBDIVISION", 72, 76], ["liver", "ORGAN", 87, 92], ["spleen", "ORGAN", 94, 100], ["uterus", "ORGAN", 102, 108], ["placenta", "MULTI-TISSUE_STRUCTURE", 110, 118], ["blood", "ORGANISM_SUBSTANCE", 120, 125], ["small intestine", "ORGAN", 131, 146], ["C. jejuni", "SPECIES", 0, 9], ["C. jejuni", "SPECIES", 0, 9], ["C. jejuni", "PROBLEM", 0, 9], ["placenta, blood, and small intestine", "PROBLEM", 110, 146], ["jejuni", "OBSERVATION", 3, 9], ["euthanized ewes", "OBSERVATION", 61, 76], ["liver", "ANATOMY", 87, 92], ["spleen", "ANATOMY", 94, 100], ["uterus", "ANATOMY", 102, 108], ["placenta", "ANATOMY", 110, 118], ["blood", "ANATOMY", 120, 125], ["small intestine", "ANATOMY", 131, 146], ["both", "ANATOMY_MODIFIER", 150, 154], ["G2", "ANATOMY", 155, 157], ["G3 groups", "ANATOMY_MODIFIER", 162, 171]]], ["However, C. jejuni was isolated by direct plating from placenta and uterus from the abortion and LiverBacteriological studiesS.", [["placenta", "ANATOMY", 55, 63], ["uterus", "ANATOMY", 68, 74], ["C. jejuni", "ORGANISM", 9, 18], ["placenta", "ORGAN", 55, 63], ["uterus", "ORGAN", 68, 74], ["C. jejuni", "SPECIES", 9, 18], ["C. jejuni", "SPECIES", 9, 18], ["C. jejuni", "PROBLEM", 9, 18], ["direct plating from placenta and uterus", "TREATMENT", 35, 74], ["the abortion", "TREATMENT", 80, 92], ["LiverBacteriological studiesS", "TEST", 97, 126], ["jejuni", "OBSERVATION", 12, 18], ["placenta", "ANATOMY", 55, 63], ["uterus", "ANATOMY", 68, 74]]], ["Intestine --+ + + + + + + + + + + + + + + + + + -(highly congested) -Bacteriological studiesmild growth: less than 100 CFU), ++ = (moderate growth: less than 300 CFU), +++ = (heavy growth: too many to count), -= (No Growth), N/A, Not applicable; a Ewe (G3-V-2) no C. jejuni was isolated from any tissues; however, at postmortem this ewe was found to be heavily infested with tapeworm.Bacteriological studiesstillbirth cases from both the G2 and G3 with counts ranging from 4 \u00d7 10 5 to 2 \u00d7 10 8 CFU ml -1 .", [["Intestine --+ + + + + + + + + + + + + + + +", "ANATOMY", 0, 43], ["tissues", "ANATOMY", 296, 303], ["--+ + + + + + + + + + + + + + + + + +", "CHEMICAL", 10, 47], ["Intestine", "ORGAN", 0, 9], ["C. jejuni", "ORGANISM", 264, 273], ["tissues", "TISSUE", 296, 303], ["ewe", "ORGAN", 333, 336], ["C. jejuni", "SPECIES", 264, 273], ["C. jejuni", "SPECIES", 264, 273], ["Intestine", "TEST", 0, 9], ["highly congested)", "PROBLEM", 50, 67], ["Bacteriological studiesmild growth", "TEST", 69, 103], ["C. jejuni", "PROBLEM", 264, 273], ["Bacteriological studiesstillbirth cases", "TEST", 384, 423], ["counts", "TEST", 453, 459], ["+ + + + + + + + +", "ANATOMY_MODIFIER", 16, 33], ["moderate", "OBSERVATION_MODIFIER", 131, 139], ["jejuni", "OBSERVATION", 267, 273], ["heavily", "OBSERVATION_MODIFIER", 353, 360], ["infested", "OBSERVATION", 361, 369], ["tapeworm", "OBSERVATION", 375, 383]]], ["C. jejuni was also retrieved in large numbers from lungs of one of the aborted ewes (G3-O-2) ( Table 1) .", [["lungs", "ANATOMY", 51, 56], ["C. jejuni", "ORGANISM", 0, 9], ["lungs", "ORGAN", 51, 56], ["G3-O-2", "CELL", 85, 91], ["C. jejuni", "SPECIES", 0, 9], ["C. jejuni", "SPECIES", 0, 9], ["C. jejuni", "PROBLEM", 0, 9], ["jejuni", "OBSERVATION", 3, 9], ["large", "OBSERVATION_MODIFIER", 32, 37], ["numbers", "OBSERVATION_MODIFIER", 38, 45], ["lungs", "ANATOMY", 51, 56]]], ["C. jejuni was also retrieved from small intestines of the four ewes in G1.", [["intestines", "ANATOMY", 40, 50], ["C. jejuni", "ORGANISM", 0, 9], ["small intestines", "ORGAN", 34, 50], ["C. jejuni", "SPECIES", 0, 9], ["C. jejuni", "SPECIES", 0, 9], ["C. jejuni", "PROBLEM", 0, 9], ["jejuni", "OBSERVATION", 3, 9], ["small", "OBSERVATION_MODIFIER", 34, 39], ["intestines", "ANATOMY", 40, 50]]], ["Furthermore, C. jejuni was occasionally retrieved from lambs' feces and fetuses' meconium as well as small intestine and blood (Table 1) .Host gene expressionSummary of transcriptome responses following C. jejuni administration is listed in Additional file 1: Table S1 .", [["feces", "ANATOMY", 62, 67], ["fetuses", "ANATOMY", 72, 79], ["meconium", "ANATOMY", 81, 89], ["small intestine", "ANATOMY", 101, 116], ["blood", "ANATOMY", 121, 126], ["C. jejuni", "ORGANISM", 13, 22], ["lambs", "ORGANISM", 55, 60], ["feces", "ORGANISM_SUBSTANCE", 62, 67], ["meconium", "ORGANISM_SUBSTANCE", 81, 89], ["intestine", "ORGAN", 107, 116], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["C. jejuni", "ORGANISM", 203, 212], ["C. jejuni", "SPECIES", 13, 22], ["lambs", "SPECIES", 55, 60], ["C. jejuni", "SPECIES", 203, 212], ["C. jejuni", "SPECIES", 13, 22], ["C. jejuni", "SPECIES", 203, 212], ["C. jejuni", "PROBLEM", 13, 22], ["fetuses' meconium", "PROBLEM", 72, 89], ["C. jejuni administration", "TREATMENT", 203, 227], ["jejuni", "OBSERVATION", 16, 22], ["meconium", "OBSERVATION", 81, 89], ["small", "OBSERVATION_MODIFIER", 101, 106], ["intestine", "ANATOMY", 107, 116], ["blood", "ANATOMY", 121, 126]]], ["The microarray generated transcripts were further mapped to available gene annotation in IPA.", [["gene annotation", "TEST", 70, 85]]], ["The number of IPA mapped genes was further compared across different treatment groups.", [["IPA mapped genes", "DNA", 14, 30], ["IPA mapped genes", "PROBLEM", 14, 30], ["different treatment groups", "TREATMENT", 59, 85]]], ["Despite the poor annotation of the Ovis aries genome, BLAST searches against IPA knowledge database using human, rat, and mouse reference species allowed identification of a total of 51 mapped probes displaying expression changes greater or lesser than 2 folds between non-inoculated controls and 81-176, bovine, or ovine C. jejuni clone SA infected ewes from the complete set of differentially expressed genes ( Table 2) .", [["human", "ORGANISM", 106, 111], ["rat", "ORGANISM", 113, 116], ["mouse", "ORGANISM", 122, 127], ["bovine", "ORGANISM", 305, 311], ["ovine", "ORGANISM", 316, 321], ["C. jejuni clone SA", "ORGANISM", 322, 340], ["Ovis aries genome", "DNA", 35, 52], ["differentially expressed genes", "DNA", 380, 410], ["human", "SPECIES", 106, 111], ["rat", "SPECIES", 113, 116], ["mouse", "SPECIES", 122, 127], ["bovine", "SPECIES", 305, 311], ["C. jejuni", "SPECIES", 322, 331], ["Ovis aries", "SPECIES", 35, 45], ["human", "SPECIES", 106, 111], ["rat", "SPECIES", 113, 116], ["mouse", "SPECIES", 122, 127], ["bovine", "SPECIES", 305, 311], ["C. jejuni", "SPECIES", 322, 331], ["expression changes", "PROBLEM", 211, 229], ["lesser", "OBSERVATION_MODIFIER", 241, 247]]], ["IPA was used for gene ontology (GO) analysis.", [["IPA", "CHEMICAL", 0, 3], ["IPA", "TREATMENT", 0, 3]]], ["Datasets from a total of 6 groups were analyzed for GO; (control) cont-vs-G1 (81-176 strain), cont-vs-G2 (bovine strain), and cont-vs-G3 (ovine strain), G1-vs-G2, G1 vs G3 and G2 vs G3.", [["strain", "ANATOMY", 113, 119], ["strain", "ANATOMY", 144, 150], ["bovine", "ORGANISM", 106, 112], ["cont-vs-G3", "ORGANISM", 126, 136], ["ovine", "ORGANISM", 138, 143], ["bovine", "SPECIES", 106, 112], ["a total of 6 groups", "TREATMENT", 14, 33], ["G2 (bovine strain", "PROBLEM", 102, 119], ["-vs", "TEST", 130, 133]]], ["Of the 51 genes analyzed, 14 (~27%) of upand/or -down regulated genes were common among different datasets (Table 2) only, and 14 (~27%) were down-regulated across all groups compared.", [["upand/or -down regulated genes", "DNA", 39, 69], ["upand", "TEST", 39, 44]]], ["The genes encoding extracellular marker proteins and other proteins involved in immune responses, cellular apoptosis and necrosis, embryonic development, cellular growth, proliferation and differentiation, and organismal injury and abnormalities were also differentially expressed among the different comparisons (Table 2) .", [["extracellular", "ANATOMY", 19, 32], ["cellular", "ANATOMY", 98, 106], ["embryonic", "ANATOMY", 131, 140], ["cellular", "ANATOMY", 154, 162], ["necrosis", "DISEASE", 121, 129], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 19, 32], ["cellular", "CELL", 98, 106], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 131, 140], ["cellular", "CELL", 154, 162], ["extracellular marker proteins", "PROTEIN", 19, 48], ["The genes encoding extracellular marker proteins", "PROBLEM", 0, 48], ["cellular apoptosis", "PROBLEM", 98, 116], ["necrosis", "PROBLEM", 121, 129], ["embryonic development", "PROBLEM", 131, 152], ["cellular growth", "PROBLEM", 154, 169], ["proliferation", "PROBLEM", 171, 184], ["organismal injury", "PROBLEM", 210, 227], ["abnormalities", "PROBLEM", 232, 245], ["cellular apoptosis", "OBSERVATION", 98, 116], ["necrosis", "OBSERVATION", 121, 129], ["embryonic", "OBSERVATION_MODIFIER", 131, 140], ["cellular", "OBSERVATION_MODIFIER", 154, 162], ["growth", "OBSERVATION_MODIFIER", 163, 169], ["proliferation", "OBSERVATION_MODIFIER", 171, 184], ["differentiation", "OBSERVATION_MODIFIER", 189, 204], ["organismal", "OBSERVATION_MODIFIER", 210, 220], ["injury", "OBSERVATION", 221, 227]]], ["Of particular interest, several genes evidently showed down shift expression in animals from G2 and G3 compared to either G1 (infected with 81-176 C. jejuni) or the control non-inoculated group ( Table 2) .", [["C. jejuni", "ORGANISM", 147, 156], ["C. jejuni", "SPECIES", 147, 156], ["C. jejuni", "SPECIES", 147, 156]]], ["For example, the gene encoding GATA binding protein 6 (GATA6) was down-regulated by approximately 2 folds in G2 and G3 as compared to the control non-inoculated group.", [["GATA binding protein 6", "GENE_OR_GENE_PRODUCT", 31, 53], ["GATA6", "GENE_OR_GENE_PRODUCT", 55, 60], ["GATA binding protein 6", "PROTEIN", 31, 53], ["GATA6", "PROTEIN", 55, 60], ["the gene encoding GATA binding protein", "TREATMENT", 13, 51]]], ["Similarly, gene encoding insulin-like 3 (Leydig cell; INSL3) was downregulated by approximately 2 and 3 folds in G2 and G3, respectively, compared to the negative control group.", [["Leydig cell", "ANATOMY", 41, 52], ["insulin-like 3", "GENE_OR_GENE_PRODUCT", 25, 39], ["Leydig cell", "GENE_OR_GENE_PRODUCT", 41, 52], ["INSL3", "GENE_OR_GENE_PRODUCT", 54, 59], ["insulin-like 3", "PROTEIN", 25, 39], ["INSL3", "PROTEIN", 54, 59], ["gene encoding insulin", "TREATMENT", 11, 32]]], ["The gene encoding chordin (CHRD) was down-regulated by approximately 2 and 2.4 folds in G2 and G3, respectively.", [["chordin", "GENE_OR_GENE_PRODUCT", 18, 25], ["CHRD", "GENE_OR_GENE_PRODUCT", 27, 31], ["chordin", "PROTEIN", 18, 25], ["CHRD", "PROTEIN", 27, 31], ["The gene encoding chordin (CHRD)", "TREATMENT", 0, 32]]], ["For example, the gene encoding matrix metallopeptidase 2 (MMP2) was up-regulated by around 2.1 and 2.4 folds in G2 and G3, respectively.", [["matrix metallopeptidase 2", "GENE_OR_GENE_PRODUCT", 31, 56], ["MMP2", "GENE_OR_GENE_PRODUCT", 58, 62], ["matrix metallopeptidase 2", "PROTEIN", 31, 56], ["MMP2", "PROTEIN", 58, 62], ["the gene encoding matrix metallopeptidase", "TREATMENT", 13, 54], ["MMP2", "TEST", 58, 62]]], ["The gene encoding tumor necrosis factor receptor-associated factor 3 (TRAF3) was up-regulated by around 2 folds in both G2 and G3 as compared to G1.", [["tumor", "DISEASE", 18, 23], ["tumor necrosis factor receptor-associated factor 3", "GENE_OR_GENE_PRODUCT", 18, 68], ["TRAF3", "GENE_OR_GENE_PRODUCT", 70, 75], ["tumor necrosis factor receptor-associated factor 3", "PROTEIN", 18, 68], ["TRAF3", "PROTEIN", 70, 75], ["The gene encoding tumor necrosis", "PROBLEM", 0, 32], ["associated factor", "PROBLEM", 49, 66], ["tumor", "OBSERVATION_MODIFIER", 18, 23], ["necrosis", "OBSERVATION_MODIFIER", 24, 32], ["both", "ANATOMY_MODIFIER", 115, 119], ["G2", "ANATOMY", 120, 122]]], ["The gene encoding gamma-glutamyl carboxylase (GGCX) was up-regulated by 2.4 and 3.5 in G2 and G3, respectively ( Table 2) .Host gene expressionOf particular interest, expression patterns of several genes were found only in G3 group ewes.", [["gamma-glutamyl", "CHEMICAL", 18, 32], ["gamma-glutamyl carboxylase", "GENE_OR_GENE_PRODUCT", 18, 44], ["GGCX", "GENE_OR_GENE_PRODUCT", 46, 50], ["gamma-glutamyl carboxylase", "PROTEIN", 18, 44], ["GGCX", "PROTEIN", 46, 50], ["The gene encoding gamma-glutamyl carboxylase", "TEST", 0, 44]]], ["Interleukin 6 (IL-6) was up-regulated approximately 2.0 fold in the G3 compared to G1, G2, and control non-inoculated group ewes.", [["Interleukin 6", "GENE_OR_GENE_PRODUCT", 0, 13], ["IL-6", "GENE_OR_GENE_PRODUCT", 15, 19], ["Interleukin 6", "PROTEIN", 0, 13], ["IL-6", "PROTEIN", 15, 19], ["Interleukin 6 (IL", "TREATMENT", 0, 17]]], ["IL-15 was up-regulated in G3 by 3.6 and 2 folds compared to G1 and G2, respectively.", [["IL-15", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-15", "PROTEIN", 0, 5], ["IL", "TEST", 0, 2]]], ["The gene encoding early growth response protein (EGR1) was up-regulated by around 2 folds in G3 as compared to G1 and G2.", [["early growth response protein", "GENE_OR_GENE_PRODUCT", 18, 47], ["EGR1", "GENE_OR_GENE_PRODUCT", 49, 53], ["early growth response protein", "PROTEIN", 18, 47], ["EGR1", "PROTEIN", 49, 53]]], ["Whereas, the gene encoding prostaglandin E receptor 4 (PTGER4) was down-regulated by around 2 folds in G3, as compared to G1, G2, and control group ewes (Table 2 ).", [["prostaglandin E", "CHEMICAL", 27, 42], ["prostaglandin E", "CHEMICAL", 27, 42], ["prostaglandin E receptor 4", "GENE_OR_GENE_PRODUCT", 27, 53], ["PTGER4", "GENE_OR_GENE_PRODUCT", 55, 61], ["prostaglandin E receptor 4", "PROTEIN", 27, 53], ["PTGER4", "PROTEIN", 55, 61], ["the gene encoding prostaglandin E receptor", "TREATMENT", 9, 51]]], ["In general, the data generated from the microarray analysis, mainly the differential expression of certain genes, gave further insights and supported the clinical and histopathological observations.DiscussionPathogenesis of C. jejuni clone SA induced abortion is not well understood.", [["abortion", "DISEASE", 251, 259], ["C. jejuni clone", "ORGANISM", 224, 239], ["C. jejuni", "SPECIES", 224, 233], ["C. jejuni", "SPECIES", 224, 233], ["the microarray analysis", "TEST", 36, 59], ["jejuni clone", "OBSERVATION", 227, 239]]], ["Recently, it was shown that the C. jejuni clone SA can effectively induce abortion in pregnant guinea pigs [9] .", [["SA", "CHEMICAL", 48, 50], ["C. jejuni", "ORGANISM", 32, 41], ["clone SA", "ORGANISM", 42, 50], ["guinea pigs", "ORGANISM", 95, 106], ["C. jejuni", "SPECIES", 32, 41], ["guinea pigs", "SPECIES", 95, 106], ["C. jejuni", "SPECIES", 32, 41], ["the C. jejuni clone SA", "TREATMENT", 28, 50]]], ["However, no studies have characterized the virulence of these strains in a natural host (sheep).", [["sheep", "ORGANISM", 89, 94], ["sheep", "SPECIES", 89, 94], ["sheep", "SPECIES", 89, 94], ["studies", "TEST", 12, 19], ["these strains", "PROBLEM", 56, 69]]], ["In this study, under experimental conditions, abortion-associated C. jejuni belonging to clone SA seemed to effectively induce abortion or stillbirth in pregnant sheep when high doses of inoculum (10 9 CFU in 1.5 ml of SS for i/v) were used.", [["SA", "CHEMICAL", 95, 97], ["abortion", "DISEASE", 127, 135], ["stillbirth", "DISEASE", 139, 149], ["C. jejuni", "ORGANISM", 66, 75], ["clone", "ORGANISM", 89, 94], ["SA", "GENE_OR_GENE_PRODUCT", 95, 97], ["sheep", "ORGANISM", 162, 167], ["C. jejuni", "SPECIES", 66, 75], ["sheep", "SPECIES", 162, 167], ["C. jejuni", "SPECIES", 66, 75], ["sheep", "SPECIES", 162, 167], ["this study", "TEST", 3, 13], ["abortion", "PROBLEM", 46, 54], ["C. jejuni", "PROBLEM", 66, 75], ["high doses of inoculum", "TREATMENT", 173, 195], ["SS for i/v)", "TREATMENT", 219, 230]]], ["This corroborated a previous study [8] and was further confirmed in our preliminary trials where no abortion was observed in pregnant ewes infected with lower doses of C. jejuni (10 6 CFU in 1.5 ml of SS for i/v), although several significant clinical signs such as uterine prolapse and retained placenta were noted (data not shown).", [["uterine", "ANATOMY", 266, 273], ["placenta", "ANATOMY", 296, 304], ["uterine prolapse", "DISEASE", 266, 282], ["ewes", "ORGANISM", 134, 138], ["C. jejuni", "ORGANISM", 168, 177], ["uterine", "ORGAN", 266, 273], ["placenta", "ORGAN", 296, 304], ["C. jejuni", "SPECIES", 168, 177], ["C. jejuni", "SPECIES", 168, 177], ["a previous study", "TEST", 18, 34], ["abortion", "PROBLEM", 100, 108], ["C. jejuni", "TREATMENT", 168, 177], ["i/v", "TREATMENT", 208, 211], ["several significant clinical signs", "PROBLEM", 223, 257], ["uterine prolapse", "PROBLEM", 266, 282], ["retained placenta", "PROBLEM", 287, 304], ["significant", "OBSERVATION_MODIFIER", 231, 242], ["uterine", "ANATOMY", 266, 273], ["prolapse", "OBSERVATION", 274, 282], ["retained placenta", "OBSERVATION", 287, 304]]], ["Additionally, based on our preliminary trials, the differences in the pregnancy stages of ewes might result in disparity in the induction of abortion.", [["ewes", "ORGANISM", 90, 94], ["the pregnancy stages of ewes", "PROBLEM", 66, 94], ["abortion", "PROBLEM", 141, 149]]], ["However, when using the higher dose of C. jejuni and ewes with synchronized pregnancies, typical abortion occurred in one (G3-O-2) of the ewes that were orally inoculated with the ovine isolate from G3 at PID 15 ( Figure 1A ).", [["abortion", "DISEASE", 97, 105], ["C. jejuni", "ORGANISM", 39, 48], ["ewes", "ORGANISM", 138, 142], ["ovine", "ORGANISM", 180, 185], ["C. jejuni", "SPECIES", 39, 48], ["C. jejuni", "SPECIES", 39, 48], ["C. jejuni", "TREATMENT", 39, 48], ["synchronized pregnancies", "PROBLEM", 63, 87], ["typical abortion", "PROBLEM", 89, 105], ["the ovine isolate", "PROBLEM", 176, 193]]], ["Stillbirths were also observed in 2 cases (G2-V-1 and G2-V-2) from G2 and one case (G3-O-1) from G3, which were inoculated i/v and orally with bovine and ovine isolates, respectively (Table 1) .", [["Stillbirths", "DISEASE", 0, 11], ["G2-V-2", "CELL", 54, 60], ["bovine", "ORGANISM", 143, 149], ["ovine", "ORGANISM", 154, 159], ["bovine", "SPECIES", 143, 149], ["bovine", "SPECIES", 143, 149], ["ovine", "SPECIES", 154, 159], ["bovine and ovine isolates", "TREATMENT", 143, 168]]], ["Furthermore, one ewe (G3-V-1) infected i/v, died 20 h postinoculation and in the other ewe (G3-V-2) no C. jejuni was isolated from any tissues.", [["tissues", "ANATOMY", 135, 142], ["G3-V-2", "CELL", 92, 98], ["C. jejuni", "ORGANISM", 103, 112], ["tissues", "TISSUE", 135, 142], ["C. jejuni", "SPECIES", 103, 112], ["C. jejuni", "SPECIES", 103, 112], ["infected i/v", "PROBLEM", 30, 42], ["C. jejuni", "PROBLEM", 103, 112], ["jejuni", "OBSERVATION", 106, 112]]], ["However, at postmortem G3-V-2 was found to be heavily infested with tapeworm, which might have affected C. jejuni colonization.", [["C. jejuni", "DISEASE", 104, 113], ["C. jejuni", "ORGANISM", 104, 113], ["C. jejuni", "SPECIES", 104, 113], ["C. jejuni", "SPECIES", 104, 113], ["heavily infested", "PROBLEM", 46, 62], ["tapeworm", "PROBLEM", 68, 76], ["C. jejuni colonization", "PROBLEM", 104, 126], ["heavily", "OBSERVATION_MODIFIER", 46, 53], ["infested", "OBSERVATION", 54, 62], ["tapeworm", "OBSERVATION", 68, 76], ["jejuni colonization", "OBSERVATION", 107, 126]]], ["The cause of sudden death might be due to acute septicemia and uterine sepsis or due to the septic shock which can be caused by the systemic inflammatory response to the bacteremia of Gram negative bacteria [4, 15] .", [["uterine", "ANATOMY", 63, 70], ["death", "DISEASE", 20, 25], ["septicemia", "DISEASE", 48, 58], ["uterine sepsis", "DISEASE", 63, 77], ["septic shock", "DISEASE", 92, 104], ["bacteremia", "DISEASE", 170, 180], ["uterine", "ORGAN", 63, 70], ["sudden death", "PROBLEM", 13, 25], ["acute septicemia", "PROBLEM", 42, 58], ["uterine sepsis", "PROBLEM", 63, 77], ["the septic shock", "PROBLEM", 88, 104], ["the systemic inflammatory response", "PROBLEM", 128, 162], ["the bacteremia", "PROBLEM", 166, 180], ["Gram negative bacteria", "PROBLEM", 184, 206], ["might be due to", "UNCERTAINTY", 26, 41], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["septicemia", "OBSERVATION", 48, 58], ["uterine", "ANATOMY", 63, 70], ["sepsis", "OBSERVATION", 71, 77], ["septic shock", "OBSERVATION", 92, 104], ["systemic", "OBSERVATION_MODIFIER", 132, 140], ["inflammatory", "OBSERVATION", 141, 153], ["bacteremia", "OBSERVATION", 170, 180]]], ["Macroscopic observations in aborted ewes or fetuses in this study were mostly in agreement with previous findings [5, 8] .", [["fetuses", "ANATOMY", 44, 51], ["ewes", "MULTI-TISSUE_STRUCTURE", 36, 40], ["fetuses", "ORGAN", 44, 51], ["Macroscopic observations", "TEST", 0, 24], ["fetuses", "PROBLEM", 44, 51], ["this study", "TEST", 55, 65]]], ["Gross lesions that mostly consisted of hemorrhagic fibrinosuppurative placentitis and endometritis were evident in the majority of ewes infected with the abortion-associated C. jejuni ( Figure 1B ).", [["Gross lesions", "ANATOMY", 0, 13], ["hemorrhagic", "DISEASE", 39, 50], ["placentitis", "DISEASE", 70, 81], ["endometritis", "DISEASE", 86, 98], ["abortion", "DISEASE", 154, 162], ["C. jejuni", "DISEASE", 174, 183], ["Gross lesions", "PATHOLOGICAL_FORMATION", 0, 13], ["ewes", "ORGANISM", 131, 135], ["C. jejuni", "ORGANISM", 174, 183], ["C. jejuni", "SPECIES", 174, 183], ["C. jejuni", "SPECIES", 174, 183], ["Gross lesions", "PROBLEM", 0, 13], ["hemorrhagic fibrinosuppurative placentitis", "PROBLEM", 39, 81], ["endometritis", "PROBLEM", 86, 98], ["the abortion", "PROBLEM", 150, 162], ["C. jejuni", "PROBLEM", 174, 183], ["lesions", "OBSERVATION", 6, 13], ["hemorrhagic", "OBSERVATION_MODIFIER", 39, 50], ["fibrinosuppurative placentitis", "OBSERVATION", 51, 81], ["endometritis", "OBSERVATION", 86, 98], ["jejuni", "ANATOMY", 177, 183]]], ["In addition, petechial hemorrhages were seen on the liver and spleen of i/v inoculated ewes from both groups (G2 and G3).", [["petechial", "ANATOMY", 13, 22], ["liver", "ANATOMY", 52, 57], ["spleen", "ANATOMY", 62, 68], ["hemorrhages", "DISEASE", 23, 34], ["petechial", "PATHOLOGICAL_FORMATION", 13, 22], ["liver", "ORGAN", 52, 57], ["spleen", "ORGAN", 62, 68], ["petechial hemorrhages", "PROBLEM", 13, 34], ["petechial", "OBSERVATION_MODIFIER", 13, 22], ["hemorrhages", "OBSERVATION", 23, 34], ["liver", "ANATOMY", 52, 57], ["spleen", "ANATOMY", 62, 68]]], ["In the guinea pig model, rather than hemorrhagic lesions, multiple round and white foci of variable sizes were identified on liver in 90% of pregnant guinea pigs infected with ovine abortion inducing C. jejuni strain [9] .DiscussionPregnant ewes i/v or orally infected with the abortionassociated C. jejuni exhibited histopathological changes in the placental and uterine tissues.", [["hemorrhagic lesions", "ANATOMY", 37, 56], ["white foci", "ANATOMY", 77, 87], ["liver", "ANATOMY", 125, 130], ["placental", "ANATOMY", 350, 359], ["uterine tissues", "ANATOMY", 364, 379], ["hemorrhagic", "DISEASE", 37, 48], ["ovine abortion", "DISEASE", 176, 190], ["guinea pig", "ORGANISM", 7, 17], ["hemorrhagic lesions", "PATHOLOGICAL_FORMATION", 37, 56], ["liver", "ORGAN", 125, 130], ["guinea", "ORGANISM", 150, 156], ["pigs", "ORGANISM", 157, 161], ["ovine", "ORGANISM", 176, 181], ["C. jejuni", "ORGANISM", 200, 209], ["C. jejuni", "ORGANISM", 297, 306], ["placental", "TISSUE", 350, 359], ["uterine tissues", "TISSUE", 364, 379], ["guinea pig", "SPECIES", 7, 17], ["guinea pigs", "SPECIES", 150, 161], ["C. jejuni", "SPECIES", 200, 209], ["C. jejuni", "SPECIES", 297, 306], ["guinea pig", "SPECIES", 7, 17], ["guinea pigs", "SPECIES", 150, 161], ["ovine", "SPECIES", 176, 181], ["C. jejuni", "SPECIES", 200, 209], ["C. jejuni", "SPECIES", 297, 306], ["hemorrhagic lesions", "PROBLEM", 37, 56], ["multiple round and white foci of variable sizes", "PROBLEM", 58, 105], ["pregnant guinea pigs", "TREATMENT", 141, 161], ["ovine abortion", "TREATMENT", 176, 190], ["C. jejuni strain", "PROBLEM", 200, 216], ["orally infected", "PROBLEM", 253, 268], ["the abortionassociated C. jejuni", "PROBLEM", 274, 306], ["histopathological changes in the placental and uterine tissues", "PROBLEM", 317, 379], ["hemorrhagic", "OBSERVATION_MODIFIER", 37, 48], ["lesions", "OBSERVATION", 49, 56], ["multiple", "OBSERVATION_MODIFIER", 58, 66], ["round", "OBSERVATION_MODIFIER", 67, 72], ["white", "OBSERVATION_MODIFIER", 77, 82], ["foci", "OBSERVATION", 83, 87], ["variable", "OBSERVATION_MODIFIER", 91, 99], ["sizes", "OBSERVATION_MODIFIER", 100, 105], ["liver", "ANATOMY", 125, 130], ["jejuni strain", "OBSERVATION", 203, 216], ["histopathological", "OBSERVATION", 317, 334], ["placental", "ANATOMY", 350, 359], ["uterine tissues", "ANATOMY", 364, 379]]], ["Based on this observation, it is presumed that these strains might employ bacteremia to establish their infection in the reproductive organs.", [["organs", "ANATOMY", 134, 140], ["bacteremia", "DISEASE", 74, 84], ["infection", "DISEASE", 104, 113], ["reproductive", "ORGAN", 121, 133], ["organs", "ORGAN", 134, 140], ["this observation", "TEST", 9, 25], ["these strains", "PROBLEM", 47, 60], ["bacteremia", "PROBLEM", 74, 84], ["their infection in the reproductive organs", "PROBLEM", 98, 140], ["bacteremia", "OBSERVATION", 74, 84], ["infection", "OBSERVATION", 104, 113]]], ["Using IHC, bacterial antigens were mainly detected in trophoblasts lining the chorioallontoic membrane, usually undergoing necrosis ( Figure 2E and F).", [["trophoblasts", "ANATOMY", 54, 66], ["chorioallontoic membrane", "ANATOMY", 78, 102], ["necrosis", "DISEASE", 123, 131], ["bacterial antigens", "GENE_OR_GENE_PRODUCT", 11, 29], ["trophoblasts", "CELL", 54, 66], ["chorioallontoic membrane", "CELLULAR_COMPONENT", 78, 102], ["bacterial antigens", "PROTEIN", 11, 29], ["trophoblasts", "CELL_TYPE", 54, 66], ["IHC, bacterial antigens", "TEST", 6, 29], ["necrosis", "PROBLEM", 123, 131], ["bacterial antigens", "OBSERVATION", 11, 29], ["chorioallontoic membrane", "ANATOMY", 78, 102], ["necrosis", "OBSERVATION", 123, 131]]], ["Placentomes also exhibited severe suppurative inflammatory and necrotic lesions possibly caused by C. jejuni, which was frequently observed within the lesions ( Figure 2C and D).", [["necrotic lesions", "ANATOMY", 63, 79], ["lesions", "ANATOMY", 151, 158], ["necrotic lesions", "PATHOLOGICAL_FORMATION", 63, 79], ["C. jejuni", "ORGANISM", 99, 108], ["lesions", "PATHOLOGICAL_FORMATION", 151, 158], ["C. jejuni", "SPECIES", 99, 108], ["C. jejuni", "SPECIES", 99, 108], ["severe suppurative inflammatory and necrotic lesions", "PROBLEM", 27, 79], ["C. jejuni", "PROBLEM", 99, 108], ["the lesions", "PROBLEM", 147, 158], ["severe", "OBSERVATION_MODIFIER", 27, 33], ["suppurative", "OBSERVATION_MODIFIER", 34, 45], ["inflammatory", "OBSERVATION_MODIFIER", 46, 58], ["necrotic", "OBSERVATION_MODIFIER", 63, 71], ["lesions", "OBSERVATION", 72, 79], ["C. jejuni", "OBSERVATION", 99, 108], ["lesions", "OBSERVATION", 151, 158]]], ["Similar necrotic lesions with numerous large C. jejuni aggregates (colonies) in the placental villi and adjacent stroma were previously identified in inoculated ewes [8] .", [["necrotic lesions", "ANATOMY", 8, 24], ["colonies", "ANATOMY", 67, 75], ["placental villi", "ANATOMY", 84, 99], ["stroma", "ANATOMY", 113, 119], ["necrotic", "DISEASE", 8, 16], ["necrotic lesions", "PATHOLOGICAL_FORMATION", 8, 24], ["C. jejuni", "ORGANISM", 45, 54], ["placental villi", "MULTI-TISSUE_STRUCTURE", 84, 99], ["stroma", "TISSUE", 113, 119], ["C. jejuni", "SPECIES", 45, 54], ["C. jejuni", "SPECIES", 45, 54], ["Similar necrotic lesions", "PROBLEM", 0, 24], ["numerous large C. jejuni aggregates (colonies) in the placental villi and adjacent stroma", "PROBLEM", 30, 119], ["necrotic", "OBSERVATION_MODIFIER", 8, 16], ["lesions", "OBSERVATION", 17, 24], ["numerous", "OBSERVATION_MODIFIER", 30, 38], ["large", "OBSERVATION_MODIFIER", 39, 44], ["C.", "OBSERVATION_MODIFIER", 45, 47], ["jejuni aggregates", "OBSERVATION", 48, 65], ["colonies", "OBSERVATION_MODIFIER", 67, 75], ["placental villi", "ANATOMY", 84, 99]]], ["These data indicate a possible cellular tropism of abortion-associated C. jejuni in the placental epithelial cells possibly transported via the bloodstream.", [["cellular", "ANATOMY", 31, 39], ["placental epithelial cells", "ANATOMY", 88, 114], ["bloodstream", "ANATOMY", 144, 155], ["abortion", "DISEASE", 51, 59], ["cellular", "CELL", 31, 39], ["C. jejuni", "ORGANISM", 71, 80], ["placental epithelial cells", "CELL", 88, 114], ["placental epithelial cells", "CELL_TYPE", 88, 114], ["C. jejuni", "SPECIES", 71, 80], ["C. jejuni", "SPECIES", 71, 80], ["cellular tropism of abortion", "PROBLEM", 31, 59], ["C. jejuni", "PROBLEM", 71, 80], ["the placental epithelial cells", "PROBLEM", 84, 114], ["possible", "UNCERTAINTY", 22, 30], ["cellular tropism", "OBSERVATION", 31, 47], ["abortion", "OBSERVATION", 51, 59], ["jejuni", "OBSERVATION", 74, 80], ["placental", "ANATOMY", 88, 97], ["epithelial cells", "OBSERVATION", 98, 114], ["bloodstream", "OBSERVATION", 144, 155]]], ["Consistent with suppurative inflammatory lesions in other major organs, such as uterus, liver, spleen, and lymph node, the bacteriological examination revealed C. jejuni in multiple tissues, including liver, spleen, uterus, placenta, blood, small intestine of infected ewes, as well as from offspring's feces, fetuses' meconium, small intestine and blood as shown in Table 1 .", [["suppurative inflammatory lesions", "ANATOMY", 16, 48], ["organs", "ANATOMY", 64, 70], ["uterus", "ANATOMY", 80, 86], ["liver", "ANATOMY", 88, 93], ["spleen", "ANATOMY", 95, 101], ["lymph node", "ANATOMY", 107, 117], ["tissues", "ANATOMY", 182, 189], ["liver", "ANATOMY", 201, 206], ["spleen", "ANATOMY", 208, 214], ["uterus", "ANATOMY", 216, 222], ["placenta", "ANATOMY", 224, 232], ["blood", "ANATOMY", 234, 239], ["small intestine", "ANATOMY", 241, 256], ["ewes", "ANATOMY", 269, 273], ["feces", "ANATOMY", 303, 308], ["fetuses", "ANATOMY", 310, 317], ["meconium", "ANATOMY", 319, 327], ["small intestine", "ANATOMY", 329, 344], ["blood", "ANATOMY", 349, 354], ["C. jejuni", "DISEASE", 160, 169], ["suppurative inflammatory lesions", "PATHOLOGICAL_FORMATION", 16, 48], ["organs", "ORGAN", 64, 70], ["uterus", "ORGAN", 80, 86], ["liver", "ORGAN", 88, 93], ["spleen", "ORGAN", 95, 101], ["lymph node", "MULTI-TISSUE_STRUCTURE", 107, 117], ["C. jejuni", "ORGANISM", 160, 169], ["tissues", "TISSUE", 182, 189], ["liver", "ORGAN", 201, 206], ["spleen", "ORGAN", 208, 214], ["uterus", "ORGAN", 216, 222], ["placenta", "MULTI-TISSUE_STRUCTURE", 224, 232], ["blood", "ORGANISM_SUBSTANCE", 234, 239], ["small intestine", "ORGAN", 241, 256], ["ewes", "ORGANISM_SUBDIVISION", 269, 273], ["feces", "ORGANISM_SUBDIVISION", 303, 308], ["fetuses", "ORGANISM_SUBDIVISION", 310, 317], ["meconium", "ORGANISM_SUBDIVISION", 319, 327], ["small intestine", "ORGAN", 329, 344], ["blood", "ORGANISM_SUBSTANCE", 349, 354], ["C. jejuni", "SPECIES", 160, 169], ["C. jejuni", "SPECIES", 160, 169], ["suppurative inflammatory lesions in other major organs, such as uterus, liver, spleen, and lymph node", "PROBLEM", 16, 117], ["the bacteriological examination", "TEST", 119, 150], ["C. jejuni in multiple tissues", "PROBLEM", 160, 189], ["small intestine of infected ewes", "PROBLEM", 241, 273], ["fetuses' meconium", "PROBLEM", 310, 327], ["small intestine and blood", "PROBLEM", 329, 354], ["suppurative", "OBSERVATION_MODIFIER", 16, 27], ["inflammatory", "OBSERVATION_MODIFIER", 28, 40], ["lesions", "OBSERVATION", 41, 48], ["uterus", "ANATOMY", 80, 86], ["liver", "ANATOMY", 88, 93], ["spleen", "ANATOMY", 95, 101], ["lymph node", "OBSERVATION", 107, 117], ["C. jejuni", "OBSERVATION", 160, 169], ["multiple tissues", "OBSERVATION", 173, 189], ["liver", "ANATOMY", 201, 206], ["spleen", "ANATOMY", 208, 214], ["uterus", "ANATOMY", 216, 222], ["placenta", "ANATOMY", 224, 232], ["blood", "ANATOMY", 234, 239], ["small", "OBSERVATION_MODIFIER", 241, 246], ["intestine", "ANATOMY", 247, 256], ["infected ewes", "OBSERVATION", 260, 273], ["feces", "OBSERVATION", 303, 308], ["meconium", "OBSERVATION", 319, 327], ["small intestine", "ANATOMY", 329, 344]]], ["Based on the data, the abortionassociated C. jejuni might be able to induce systemic infection, usually accompanied by intestinal and reproductive infection.", [["intestinal", "ANATOMY", 119, 129], ["systemic infection", "DISEASE", 76, 94], ["intestinal and reproductive infection", "DISEASE", 119, 156], ["C. jejuni", "ORGANISM", 42, 51], ["intestinal", "ORGAN", 119, 129], ["C. jejuni", "SPECIES", 42, 51], ["C. jejuni", "SPECIES", 42, 51], ["the data", "TEST", 9, 17], ["the abortionassociated C. jejuni", "PROBLEM", 19, 51], ["systemic infection", "PROBLEM", 76, 94], ["intestinal and reproductive infection", "PROBLEM", 119, 156], ["jejuni", "OBSERVATION", 45, 51], ["systemic", "OBSERVATION_MODIFIER", 76, 84], ["infection", "OBSERVATION", 85, 94], ["intestinal", "ANATOMY", 119, 129], ["reproductive", "OBSERVATION_MODIFIER", 134, 146], ["infection", "OBSERVATION", 147, 156]]], ["In the pregnant guinea pig model, large numbers of C. jejuni were mainly retrieved from placental and uterine tissues, while small to moderate numbers of bacteria were recovered from feces and blood as well as from fetal liver and lung samples [9] .", [["placental", "ANATOMY", 88, 97], ["uterine tissues", "ANATOMY", 102, 117], ["feces", "ANATOMY", 183, 188], ["blood", "ANATOMY", 193, 198], ["fetal liver", "ANATOMY", 215, 226], ["lung samples", "ANATOMY", 231, 243], ["guinea pig", "ORGANISM", 16, 26], ["C. jejuni", "ORGANISM", 51, 60], ["placental", "TISSUE", 88, 97], ["uterine tissues", "TISSUE", 102, 117], ["feces", "ORGANISM_SUBSTANCE", 183, 188], ["blood", "ORGANISM_SUBSTANCE", 193, 198], ["fetal liver", "MULTI-TISSUE_STRUCTURE", 215, 226], ["lung", "ORGAN", 231, 235], ["guinea pig", "SPECIES", 16, 26], ["C. jejuni", "SPECIES", 51, 60], ["pig", "SPECIES", 23, 26], ["C. jejuni", "SPECIES", 51, 60], ["the pregnant guinea pig model", "TREATMENT", 3, 32], ["C. jejuni", "PROBLEM", 51, 60], ["small to moderate numbers of bacteria", "PROBLEM", 125, 162], ["blood", "TEST", 193, 198], ["fetal liver and lung samples", "TEST", 215, 243], ["large", "OBSERVATION_MODIFIER", 34, 39], ["numbers", "OBSERVATION_MODIFIER", 40, 47], ["C. jejuni", "OBSERVATION", 51, 60], ["uterine tissues", "ANATOMY", 102, 117], ["small", "OBSERVATION_MODIFIER", 125, 130], ["moderate", "OBSERVATION_MODIFIER", 134, 142], ["numbers", "OBSERVATION_MODIFIER", 143, 150], ["bacteria", "OBSERVATION", 154, 162], ["liver", "ANATOMY", 221, 226], ["lung", "ANATOMY", 231, 235]]], ["Similarly, high counts of C. jejuni were detected in uterine and placental tissues and from stomach content, bile, and feces of ewes infected with ovine abortion C. jejuni as well as from aborted fetuses [8] .DiscussionTo acquire more insights into the pathogenic mechanisms of abortion-associated C. jejuni, host gene expression profiles in uterine tissues from aborted ewes were determined using microarray analysis.", [["uterine", "ANATOMY", 53, 60], ["placental tissues", "ANATOMY", 65, 82], ["stomach", "ANATOMY", 92, 99], ["bile", "ANATOMY", 109, 113], ["feces", "ANATOMY", 119, 124], ["fetuses", "ANATOMY", 196, 203], ["uterine tissues", "ANATOMY", 342, 357], ["abortion", "DISEASE", 278, 286], ["C. jejuni", "DISEASE", 298, 307], ["C. jejuni", "ORGANISM", 26, 35], ["uterine", "TISSUE", 53, 60], ["placental tissues", "TISSUE", 65, 82], ["stomach", "ORGAN", 92, 99], ["bile", "MULTI-TISSUE_STRUCTURE", 109, 113], ["feces", "ORGANISM_SUBDIVISION", 119, 124], ["ovine", "ORGANISM", 147, 152], ["C. jejuni", "ORGANISM", 162, 171], ["C. jejuni", "ORGANISM", 298, 307], ["uterine tissues", "TISSUE", 342, 357], ["ewes", "MULTI-TISSUE_STRUCTURE", 371, 375], ["C. jejuni", "SPECIES", 26, 35], ["C. jejuni", "SPECIES", 162, 171], ["C. jejuni", "SPECIES", 298, 307], ["C. jejuni", "SPECIES", 26, 35], ["ovine", "SPECIES", 147, 152], ["C. jejuni", "SPECIES", 162, 171], ["C. jejuni", "SPECIES", 298, 307], ["C. jejuni", "PROBLEM", 26, 35], ["ovine abortion C. jejuni", "PROBLEM", 147, 171], ["abortion", "PROBLEM", 278, 286], ["C. jejuni", "PROBLEM", 298, 307], ["host gene expression profiles in uterine tissues", "PROBLEM", 309, 357], ["microarray analysis", "TEST", 398, 417], ["high counts", "OBSERVATION_MODIFIER", 11, 22], ["jejuni", "OBSERVATION", 29, 35], ["uterine", "ANATOMY", 53, 60], ["placental tissues", "ANATOMY", 65, 82], ["stomach", "ANATOMY", 92, 99], ["bile", "ANATOMY", 109, 113], ["jejuni", "ANATOMY", 301, 307], ["uterine tissues", "ANATOMY", 342, 357]]], ["The genes encoding GATA binding protein 6 (GATA6) and chordin (CHRD) that account for embryonic development [22, 23] and dorsalization of early vertebrate embryonic tissues [24] , respectively, were down-regulated in G2 and G3 vs. the control non-inoculated group or the G1 infected with 81-176 (Table 2 ).", [["embryonic", "ANATOMY", 86, 95], ["embryonic tissues", "ANATOMY", 155, 172], ["GATA binding protein 6", "GENE_OR_GENE_PRODUCT", 19, 41], ["GATA6", "GENE_OR_GENE_PRODUCT", 43, 48], ["chordin", "GENE_OR_GENE_PRODUCT", 54, 61], ["CHRD", "GENE_OR_GENE_PRODUCT", 63, 67], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 86, 95], ["embryonic tissues", "TISSUE", 155, 172], ["GATA binding protein 6", "PROTEIN", 19, 41], ["GATA6", "PROTEIN", 43, 48], ["chordin", "PROTEIN", 54, 61], ["CHRD", "PROTEIN", 63, 67], ["The genes encoding GATA binding protein", "TREATMENT", 0, 39], ["chordin (CHRD)", "TREATMENT", 54, 68], ["embryonic development", "PROBLEM", 86, 107], ["early vertebrate embryonic tissues", "PROBLEM", 138, 172], ["early", "OBSERVATION_MODIFIER", 138, 143], ["vertebrate embryonic tissues", "OBSERVATION", 144, 172]]], ["In addition, insulin-like 3 (Leydig cell; INSL3) that is essential for the embryonic development [25] was down-regulated in G2 and G3 vs. the control group.", [["Leydig cell", "ANATOMY", 29, 40], ["embryonic", "ANATOMY", 75, 84], ["insulin-like 3", "GENE_OR_GENE_PRODUCT", 13, 27], ["Leydig cell", "CELL", 29, 40], ["INSL3", "GENE_OR_GENE_PRODUCT", 42, 47], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 75, 84], ["insulin", "PROTEIN", 13, 20], ["INSL3", "PROTEIN", 42, 47], ["insulin", "TREATMENT", 13, 20]]], ["These data suggest that the impairment of embryonic development caused by abortion-associated C. jejuni infection might be in part responsible for abortion of fetuses identified in the G3.DiscussionIn the G3 infected with ovine C. jejuni, the gene encoding EGR1 which stimulates apoptosis and inflammatory response [26] was up-regulated compared to G1 and G2.", [["embryonic", "ANATOMY", 42, 51], ["fetuses", "ANATOMY", 159, 166], ["impairment of embryonic development", "DISEASE", 28, 63], ["abortion", "DISEASE", 74, 82], ["C. jejuni infection", "DISEASE", 94, 113], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 42, 51], ["C. jejuni", "ORGANISM", 94, 103], ["fetuses", "ORGANISM", 159, 166], ["ovine", "ORGANISM", 222, 227], ["C. jejuni", "ORGANISM", 228, 237], ["EGR1", "GENE_OR_GENE_PRODUCT", 257, 261], ["EGR1", "PROTEIN", 257, 261], ["C. jejuni", "SPECIES", 94, 103], ["ovine", "SPECIES", 222, 227], ["C. jejuni", "SPECIES", 228, 237], ["C. jejuni", "SPECIES", 94, 103], ["C. jejuni", "SPECIES", 228, 237], ["These data", "TEST", 0, 10], ["embryonic development", "PROBLEM", 42, 63], ["abortion", "PROBLEM", 74, 82], ["C. jejuni infection", "PROBLEM", 94, 113], ["abortion of fetuses", "PROBLEM", 147, 166], ["ovine C. jejuni", "TREATMENT", 222, 237], ["inflammatory response", "TEST", 293, 314], ["jejuni infection", "OBSERVATION", 97, 113], ["inflammatory", "OBSERVATION_MODIFIER", 293, 305]]], ["Concomitantly, there was an increase in the gene expression of a pro-inflammatory cytokine, IL-6, in G3 compared to G1 and G2 (Table 2) .", [["IL-6", "GENE_OR_GENE_PRODUCT", 92, 96], ["pro-inflammatory cytokine", "PROTEIN", 65, 90], ["IL-6", "PROTEIN", 92, 96], ["increase", "OBSERVATION_MODIFIER", 28, 36], ["gene expression", "OBSERVATION", 44, 59], ["pro-inflammatory", "OBSERVATION_MODIFIER", 65, 81]]], ["Elevated levels of IL-6 in the placenta, amniotic cells, and endometrium have been demonstrated in pregnancies complicated by preterm premature rupture of the membranes, intrauterine infection, and prematurity [27, 28] .", [["placenta", "ANATOMY", 31, 39], ["amniotic cells", "ANATOMY", 41, 55], ["endometrium", "ANATOMY", 61, 72], ["membranes", "ANATOMY", 159, 168], ["intrauterine", "ANATOMY", 170, 182], ["preterm premature rupture of the membranes", "DISEASE", 126, 168], ["intrauterine infection", "DISEASE", 170, 192], ["prematurity", "DISEASE", 198, 209], ["IL-6", "GENE_OR_GENE_PRODUCT", 19, 23], ["placenta", "CELL", 31, 39], ["amniotic cells", "CELL", 41, 55], ["endometrium", "MULTI-TISSUE_STRUCTURE", 61, 72], ["membranes", "CELLULAR_COMPONENT", 159, 168], ["intrauterine", "IMMATERIAL_ANATOMICAL_ENTITY", 170, 182], ["IL-6", "PROTEIN", 19, 23], ["amniotic cells", "CELL_TYPE", 41, 55], ["Elevated levels", "PROBLEM", 0, 15], ["IL", "TEST", 19, 21], ["amniotic cells", "PROBLEM", 41, 55], ["preterm premature rupture of the membranes", "PROBLEM", 126, 168], ["intrauterine infection", "PROBLEM", 170, 192], ["prematurity", "PROBLEM", 198, 209], ["IL", "ANATOMY_MODIFIER", 19, 21], ["placenta", "ANATOMY", 31, 39], ["amniotic cells", "OBSERVATION", 41, 55], ["endometrium", "ANATOMY", 61, 72], ["preterm", "OBSERVATION_MODIFIER", 126, 133], ["premature", "OBSERVATION_MODIFIER", 134, 143], ["rupture", "OBSERVATION", 144, 151], ["membranes", "OBSERVATION_MODIFIER", 159, 168], ["intrauterine", "OBSERVATION_MODIFIER", 170, 182], ["infection", "OBSERVATION", 183, 192], ["prematurity", "OBSERVATION", 198, 209]]], ["Consistent with the increased levels of prostaglandin receptor EP4 (Ptger4) in uterine tissue of IL6-/-mice compared with wild type mice [29] , down-regulation of Ptger4 gene was significantly observed in the G3 showing increased IL-6.", [["uterine tissue", "ANATOMY", 79, 93], ["prostaglandin", "CHEMICAL", 40, 53], ["prostaglandin", "CHEMICAL", 40, 53], ["prostaglandin receptor EP4", "GENE_OR_GENE_PRODUCT", 40, 66], ["Ptger4", "GENE_OR_GENE_PRODUCT", 68, 74], ["uterine tissue", "TISSUE", 79, 93], ["IL6", "GENE_OR_GENE_PRODUCT", 97, 100], ["wild type mice", "ORGANISM", 122, 136], ["Ptger4", "GENE_OR_GENE_PRODUCT", 163, 169], ["IL-6", "GENE_OR_GENE_PRODUCT", 230, 234], ["prostaglandin receptor EP4", "PROTEIN", 40, 66], ["Ptger4", "PROTEIN", 68, 74], ["IL6", "PROTEIN", 97, 100], ["Ptger4 gene", "DNA", 163, 174], ["IL-6", "PROTEIN", 230, 234], ["mice", "SPECIES", 103, 107], ["mice", "SPECIES", 132, 136], ["mice", "SPECIES", 132, 136], ["prostaglandin receptor EP4", "TREATMENT", 40, 66], ["IL6", "TEST", 97, 100], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["uterine tissue", "ANATOMY", 79, 93], ["increased", "OBSERVATION_MODIFIER", 220, 229]]], ["In addition to increased expression of IL-6 gene, up-regulation in the gene expression of TNF receptor associated factor 3 (TRAF3) was detected in the G3 vs. G1 and G2.", [["IL-6", "GENE_OR_GENE_PRODUCT", 39, 43], ["TNF receptor associated factor 3", "GENE_OR_GENE_PRODUCT", 90, 122], ["TRAF3", "GENE_OR_GENE_PRODUCT", 124, 129], ["IL-6 gene", "DNA", 39, 48], ["TNF receptor associated factor 3", "PROTEIN", 90, 122], ["TRAF3", "PROTEIN", 124, 129], ["increased", "OBSERVATION_MODIFIER", 15, 24], ["expression", "OBSERVATION_MODIFIER", 25, 35]]], ["The TRAF3 plays a role in the activation of the immune response [30] .", [["TRAF3", "GENE_OR_GENE_PRODUCT", 4, 9], ["TRAF3", "PROTEIN", 4, 9]]], ["Increased pro-inflammatory responses detected in the lesions in this study might be in part implicated in increased apoptotic death of infected placental cells.", [["lesions", "ANATOMY", 53, 60], ["placental cells", "ANATOMY", 144, 159], ["lesions", "PATHOLOGICAL_FORMATION", 53, 60], ["placental cells", "CELL", 144, 159], ["infected placental cells", "CELL_TYPE", 135, 159], ["Increased pro-inflammatory responses", "PROBLEM", 0, 36], ["the lesions", "PROBLEM", 49, 60], ["this study", "TEST", 64, 74], ["increased apoptotic death", "PROBLEM", 106, 131], ["infected placental cells", "PROBLEM", 135, 159], ["pro-inflammatory responses", "OBSERVATION", 10, 36], ["lesions", "OBSERVATION", 53, 60], ["increased", "OBSERVATION_MODIFIER", 106, 115], ["apoptotic death", "OBSERVATION", 116, 131], ["infected placental cells", "OBSERVATION", 135, 159]]], ["The IL-15 plays a regulatory role in mediating the inflammatory environment [31, 32] .", [["IL-15", "GENE_OR_GENE_PRODUCT", 4, 9], ["IL-15", "PROTEIN", 4, 9], ["inflammatory", "OBSERVATION_MODIFIER", 51, 63]]], ["Of interest, this cytokine might be associated with abortion [33, 34] .", [["cytokine", "PROTEIN", 18, 26]]], ["Previous studies showed that up-regulation of IL-15 gene in trophoblasts contributed to recurrent abortions, suggesting that this cytokine can be a marker for pregnancy failure [33, 34] .", [["trophoblasts", "ANATOMY", 60, 72], ["abortions", "DISEASE", 98, 107], ["pregnancy failure", "DISEASE", 159, 176], ["IL-15", "GENE_OR_GENE_PRODUCT", 46, 51], ["trophoblasts", "CELL", 60, 72], ["IL-15 gene", "DNA", 46, 56], ["trophoblasts", "CELL_TYPE", 60, 72], ["cytokine", "PROTEIN", 130, 138], ["Previous studies", "TEST", 0, 16], ["IL", "TEST", 46, 48], ["recurrent abortions", "PROBLEM", 88, 107], ["this cytokine", "PROBLEM", 125, 138], ["pregnancy failure", "PROBLEM", 159, 176], ["recurrent", "OBSERVATION_MODIFIER", 88, 97], ["abortions", "OBSERVATION", 98, 107]]], ["Similar to increased expression of IL-6 gene stated earlier, up-regulation of IL-15 gene expression was detected in the G3 and G2 vs. the negative control.", [["IL-6", "GENE_OR_GENE_PRODUCT", 35, 39], ["IL-15", "GENE_OR_GENE_PRODUCT", 78, 83], ["IL-6 gene", "DNA", 35, 44], ["IL-15 gene", "DNA", 78, 88], ["IL", "TREATMENT", 78, 80], ["increased", "OBSERVATION_MODIFIER", 11, 20], ["expression", "OBSERVATION_MODIFIER", 21, 31], ["negative", "OBSERVATION", 138, 146]]], ["The activated immunological status during pregnancy after inoculation with the abortion-associated C. jejuni might be implicated in the related abortive pathogenesis.", [["C. jejuni", "ORGANISM", 99, 108], ["C. jejuni", "SPECIES", 99, 108], ["C. jejuni", "SPECIES", 99, 108], ["inoculation", "TREATMENT", 58, 69], ["the abortion", "TREATMENT", 75, 87], ["C. jejuni", "PROBLEM", 99, 108]]], ["The increased apoptotic cell death in placental tissues particularly from aborted ewes in G2 and G3 vs. the G1 or control group (Figure 4 ) might be related to the increased responses of pro-inflammatory cytokine, IL-6, and IL-15 as described previously [35] [36] [37] .DiscussionBoth the ovine and bovine abortion isolates possess identical sequence types (ST-8) (Additional file 1: Figure S1 ).", [["cell", "ANATOMY", 24, 28], ["placental tissues", "ANATOMY", 38, 55], ["cell", "CELL", 24, 28], ["placental tissues", "TISSUE", 38, 55], ["IL-6", "GENE_OR_GENE_PRODUCT", 214, 218], ["IL-15", "GENE_OR_GENE_PRODUCT", 224, 229], ["ovine", "ORGANISM", 289, 294], ["bovine", "ORGANISM", 299, 305], ["pro-inflammatory cytokine", "PROTEIN", 187, 212], ["IL-6", "PROTEIN", 214, 218], ["IL", "PROTEIN", 224, 226], ["bovine", "SPECIES", 299, 305], ["The increased apoptotic cell death in placental tissues", "PROBLEM", 0, 55], ["pro-inflammatory cytokine", "TEST", 187, 212], ["IL", "TEST", 214, 216], ["the ovine and bovine abortion isolates", "TREATMENT", 285, 323], ["ST", "TEST", 358, 360], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["apoptotic cell death", "OBSERVATION", 14, 34], ["placental tissues", "ANATOMY", 38, 55]]], ["ST-8 has been previously recorded in different hosts, including humans [5, 13] , thus the abortion isolates may have zoonotic potential warranting further investigation of their implications to public health.", [["ST-8", "GENE_OR_GENE_PRODUCT", 0, 4], ["humans", "ORGANISM", 64, 70], ["ST-8", "DNA", 0, 4], ["humans", "SPECIES", 64, 70], ["humans", "SPECIES", 64, 70], ["ST", "TEST", 0, 2], ["the abortion isolates", "TREATMENT", 86, 107]]], ["Although there are no reports on associating clone SA to human abortions, the highly abortificient nature and the presence of large number of bacteria in aborted materials as well as in fetal tissues [9] may pose a potential environmental risk for zoonotic infections.", [["fetal tissues", "ANATOMY", 186, 199], ["human abortions", "DISEASE", 57, 72], ["zoonotic infections", "DISEASE", 248, 267], ["clone", "ORGANISM", 45, 50], ["SA", "GENE_OR_GENE_PRODUCT", 51, 53], ["human", "ORGANISM", 57, 62], ["fetal tissues", "TISSUE", 186, 199], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["bacteria in aborted materials", "PROBLEM", 142, 171], ["zoonotic infections", "PROBLEM", 248, 267], ["no", "UNCERTAINTY", 19, 21], ["large", "OBSERVATION_MODIFIER", 126, 131], ["number", "OBSERVATION_MODIFIER", 132, 138], ["bacteria", "OBSERVATION", 142, 150], ["fetal tissues", "ANATOMY", 186, 199], ["zoonotic", "OBSERVATION_MODIFIER", 248, 256], ["infections", "OBSERVATION", 257, 267]]], ["The latter is also indicated by existing evidence that suggest that the clone SA is associated with human gastroenteritis [5, 7] .", [["gastroenteritis", "DISEASE", 106, 121], ["SA", "GENE_OR_GENE_PRODUCT", 78, 80], ["human", "ORGANISM", 100, 105], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 100, 105], ["the clone SA", "PROBLEM", 68, 80], ["human gastroenteritis", "PROBLEM", 100, 121], ["gastroenteritis", "OBSERVATION", 106, 121]]], ["Both ovine and bovine abortion associated C. jejuni in this study were capable of invading the human intestinal epithelial cells (INT407).", [["intestinal epithelial cells", "ANATOMY", 101, 128], ["INT407", "ANATOMY", 130, 136], ["ovine", "ORGANISM", 5, 10], ["bovine", "ORGANISM", 15, 21], ["C. jejuni", "ORGANISM", 42, 51], ["human", "ORGANISM", 95, 100], ["intestinal epithelial cells", "CELL", 101, 128], ["INT407", "CELL", 130, 136], ["human intestinal epithelial cells", "CELL_TYPE", 95, 128], ["INT407", "CELL_LINE", 130, 136], ["ovine", "SPECIES", 5, 10], ["bovine", "SPECIES", 15, 21], ["C. jejuni", "SPECIES", 42, 51], ["human", "SPECIES", 95, 100], ["ovine", "SPECIES", 5, 10], ["bovine", "SPECIES", 15, 21], ["C. jejuni", "SPECIES", 42, 51], ["human", "SPECIES", 95, 100], ["Both ovine and bovine abortion", "TREATMENT", 0, 30], ["C. jejuni", "PROBLEM", 42, 51], ["this study", "TEST", 55, 65], ["bovine abortion", "OBSERVATION", 15, 30], ["jejuni", "OBSERVATION", 45, 51], ["human intestinal", "ANATOMY", 95, 111], ["epithelial cells", "OBSERVATION", 112, 128]]], ["Specifically, ovine abortion-II was as invasive in INT407 as the hyper-invasive strain C. jejuni 81-176 (Additional file 1: Figure S2 ) and showed significantly higher intracellular survival than that of the NCTC11168 (P < 0.05), a poorly invasive strain [38] .", [["intracellular", "ANATOMY", 168, 181], ["NCTC11168", "CHEMICAL", 208, 217], ["ovine", "ORGANISM", 14, 19], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 168, 181], ["NCTC11168", "CELL", 208, 217], ["C. jejuni", "SPECIES", 87, 96], ["C. jejuni", "SPECIES", 87, 96], ["NCTC11168", "SPECIES", 208, 217], ["the hyper-invasive strain C. jejuni", "PROBLEM", 61, 96], ["significantly higher intracellular survival", "PROBLEM", 147, 190], ["the NCTC", "TEST", 204, 212], ["a poorly invasive strain", "PROBLEM", 230, 254], ["intracellular survival", "OBSERVATION", 168, 190], ["invasive", "OBSERVATION_MODIFIER", 239, 247]]], ["These findings further highlight the potential public health impact of the abortion associated C. jejuni strains.ConclusionsThe results of this study revealed that bovine and ovine C. jejuni abortion isolates have the potential to induce necrotizing suppurative placentitis and endometritis, thereby causing abortion or stillbirth in pregnant sheep.", [["placentitis", "DISEASE", 262, 273], ["endometritis", "DISEASE", 278, 290], ["abortion", "DISEASE", 308, 316], ["stillbirth", "DISEASE", 320, 330], ["C. jejuni", "ORGANISM", 95, 104], ["bovine", "ORGANISM", 164, 170], ["ovine", "ORGANISM", 175, 180], ["C. jejuni", "ORGANISM", 181, 190], ["sheep", "ORGANISM", 343, 348], ["C. jejuni", "SPECIES", 95, 104], ["bovine", "SPECIES", 164, 170], ["C. jejuni", "SPECIES", 181, 190], ["sheep", "SPECIES", 343, 348], ["C. jejuni", "SPECIES", 95, 104], ["bovine", "SPECIES", 164, 170], ["C. jejuni", "SPECIES", 181, 190], ["sheep", "SPECIES", 343, 348], ["C. jejuni strains", "PROBLEM", 95, 112], ["this study", "TEST", 139, 149], ["bovine and ovine C. jejuni abortion", "TREATMENT", 164, 199], ["necrotizing suppurative placentitis", "PROBLEM", 238, 273], ["endometritis", "PROBLEM", 278, 290], ["abortion", "PROBLEM", 308, 316], ["stillbirth in pregnant sheep", "PROBLEM", 320, 348], ["jejuni strains", "OBSERVATION", 98, 112], ["necrotizing", "OBSERVATION_MODIFIER", 238, 249], ["suppurative", "OBSERVATION_MODIFIER", 250, 261], ["placentitis", "OBSERVATION", 262, 273], ["endometritis", "OBSERVATION", 278, 290]]], ["Necrotic lesions and suppurative inflammation in the placenta and endometrium coincided with increased expression of the genes related to cellular necrosis and pro-inflammatory responses accompanied by decreased expression of the genes that account for embryonic development.", [["Necrotic lesions", "ANATOMY", 0, 16], ["placenta", "ANATOMY", 53, 61], ["endometrium", "ANATOMY", 66, 77], ["cellular", "ANATOMY", 138, 146], ["embryonic", "ANATOMY", 253, 262], ["inflammation", "DISEASE", 33, 45], ["necrosis", "DISEASE", 147, 155], ["Necrotic lesions", "PATHOLOGICAL_FORMATION", 0, 16], ["placenta", "MULTI-TISSUE_STRUCTURE", 53, 61], ["endometrium", "MULTI-TISSUE_STRUCTURE", 66, 77], ["cellular", "CELL", 138, 146], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 253, 262], ["Necrotic lesions", "PROBLEM", 0, 16], ["suppurative inflammation in the placenta and endometrium", "PROBLEM", 21, 77], ["the genes", "PROBLEM", 117, 126], ["cellular necrosis", "PROBLEM", 138, 155], ["pro-inflammatory responses", "PROBLEM", 160, 186], ["decreased expression of the genes", "PROBLEM", 202, 235], ["embryonic development", "PROBLEM", 253, 274], ["lesions", "OBSERVATION", 9, 16], ["suppurative", "OBSERVATION_MODIFIER", 21, 32], ["inflammation", "OBSERVATION", 33, 45], ["placenta", "ANATOMY", 53, 61], ["endometrium", "ANATOMY", 66, 77], ["increased", "OBSERVATION_MODIFIER", 93, 102], ["cellular", "OBSERVATION_MODIFIER", 138, 146], ["necrosis", "OBSERVATION", 147, 155], ["pro-inflammatory", "OBSERVATION_MODIFIER", 160, 176], ["decreased", "OBSERVATION_MODIFIER", 202, 211], ["expression", "OBSERVATION", 212, 222]]], ["The distinct genomic contents and transcriptome responses of clone SA may facilitate its systemic spread and subsequent localization in the sheep uterus leading to abortion.", [["uterus", "ANATOMY", 146, 152], ["abortion", "DISEASE", 164, 172], ["SA", "GENE_OR_GENE_PRODUCT", 67, 69], ["sheep", "ORGANISM", 140, 145], ["uterus", "ORGAN", 146, 152], ["sheep", "SPECIES", 140, 145], ["sheep", "SPECIES", 140, 145], ["The distinct genomic contents", "PROBLEM", 0, 29], ["clone SA", "TEST", 61, 69], ["its systemic spread", "PROBLEM", 85, 104], ["subsequent localization in the sheep uterus", "PROBLEM", 109, 152], ["abortion", "PROBLEM", 164, 172], ["distinct", "OBSERVATION_MODIFIER", 4, 12], ["genomic contents", "OBSERVATION", 13, 29], ["systemic", "OBSERVATION_MODIFIER", 89, 97], ["spread", "OBSERVATION", 98, 104], ["sheep uterus", "ANATOMY", 140, 152]]], ["However, further studies are needed to define the bacterial factors contributing to clone SA's unique virulence and pathogenesis in sheep.", [["SA", "CHEMICAL", 90, 92], ["SA", "GENE_OR_GENE_PRODUCT", 90, 92], ["sheep", "ORGANISM", 132, 137], ["bacterial factors", "PROTEIN", 50, 67], ["sheep", "SPECIES", 132, 137], ["sheep", "SPECIES", 132, 137], ["further studies", "TEST", 9, 24], ["the bacterial factors", "PROBLEM", 46, 67], ["clone SA's unique virulence", "PROBLEM", 84, 111], ["pathogenesis in sheep", "PROBLEM", 116, 137]]], ["Although a relatively limited number of animals was used in this study, the results show that, sheep as an animal model, can provide useful and novel insights into the pathogenesis and the host responses triggered by bovine and ovine abortionassociated C. jejuni clone SA.Additional fileAdditional file 1: Table S1 .", [["animals", "ORGANISM", 40, 47], ["sheep", "ORGANISM", 95, 100], ["bovine", "ORGANISM", 217, 223], ["ovine abortionassociated C. jejuni clone SA", "ORGANISM", 228, 271], ["sheep", "SPECIES", 95, 100], ["bovine", "SPECIES", 217, 223], ["C. jejuni", "SPECIES", 253, 262], ["sheep", "SPECIES", 95, 100], ["bovine", "SPECIES", 217, 223], ["ovine", "SPECIES", 228, 233], ["C. jejuni", "SPECIES", 253, 262], ["this study", "TEST", 60, 70], ["jejuni clone", "OBSERVATION", 256, 268], ["S1", "ANATOMY", 312, 314]]], ["SmaI Macro Restriction Profiles, Sequence Types and antimicrobial resistance profiles of ovine and bovine C.jejuni abortionassociated isolates.", [["ovine", "ORGANISM", 89, 94], ["bovine", "ORGANISM", 99, 105], ["C.jejuni", "ORGANISM", 106, 114], ["ovine", "SPECIES", 89, 94], ["bovine", "SPECIES", 99, 105], ["ovine", "SPECIES", 89, 94], ["bovine", "SPECIES", 99, 105], ["SmaI Macro Restriction Profiles", "TEST", 0, 31], ["Sequence Types", "TEST", 33, 47], ["antimicrobial resistance profiles", "TEST", 52, 85], ["ovine and bovine C.jejuni abortionassociated isolates", "TREATMENT", 89, 142], ["antimicrobial resistance", "OBSERVATION", 52, 76]]], ["Invasion and intracellular survival of ovine and bovine C. jejuni isolates in INT407 cells.", [["intracellular", "ANATOMY", 13, 26], ["INT407 cells", "ANATOMY", 78, 90], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 13, 26], ["ovine", "ORGANISM", 39, 44], ["bovine", "ORGANISM", 49, 55], ["C. jejuni", "ORGANISM", 56, 65], ["INT407 cells", "CELL", 78, 90], ["INT407 cells", "CELL_LINE", 78, 90], ["bovine", "SPECIES", 49, 55], ["C. jejuni", "SPECIES", 56, 65], ["ovine", "SPECIES", 39, 44], ["C. jejuni", "SPECIES", 56, 65], ["Invasion", "PROBLEM", 0, 8], ["intracellular survival of ovine", "TREATMENT", 13, 44], ["bovine C. jejuni isolates", "TREATMENT", 49, 74], ["jejuni isolates", "OBSERVATION", 59, 74]]]], "PMC7459358": [["Some initiatives do exist, including those in, for instance, France, the Netherlands, and Norway.1Dietz et al. (2016) estimate the expected climate change value at risk of global financial assets to be 1.8% along a business-as-usual emissions path (i.e., US$2.5 trillion and possibly as high as US$24.2 trillion).", [["global financial assets", "PROBLEM", 172, 195]]], ["Banks need to consider current and future risks where global climate change risks appear to be growing (Intergovernmental Panel on Climate Change, 2014) not only for their own self-sustainable development and value creation, but also for general sustainable development and value creation around the world.IntroductionBased on these developments, it has recently become of paramount importance for banks to demonstrate their commitment to sustainable development and the fight against climate change.", [["global climate change risks", "PROBLEM", 54, 81]]], ["Numerous initiatives have emerged in recent years, among them general plans (e.g., Global Reporting Initiative, Global Compact, Carbon Disclosure Project, and Greenhouse Gas Protocol) and those specific to the finance industry (e.g., Principles for Responsible Banking, Task Force on Climate-related Financial Disclosure, Banking Environment Initiative, Principles for Sustainable Banking, Paris Pledge on Coal Financing, and Montr\u00e9al Carbon Pledge).", [["Greenhouse Gas Protocol", "TREATMENT", 159, 182]]], ["For instance, a new challenging task is to integrate a climate-risk identification scenario into each bank's internal risk management and risk appetite framework.", [["internal risk management", "TREATMENT", 109, 133]]], ["In this respect, some methods provide a scorecard or climate risk rating and estimates of the carbon impact of a portfolio (e.g., Carbone 4).2In addition, regulators and supervisors are considering the possibility of introducing new capital requirements for banks with regard to compliance with climate change-related indicators (Bank for International Settlements, 2020).IntroductionThe literature has extensively addressed the relationship between firm performance and corporate social responsibility (CSR)/environmental social governance (ESG), but the results remain inconclusive (Waddock and Graves, 1997; Allouche and Laroche, 2005; Zhao and Murrel, 2016).", [["carbon", "CHEMICAL", 94, 100], ["Carbone 4", "CHEMICAL", 130, 139], ["climate risk rating", "TEST", 53, 72], ["carbon impact", "OBSERVATION", 94, 107]]], ["Within the banking industry, such empirical investigations are far less frequent, because the financial industry is often excluded from samples for methodological reasons.", [["empirical investigations", "TEST", 34, 58]]], ["Of the empirical studies that have focused on banking, as with other industries, the results are mixed (Simpson and Kohers, 2002; Soana, 2011; Wu and Chen, 2013; Cornett et al., 2016; Shen et al., 2016; Esteban-Sanchez et al., 2017; Miralles-Quiros et al., 2019).IntroductionThe aim of this research is not to add further information about the impact of CSR/ESG performance on bank performance or to focus on the influence of environmental performance (e.g., Albertini, 2013; Busch and Lewandoski, 2018).", [["the empirical studies", "TEST", 3, 24], ["Esteban", "TEST", 203, 210], ["Miralles", "TEST", 233, 241], ["bank performance", "TEST", 377, 393]]], ["As illustrated by the \u201cDieselgate\u201d scandal in the automotive industry, misconduct related to environmental disclosure can create a breach of trust with a company's stakeholders and have damaging consequences for the firm's reputation and finances.", [["the firm's reputation", "TREATMENT", 212, 233]]], ["Banks have come to realize that banking operations, particularly lending operations, affect and are affected by the environment (Weber et al., 2010; Rosella, 2017; Herbohn et al., 2019).", [["banking operations", "TREATMENT", 32, 50]]], ["Shrivastava et al. (2019) call for a radical change in the criteria for financial decisions, lending, or investment, for example, to include non-financial variables and long-term environmental impact.", [["a radical change", "PROBLEM", 35, 51], ["non-financial variables", "PROBLEM", 141, 164], ["long-term environmental impact", "PROBLEM", 169, 199]]], ["Shrivastava et al., 32) also stress that \u201cthe financial system plays a very important role in the transition to a sustainable low-carbon economy since it allocates funds, administers portfolios, and manages risks.\u201dIntroductionThus, carbon performance and disclosure appear to be crucial, and are becoming management tools not only to address stakeholder demands but also to manage firms and ultimately to achieve a transition to a low-carbon global economy.", [["carbon", "CHEMICAL", 130, 136], ["carbon", "CHEMICAL", 232, 238], ["carbon", "CHEMICAL", 435, 441], ["a sustainable low-carbon economy", "TREATMENT", 112, 144], ["carbon performance", "TEST", 232, 250], ["a low-carbon global economy", "TREATMENT", 429, 456]]], ["Carbon performance refers to the reduction of carbon greenhouse gas (GHG) emissions in accordance with the 2016 Paris Climate Agreement to hold global warming to well below 2\u00b0C and to \u201cpursue efforts\u201d to limit it to 1.5 \u00b0C (Rogelj et al., 2016).", [["carbon greenhouse gas", "CHEMICAL", 46, 67], ["GHG", "CHEMICAL", 69, 72], ["Carbon", "CHEMICAL", 0, 6], ["carbon", "CHEMICAL", 46, 52], ["Carbon performance", "TREATMENT", 0, 18], ["carbon greenhouse gas", "TREATMENT", 46, 67], ["global warming", "TREATMENT", 144, 158]]], ["Interestingly, some countries and regions have conditioned economic support to enterprises amid the Covid-19 pandemic on decarbonization objectives, particularly in the airline industry (Austria, France, etc.) although the United States has opted for the opposite direction.", [["conditioned economic support", "TREATMENT", 47, 75], ["the Covid", "TEST", 96, 105]]], ["To achieve these goals, carbon disclosure is an essential first step toward implementing a successful GHG-reduction policy.", [["carbon", "CHEMICAL", 24, 30], ["carbon", "SIMPLE_CHEMICAL", 24, 30], ["a successful GHG-reduction policy", "TREATMENT", 89, 122]]], ["Previous studies show that carbon disclosure is positively impacted by national context, business landscape and nature, corporate governance characteristics, and firm size rather than by financial performance or leverage (Brammer and Pavelin, 2008; Hahn et al., 2015; Grauel and Gotthardt, 2016; Ott et al., 2017; Velte et al., 2020), but empirical evidence regarding the banking industry is so far very limited.IntroductionThis research addresses the following two main questions.", [["carbon", "CHEMICAL", 27, 33], ["carbon", "CHEMICAL", 27, 33], ["carbon", "SIMPLE_CHEMICAL", 27, 33], ["Previous studies", "TEST", 0, 16], ["carbon disclosure", "PROBLEM", 27, 44], ["firm", "OBSERVATION_MODIFIER", 162, 166], ["size", "OBSERVATION_MODIFIER", 167, 171]]], ["Using commitment to climate change disclosure and quality of voluntary disclosure as independent variables, we test our models on 117 banks around the world employing ordinary least square (OLS) regression and multivariate logit analysis.", [["multivariate logit analysis", "TEST", 210, 237]]], ["We show that country-level and bank-level characteristics are much better predictors of bank commitment to voluntary carbon disclosure initiatives and environmental scores than they are of carbon disclosure quality.", [["carbon", "CHEMICAL", 117, 123], ["carbon", "CHEMICAL", 189, 195], ["voluntary carbon disclosure initiatives", "TREATMENT", 107, 146]]], ["This leads us to consider that banks\u2019 commitment to voluntary carbon disclosure is mainly backed by stakeholder and legitimacy theory and greenwashing.", [["carbon", "CHEMICAL", 62, 68], ["carbon", "CHEMICAL", 62, 68], ["voluntary carbon disclosure", "TREATMENT", 52, 79]]], ["However, the picture becomes unclear when it comes to the implementation of rigorous carbon disclosure, when country- and bank-level characteristics are much less explanatory.", [["carbon", "CHEMICAL", 85, 91], ["rigorous carbon disclosure", "TREATMENT", 76, 102]]], ["In addition, we extend the current state of knowledge regarding the impact of size and country-level characteristics on carbon disclosure, and find that size and national context are not independent of carbon disclosure.", [["carbon", "CHEMICAL", 120, 126], ["carbon", "CHEMICAL", 202, 208], ["carbon", "SIMPLE_CHEMICAL", 120, 126], ["carbon", "SIMPLE_CHEMICAL", 202, 208], ["carbon disclosure", "TEST", 120, 137], ["size", "OBSERVATION_MODIFIER", 78, 82], ["size", "OBSERVATION_MODIFIER", 153, 157]]], ["Regarding the positive impact of multiple listings, we confirm the findings of previous studies (for the banking industry, see Hossain and Reaz, 2007; Kili\u00e7 and Kuzey, 2019a; others are Ben-Amar and McIlkenny, 2015; Del Bosco and Misani, 2016).IntroductionThe rest of the paper is structured as follows.", [["previous studies", "TEST", 79, 95]]], ["Section 6 concludes.Theoretical perspectives ::: Literature reviewThe first concern that arises in the carbon disclosure dimension of CSR is greenwashing, as disclosure tends to be voluntary, although some regulations have emerged, for example, the European directive of October 22, 2014 regarding the disclosure of non-financial information.", [["carbon", "CHEMICAL", 103, 109]]], ["According to the signaling theory, firms use CSR reports as a signal of their superior commitment to CSR.", [["CSR", "PROTEIN", 101, 104]]], ["Both hypotheses are reinforced by cost analysis, as the benefits of voluntary CSR disclosure should exceed the associated costs (Verrechia, 1983; Caby and Pineiro-Chousa, 2006).Theoretical perspectives ::: Literature review", [["cost analysis", "TEST", 34, 47], ["voluntary CSR disclosure", "TREATMENT", 68, 92]]]], "6a5aa98060cd22a908ea96f5b4a62d5faccf7263": [["Establishment of the \"Tracker\"The data included in the \"Tracker\" are collected from resources in the public domain by volunteers from The Antibody Society and the Chinese Antibody Society on an ongoing basis.", [["volunteers", "ORGANISM", 118, 128]]], ["To reduce the amount of the manual work, when possible, an automatic process is being developed and integrated to retrieve data from online databases such as ClinicalTrials.gov by command-line tools (4) .", [["an automatic process", "PROBLEM", 56, 76], ["online databases", "TEST", 133, 149], ["amount", "OBSERVATION_MODIFIER", 14, 20]]], ["For example, to construct queries based on the Application Programming Interface (API) tool of ClinicalTrials.gov, query uniform resource locator (url) for all study records (i.e \"full studies url\") was used as the base query and supplied with additional parameters, including a search expression string containing search fields, values, and logical operators for search and filtering.", [["all study records", "TEST", 156, 173]]], ["Returned hits from both queries, in JavaScript Object Notation (JSON) format, were further processed by the Python script for manual inspection to ensure relevancy.", [["manual inspection", "TEST", 126, 143]]], ["When updating the database, the NCTID of a returned hit will be compared with that of existing entries in the database.", [["NCTID", "DNA", 32, 37]]], ["If it does not exist in the database, it will be flagged for manual review and if relevant, it will be entered into the database.", [["manual review", "TEST", 61, 74]]], ["An example of our script with detailed explanation for usage can be found in the Github repository (https://github.com/xinyu-dev/cas-covid-mab-tracker).Establishment of the \"Tracker\"Therapeutics programs based on non-antibody proteins with the similar mechanisms of actions as antibodies, such as recombinant ACE2 protein and Fc-fusion proteins, are also included.", [["ACE2", "GENE_OR_GENE_PRODUCT", 309, 313], ["Fc", "GENE_OR_GENE_PRODUCT", 326, 328], ["non-antibody proteins", "PROTEIN", 213, 234], ["antibodies", "PROTEIN", 277, 287], ["recombinant ACE2 protein", "PROTEIN", 297, 321], ["Fc", "PROTEIN", 326, 328], ["fusion proteins", "PROTEIN", 329, 344], ["Therapeutics programs", "TREATMENT", 182, 203], ["non-antibody proteins", "TREATMENT", 213, 234], ["antibodies", "TEST", 277, 287], ["recombinant ACE2 protein", "TEST", 297, 321], ["Fc-fusion proteins", "TREATMENT", 326, 344]]], ["Unrelated information such as diagnostic antibodies, polyclonal plasma from I P T convalescent patients, and clinical trials without specific indications to COVID-19 patients in experimental design, were excluded.", [["plasma", "ANATOMY", 64, 70], ["plasma", "ORGANISM_SUBSTANCE", 64, 70], ["patients", "ORGANISM", 95, 103], ["patients", "ORGANISM", 166, 174], ["diagnostic antibodies", "PROTEIN", 30, 51], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 166, 174], ["diagnostic antibodies", "TEST", 30, 51]]], ["For quality evaluation, all the final data included in the \"Tracker\" were cross-verified manually by at least two independent volunteers.Establishment of the \"Tracker\"For presentation in the \"Tracker\", we categorized the following data: target, molecular format, development status, developer, country of origin and the supporting reference.Establishment of the \"Tracker\"To build the \"Tracker\", the data table containing filtered results was uploaded to the website of the Chinese Antibody Society, which was build using WordPress.", [["volunteers", "ORGANISM", 126, 136], ["quality evaluation", "TEST", 4, 22]]], ["We used WPDatatable Plugin to integrate the data table from backend to front end of the webpage.Establishment of the \"Tracker\"On our \"Tracker\" website, the whole dataset was displayed as an interactive table, and grouped by the categories we defined above.Establishment of the \"Tracker\"We also performed analysis and visualization based on the key features of the collected antibody therapeutic data that are most relevant to the scientific community and general public.", [["WPDatatable Plugin", "TREATMENT", 8, 26], ["analysis", "TEST", 304, 312], ["visualization", "TEST", 317, 330]]], ["These include the numbers of therapeutic targets, formats, and program development status of the antibody therapeutics.", [["the antibody therapeutics", "TREATMENT", 93, 118]]], ["In addition, we plotted the distribution of program development status by country to track the progress of COVID-19 antibody therapeutics programs globally.Data analysisTo further elaborate the function of the \"Tracker\", we performed data visualization and analysis based on the key features of the collected antibody therapeutic data, including antibody targets, formats, and development status.1) Antibody targetsNeutralizing antibodies are critical components in host immune responses to viral pathogens (3) .", [["Neutralizing antibodies", "PROTEIN", 415, 438], ["COVID-19 antibody therapeutics programs", "TREATMENT", 107, 146], ["Data analysisTo", "TEST", 156, 171], ["data visualization", "TEST", 234, 252], ["analysis", "TEST", 257, 265], ["the collected antibody therapeutic data", "TEST", 295, 334], ["antibody targets", "TEST", 346, 362], ["Antibody targets", "TEST", 399, 415], ["Neutralizing antibodies", "TEST", 415, 438], ["critical components", "PROBLEM", 443, 462], ["viral pathogens", "PROBLEM", 491, 506]]], ["As an enveloped singlestrand RNA virus, SARS-CoV-2 enters into a human cell through its spike (S) protein binding to angiotensin-converting enzyme 2 (ACE2) (5, 6) .", [["cell", "ANATOMY", 71, 75], ["angiotensin", "CHEMICAL", 117, 128], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 40, 50], ["human", "ORGANISM", 65, 70], ["cell", "CELL", 71, 75], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 117, 148], ["ACE2", "GENE_OR_GENE_PRODUCT", 150, 154], ["human cell", "CELL_TYPE", 65, 75], ["spike (S) protein", "PROTEIN", 88, 105], ["angiotensin-converting enzyme 2", "PROTEIN", 117, 148], ["ACE2", "PROTEIN", 150, 154], ["human", "SPECIES", 65, 70], ["SARS-CoV", "SPECIES", 40, 48], ["human", "SPECIES", 65, 70], ["an enveloped singlestrand RNA virus", "PROBLEM", 3, 38], ["SARS", "PROBLEM", 40, 44], ["CoV", "TEST", 45, 48], ["a human cell", "TREATMENT", 63, 75], ["protein binding", "PROBLEM", 98, 113], ["angiotensin", "TEST", 117, 128], ["enzyme", "TEST", 140, 146]]], ["The structures of SARS-CoV-2 S protein trimer (7) and human ACE2 (8) shows that the receptor binding domain (RBD) on the SARS-CoV-2 S protein S1 subunit directly contacts with human ACE2 (8) .", [["SARS-CoV-2 S protein trimer (7)", "GENE_OR_GENE_PRODUCT", 18, 49], ["human", "ORGANISM", 54, 59], ["ACE2", "GENE_OR_GENE_PRODUCT", 60, 64], ["SARS-CoV-2 S protein S1", "GENE_OR_GENE_PRODUCT", 121, 144], ["human", "ORGANISM", 176, 181], ["ACE2", "GENE_OR_GENE_PRODUCT", 182, 186], ["SARS-CoV-2 S protein trimer", "PROTEIN", 18, 45], ["human ACE2 (8", "PROTEIN", 54, 67], ["receptor binding domain", "PROTEIN", 84, 107], ["RBD", "PROTEIN", 109, 112], ["SARS-CoV-2 S protein S1 subunit", "PROTEIN", 121, 152], ["human ACE2 (8)", "PROTEIN", 176, 190], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 176, 181], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 176, 181], ["SARS", "TEST", 18, 22], ["CoV", "TEST", 23, 26], ["S protein trimer", "TEST", 29, 45], ["human ACE2", "TEST", 54, 64], ["the receptor binding domain (RBD", "PROBLEM", 80, 112], ["the SARS", "TEST", 117, 125], ["CoV", "TEST", 126, 129], ["human ACE2", "TREATMENT", 176, 186], ["SARS", "OBSERVATION", 18, 22]]], ["Therefore, the S protein, in particularly the RBD or the S1 subunit, is the primary target for most neutralizing antibodies.1) Antibody targetsAs shown in Figure 1A , the \"Tracker\" is currently tracking 153 programs and molecules for COVID-19 interventions from discovery to clinical development.", [["RBD", "GENE_OR_GENE_PRODUCT", 46, 49], ["S protein", "PROTEIN", 15, 24], ["RBD", "PROTEIN", 46, 49], ["S1 subunit", "PROTEIN", 57, 67], ["neutralizing antibodies", "PROTEIN", 100, 123], ["the S protein", "TEST", 11, 24], ["most neutralizing antibodies", "PROBLEM", 95, 123], ["Antibody targets", "TEST", 127, 143], ["COVID-19 interventions", "TREATMENT", 234, 256]]], ["Among these, 89 target the SARS-COV-2 S protein as antiviral interventions by blocking virus entry.", [["COV-2", "GENE_OR_GENE_PRODUCT", 32, 37], ["SARS-COV-2 S protein", "PROTEIN", 27, 47], ["the SARS", "TEST", 23, 31], ["COV", "TEST", 32, 35], ["antiviral interventions", "TREATMENT", 51, 74], ["blocking virus entry", "TREATMENT", 78, 98]]], ["Most of the anti-SARS-COV-2 antibodies were isolated from single memory B cells derived from convalescent patients or immunized transgenic animals.1) Antibody targetsRegeneron Pharmaceuticals Inc (Regeneron) used both approaches to isolate antibodies that bind distinct and non-overlapping epitopes on the monomeric RBD of the spike protein with high affinity (K D = 0.56 to 45.2 nM) (9).", [["memory B cells", "ANATOMY", 65, 79], ["anti-SARS-COV-2 antibodies", "GENE_OR_GENE_PRODUCT", 12, 38], ["memory B cells", "CELL", 65, 79], ["patients", "ORGANISM", 106, 114], ["anti-SARS-COV-2 antibodies", "PROTEIN", 12, 38], ["memory B cells", "CELL_TYPE", 65, 79], ["antibodies", "PROTEIN", 240, 250], ["epitopes", "PROTEIN", 290, 298], ["monomeric RBD", "PROTEIN", 306, 319], ["spike protein", "PROTEIN", 327, 340], ["patients", "SPECIES", 106, 114], ["the anti-SARS", "TEST", 8, 21], ["COV-2 antibodies", "TEST", 22, 38], ["immunized transgenic animals", "PROBLEM", 118, 146], ["Antibody targets", "TEST", 150, 166], ["Regeneron Pharmaceuticals", "TREATMENT", 166, 191], ["Inc (Regeneron)", "TREATMENT", 192, 207], ["isolate antibodies", "TREATMENT", 232, 250], ["the spike protein", "TEST", 323, 340], ["high affinity", "PROBLEM", 346, 359], ["K D", "TEST", 361, 364]]], ["These antibodies have potent neutralization activities against pseudoviral particles or live virus with IC 50 values of 1-10 pM (10) Using an in vitro assay, they found escape mutants were not generated following treatment with a cocktail composed of non-competing antibodies.", [["pseudoviral particles", "ORGANISM", 63, 84], ["antibodies", "PROTEIN", 6, 16], ["non-competing antibodies", "PROTEIN", 251, 275], ["These antibodies", "TEST", 0, 16], ["potent neutralization activities", "PROBLEM", 22, 54], ["pseudoviral particles", "PROBLEM", 63, 84], ["live virus", "PROBLEM", 88, 98], ["an in vitro assay", "TEST", 139, 156], ["escape mutants", "PROBLEM", 169, 183], ["treatment", "TREATMENT", 213, 222], ["a cocktail", "TREATMENT", 228, 238], ["non-competing antibodies", "PROBLEM", 251, 275]]], ["Regeneron is developing two of their antibodies as the cocktail treatment REGN-COV2 (REGN10933+REGN10987) ( Table 2 ).1) Antibody targetsIn another study, groups from Chinese Academy of Sciences in Beijing and Junshi Biosciences in Shanghai reported two human antibodies (CA1 and CB6) have been isolated from a convalescent COVID-19 patient using single B cell sorting and cloning1) Antibody targetstechniques (11) .", [["B cell", "ANATOMY", 354, 360], ["REGN10933", "CHEMICAL", 85, 94], ["REGN10987", "CHEMICAL", 95, 104], ["human", "ORGANISM", 254, 259], ["CB6", "GENE_OR_GENE_PRODUCT", 280, 283], ["patient", "ORGANISM", 333, 340], ["B cell", "CELL", 354, 360], ["antibodies", "PROTEIN", 37, 47], ["human antibodies", "PROTEIN", 254, 270], ["CA1", "PROTEIN", 272, 275], ["CB6", "PROTEIN", 280, 283], ["human", "SPECIES", 254, 259], ["patient", "SPECIES", 333, 340], ["human", "SPECIES", 254, 259], ["Regeneron", "TREATMENT", 0, 9], ["their antibodies", "TREATMENT", 31, 47], ["the cocktail treatment", "TREATMENT", 51, 73], ["Antibody targets", "TEST", 121, 137], ["another study", "TEST", 140, 153], ["two human antibodies", "TEST", 250, 270], ["a convalescent COVID", "TEST", 309, 329], ["single B cell sorting", "TREATMENT", 347, 368], ["Antibody targetstechniques", "TEST", 383, 409]]], ["The human antibodies showed potent neutralization activity in vitro against SARS-CoV-2 with IC 50 of 0.036 \u00b1 0.007 \u03bcg/mL (0.24 \u00b1 0.047 nM) for CB6 and 0.38 \u03bcg/mL (2.53 nM) for CA1.", [["CB6", "CHEMICAL", 143, 146], ["human", "ORGANISM", 4, 9], ["SARS-CoV-2", "ORGANISM", 76, 86], ["human antibodies", "PROTEIN", 4, 20], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["SARS-CoV", "SPECIES", 76, 84], ["The human antibodies", "TEST", 0, 20], ["potent neutralization activity", "PROBLEM", 28, 58], ["CoV", "TEST", 81, 84], ["IC", "TEST", 92, 94], ["CB6", "TEST", 143, 146], ["CA1", "PROBLEM", 176, 179], ["potent", "OBSERVATION_MODIFIER", 28, 34], ["neutralization activity", "OBSERVATION", 35, 58]]], ["Structural analysis revealed that CB6 is an ACE2 blocker that (Table 2) . ).", [["CB6", "CHEMICAL", 34, 37], ["CB6", "SIMPLE_CHEMICAL", 34, 37], ["ACE2", "GENE_OR_GENE_PRODUCT", 44, 48], ["ACE2", "PROTEIN", 44, 48], ["Structural analysis", "TEST", 0, 19], ["CB6", "TEST", 34, 37], ["an ACE2 blocker", "TREATMENT", 41, 56]]], ["Considering the proven role of cytokine dysregulation in causing this hyperinflammation, especially in the lungs, existing drugs targeting these mediators are being repurposed for the treatment of COVID-19 (12) .", [["lungs", "ANATOMY", 107, 112], ["hyperinflammation", "DISEASE", 70, 87], ["COVID-19", "CHEMICAL", 197, 205], ["lungs", "ORGAN", 107, 112], ["cytokine", "PROTEIN", 31, 39], ["cytokine dysregulation", "PROBLEM", 31, 53], ["this hyperinflammation", "PROBLEM", 65, 87], ["existing drugs", "TREATMENT", 114, 128], ["COVID", "TEST", 197, 202], ["cytokine dysregulation", "OBSERVATION", 31, 53], ["hyperinflammation", "OBSERVATION", 70, 87], ["lungs", "ANATOMY", 107, 112]]], ["As shown in Figure 1A , 61 of the molecules included in the \"Tracker\" were developed to target the host immune system for other indications, but were repurposed to treatCOVID-19 invokes a hyperinflammatory state driven by multiple cells and mediators like interleukinCOVID-19 by potentially alleviating COVID-19-related symptoms, such as cytokine storm and inflammation, instead of directly killing the viruses.", [["cells", "ANATOMY", 231, 236], ["treatCOVID-19", "CHEMICAL", 164, 177], ["inflammation", "DISEASE", 357, 369], ["treatCOVID-19", "CHEMICAL", 164, 177], ["cells", "CELL", 231, 236], ["interleukinCOVID-19", "GENE_OR_GENE_PRODUCT", 256, 275], ["interleukinCOVID-19", "PROTEIN", 256, 275], ["cytokine", "PROTEIN", 338, 346], ["treatCOVID", "TEST", 164, 174], ["a hyperinflammatory state", "PROBLEM", 186, 211], ["interleukinCOVID", "TEST", 256, 272], ["COVID", "TEST", 303, 308], ["related symptoms", "PROBLEM", 312, 328], ["cytokine storm", "PROBLEM", 338, 352], ["inflammation", "PROBLEM", 357, 369], ["inflammation", "OBSERVATION", 357, 369], ["viruses", "OBSERVATION", 403, 410]]], ["For example, the IL-6 inhibitors levilimab, tocilizumab, sarilumab, olokizumab and siltuximab are being tested against COVID-19 (12-14).2) Antibody formatsAs shown in Figure (https://kodiak.com/press-releases/kodiak-sciences-announces-first-quarter-2020-financial-results-and-recent-business-highlights/), CD16/SARS-CoV-2 (https://www.gtbiopharma.com/news-media/press-releases/detail/182/gt-biopharma-and-cytovance-biologicsannounce-collaboration%7C%7CGT%20Biopharma).", [["levilimab", "CHEMICAL", 33, 42], ["tocilizumab", "CHEMICAL", 44, 55], ["sarilumab", "CHEMICAL", 57, 66], ["olokizumab", "CHEMICAL", 68, 78], ["siltuximab", "CHEMICAL", 83, 93], ["levilimab", "CHEMICAL", 33, 42], ["sarilumab", "CHEMICAL", 57, 66], ["olokizumab", "CHEMICAL", 68, 78], ["siltuximab", "CHEMICAL", 83, 93], ["IL-6", "GENE_OR_GENE_PRODUCT", 17, 21], ["levilimab", "SIMPLE_CHEMICAL", 33, 42], ["tocilizumab", "SIMPLE_CHEMICAL", 44, 55], ["sarilumab", "SIMPLE_CHEMICAL", 57, 66], ["olokizumab", "SIMPLE_CHEMICAL", 68, 78], ["siltuximab", "SIMPLE_CHEMICAL", 83, 93], ["the IL", "TREATMENT", 13, 19], ["inhibitors levilimab", "TREATMENT", 22, 42], ["tocilizumab", "TREATMENT", 44, 55], ["sarilumab", "TREATMENT", 57, 66], ["olokizumab", "TREATMENT", 68, 78], ["siltuximab", "TREATMENT", 83, 93], ["COVID", "TEST", 119, 124], ["Antibody formats", "TEST", 139, 155]]], ["Fusion protein and other formats, such as DARPin, mRNA-encoding mAb,2) Antibody formatsradiotherapeutics, are also being tested for the treatment of COVID-19.3) Antibody development statusAmong the programs and molecules we are tracking, over 60% are in discovery and preclinical stages (Figure 2A) Table 2 ).", [["DARPin", "GENE_OR_GENE_PRODUCT", 42, 48], ["Fusion protein", "PROTEIN", 0, 14], ["DARPin", "PROTEIN", 42, 48], ["mRNA", "RNA", 50, 54], ["mAb", "PROTEIN", 64, 67], ["Fusion protein", "TEST", 0, 14], ["other formats", "TEST", 19, 32], ["DARPin", "TREATMENT", 42, 48], ["COVID", "TEST", 149, 154]]], ["The trial is a randomized, double-blind and placebo-controlled study to evaluate the tolerability, safety, pharmacokinetic and immunogenicity of JS016 in healthy subjects.", [["JS016", "CHEMICAL", 145, 150], ["JS016", "CHEMICAL", 145, 150], ["JS016", "SIMPLE_CHEMICAL", 145, 150], ["double-blind", "TREATMENT", 27, 39], ["placebo", "TREATMENT", 44, 51], ["controlled study", "TEST", 52, 68]]], ["TY027 was developed by Tychan in partnership with the whole-of-Singapore government engagement (Table 2 ).", [["TY027", "CHEMICAL", 0, 5]]], ["TY027 is being explored for the treatment of patients with COVID-19 to slow the progression of the disease and accelerate recovery, as well as for its potential to provide temporary protection against infection of3) Antibody development statusBased on the number of research and development programs, the United States and China are the top two countries in developing COVID-19 antibody therapeutics, followed by Canada, Germany, South Korea, UK, and France ( Figure 2B ).Conclusion and PerspectivesThe COVID-19 pandemic is causing unprecedented worldwide impacts on healthcare, research and economies.", [["TY027", "CHEMICAL", 0, 5], ["COVID-19", "CHEMICAL", 59, 67], ["infection", "DISEASE", 201, 210], ["TY027", "CHEMICAL", 0, 5], ["COVID-19", "CHEMICAL", 59, 67], ["TY027", "SIMPLE_CHEMICAL", 0, 5], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["COVID", "TREATMENT", 59, 64], ["the disease", "PROBLEM", 95, 106], ["temporary protection", "TREATMENT", 172, 192], ["infection", "PROBLEM", 201, 210], ["COVID", "TEST", 369, 374], ["The COVID", "TEST", 499, 508]]], ["To bring the pandemic under control, development of effective treatments is urgently needed.", [["effective treatments", "TREATMENT", 52, 72]]], ["To help address the emergent information needs, our \"Tracker\" provides a useful reference for researchers and the public to track current progress of drugs developed for COVID-19.", [["COVID-19", "CHEMICAL", 170, 178], ["drugs", "TREATMENT", 150, 155], ["COVID", "TEST", 170, 175]]], ["(22), SARS-CoV-2 (23-26) have caused major outbreaks and substantial disruption due to the lack of human immunity and facile transmission of the virus.", [["SARS-CoV-2 (23-26)", "CHEMICAL", 6, 24], ["SARS-CoV-2", "ORGANISM", 6, 16], ["human", "ORGANISM", 99, 104], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["SARS-CoV", "TEST", 6, 14], ["major outbreaks", "PROBLEM", 37, 52], ["substantial disruption", "PROBLEM", 57, 79], ["the virus", "PROBLEM", 141, 150], ["substantial", "OBSERVATION_MODIFIER", 57, 68], ["disruption", "OBSERVATION", 69, 79]]], ["It has been proposed that a so-called \"universal\" target or strategy for inhibiting both SARS-CoV and SARS-CoV-2 or even all coronaviruses should be identified to allow treatment of not only the current COVID-19 pandemic, but also future SARS-related coronavirus infections (3) .", [["SARS", "DISEASE", 89, 93], ["SARS", "DISEASE", 238, 242], ["coronavirus infections", "DISEASE", 251, 273], ["SARS-CoV", "ORGANISM", 89, 97], ["SARS-CoV-2", "ORGANISM", 102, 112], ["coronaviruses", "ORGANISM", 125, 138], ["coronavirus", "ORGANISM", 251, 262], ["SARS-CoV", "SPECIES", 89, 97], ["SARS-CoV", "SPECIES", 102, 110], ["a so-called \"universal\" target", "TREATMENT", 26, 56], ["SARS", "PROBLEM", 102, 106], ["CoV", "TEST", 107, 110], ["all coronaviruses", "PROBLEM", 121, 138], ["the current COVID", "TEST", 191, 208], ["pandemic", "PROBLEM", 212, 220], ["SARS", "PROBLEM", 238, 242], ["coronavirus infections", "PROBLEM", 251, 273]]], ["In proof-of-concept studies, neutralizing antibodies, such as 47D11 (27), S309(28), VHH-72 (29) , and ADI55689/ADI56046 (30), against highly conserved region of RBD or the S1 subunit of the SARS-CoV-2 spike protein have also been shown to possess neutralizing activities against SARS-CoV.", [["ADI55689", "CHEMICAL", 102, 110], ["ADI56046", "CHEMICAL", 111, 119], ["SARS-CoV", "DISEASE", 279, 287], ["RBD", "GENE_OR_GENE_PRODUCT", 161, 164], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 190, 200], ["SARS-CoV", "ORGANISM", 279, 287], ["neutralizing antibodies", "PROTEIN", 29, 52], ["RBD", "PROTEIN", 161, 164], ["S1 subunit", "PROTEIN", 172, 182], ["SARS-CoV-2 spike protein", "PROTEIN", 190, 214], ["SARS-CoV", "SPECIES", 190, 198], ["SARS-CoV", "SPECIES", 279, 287], ["concept studies", "TEST", 12, 27], ["neutralizing antibodies", "TEST", 29, 52], ["VHH", "TEST", 84, 87], ["ADI55689", "TEST", 102, 110], ["RBD", "PROBLEM", 161, 164], ["the SARS", "PROBLEM", 186, 194], ["CoV", "TEST", 195, 198], ["2 spike protein", "PROBLEM", 199, 214], ["SARS", "PROBLEM", 279, 283], ["CoV", "PROBLEM", 284, 287], ["RBD", "OBSERVATION", 161, 164]]], ["With an exception of VHH-72, these mAbs are fully human IgG molecules, which is a format suitable for therapeutic development, but more potent cross-neutralizing antibodies might be needed for clinical studies.", [["VHH-72", "GENE_OR_GENE_PRODUCT", 21, 27], ["mAbs", "GENE_OR_GENE_PRODUCT", 35, 39], ["human", "ORGANISM", 50, 55], ["IgG", "GENE_OR_GENE_PRODUCT", 56, 59], ["VHH", "PROTEIN", 21, 24], ["mAbs", "PROTEIN", 35, 39], ["human IgG molecules", "PROTEIN", 50, 69], ["neutralizing antibodies", "PROTEIN", 149, 172], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["VHH", "TEST", 21, 24], ["these mAbs", "TEST", 29, 39], ["fully human IgG molecules", "PROBLEM", 44, 69], ["more potent cross-neutralizing antibodies", "PROBLEM", 131, 172], ["clinical studies", "TEST", 193, 209]]], ["Although it is challenging to develop \"universal\" antibodies targeting coronaviruses, efforts are currently being made to isolate broad and potent neutralizing antibodies against multipleSARS-CoV (20,21), MERS-CoVcoronaviruses, including SARS-CoV-2 (https://www.fiercebiotech.com/biotech/adagio-debuts-50m-to-fight-covid-19-and-nextpandemic).SARS-CoV (20,21), MERS-CoVCurrent challenges in developing neutralizing antibodies against SARS-CoV-2 include mutations in the spike protein (31) .SARS-CoV (20,21), MERS-CoVMutations in the virus can lead to escape variants (32) .", [["SARS", "DISEASE", 489, 493], ["multipleSARS-CoV", "ORGANISM", 179, 195], ["MERS-CoVcoronaviruses", "SIMPLE_CHEMICAL", 205, 226], ["SARS-CoV-2", "ORGANISM", 238, 248], ["SARS-CoV-2", "ORGANISM", 433, 443], ["SARS-CoV", "ORGANISM", 489, 497], ["MERS-CoVMutations", "GENE_OR_GENE_PRODUCT", 507, 524], ["neutralizing antibodies", "PROTEIN", 147, 170], ["neutralizing antibodies", "PROTEIN", 401, 424], ["spike protein", "PROTEIN", 469, 482], ["SARS-CoV", "SPECIES", 433, 441], ["multipleSARS-CoV", "SPECIES", 179, 195], ["SARS-CoV", "SPECIES", 433, 441], ["SARS-CoV", "SPECIES", 489, 497], ["universal\" antibodies targeting coronaviruses", "PROBLEM", 39, 84], ["potent neutralizing antibodies", "TEST", 140, 170], ["multipleSARS", "TEST", 179, 191], ["CoV", "TEST", 192, 195], ["MERS", "PROBLEM", 205, 209], ["SARS-CoV", "PROBLEM", 238, 246], ["SARS-CoV", "PROBLEM", 342, 350], ["CoVCurrent challenges", "TREATMENT", 365, 386], ["neutralizing antibodies", "TEST", 401, 424], ["SARS", "PROBLEM", 433, 437], ["CoV", "TEST", 438, 441], ["mutations", "PROBLEM", 452, 461], ["the spike protein", "TEST", 465, 482], ["MERS", "PROBLEM", 507, 511], ["CoVMutations", "TREATMENT", 512, 524], ["the virus", "PROBLEM", 528, 537]]], ["Combination of multiple mechanisms and binding domains has been reported in MERS-CoV (33) and SARS-CoV (32) antibody development.", [["MERS-CoV", "ORGANISM", 76, 84], ["SARS-CoV", "ORGANISM", 94, 102], ["binding domains", "PROTEIN", 39, 54], ["MERS-CoV", "SPECIES", 76, 84], ["SARS-CoV", "SPECIES", 94, 102], ["multiple mechanisms and binding domains", "PROBLEM", 15, 54], ["SARS-CoV (32) antibody development", "PROBLEM", 94, 128], ["multiple", "OBSERVATION_MODIFIER", 15, 23]]], ["A combination (cocktail) of two antibodies that recognize different non-competing epitopes of the RBD or the spike protein of SARS-CoV-2 has been developed for clinical trials to treat COVID-19 (10) .", [["COVID-19", "CHEMICAL", 185, 193], ["RBD", "GENE_OR_GENE_PRODUCT", 98, 101], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 126, 136], ["antibodies", "PROTEIN", 32, 42], ["non-competing epitopes", "PROTEIN", 68, 90], ["RBD", "PROTEIN", 98, 101], ["spike protein", "PROTEIN", 109, 122], ["SARS-CoV", "SPECIES", 126, 134], ["A combination (cocktail", "TREATMENT", 0, 23], ["the RBD", "PROBLEM", 94, 101], ["the spike protein of SARS", "PROBLEM", 105, 130], ["CoV", "TEST", 131, 134], ["COVID", "TEST", 185, 190]]], ["Since each of the non-competing neutralizing antibodies targeting the RBD of the spike protein has potent activity against the SARS-CoV-2 virus, combination of these antibodies does not show superior neutralizing activities in culture.", [["SARS-CoV-2 virus", "ORGANISM", 127, 143], ["non-competing neutralizing antibodies", "PROTEIN", 18, 55], ["RBD", "PROTEIN", 70, 73], ["spike protein", "PROTEIN", 81, 94], ["antibodies", "PROTEIN", 166, 176], ["CoV-2 virus", "SPECIES", 132, 143], ["SARS-CoV-2 virus", "SPECIES", 127, 143], ["the non-competing neutralizing antibodies", "TREATMENT", 14, 55], ["the spike protein", "PROBLEM", 77, 94], ["the SARS", "PROBLEM", 123, 131], ["CoV-2 virus", "PROBLEM", 132, 143], ["these antibodies", "TEST", 160, 176], ["superior neutralizing activities in culture", "PROBLEM", 191, 234], ["potent activity", "OBSERVATION_MODIFIER", 99, 114], ["superior", "OBSERVATION_MODIFIER", 191, 199], ["neutralizing", "OBSERVATION", 200, 212]]], ["Nevertheless, the major advantage for the cocktail strategy is the ability to prevent epitope escape.", [["the cocktail strategy", "TREATMENT", 38, 59], ["epitope escape", "PROBLEM", 86, 100]]], ["More cocktail therapies that involve multiple targets or Antibodies that target the spike protein other than the S1 subunit have rarely been reported so far.", [["S1", "GENE_OR_GENE_PRODUCT", 113, 115], ["Antibodies", "PROTEIN", 57, 67], ["spike protein", "PROTEIN", 84, 97], ["S1 subunit", "PROTEIN", 113, 123], ["More cocktail therapies", "TREATMENT", 0, 23], ["multiple targets", "PROBLEM", 37, 53], ["Antibodies", "TREATMENT", 57, 67], ["the spike protein", "TEST", 80, 97]]], ["The S2 subunit, in particular heptad repeat (HR) loops including HR1 and HR2 domains, required for membrane fusion has been suggested as another potentially (3) .", [["membrane", "ANATOMY", 99, 107], ["S2", "GENE_OR_GENE_PRODUCT", 4, 6], ["HR1", "GENE_OR_GENE_PRODUCT", 65, 68], ["HR2", "GENE_OR_GENE_PRODUCT", 73, 76], ["membrane", "CELLULAR_COMPONENT", 99, 107], ["S2 subunit", "PROTEIN", 4, 14], ["heptad repeat (HR) loops", "PROTEIN", 30, 54], ["HR1", "PROTEIN", 65, 68], ["HR2 domains", "PROTEIN", 73, 84], ["HR1 and HR2 domains", "TEST", 65, 84], ["membrane fusion", "TREATMENT", 99, 114]]], ["The 1A9 antibody is a monoclonal antibody that binds the HR2 domain on the S2 subunit of SARS-CoV (35) .SARS-CoV (20,21), MERS-CoVSince the S2 subunit is highly conserved, it would be interesting to explore whether such antibodies have broad neutralizing activities against both SARS-CoV and SARS-CoV-2.", [["SARS", "DISEASE", 104, 108], ["SARS", "DISEASE", 279, 283], ["1A9 antibody", "GENE_OR_GENE_PRODUCT", 4, 16], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 89, 97], ["SARS-CoV", "ORGANISM", 104, 112], ["MERS-CoVSince", "GENE_OR_GENE_PRODUCT", 122, 135], ["S2", "GENE_OR_GENE_PRODUCT", 140, 142], ["SARS-CoV", "ORGANISM", 279, 287], ["SARS-CoV-2", "ORGANISM", 292, 302], ["1A9 antibody", "PROTEIN", 4, 16], ["monoclonal antibody", "PROTEIN", 22, 41], ["HR2 domain", "PROTEIN", 57, 67], ["S2 subunit", "PROTEIN", 75, 85], ["MERS-CoVSince", "DNA", 122, 135], ["S2 subunit", "PROTEIN", 140, 150], ["antibodies", "PROTEIN", 220, 230], ["SARS-CoV", "SPECIES", 89, 97], ["SARS-CoV", "SPECIES", 104, 112], ["SARS-CoV", "SPECIES", 279, 287], ["SARS-CoV", "SPECIES", 292, 300], ["The 1A9 antibody", "TEST", 0, 16], ["a monoclonal antibody", "PROBLEM", 20, 41], ["CoV", "TEST", 94, 97], ["such antibodies", "PROBLEM", 215, 230], ["broad neutralizing activities", "PROBLEM", 236, 265], ["both SARS", "PROBLEM", 274, 283], ["SARS", "TEST", 292, 296], ["CoV", "TEST", 297, 300]]], ["A broad inhibitor targeting the HR region might be useful for treatment of infection by current and future SARS-related coronavirus.", [["infection", "DISEASE", 75, 84], ["SARS", "DISEASE", 107, 111], ["SARS-related coronavirus", "ORGANISM", 107, 131], ["HR region", "DNA", 32, 41], ["A broad inhibitor targeting the HR region", "TREATMENT", 0, 41], ["infection", "PROBLEM", 75, 84], ["coronavirus", "PROBLEM", 120, 131], ["infection", "OBSERVATION", 75, 84]]], ["Such a concept has been demonstrated in studies of peptide-based pan-coronavirus fusion inhibitors (36, 37) .", [["peptide-based pan-coronavirus fusion inhibitors", "TREATMENT", 51, 98]]], ["A cocktail therapy that combines both ACE2 (S1) blockers and S2 inhibitors in two distinct functional domains of the spike protein would be worthwhile developing and testing.", [["ACE2 (S1) blockers", "GENE_OR_GENE_PRODUCT", 38, 56], ["S2", "GENE_OR_GENE_PRODUCT", 61, 63], ["ACE2", "PROTEIN", 38, 42], ["S1", "PROTEIN", 44, 46], ["spike protein", "PROTEIN", 117, 130], ["A cocktail therapy", "TREATMENT", 0, 18], ["both ACE2 (S1) blockers", "TREATMENT", 33, 56], ["S2 inhibitors", "TREATMENT", 61, 74], ["the spike protein", "PROBLEM", 113, 130], ["testing", "TEST", 166, 173]]], ["Host cell targets such as heparan sulfate proteoglycans (HSPGs) may provide the initial sites for virus attachment and entry (38) .", [["cell", "ANATOMY", 5, 9], ["heparan sulfate", "CHEMICAL", 26, 41], ["Host cell", "CELL", 0, 9], ["heparan sulfate proteoglycans", "GENE_OR_GENE_PRODUCT", 26, 55], ["HSPGs", "GENE_OR_GENE_PRODUCT", 57, 62], ["heparan sulfate proteoglycans", "PROTEIN", 26, 55], ["HSPGs", "PROTEIN", 57, 62], ["Host cell targets", "TREATMENT", 0, 17], ["heparan sulfate proteoglycans (HSPGs)", "TREATMENT", 26, 63], ["virus attachment", "PROBLEM", 98, 114], ["cell targets", "OBSERVATION", 5, 17]]], ["Blocking the HSPGs on human cells by therapeutic antibodies has been proposed for treating COVID-19 and other virus infections (3, 39) .SARS-CoV (20,21), MERS-CoVThe D614G mutation on the SARS-CoV-2 spike protein has been recently identified for its role in increasing infectivity (15) .SARS-CoV (20,21), MERS-CoVStructural models predict that D614G would disrupt contacts between the S1 and S2 domains of the spike protein and cause significant shifts in conformation.", [["cells", "ANATOMY", 28, 33], ["infections", "DISEASE", 116, 126], ["SARS", "DISEASE", 136, 140], ["SARS", "DISEASE", 287, 291], ["HSPGs", "GENE_OR_GENE_PRODUCT", 13, 18], ["human", "ORGANISM", 22, 27], ["cells", "CELL", 28, 33], ["COVID-19", "ORGANISM", 91, 99], ["SARS-CoV", "ORGANISM", 136, 144], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 188, 198], ["HSPGs", "PROTEIN", 13, 18], ["human cells", "CELL_TYPE", 22, 33], ["therapeutic antibodies", "PROTEIN", 37, 59], ["SARS-CoV-2 spike protein", "PROTEIN", 188, 212], ["S1 and S2 domains", "PROTEIN", 385, 402], ["spike protein", "PROTEIN", 410, 423], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["COVID-19", "SPECIES", 91, 99], ["SARS-CoV", "SPECIES", 136, 144], ["SARS-CoV", "SPECIES", 188, 196], ["SARS-CoV", "SPECIES", 287, 295], ["human cells", "TREATMENT", 22, 33], ["therapeutic antibodies", "TREATMENT", 37, 59], ["COVID", "TEST", 91, 96], ["other virus infections", "PROBLEM", 104, 126], ["the SARS", "TEST", 184, 192], ["CoV", "TEST", 193, 196], ["spike protein", "PROBLEM", 199, 212], ["increasing infectivity", "PROBLEM", 258, 280], ["the spike protein", "TEST", 406, 423], ["significant shifts in conformation", "PROBLEM", 434, 468], ["increasing", "OBSERVATION_MODIFIER", 258, 268], ["infectivity", "OBSERVATION", 269, 280], ["significant shifts", "OBSERVATION", 434, 452]]], ["It should be useful to closely monitor and analyze the mutations of SARS-CoV-2 as it spreads worldwide so neutralizing antibodies effective for multiple strains of the virus can be developed (40) (41) (42) .Table 2.", [["SARS", "DISEASE", 68, 72], ["SARS-CoV-2", "ORGANISM", 68, 78], ["neutralizing antibodies", "PROTEIN", 106, 129], ["SARS-CoV", "SPECIES", 68, 76], ["SARS", "PROBLEM", 68, 72], ["neutralizing antibodies", "TREATMENT", 106, 129], ["multiple strains of the virus", "PROBLEM", 144, 173]]], ["Summary of the Eight SARS-CoV-2 S Specific Programs in Clinical TrialsStep 1 Data Acquisition Source: public domains Method: 1) Entries from search engines, company websites, biotech news feed, social media, and government databases were collected.", [["SARS", "DISEASE", 21, 25]]], ["2) When an Application Programming Interface (API) tool is available, such as in the case of ClinicalTrials.gov, Python scripts developed in-house were used for automatic querying and retrieval.Step 2 Filtering & ValidationFiltering: Entries describing preclinical or clinical development of diagnostic antibodies, polyclonal antibodies, convalescent plasma therapies, immune globulin intravenous (IGIV) therapies, small molecules, and recombinant proteins other than immunoglobin (Ig), Ig fragments, and Ig fusion proteins were removed from our collection.", [["plasma", "ANATOMY", 351, 357], ["plasma", "ORGANISM_SUBSTANCE", 351, 357], ["immune globulin", "SIMPLE_CHEMICAL", 369, 384], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 385, 396], ["IGIV", "SIMPLE_CHEMICAL", 398, 402], ["immunoglobin", "GENE_OR_GENE_PRODUCT", 468, 480], ["Ig", "GENE_OR_GENE_PRODUCT", 482, 484], ["Ig", "GENE_OR_GENE_PRODUCT", 487, 489], ["Ig fusion proteins", "GENE_OR_GENE_PRODUCT", 505, 523], ["diagnostic antibodies", "PROTEIN", 292, 313], ["polyclonal antibodies", "PROTEIN", 315, 336], ["recombinant proteins", "PROTEIN", 436, 456], ["immunoglobin", "PROTEIN", 468, 480], ["Ig", "PROTEIN", 482, 484], ["Ig fragments", "PROTEIN", 487, 499], ["Ig fusion proteins", "PROTEIN", 505, 523], ["diagnostic antibodies", "TEST", 292, 313], ["polyclonal antibodies", "TREATMENT", 315, 336], ["convalescent plasma therapies", "TREATMENT", 338, 367], ["immune globulin intravenous (IGIV) therapies", "TREATMENT", 369, 413], ["small molecules", "PROBLEM", 415, 430], ["recombinant proteins", "TREATMENT", 436, 456], ["immunoglobin (Ig)", "TREATMENT", 468, 485], ["Ig fragments", "TREATMENT", 487, 499], ["Ig fusion proteins", "TREATMENT", 505, 523]]], ["Studies and clinical trials without explicitly stating COVID-19 or SARS-CoV-2 as their indication or target were also eliminated.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 55, 63], ["SARS-CoV-2", "ORGANISM", 67, 77], ["Studies", "TEST", 0, 7], ["clinical trials", "TEST", 12, 27], ["COVID", "TEST", 55, 60], ["SARS", "PROBLEM", 67, 71], ["CoV", "TEST", 72, 75]]], ["Filtering was performed manually unless an API tool was available, in which case, it was performed by the Python scripts mentioned above.", [["an API tool", "TEST", 40, 51]]], ["Validation: Validation of each entries we retained in our collection is performed manually, by inspecting and cross-validating using multiple sources if possible.Step 3 Data AnalysisData analysis was performed, and statistics on key aspects, such as drug targets, format and clinical status were generated using R and PythonStep 4 Data VisualizationInteractive non-antibody recombinant protein (rhACE2), and DARPin, mRNA-encoding mAb and radiotherapeutic formats.", [["rhACE2", "GENE_OR_GENE_PRODUCT", 395, 401], ["DARPin", "GENE_OR_GENE_PRODUCT", 408, 414], ["non-antibody recombinant protein", "PROTEIN", 361, 393], ["rhACE2", "PROTEIN", 395, 401], ["DARPin", "PROTEIN", 408, 414], ["mRNA", "RNA", 416, 420], ["mAb", "PROTEIN", 430, 433], ["AnalysisData analysis", "TEST", 174, 195], ["Data Visualization", "TEST", 331, 349], ["DARPin", "TREATMENT", 408, 414], ["mRNA", "TEST", 416, 420], ["radiotherapeutic formats", "TEST", 438, 462]]], ["Figure 1 is based on \"Tracker\" data as of August 8 th , 2020. clinical trials is color-coded from dark blue (the earliest phase) to dark red (the latest phase).", [["color", "TEST", 81, 86], ["dark blue", "PROBLEM", 98, 107]]], ["For therapeutic candidates being developed across multiple countries, each participating country has been counted separately in this chart.", [["therapeutic candidates", "TREATMENT", 4, 26]]]], "a4f7c8161bee0d7f48186b41cbe9d09e19096b00": [["IntroductionThe global COVID-19 pandemic caused by SARS-CoV-2 has infected over 29 million individuals and claimed over 925,000 lives worldwide as of September 15, 2020.", [["SARS", "DISEASE", 51, 55], ["COVID-19", "ORGANISM", 23, 31], ["SARS-CoV-2", "ORGANISM", 51, 61], ["SARS-CoV-2", "SPECIES", 51, 61], ["The global COVID", "TEST", 12, 28], ["pandemic", "PROBLEM", 32, 40], ["SARS", "PROBLEM", 51, 55]]], ["3 The transmission of SARS-CoV-2 is thought to mostly occur via respiratory droplets and aerosol, both targeting the respiratory system.", [["respiratory droplets", "ANATOMY", 64, 84], ["SARS", "DISEASE", 22, 26], ["SARS-CoV-2", "ORGANISM", 22, 32], ["SARS-CoV", "SPECIES", 22, 30], ["SARS", "PROBLEM", 22, 26], ["respiratory droplets", "TREATMENT", 64, 84], ["aerosol", "TREATMENT", 89, 96], ["respiratory droplets", "OBSERVATION", 64, 84], ["respiratory system", "ANATOMY", 117, 135]]], ["4, 5 The SARS-CoV-2 spike (S) glycoprotein allows viral entry into the cell by binding to the extracellular domain of the ACE2 receptor.", [["cell", "ANATOMY", 71, 75], ["extracellular", "ANATOMY", 94, 107], ["cell", "CELL", 71, 75], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 94, 107], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 122, 135], ["SARS-CoV-2 spike (S) glycoprotein", "PROTEIN", 9, 42], ["extracellular domain", "PROTEIN", 94, 114], ["ACE2 receptor", "PROTEIN", 122, 135], ["The SARS", "TEST", 5, 13], ["CoV", "TEST", 14, 17], ["glycoprotein", "TREATMENT", 30, 42]]], ["6, 7 It is thought that ACE2 is necessary for infection by SARS-CoV-2 and that it contributes to disease severity.", [["infection", "DISEASE", 46, 55], ["SARS", "DISEASE", 59, 63], ["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["SARS-CoV-2", "ORGANISM", 59, 69], ["ACE2", "PROTEIN", 24, 28], ["SARS-CoV", "SPECIES", 59, 67], ["ACE2", "PROBLEM", 24, 28], ["infection", "PROBLEM", 46, 55], ["SARS", "PROBLEM", 59, 63], ["CoV", "TEST", 64, 67], ["disease severity", "PROBLEM", 97, 113], ["disease", "OBSERVATION", 97, 104]]], ["8 In a different strain of SARS coronavirus, transgenic mice expressing human ACE2 in airway and other epithelia cells develop a rapidly lethal infection.", [["airway", "ANATOMY", 86, 92], ["epithelia cells", "ANATOMY", 103, 118], ["SARS coronavirus", "DISEASE", 27, 43], ["infection", "DISEASE", 144, 153], ["SARS coronavirus", "ORGANISM", 27, 43], ["transgenic mice", "ORGANISM", 45, 60], ["human", "ORGANISM", 72, 77], ["ACE2", "GENE_OR_GENE_PRODUCT", 78, 82], ["airway", "MULTI-TISSUE_STRUCTURE", 86, 92], ["epithelia cells", "CELL", 103, 118], ["human ACE2", "PROTEIN", 72, 82], ["epithelia cells", "CELL_TYPE", 103, 118], ["coronavirus", "SPECIES", 32, 43], ["mice", "SPECIES", 56, 60], ["human", "SPECIES", 72, 77], ["SARS coronavirus", "SPECIES", 27, 43], ["mice", "SPECIES", 56, 60], ["human", "SPECIES", 72, 77], ["SARS coronavirus", "PROBLEM", 27, 43], ["human ACE2 in airway", "PROBLEM", 72, 92], ["other epithelia cells", "PROBLEM", 97, 118], ["a rapidly lethal infection", "PROBLEM", 127, 153], ["SARS coronavirus", "OBSERVATION", 27, 43], ["airway", "ANATOMY", 86, 92], ["rapidly", "OBSERVATION_MODIFIER", 129, 136], ["lethal", "OBSERVATION_MODIFIER", 137, 143], ["infection", "OBSERVATION", 144, 153]]], ["9 The nasal epithelium, in direct contact with the environment, is a primary target of SARS-CoV-2 infection.", [["nasal epithelium", "ANATOMY", 6, 22], ["SARS-CoV-2 infection", "DISEASE", 87, 107], ["nasal epithelium", "TISSUE", 6, 22], ["SARS-CoV-2", "ORGANISM", 87, 97], ["SARS-CoV-2", "SPECIES", 87, 97], ["The nasal epithelium", "PROBLEM", 2, 22], ["SARS", "PROBLEM", 87, 91], ["CoV-2 infection", "PROBLEM", 92, 107], ["nasal epithelium", "ANATOMY", 6, 22], ["infection", "OBSERVATION", 98, 107]]], ["Both ACE2 expression and SARS-CoV-2 infectivity are higher in nasal epithelium relative to the lungs.", [["nasal epithelium", "ANATOMY", 62, 78], ["lungs", "ANATOMY", 95, 100], ["ACE2", "GENE_OR_GENE_PRODUCT", 5, 9], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 25, 35], ["nasal epithelium", "TISSUE", 62, 78], ["lungs", "ORGAN", 95, 100], ["ACE2", "PROTEIN", 5, 9], ["Both ACE2 expression", "TEST", 0, 20], ["SARS", "TEST", 25, 29], ["CoV", "TEST", 30, 33], ["expression", "OBSERVATION_MODIFIER", 10, 20], ["SARS", "OBSERVATION_MODIFIER", 25, 29], ["CoV", "OBSERVATION_MODIFIER", 30, 33], ["infectivity", "OBSERVATION_MODIFIER", 36, 47], ["higher", "OBSERVATION_MODIFIER", 52, 58], ["nasal", "ANATOMY", 62, 67], ["epithelium", "ANATOMY_MODIFIER", 68, 78], ["lungs", "ANATOMY", 95, 100]]], ["1 The nose is exposed to environmental challenges such as air pollution, cigarette smoke, and allergens that could modulate SARS-CoV-2 infectivity and COVID-19 severity and may explain disparities.", [["nose", "ANATOMY", 6, 10], ["nose", "ORGAN", 6, 10], ["cigarette", "ORGANISM_SUBDIVISION", 73, 82], ["SARS-CoV-2", "ORGANISM", 124, 134], ["environmental challenges", "TREATMENT", 25, 49], ["allergens", "PROBLEM", 94, 103], ["modulate SARS", "PROBLEM", 115, 128], ["CoV", "TEST", 129, 132], ["COVID", "TEST", 151, 156], ["nose", "ANATOMY", 6, 10]]], ["For example, it has been hypothesized that exposure to air pollution and cigarette smoke could worsen immune response to SARS-CoV-2.", [["smoke", "CHEMICAL", 83, 88], ["SARS", "DISEASE", 121, 125], ["cigarette", "ORGANISM", 73, 82], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 121, 131], ["SARS-CoV", "SPECIES", 121, 129], ["immune response", "PROBLEM", 102, 117], ["CoV", "TEST", 126, 129], ["air pollution", "OBSERVATION", 55, 68]]], ["10,11 This is in part supported by studies demonstrating that ACE2 expression is increased after PM2.5 exposure 12,13 and among current smokers.", [["PM2.5", "CHEMICAL", 97, 102], ["PM2.5", "CHEMICAL", 97, 102], ["ACE2", "GENE_OR_GENE_PRODUCT", 62, 66], ["ACE2", "PROTEIN", 62, 66], ["ACE2 expression", "PROBLEM", 62, 77], ["increased", "OBSERVATION_MODIFIER", 81, 90]]], ["8, 14 Transcriptional regulation via DNAm of ACE2 has been documented in peripheral leukocytes and T cells 15, 16 and hypothesized to modulate SARS-CoV-2 infectivity and COVID-19 severity.", [["peripheral leukocytes", "ANATOMY", 73, 94], ["T cells", "ANATOMY", 99, 106], ["DNAm", "GENE_OR_GENE_PRODUCT", 37, 41], ["ACE2", "GENE_OR_GENE_PRODUCT", 45, 49], ["peripheral leukocytes", "CELL", 73, 94], ["T cells", "CELL", 99, 106], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 143, 153], ["DNAm", "PROTEIN", 37, 41], ["ACE2", "PROTEIN", 45, 49], ["peripheral leukocytes", "CELL_TYPE", 73, 94], ["T cells", "CELL_TYPE", 99, 106], ["DNAm of ACE2", "TEST", 37, 49], ["peripheral leukocytes", "TEST", 73, 94], ["T cells", "TEST", 99, 106], ["modulate SARS", "TEST", 134, 147], ["CoV", "TEST", 148, 151], ["COVID", "TEST", 170, 175], ["peripheral leukocytes", "ANATOMY", 73, 94]]], ["17, 18 The ACE gene is located in the X-chromosome and shown to escape X-inactivation in females 18 with heterogeneous but significant male-bias in expression in several tissues.", [["X-chromosome", "ANATOMY", 38, 50], ["tissues", "ANATOMY", 170, 177], ["ACE", "GENE_OR_GENE_PRODUCT", 11, 14], ["tissues", "TISSUE", 170, 177], ["ACE gene", "DNA", 11, 19], ["X-chromosome", "DNA", 38, 50], ["The ACE gene", "TREATMENT", 7, 19], ["escape X-inactivation", "OBSERVATION", 64, 85], ["heterogeneous", "OBSERVATION_MODIFIER", 105, 118], ["significant", "OBSERVATION_MODIFIER", 123, 134], ["male", "OBSERVATION", 135, 139], ["bias", "OBSERVATION", 140, 144], ["several tissues", "ANATOMY", 162, 177]]], ["19 However, no study has examined the DNAm landscape of the ACE2 gene in target nasal cells.Introduction.", [["nasal cells", "ANATOMY", 80, 91], ["ACE2", "GENE_OR_GENE_PRODUCT", 60, 64], ["nasal cells", "CELL", 80, 91], ["ACE2 gene", "DNA", 60, 69], ["target nasal cells", "CELL_TYPE", 73, 91], ["study", "TEST", 15, 20], ["nasal cells", "ANATOMY", 80, 91]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintIntroductionThe copyright holder for this this version posted September 16, 2020 Figure 1 -B.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Given large differences by sex and ACE2 escaping X-inactivation, we analyzed age associations stratified by .", [["ACE2", "GENE_OR_GENE_PRODUCT", 35, 39], ["ACE2", "PROTEIN", 35, 39], ["X", "DNA", 49, 50], ["large", "OBSERVATION_MODIFIER", 6, 11]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintIntroductionThe copyright holder for this this version posted September 16, 2020. . https://doi.org/10.1101/2020.08.25.20182105 doi: medRxiv preprint sex and observed that chronological age was associated with consistently lower but weak DNAm among females and only 4 CpGs reached unadjusted significance (p<0.05); associations did not survive false discovery adjustment.", [["CC", "CHEMICAL", 0, 2], ["weak DNAm among females", "PROBLEM", 441, 464], ["med", "ANATOMY", 102, 105]]], ["However, power was limited by the narrow age range.IntroductionHispanic females had significantly greater DNAm of 6.63% at cg03536816, 1.12% at cg08559914, 4.44% at cg16734967 and 2.21% at cg23232263 while cg10408040 showed a 1.69% lower DNAm relative to white females (FDR<0.05), Table 2 .", [["cg10408040", "CHEMICAL", 206, 216], ["cg16734967", "TEST", 165, 175], ["cg", "TEST", 206, 208], ["a 1.69% lower DNAm relative to white females", "PROBLEM", 224, 268], ["FDR", "TEST", 270, 273], ["narrow", "OBSERVATION_MODIFIER", 34, 40]]], ["A local ACE2 gene Manhattan plot for the association with Hispanic females with genomic annotation and correlation structure is shown in Figure 1 -C.", [["ACE2", "GENE_OR_GENE_PRODUCT", 8, 12], ["ACE2 gene", "DNA", 8, 17], ["genomic annotation", "TEST", 80, 98]]], ["Among Black males, significantly lower DNAm at 8 CpG sites was present relative to white males.", [["CpG", "CHEMICAL", 49, 52], ["Black males", "PROBLEM", 6, 17], ["significantly lower DNAm at 8 CpG sites", "PROBLEM", 19, 58], ["Black", "OBSERVATION_MODIFIER", 6, 11], ["males", "OBSERVATION", 12, 17], ["significantly", "OBSERVATION_MODIFIER", 19, 32], ["lower DNAm", "OBSERVATION_MODIFIER", 33, 43], ["white males", "OBSERVATION", 83, 94]]], ["Specifically, lower DNAm of 0.75% at cg18458833, 0.77% at cg18877734, 1.76% at cg08559914, 3.44% at cg16734967, 1.36% at cg05241917, 1.30% at cg20119767, 0.64% at cg25176872 and 0.60% at cg23232263 for Black relative to white males was observed, adjusting for age (FDR<0.05), Table 2 .", [["lower DNAm", "TEST", 14, 24], ["cg25176872", "TEST", 163, 173], ["Black relative to white males", "PROBLEM", 202, 231], ["lower", "ANATOMY_MODIFIER", 14, 19]]], ["A local ACE2 gene Manhattan plot for the association among Black males with genomic annotation and correlation structure is presented in Figure 1 -D.", [["ACE2", "GENE_OR_GENE_PRODUCT", 8, 12], ["ACE2 gene", "DNA", 8, 17], ["A local ACE2 gene Manhattan plot", "TREATMENT", 0, 32], ["genomic annotation", "TEST", 76, 94]]], ["No differences were observed among Asian or participants of more than one race, Table S2 .IntroductionDNAm telomere length (DNAmTL) and the Skin and Blood Epigenetic clock were chosen as markers of epigenetic aging as they performed relatively well against chronological age, Figure S1 .", [["telomere", "ANATOMY", 107, 115], ["Skin", "ANATOMY", 140, 144], ["Blood", "ANATOMY", 149, 154], ["IntroductionDNAm", "GENE_OR_GENE_PRODUCT", 90, 106], ["telomere", "CELLULAR_COMPONENT", 107, 115], ["Skin", "ORGAN", 140, 144], ["Blood", "ORGANISM_SUBSTANCE", 149, 154], ["DNAmTL", "DNA", 124, 130], ["participants", "SPECIES", 44, 56], ["IntroductionDNAm telomere length (DNAmTL)", "TREATMENT", 90, 131], ["the Skin and Blood Epigenetic clock", "TREATMENT", 136, 171], ["epigenetic aging", "TREATMENT", 198, 214], ["length", "OBSERVATION_MODIFIER", 116, 122], ["Skin", "ANATOMY", 140, 144]]], ["Longer DNAm telomere length adjusted for age (DNAmTLadjAge) was consistently and strongly associated with greater ACE2 DNAm for males with a mean increase of 7.86% increased across 11 CpGs.", [["telomere", "ANATOMY", 12, 20], ["CpGs", "CHEMICAL", 184, 188], ["DNAm telomere", "CELLULAR_COMPONENT", 7, 20], ["ACE2", "GENE_OR_GENE_PRODUCT", 114, 118], ["ACE2", "PROTEIN", 114, 118], ["length", "OBSERVATION_MODIFIER", 21, 27]]], ["For females a mean of 8.21% greater DNAm across 13 CpGs was observed.", [["CpGs", "CHEMICAL", 51, 55]]], ["Weaker positive relationships were observed for 5 CpGs with epigenetic age acceleration of the skin and blood clock, Table 3 .Introduction.", [["skin", "ANATOMY", 95, 99], ["blood", "ANATOMY", 104, 109], ["skin", "ORGAN", 95, 99], ["blood", "ORGANISM_SUBSTANCE", 104, 109], ["Weaker positive relationships", "PROBLEM", 0, 29], ["blood clock", "TEST", 104, 115], ["skin", "ANATOMY", 95, 99], ["blood", "ANATOMY", 104, 109]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintIntroductionThe copyright holder for this this version posted September 16, 2020. . https://doi.org/10.1101/2020.08.25.20182105 doi: medRxiv preprintDISCUSSIONIn summary, all ACE2 CpGs tested differed strongly and significantly by sex with most sites showing a decrease in DNAm among females relative to males.", [["CC", "CHEMICAL", 0, 2], ["ACE2", "GENE_OR_GENE_PRODUCT", 383, 387], ["DNAm", "GENE_OR_GENE_PRODUCT", 481, 485], ["ACE2 CpGs", "DNA", 383, 392], ["all ACE2 CpGs", "TREATMENT", 379, 392], ["a decrease in DNAm", "PROBLEM", 467, 485], ["med", "ANATOMY", 102, 105], ["decrease", "OBSERVATION_MODIFIER", 469, 477]]], ["In sex stratified analyses, moderate greater DNAm for Hispanic females and consistently lower DNAm among Black males relative to white participants was observed.", [["participants", "SPECIES", 135, 147], ["moderate greater DNAm", "PROBLEM", 28, 49], ["Hispanic females", "PROBLEM", 54, 70], ["consistently lower DNAm", "PROBLEM", 75, 98], ["moderate", "OBSERVATION_MODIFIER", 28, 36]]], ["Longer telomere length adjusted for age was strongly associated with greater ACE2 DNAm and this was consistent among males and females across most CpGs.DISCUSSIONThe ACE2 gene is located in the X-chromosome and escapes X-inactivation in females with potential tissue specificity and heterogenous male expression bias, partially attributed to sex steroids.", [["telomere", "ANATOMY", 7, 15], ["X-chromosome", "ANATOMY", 194, 206], ["tissue", "ANATOMY", 260, 266], ["steroids", "CHEMICAL", 346, 354], ["CpGs", "CHEMICAL", 147, 151], ["steroids", "CHEMICAL", 346, 354], ["telomere", "CELLULAR_COMPONENT", 7, 15], ["ACE2", "GENE_OR_GENE_PRODUCT", 77, 81], ["ACE2", "GENE_OR_GENE_PRODUCT", 166, 170], ["tissue", "TISSUE", 260, 266], ["ACE2", "PROTEIN", 77, 81], ["ACE2 gene", "DNA", 166, 175], ["X-chromosome", "DNA", 194, 206], ["greater ACE2 DNAm", "PROBLEM", 69, 86], ["potential tissue specificity", "PROBLEM", 250, 278], ["heterogenous male expression bias", "PROBLEM", 283, 316], ["sex steroids", "TREATMENT", 342, 354], ["heterogenous", "OBSERVATION_MODIFIER", 283, 295]]], ["20 This heterogeneity has been documented in data from an RNAseq Atlas identifying co-expression of both ACE2 and the accessory proteases among subsets of respiratory epithelial cells as putative targets of SARS-CoV-2 infection.", [["respiratory epithelial cells", "ANATOMY", 155, 183], ["infection", "DISEASE", 218, 227], ["ACE2", "GENE_OR_GENE_PRODUCT", 105, 109], ["respiratory epithelial cells", "CELL", 155, 183], ["SARS-CoV-2", "ORGANISM", 207, 217], ["ACE2", "PROTEIN", 105, 109], ["accessory proteases", "PROTEIN", 118, 137], ["respiratory epithelial cells", "CELL_TYPE", 155, 183], ["SARS-CoV-2", "SPECIES", 207, 217], ["the accessory proteases", "PROBLEM", 114, 137], ["respiratory epithelial cells", "PROBLEM", 155, 183], ["SARS", "PROBLEM", 207, 211], ["CoV-2 infection", "PROBLEM", 212, 227], ["respiratory epithelial cells", "OBSERVATION", 155, 183], ["infection", "OBSERVATION", 218, 227]]], ["Specifically, nasal goblet cells and ciliated cells comprised the highest fraction of cells expressing both ACE2 and the viral entry associated protease TMPRSS2.", [["nasal goblet cells", "ANATOMY", 14, 32], ["ciliated cells", "ANATOMY", 37, 51], ["cells", "ANATOMY", 86, 91], ["nasal goblet cells", "CELL", 14, 32], ["ciliated cells", "CELL", 37, 51], ["cells", "CELL", 86, 91], ["ACE2", "GENE_OR_GENE_PRODUCT", 108, 112], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 153, 160], ["nasal goblet cells", "CELL_TYPE", 14, 32], ["ciliated cells", "CELL_TYPE", 37, 51], ["ACE2", "PROTEIN", 108, 112], ["viral entry associated protease", "PROTEIN", 121, 152], ["TMPRSS2", "PROTEIN", 153, 160], ["nasal goblet cells", "TEST", 14, 32], ["ciliated cells", "PROBLEM", 37, 51], ["nasal", "ANATOMY", 14, 19], ["goblet cells", "OBSERVATION", 20, 32], ["ciliated cells", "OBSERVATION", 37, 51], ["highest fraction", "OBSERVATION_MODIFIER", 66, 82], ["viral entry", "OBSERVATION", 121, 132]]], ["2, 21 The relatively high ACE2 expression in the nasal epithelium its coupled with high infectivity in nasal epithelium with progressively lower expression and infectivity in the bronchial and alveolar regions.", [["nasal epithelium", "ANATOMY", 49, 65], ["nasal epithelium", "ANATOMY", 103, 119], ["bronchial", "ANATOMY", 179, 188], ["alveolar regions", "ANATOMY", 193, 209], ["ACE2", "GENE_OR_GENE_PRODUCT", 26, 30], ["nasal epithelium", "TISSUE", 49, 65], ["nasal epithelium", "TISSUE", 103, 119], ["bronchial", "MULTI-TISSUE_STRUCTURE", 179, 188], ["alveolar regions", "MULTI-TISSUE_STRUCTURE", 193, 209], ["ACE2", "PROTEIN", 26, 30], ["The relatively high ACE2 expression in the nasal epithelium", "PROBLEM", 6, 65], ["high infectivity in nasal epithelium", "PROBLEM", 83, 119], ["progressively lower expression and infectivity in the bronchial and alveolar regions", "PROBLEM", 125, 209], ["relatively", "OBSERVATION_MODIFIER", 10, 20], ["high", "OBSERVATION_MODIFIER", 21, 25], ["ACE2 expression", "OBSERVATION", 26, 41], ["nasal epithelium", "ANATOMY", 49, 65], ["high", "OBSERVATION_MODIFIER", 83, 87], ["infectivity", "OBSERVATION", 88, 99], ["nasal epithelium", "ANATOMY", 103, 119], ["progressively", "OBSERVATION_MODIFIER", 125, 138], ["lower", "OBSERVATION_MODIFIER", 139, 144], ["expression", "OBSERVATION", 145, 155], ["infectivity", "OBSERVATION_MODIFIER", 160, 171], ["bronchial", "ANATOMY", 179, 188], ["alveolar", "ANATOMY_MODIFIER", 193, 201], ["regions", "ANATOMY_MODIFIER", 202, 209]]], ["1, 22 Increased ACE2 expression has been hypothesized to partially explain differences in COVID-19 severity.", [["ACE2", "GENE_OR_GENE_PRODUCT", 16, 20], ["ACE2", "PROTEIN", 16, 20], ["COVID", "PROTEIN", 90, 95], ["Increased ACE2 expression", "PROBLEM", 6, 31], ["COVID", "TEST", 90, 95], ["Increased", "OBSERVATION_MODIFIER", 6, 15], ["ACE2 expression", "OBSERVATION", 16, 31]]], ["23 For example, lung transcriptome data from patients with comorbid conditions associated with increased risk of severe COVID-19 like hypertension, diabetes, and chronic obstructive lung disease show increased ACE2 expression.", [["lung", "ANATOMY", 16, 20], ["lung", "ANATOMY", 182, 186], ["COVID", "DISEASE", 120, 125], ["hypertension", "DISEASE", 134, 146], ["diabetes", "DISEASE", 148, 156], ["chronic obstructive lung disease", "DISEASE", 162, 194], ["lung", "ORGAN", 16, 20], ["patients", "ORGANISM", 45, 53], ["lung", "ORGAN", 182, 186], ["ACE2", "GENE_OR_GENE_PRODUCT", 210, 214], ["ACE2", "PROTEIN", 210, 214], ["patients", "SPECIES", 45, 53], ["comorbid conditions", "PROBLEM", 59, 78], ["severe COVID", "PROBLEM", 113, 125], ["hypertension", "PROBLEM", 134, 146], ["diabetes", "PROBLEM", 148, 156], ["chronic obstructive lung disease", "PROBLEM", 162, 194], ["increased ACE2 expression", "PROBLEM", 200, 225], ["lung", "ANATOMY", 16, 20], ["transcriptome", "OBSERVATION", 21, 34], ["increased", "OBSERVATION_MODIFIER", 95, 104], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["hypertension", "OBSERVATION", 134, 146], ["diabetes", "OBSERVATION", 148, 156], ["chronic", "OBSERVATION_MODIFIER", 162, 169], ["obstructive", "OBSERVATION_MODIFIER", 170, 181], ["lung", "ANATOMY", 182, 186], ["disease", "OBSERVATION", 187, 194], ["increased", "OBSERVATION_MODIFIER", 200, 209], ["ACE2 expression", "OBSERVATION", 210, 225]]], ["24 ACE2 expression has been reported to be higher in Asians compared with white and African Americans from type II alveolar cells.", [["alveolar cells", "ANATOMY", 115, 129], ["ACE2", "GENE_OR_GENE_PRODUCT", 3, 7], ["type II alveolar cells", "CELL", 107, 129], ["ACE2", "PROTEIN", 3, 7], ["type II alveolar cells", "CELL_TYPE", 107, 129], ["type II alveolar cells", "PROBLEM", 107, 129], ["higher", "OBSERVATION_MODIFIER", 43, 49], ["alveolar cells", "OBSERVATION", 115, 129]]], ["25 However, other reports have found no difference in ACE2 expression by race.", [["ACE2", "GENE_OR_GENE_PRODUCT", 54, 58], ["ACE2", "PROTEIN", 54, 58]]], ["26 Data from lung tissue has shown lower DNAm in females relative to males at cg23232263 and cg16734967 consistent with our finding for females using nasal .", [["lung tissue", "ANATOMY", 13, 24], ["nasal", "ANATOMY", 150, 155], ["lung tissue", "TISSUE", 13, 24], ["DNAm", "GENE_OR_GENE_PRODUCT", 41, 45], ["cg23232263", "GENE_OR_GENE_PRODUCT", 78, 88], ["nasal", "ORGAN", 150, 155], ["lower DNAm in females", "PROBLEM", 35, 56], ["lung", "ANATOMY", 13, 17], ["tissue", "OBSERVATION", 18, 24], ["lower DNAm", "OBSERVATION", 35, 45], ["nasal", "ANATOMY", 150, 155]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintDISCUSSIONThe copyright holder for this this version posted September 16, 2020. . https://doi.org/10.1101/2020.08.25.20182105 doi: medRxiv preprint cells.", [["medRxiv preprint cells", "ANATOMY", 339, 361], ["CC", "CHEMICAL", 0, 2], ["medRxiv preprint cells", "CELL", 339, 361], ["doi: medRxiv preprint cells", "CELL_LINE", 334, 361], ["medRxiv preprint cells", "TREATMENT", 339, 361], ["med", "ANATOMY", 102, 105], ["preprint cells", "OBSERVATION", 347, 361]]], ["27 In addition, a strong negative association between chronological age and DNAm of cg08559914 from airway epithelial cells was reported.", [["airway epithelial cells", "ANATOMY", 100, 123], ["cg08559914", "GENE_OR_GENE_PRODUCT", 84, 94], ["airway epithelial cells", "CELL", 100, 123], ["cg08559914", "PROTEIN", 84, 94], ["airway epithelial cells", "CELL_TYPE", 100, 123], ["DNAm", "TEST", 76, 80], ["airway epithelial cells", "PROBLEM", 100, 123], ["airway", "ANATOMY", 100, 106], ["epithelial cells", "OBSERVATION", 107, 123]]], ["27 However, expression of ACE2 in the lung has been demonstrated to increase with age.", [["lung", "ANATOMY", 38, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 26, 30], ["lung", "ORGAN", 38, 42], ["ACE2", "PROTEIN", 26, 30], ["ACE2 in the lung", "PROBLEM", 26, 42], ["lung", "ANATOMY", 38, 42], ["increase", "OBSERVATION_MODIFIER", 68, 76]]], ["26 In nasal samples, lower ACE2 expression among children relative to older adults has been reported.", [["nasal samples", "ANATOMY", 6, 19], ["nasal samples", "CANCER", 6, 19], ["ACE2", "GENE_OR_GENE_PRODUCT", 27, 31], ["children", "ORGANISM", 49, 57], ["ACE2", "PROTEIN", 27, 31], ["children", "SPECIES", 49, 57], ["nasal", "ANATOMY", 6, 11]]], ["28 Age associated expression differences are hypothesized to partially explain the relatively mild COVID-19 documented cases in children.DISCUSSIONYet, large racial inequalities in need for hospitalization among children have been reported.", [["children", "ORGANISM", 128, 136], ["children", "ORGANISM", 212, 220], ["children", "SPECIES", 128, 136], ["children", "SPECIES", 212, 220], ["large", "OBSERVATION_MODIFIER", 152, 157], ["racial", "OBSERVATION_MODIFIER", 158, 164]]], ["Data from the U.S. shows that hospitalizations for Hispanic and Black children are much more common relative to white children.", [["children", "ORGANISM", 70, 78], ["children", "ORGANISM", 118, 126], ["children", "SPECIES", 70, 78], ["children", "SPECIES", 118, 126]]], ["29 Our results support the hypothesis that ACE2 hypomethylation in nasal epithelium among black males could lead to increased SARS-CoV-2 infectivity and COVID-19 severity via greater abundance of ACE2 receptors.", [["nasal epithelium", "ANATOMY", 67, 83], ["ACE2", "GENE_OR_GENE_PRODUCT", 43, 47], ["nasal epithelium", "TISSUE", 67, 83], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 126, 136], ["COVID-19", "GENE_OR_GENE_PRODUCT", 153, 161], ["ACE2", "GENE_OR_GENE_PRODUCT", 196, 200], ["ACE2", "PROTEIN", 43, 47], ["ACE2 receptors", "PROTEIN", 196, 210], ["SARS-CoV", "SPECIES", 126, 134], ["the hypothesis", "PROBLEM", 23, 37], ["ACE2 hypomethylation in nasal epithelium", "PROBLEM", 43, 83], ["black males", "PROBLEM", 90, 101], ["increased SARS", "PROBLEM", 116, 130], ["CoV", "TEST", 131, 134], ["COVID", "TEST", 153, 158], ["ACE2 receptors", "TREATMENT", 196, 210], ["nasal epithelium", "ANATOMY", 67, 83]]], ["Results among females need to be cautiously interpreted given ACE2 escape from X-inactivation.", [["ACE2", "GENE_OR_GENE_PRODUCT", 62, 66], ["ACE2", "PROTEIN", 62, 66], ["ACE2 escape", "PROBLEM", 62, 73]]], ["ACE2 genetic variants are rare, not shown to differ by sex or populations.", [["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ACE2", "PROTEIN", 0, 4], ["ACE2 genetic variants", "PROBLEM", 0, 21]]], ["30,31 Therefore, we hypothesize that observed DNA methylation variation originates from social and environmental exposures which include social and environmental racism.DISCUSSIONOur study has some limitations.", [["DNA", "CELLULAR_COMPONENT", 46, 49], ["DNA methylation variation", "PROBLEM", 46, 71], ["DISCUSSIONOur study", "TEST", 169, 188]]], ["We do not have ACE2 expression which would inform the underlying hypothesis of epigenetic regulation.", [["ACE2", "GENE_OR_GENE_PRODUCT", 15, 19], ["ACE2", "PROTEIN", 15, 19], ["ACE2 expression", "TREATMENT", 15, 30]]], ["We hypothesize that the relationship between DNAm, expression and ACE2 receptors is likely complex and depends on the genomic context, cells and life-stage.", [["cells", "ANATOMY", 135, 140], ["DNAm", "GENE_OR_GENE_PRODUCT", 45, 49], ["ACE2", "GENE_OR_GENE_PRODUCT", 66, 70], ["cells", "CELL", 135, 140], ["DNAm", "PROTEIN", 45, 49], ["ACE2 receptors", "PROTEIN", 66, 80], ["ACE2 receptors", "TEST", 66, 80], ["likely", "UNCERTAINTY", 84, 90], ["complex", "OBSERVATION_MODIFIER", 91, 98]]], ["The absence of age-related DNAm changes could be due to the narrow age range and young profile of our study.", [["DNA", "CELLULAR_COMPONENT", 27, 30], ["DNAm changes", "PROBLEM", 27, 39], ["our study", "TEST", 98, 107]]], ["However, measures of epigenetic age acceleration might be more sensitive to age-related physiological changes among children as reflected in strong associations with DNAm telomere length.", [["telomere", "ANATOMY", 171, 179], ["children", "ORGANISM", 116, 124], ["DNAm telomere", "CELLULAR_COMPONENT", 166, 179], ["children", "SPECIES", 116, 124], ["epigenetic age acceleration", "PROBLEM", 21, 48]]], ["Although most participants in our cohort were white, .", [["participants", "ORGANISM", 14, 26], ["participants", "SPECIES", 14, 26]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintDISCUSSIONThe copyright holder for this this version posted September 16, 2020. . https://doi.org/10.1101/2020.08.25.20182105 doi: medRxiv preprint the relatively large sample allowed us to test differences stratifying by sex and test differences by race/ethnicity.DISCUSSIONThe epigenome is at the interface of the environment and genomic regulation.", [["CC", "CHEMICAL", 0, 2], ["medRxiv", "TREATMENT", 339, 346], ["med", "ANATOMY", 102, 105], ["genomic regulation", "OBSERVATION", 540, 558]]], ["Nasal cells which are directly in contact with the environment have been shown to play a key role in SARS-CoV-2 infection.", [["Nasal cells", "ANATOMY", 0, 11], ["SARS-CoV-2 infection", "DISEASE", 101, 121], ["Nasal cells", "CELL", 0, 11], ["SARS-CoV-2", "ORGANISM", 101, 111], ["Nasal cells", "CELL_TYPE", 0, 11], ["SARS-CoV-2", "SPECIES", 101, 111], ["Nasal cells", "PROBLEM", 0, 11], ["2 infection", "PROBLEM", 110, 121], ["cells", "OBSERVATION", 6, 11], ["infection", "OBSERVATION", 112, 121]]], ["Our results demonstrate that ACE2 nasal DNAm reflects differences by sex, race/ethnicity and biological aging.", [["nasal", "ANATOMY", 34, 39], ["ACE2", "GENE_OR_GENE_PRODUCT", 29, 33], ["ACE2", "PROTEIN", 29, 33], ["ACE2 nasal DNAm", "PROBLEM", 29, 44], ["nasal DNAm", "OBSERVATION", 34, 44]]], ["The nasal epigenetic architecture of the ACE2 gene could contribute to our understanding of COVID-19 and environmental disparities.DISCUSSION. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintDISCUSSIONThe copyright holder for this this version posted September 16, 2020. . https://doi.org/10.1101/2020.08.25.20182105 doi: medRxiv preprintMaterials and MethodsStudy Population: We included participants from Project Viva, a prospective pre-birth cohort from eastern Massachusetts recruited between 1999 and 2002 during the initial prenatal visit at Atrius Harvard Vanguard Medical Associates.", [["nasal", "ANATOMY", 4, 9], ["CC", "CHEMICAL", 143, 145], ["nasal", "ORGAN", 4, 9], ["ACE2", "GENE_OR_GENE_PRODUCT", 41, 45], ["ACE2 gene", "DNA", 41, 50], ["participants", "SPECIES", 549, 561], ["COVID", "TEST", 92, 97], ["nasal", "ANATOMY", 4, 9], ["epigenetic architecture", "OBSERVATION", 10, 33], ["med", "ANATOMY", 245, 248]]], ["32 Eligibility criteria for cohort recruitment included fluency in English, gestational age <22 weeks at the first prenatal visit, and singleton pregnancy.", [["cohort recruitment", "PROBLEM", 28, 46], ["singleton pregnancy", "PROBLEM", 135, 154]]], ["We created five racial/ethnic groups based on the mother's response including white, Black, Hispanic, Asian, and other (>1 race or other).", [["five", "OBSERVATION_MODIFIER", 11, 15], ["racial", "OBSERVATION_MODIFIER", 16, 22]]], ["Of the total 2128 live births, 547 children were re-contacted during an early-teen in-person visit at a mean age 12.9 years (range; 11.8 to 15. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review) preprintThe copyright holder for this this version posted September 16, 2020. . https://doi.org/10.1101/2020.08.25.20182105 doi: medRxiv preprint into the R statistical software and samples were excluded based quality control check as previously described.", [["children", "ORGANISM", 35, 43], ["children", "SPECIES", 35, 43], ["person", "SPECIES", 86, 92], ["medRxiv", "TREATMENT", 408, 415], ["med", "ANATOMY", 182, 185]]], ["34 We preprocessed all of the DNA methylation data using functional normalization to adjust for technical variability 35 and adjusted for probe-type variability using RCP.", [["DNA", "CELLULAR_COMPONENT", 30, 33], ["the DNA methylation data", "TEST", 26, 50], ["technical variability", "TEST", 96, 117]]], ["36 Lastly, we used ComBat from the sva package to adjust for sample plate (seven 96-well plates) as a technical variable.", [["ComBat", "TREATMENT", 19, 25], ["the sva package", "TREATMENT", 31, 46], ["sample plate", "TEST", 61, 73]]], ["37 (DNAmTLadjAge) would indicate that DNAmTL is longer than expected based on chronological age (thus marker of \"younger\" cells), while positive residuals from the skin and blood clock would indicate epigenetic age acceleration (thus marker of \"older\" cells).", [["cells", "ANATOMY", 122, 127], ["skin", "ANATOMY", 164, 168], ["blood", "ANATOMY", 173, 178], ["cells", "ANATOMY", 252, 257], ["DNAmTL", "GENE_OR_GENE_PRODUCT", 38, 44], ["cells", "CELL", 122, 127], ["skin", "ORGAN", 164, 168], ["blood", "ORGANISM_SUBSTANCE", 173, 178], ["cells", "CELL", 252, 257], ["DNAmTL", "PROTEIN", 38, 44], ["positive residuals from the skin", "PROBLEM", 136, 168], ["blood clock", "TEST", 173, 184], ["epigenetic age acceleration", "PROBLEM", 200, 227], ["skin", "ANATOMY", 164, 168]]], ["We modeled the DNAmTLadjAge and epigenetic age acceleration for the skin and blood clock to estimate associations independent of chronological age.Statistical Analyses:We described our study sample using means, standard deviations (SDs), counts and proportions.", [["skin", "ANATOMY", 68, 72], ["blood", "ANATOMY", 77, 82], ["skin", "ORGAN", 68, 72], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["the DNAmTLadjAge", "TREATMENT", 11, 27], ["blood clock", "TEST", 77, 88], ["our study sample", "TEST", 181, 197], ["standard deviations (SDs)", "TEST", 211, 236], ["skin", "ANATOMY", 68, 72]]], ["We extracted the ACE2 gene genomic annotation from Bioconductor using the IlluminaHumanMethylationEPICanno.ilm10b4.hg19 annotation package .", [["ACE2", "GENE_OR_GENE_PRODUCT", 17, 21], ["ACE2 gene", "DNA", 17, 26], ["IlluminaHumanMethylationEPICanno.ilm10b4.hg19 annotation package", "DNA", 74, 138], ["the IlluminaHumanMethylationEPICanno.ilm10b4", "TREATMENT", 70, 114]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review) preprintThe copyright holder for this this version posted September 16, 2020. . https://doi.org/10.1101/2020.08.25.20182105 doi: medRxiv preprint and calculated means and SDs of DNAm at the selected CpGs in the overall cohort and stratified by sex.", [["CC", "CHEMICAL", 0, 2], ["CpGs", "CHEMICAL", 398, 402], ["medRxiv", "TREATMENT", 328, 335], ["SDs of DNAm", "PROBLEM", 370, 381], ["med", "ANATOMY", 102, 105]]], ["We estimated the overall Spearman correlation structure among CpGs and used boxplots to visualize differences in DNAm by sex.", [["CpGs", "DNA", 62, 66], ["boxplots", "TREATMENT", 76, 84]]], ["We tested differences in DNAm by sex, age, race/ethnicity, DNAmTLadjAge, and the residuals of the skin and blood clock using robust linear regression models on beta values (0-1) to account for heteroskedasticity or influential points.", [["skin", "ANATOMY", 98, 102], ["blood", "ANATOMY", 107, 112], ["skin", "ORGAN", 98, 102], ["blood", "ORGANISM_SUBSTANCE", 107, 112], ["DNAm", "DNA", 25, 29], ["DNAmTLadjAge", "TREATMENT", 59, 71], ["blood clock", "TEST", 107, 118], ["beta values", "TEST", 160, 171], ["heteroskedasticity", "PROBLEM", 193, 211], ["skin", "ANATOMY", 98, 102], ["linear", "OBSERVATION_MODIFIER", 132, 138]]], ["Differences in epigenetic aging biomarkers were adjusted for race/ethnicity and stratified by sex.", [["epigenetic aging biomarkers", "TEST", 15, 42]]], ["40 We report findings as %-DNA methylation differences and adjusted for multiple comparisons for each model independently using a False Discovery Rate of 5% (FDR<0.05).", [["DNA", "CELLULAR_COMPONENT", 27, 30], ["a False Discovery Rate", "TEST", 128, 150]]], ["All statistical tests were two sided and analyses were carried out using R, version 4.0.2 (www.r-project.org/).12Data availability: Datasets generated and analyzed during the current study are not publicly available because we did not obtain consent for such public release of epigenetic data from participants.", [["participants", "SPECIES", 298, 310], ["All statistical tests", "TEST", 0, 21], ["analyses", "TEST", 41, 49], ["the current study", "TEST", 171, 188]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint12The copyright holder for this this version posted September 16, 2020. . https://doi.org/10.1101/2020.08.25.20182105 doi: medRxiv preprint Martin, T. C., Yet, I., Tsai, P.-C. & Bell, J. T. coMET: visualisation of regional epigenome-wide association scan results and DNA co-methylation patterns.", [["CC", "CHEMICAL", 0, 2], ["DNA", "CELLULAR_COMPONENT", 475, 478], ["wide association scan", "TEST", 441, 462], ["DNA co-methylation patterns", "TEST", 475, 502], ["med", "ANATOMY", 102, 105]]], ["BMC bioinformatics 16, 1-5 (2015) .12.", [["BMC bioinformatics", "TEST", 0, 18]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint12The copyright holder for this this version posted September 16, 2020. . https://doi.org/10.1101/2020.08.25.20182105 doi: medRxiv preprint Table 1 .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Genomic annotation of probes located within the Illumina EPIC array and nasal DNA methylation descriptive statistics for the angiotensin-converting enzyme (ACE2) gene located in the X-chromosome and sex differences.", [["angiotensin", "CHEMICAL", 125, 136], ["DNA", "CELLULAR_COMPONENT", 78, 81], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 125, 154], ["ACE2", "GENE_OR_GENE_PRODUCT", 156, 160], ["Illumina EPIC array", "DNA", 48, 67], ["angiotensin-converting enzyme (ACE2) gene", "DNA", 125, 166], ["X-chromosome", "DNA", 182, 194], ["the Illumina EPIC array", "TREATMENT", 44, 67], ["nasal DNA", "TREATMENT", 72, 81], ["the angiotensin-converting enzyme (ACE2) gene", "TREATMENT", 121, 166], ["Illumina EPIC", "OBSERVATION", 48, 61], ["nasal", "ANATOMY", 72, 77]]]], "011d752d3370e88e7cfabfef0b7ac6c0c44a6e6e": [["IntroductionPeriorbital necrotizing fasciitis is a very rare condition with a UK incidence of 0.24 cases per million per annum [1] .", [["necrotizing fasciitis", "DISEASE", 24, 45], ["IntroductionPeriorbital necrotizing fasciitis", "PROBLEM", 0, 45], ["necrotizing", "OBSERVATION_MODIFIER", 24, 35], ["fasciitis", "OBSERVATION", 36, 45]]], ["Outcomes can range from disfigurement to sight loss in 14%.", [["disfigurement", "DISEASE", 24, 37], ["sight loss", "DISEASE", 41, 51], ["sight loss", "PROBLEM", 41, 51]]], ["Risk of death is 3%, much lower than other sites where death can occur in up to 35% [2] .", [["death", "DISEASE", 8, 13], ["death", "DISEASE", 55, 60], ["death", "PROBLEM", 8, 13], ["death", "PROBLEM", 55, 60], ["death", "OBSERVATION", 8, 13]]], ["This is attributed to the earlier presentation, the rich blood supply allowing better antibiotic penetration, and also the orbital septum which provides a barrier to posterior spread [3] .", [["blood", "ANATOMY", 57, 62], ["orbital septum", "ANATOMY", 123, 137], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["orbital septum", "MULTI-TISSUE_STRUCTURE", 123, 137], ["better antibiotic penetration", "TREATMENT", 79, 108], ["orbital septum", "ANATOMY", 123, 137]]], ["The mainstay of treatment is multidisciplinary, involving infectious diseases, intensivists, plastic surgery, and ophthalmology.", [["infectious diseases", "DISEASE", 58, 77], ["treatment", "TREATMENT", 16, 25], ["infectious", "OBSERVATION", 58, 68]]], ["Emergency debridement is crucial when sight or life is threatened and the subsequent reconstructive stages can be challenging.", [["Emergency debridement", "TREATMENT", 0, 21], ["the subsequent reconstructive stages", "TREATMENT", 70, 106], ["debridement", "OBSERVATION", 10, 21]]], ["We describe two cases of periocular necrotizing fasciitis demonstrating the progression of the disease as well as the reconstructive steps and outcome.Case 1This was a 68-year-old lady who presented with periocular necrotizing fasciitis following an episode of dermatitis, a reaction to a shampoo.", [["periocular necrotizing fasciitis", "ANATOMY", 25, 57], ["necrotizing fasciitis", "DISEASE", 36, 57], ["necrotizing fasciitis", "DISEASE", 215, 236], ["dermatitis", "DISEASE", 261, 271], ["periocular necrotizing fasciitis", "PROBLEM", 25, 57], ["the disease", "PROBLEM", 91, 102], ["periocular necrotizing fasciitis", "PROBLEM", 204, 236], ["dermatitis", "PROBLEM", 261, 271], ["a reaction", "PROBLEM", 273, 283], ["a shampoo", "TREATMENT", 287, 296], ["periocular", "ANATOMY", 25, 35], ["necrotizing", "OBSERVATION_MODIFIER", 36, 47], ["fasciitis", "OBSERVATION", 48, 57], ["progression", "OBSERVATION_MODIFIER", 76, 87], ["disease", "OBSERVATION", 95, 102], ["periocular", "ANATOMY", 204, 214], ["necrotizing", "OBSERVATION_MODIFIER", 215, 226], ["fasciitis", "OBSERVATION", 227, 236], ["dermatitis", "OBSERVATION", 261, 271]]], ["She took serial selfies which demonstrated progression from a superficial dermatitis to orbital involvement (Figs.1, 2, and 3).", [["orbital", "ANATOMY", 88, 95], ["dermatitis", "DISEASE", 74, 84], ["orbital", "ORGAN", 88, 95], ["serial selfies", "TEST", 9, 23], ["a superficial dermatitis to orbital involvement", "PROBLEM", 60, 107], ["Figs.1", "TEST", 109, 115], ["progression", "OBSERVATION_MODIFIER", 43, 54], ["superficial", "OBSERVATION_MODIFIER", 62, 73], ["dermatitis", "OBSERVATION", 74, 84], ["orbital", "ANATOMY", 88, 95]]], ["On day 10, she presented to hospital with orbital pain.", [["orbital", "ANATOMY", 42, 49], ["orbital pain", "DISEASE", 42, 54], ["orbital pain", "PROBLEM", 42, 54], ["orbital", "ANATOMY", 42, 49], ["pain", "OBSERVATION", 50, 54]]], ["Even though she was afebrile (36.7\u00b0C), she had significant proptosis with pus discharging from her eye (Fig. 4) .", [["pus", "ANATOMY", 74, 77], ["eye", "ANATOMY", 99, 102], ["proptosis", "DISEASE", 59, 68], ["pus", "ORGANISM_SUBSTANCE", 74, 77], ["eye", "ORGAN", 99, 102], ["afebrile", "PROBLEM", 20, 28], ["significant proptosis", "PROBLEM", 47, 68], ["pus discharging from her eye", "PROBLEM", 74, 102], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["proptosis", "OBSERVATION", 59, 68], ["pus", "OBSERVATION", 74, 77], ["eye", "ANATOMY", 99, 102]]], ["WCC was 12.82 \u00d7 10 9 /L; CRP was 308 mg/L. She was started on tazocin, clindamycin, and piptazocin.", [["tazocin", "CHEMICAL", 62, 69], ["clindamycin", "CHEMICAL", 71, 82], ["piptazocin", "CHEMICAL", 88, 98], ["tazocin", "CHEMICAL", 62, 69], ["clindamycin", "CHEMICAL", 71, 82], ["piptazocin", "CHEMICAL", 88, 98], ["CRP", "GENE_OR_GENE_PRODUCT", 25, 28], ["tazocin", "SIMPLE_CHEMICAL", 62, 69], ["clindamycin", "SIMPLE_CHEMICAL", 71, 82], ["piptazocin", "SIMPLE_CHEMICAL", 88, 98], ["WCC", "PROTEIN", 0, 3], ["CRP", "PROTEIN", 25, 28], ["WCC", "TEST", 0, 3], ["CRP", "TEST", 25, 28], ["tazocin", "TREATMENT", 62, 69], ["clindamycin", "TREATMENT", 71, 82], ["piptazocin", "TREATMENT", 88, 98]]], ["CT scans showed extensive soft tissue thickening anterior to the right orbit with central abscess formation.", [["soft tissue", "ANATOMY", 26, 37], ["right orbit", "ANATOMY", 65, 76], ["abscess", "ANATOMY", 90, 97], ["abscess", "DISEASE", 90, 97], ["soft tissue", "TISSUE", 26, 37], ["orbit", "ORGAN", 71, 76], ["central abscess", "PATHOLOGICAL_FORMATION", 82, 97], ["CT scans", "TEST", 0, 8], ["extensive soft tissue thickening", "PROBLEM", 16, 48], ["central abscess formation", "PROBLEM", 82, 107], ["extensive", "OBSERVATION_MODIFIER", 16, 25], ["soft tissue", "ANATOMY", 26, 37], ["thickening", "OBSERVATION", 38, 48], ["anterior", "ANATOMY_MODIFIER", 49, 57], ["right", "ANATOMY_MODIFIER", 65, 70], ["orbit", "ANATOMY", 71, 76], ["central", "ANATOMY_MODIFIER", 82, 89], ["abscess", "OBSERVATION", 90, 97]]], ["Within the orbit, there was a collection at the superolateral aspect extending to the nasal side.", [["orbit", "ANATOMY", 11, 16], ["nasal", "ANATOMY", 86, 91], ["orbit", "ORGAN", 11, 16], ["nasal side", "MULTI-TISSUE_STRUCTURE", 86, 96], ["a collection at the superolateral aspect", "PROBLEM", 28, 68], ["orbit", "ANATOMY", 11, 16], ["collection", "OBSERVATION", 30, 40], ["superolateral", "ANATOMY_MODIFIER", 48, 61], ["nasal", "ANATOMY", 86, 91]]], ["She underwent immediate decompression.", [["immediate decompression", "TREATMENT", 14, 37], ["decompression", "OBSERVATION", 24, 37]]], ["Intraoperatively, pus was found in both her upper and lower eyelids, in the post-septal and retro-orbital area and there was necrotic tissue over the malar rim and cheek which was debrided (Fig. 5 ).", [["pus", "ANATOMY", 18, 21], ["upper", "ANATOMY", 44, 49], ["lower eyelids", "ANATOMY", 54, 67], ["post-septal", "ANATOMY", 76, 87], ["retro-orbital area", "ANATOMY", 92, 110], ["necrotic tissue", "ANATOMY", 125, 140], ["malar rim", "ANATOMY", 150, 159], ["cheek", "ANATOMY", 164, 169], ["necrotic", "DISEASE", 125, 133], ["pus", "PATHOLOGICAL_FORMATION", 18, 21], ["upper", "ORGANISM_SUBDIVISION", 44, 49], ["lower eyelids", "ORGANISM_SUBDIVISION", 54, 67], ["post-septal", "CANCER", 76, 87], ["retro-orbital area", "MULTI-TISSUE_STRUCTURE", 92, 110], ["necrotic tissue", "TISSUE", 125, 140], ["malar rim", "TISSUE", 150, 159], ["cheek", "ORGAN", 164, 169], ["pus", "PROBLEM", 18, 21], ["necrotic tissue over the malar rim and cheek", "PROBLEM", 125, 169], ["pus", "OBSERVATION", 18, 21], ["both", "ANATOMY_MODIFIER", 35, 39], ["upper", "ANATOMY_MODIFIER", 44, 49], ["lower eyelids", "ANATOMY", 54, 67], ["post-septal", "ANATOMY_MODIFIER", 76, 87], ["retro-orbital area", "ANATOMY", 92, 110], ["necrotic tissue", "OBSERVATION", 125, 140], ["malar", "ANATOMY", 150, 155], ["rim", "ANATOMY_MODIFIER", 156, 159], ["cheek", "ANATOMY", 164, 169], ["debrided", "OBSERVATION", 180, 188]]], ["Her right orbit was enucleated as there was a high risk of the infection spreading to the brain via the optic nerve.", [["right orbit", "ANATOMY", 4, 15], ["brain", "ANATOMY", 90, 95], ["optic nerve", "ANATOMY", 104, 115], ["infection", "DISEASE", 63, 72], ["orbit", "ORGAN", 10, 15], ["brain", "ORGAN", 90, 95], ["optic nerve", "MULTI-TISSUE_STRUCTURE", 104, 115], ["the infection", "PROBLEM", 59, 72], ["right", "ANATOMY_MODIFIER", 4, 9], ["orbit", "ANATOMY", 10, 15], ["enucleated", "OBSERVATION", 20, 30], ["infection", "OBSERVATION", 63, 72], ["brain", "ANATOMY", 90, 95], ["optic nerve", "ANATOMY", 104, 115]]], ["Her eye swab grew Streptococcus pyogenes (group A) and Staphylococcus aureus.", [["eye swab", "ANATOMY", 4, 12], ["Streptococcus pyogenes", "DISEASE", 18, 40], ["Staphylococcus aureus", "DISEASE", 55, 76], ["Streptococcus pyogenes", "ORGANISM", 18, 40], ["Staphylococcus aureus", "ORGANISM", 55, 76], ["Streptococcus pyogenes", "SPECIES", 18, 40], ["Staphylococcus aureus", "SPECIES", 55, 76], ["Streptococcus pyogenes", "SPECIES", 18, 40], ["Staphylococcus aureus", "SPECIES", 55, 76], ["Her eye swab", "TEST", 0, 12], ["Streptococcus pyogenes", "PROBLEM", 18, 40], ["Staphylococcus aureus", "PROBLEM", 55, 76], ["eye", "ANATOMY", 4, 7], ["Streptococcus pyogenes", "OBSERVATION", 18, 40], ["Staphylococcus aureus", "OBSERVATION", 55, 76]]], ["Six days later, she underwent reconstruction.", [["reconstruction", "TREATMENT", 30, 44]]], ["There was medial orbital bone loss and the ethmoidal air sinus was exposed.", [["medial orbital bone", "ANATOMY", 10, 29], ["ethmoidal air sinus", "ANATOMY", 43, 62], ["orbital bone loss", "DISEASE", 17, 34], ["medial orbital bone", "TISSUE", 10, 29], ["ethmoidal air sinus", "MULTI-TISSUE_STRUCTURE", 43, 62], ["medial orbital bone loss", "PROBLEM", 10, 34], ["medial", "ANATOMY_MODIFIER", 10, 16], ["orbital", "ANATOMY_MODIFIER", 17, 24], ["bone", "ANATOMY", 25, 29], ["loss", "OBSERVATION", 30, 34], ["ethmoidal air sinus", "ANATOMY", 43, 62]]], ["A contralateral paramedian forehead flap was raised and part deepithelialized to be tunneled through the glabellar area and used to cover the ethmoidal sinus.", [["forehead flap", "ANATOMY", 27, 40], ["glabellar area", "ANATOMY", 105, 119], ["ethmoidal sinus", "ANATOMY", 142, 157], ["forehead", "ORGAN", 27, 35], ["ethmoidal sinus", "MULTI-TISSUE_STRUCTURE", 142, 157], ["A contralateral paramedian forehead flap", "TREATMENT", 0, 40], ["contralateral", "ANATOMY_MODIFIER", 2, 15], ["paramedian", "ANATOMY_MODIFIER", 16, 26], ["forehead", "ANATOMY", 27, 35], ["flap", "OBSERVATION", 36, 40], ["tunneled", "OBSERVATION", 84, 92], ["glabellar", "ANATOMY", 105, 114], ["ethmoidal sinus", "ANATOMY", 142, 157]]], ["The tip of the flap was folded on itself and inset to provide an epithelial surface for both lining of the inner sinus as well as the orbit.", [["flap", "ANATOMY", 15, 19], ["epithelial surface", "ANATOMY", 65, 83], ["inner sinus", "ANATOMY", 107, 118], ["orbit", "ANATOMY", 134, 139], ["flap", "TISSUE", 15, 19], ["epithelial surface", "TISSUE", 65, 83], ["inner sinus", "MULTI-TISSUE_STRUCTURE", 107, 118], ["orbit", "ORGAN", 134, 139], ["the flap", "TREATMENT", 11, 19], ["an epithelial surface", "TREATMENT", 62, 83], ["tip", "OBSERVATION_MODIFIER", 4, 7], ["flap", "OBSERVATION", 15, 19], ["folded", "OBSERVATION", 24, 30], ["epithelial", "ANATOMY_MODIFIER", 65, 75], ["surface", "OBSERVATION_MODIFIER", 76, 83], ["both", "OBSERVATION_MODIFIER", 88, 92], ["lining", "OBSERVATION", 93, 99], ["inner sinus", "ANATOMY", 107, 118], ["orbit", "ANATOMY", 134, 139]]], ["A split skin graft was used to surface the remaining orbital socket.", [["skin", "ANATOMY", 8, 12], ["surface", "ANATOMY", 31, 38], ["orbital socket", "ANATOMY", 53, 67], ["skin graft", "TISSUE", 8, 18], ["orbital socket", "MULTI-TISSUE_STRUCTURE", 53, 67], ["A split skin graft", "TREATMENT", 0, 18], ["skin", "ANATOMY", 8, 12], ["graft", "OBSERVATION", 13, 18], ["remaining", "ANATOMY_MODIFIER", 43, 52], ["orbital socket", "ANATOMY", 53, 67]]], ["A cheek advancement flap was then used to cover the inferior orbital rim (Fig. 6 ).", [["cheek", "ANATOMY", 2, 7], ["flap", "ANATOMY", 20, 24], ["inferior orbital rim", "ANATOMY", 52, 72], ["cheek", "ORGAN", 2, 7], ["A cheek advancement flap", "TREATMENT", 0, 24], ["cheek", "ANATOMY", 2, 7], ["flap", "OBSERVATION", 20, 24], ["inferior", "ANATOMY_MODIFIER", 52, 60], ["orbital", "ANATOMY", 61, 68], ["rim", "ANATOMY_MODIFIER", 69, 72]]], ["Six months later once healed (Fig. 7) , 3 titanium bone anchors were placed in the orbit in stages to be fitted with an osteo-integrated prosthesis (Fig. 8 ).", [["bone", "ANATOMY", 51, 55], ["orbit", "ANATOMY", 83, 88], ["titanium", "CHEMICAL", 42, 50], ["bone", "TISSUE", 51, 55], ["orbit", "ORGAN", 83, 88], ["3 titanium bone anchors", "TREATMENT", 40, 63], ["an osteo-integrated prosthesis", "TREATMENT", 117, 147], ["orbit", "ANATOMY", 83, 88], ["osteo", "OBSERVATION", 120, 125], ["prosthesis", "OBSERVATION", 137, 147]]], ["The forehead flap can be seen medially covering the previously exposed sinus (Fig. 9 ).", [["forehead flap", "ANATOMY", 4, 17], ["forehead flap", "TISSUE", 4, 17], ["sinus", "MULTI-TISSUE_STRUCTURE", 71, 76], ["The forehead flap", "TREATMENT", 0, 17], ["forehead", "ANATOMY", 4, 12], ["flap", "OBSERVATION", 13, 17], ["medially", "ANATOMY_MODIFIER", 30, 38], ["sinus", "ANATOMY", 71, 76]]], ["The prosthesis fitting was delayed due to the COVID-19 pandemic and photos were therefore not available.Case 2This was a 62-year-old man with type 2 diabetes who was assaulted with a wooden plank and rusty nail on his frontal scalp area sustaining a laceration 3 days prior.", [["frontal scalp area", "ANATOMY", 218, 236], ["type 2 diabetes", "DISEASE", 142, 157], ["laceration", "DISEASE", 250, 260], ["man", "ORGANISM", 133, 136], ["man", "SPECIES", 133, 136], ["The prosthesis fitting", "TREATMENT", 0, 22], ["the COVID", "TEST", 42, 51], ["photos", "TREATMENT", 68, 74], ["type 2 diabetes", "PROBLEM", 142, 157], ["a wooden plank", "PROBLEM", 181, 195], ["rusty nail on his frontal scalp area", "PROBLEM", 200, 236], ["a laceration", "PROBLEM", 248, 260], ["prosthesis", "OBSERVATION", 4, 14], ["diabetes", "OBSERVATION", 149, 157], ["rusty nail", "OBSERVATION", 200, 210], ["frontal", "ANATOMY_MODIFIER", 218, 225], ["scalp", "ANATOMY", 226, 231], ["laceration", "OBSERVATION", 250, 260]]], ["The laceration was sutured and a head injury was ruled out with a CT scan.", [["head", "ANATOMY", 33, 37], ["head", "ORGAN", 33, 37], ["The laceration", "PROBLEM", 0, 14], ["a head injury", "PROBLEM", 31, 44], ["a CT scan", "TEST", 64, 73], ["laceration", "OBSERVATION", 4, 14], ["sutured", "OBSERVATION_MODIFIER", 19, 26], ["head", "ANATOMY", 33, 37], ["injury", "OBSERVATION", 38, 44]]], ["The next day, he developed a rapid progressive bilateral periorbital cellulitis and proptosis followed by transient loss of vision of his right eye (Fig. 10) .", [["periorbital", "ANATOMY", 57, 68], ["right eye", "ANATOMY", 138, 147], ["cellulitis", "DISEASE", 69, 79], ["proptosis", "DISEASE", 84, 93], ["loss of vision of his right eye", "DISEASE", 116, 147], ["eye", "ORGAN", 144, 147], ["a rapid progressive bilateral periorbital cellulitis", "PROBLEM", 27, 79], ["proptosis", "PROBLEM", 84, 93], ["transient loss of vision of his right eye", "PROBLEM", 106, 147], ["rapid", "OBSERVATION_MODIFIER", 29, 34], ["progressive", "OBSERVATION_MODIFIER", 35, 46], ["bilateral", "ANATOMY_MODIFIER", 47, 56], ["periorbital", "ANATOMY", 57, 68], ["cellulitis", "OBSERVATION", 69, 79], ["proptosis", "OBSERVATION", 84, 93], ["transient", "OBSERVATION_MODIFIER", 106, 115], ["loss", "OBSERVATION_MODIFIER", 116, 120], ["right", "ANATOMY_MODIFIER", 138, 143], ["eye", "ANATOMY", 144, 147]]], ["He was pyrexial at 38.7\u00b0C and confused.", [["pyrexial", "TEST", 7, 15], ["confused", "PROBLEM", 30, 38]]], ["WCC was 24.5 \u00d7 10 9 /L and CRP was 330 mg/ L. He was immediately started on meropenem and clindamycin.", [["meropenem", "CHEMICAL", 76, 85], ["clindamycin", "CHEMICAL", 90, 101], ["meropenem", "CHEMICAL", 76, 85], ["clindamycin", "CHEMICAL", 90, 101], ["CRP", "GENE_OR_GENE_PRODUCT", 27, 30], ["He", "ORGANISM", 46, 48], ["meropenem", "SIMPLE_CHEMICAL", 76, 85], ["clindamycin", "SIMPLE_CHEMICAL", 90, 101], ["WCC", "PROTEIN", 0, 3], ["CRP", "PROTEIN", 27, 30], ["WCC", "TEST", 0, 3], ["CRP", "TEST", 27, 30], ["meropenem", "TREATMENT", 76, 85], ["clindamycin", "TREATMENT", 90, 101]]], ["Repeat CT orbit showed extensive bilateral periorbital swelling with stranding of the subcutaneous fat with fluid collections within the pretarsal regions and lateral to the globes.", [["CT orbit", "ANATOMY", 7, 15], ["periorbital", "ANATOMY", 43, 54], ["subcutaneous fat", "ANATOMY", 86, 102], ["fluid", "ANATOMY", 108, 113], ["pretarsal regions", "ANATOMY", 137, 154], ["globes", "ANATOMY", 174, 180], ["periorbital swelling", "DISEASE", 43, 63], ["subcutaneous fat", "TISSUE", 86, 102], ["globes", "ORGAN", 174, 180], ["Repeat CT orbit", "TEST", 0, 15], ["extensive bilateral periorbital swelling", "PROBLEM", 23, 63], ["stranding of the subcutaneous fat", "PROBLEM", 69, 102], ["fluid collections", "PROBLEM", 108, 125], ["orbit", "ANATOMY", 10, 15], ["extensive", "OBSERVATION_MODIFIER", 23, 32], ["bilateral", "ANATOMY_MODIFIER", 33, 42], ["periorbital", "ANATOMY", 43, 54], ["swelling", "OBSERVATION", 55, 63], ["stranding", "OBSERVATION", 69, 78], ["subcutaneous fat", "ANATOMY", 86, 102], ["fluid collections", "OBSERVATION", 108, 125], ["pretarsal", "ANATOMY_MODIFIER", 137, 146], ["regions", "ANATOMY_MODIFIER", 147, 154], ["lateral", "ANATOMY_MODIFIER", 159, 166], ["globes", "ANATOMY", 174, 180]]], ["There was extensive soft tissue swelling over the nasal bridge (Fig. 11) .", [["soft tissue", "ANATOMY", 20, 31], ["nasal", "ANATOMY", 50, 55], ["soft tissue", "TISSUE", 20, 31], ["nasal", "ORGAN", 50, 55], ["extensive soft tissue swelling", "PROBLEM", 10, 40], ["the nasal bridge", "TREATMENT", 46, 62], ["extensive", "OBSERVATION_MODIFIER", 10, 19], ["soft tissue", "OBSERVATION_MODIFIER", 20, 31], ["swelling", "OBSERVATION", 32, 40], ["nasal bridge", "ANATOMY", 50, 62]]], ["He underwent immediate debridement of the necrotic tissues.", [["necrotic tissues", "ANATOMY", 42, 58], ["necrotic", "DISEASE", 42, 50], ["necrotic tissues", "TISSUE", 42, 58], ["immediate debridement", "TREATMENT", 13, 34], ["the necrotic tissues", "PROBLEM", 38, 58], ["debridement", "OBSERVATION", 23, 34], ["necrotic tissues", "OBSERVATION", 42, 58]]], ["This included the underlying fascia, frontalis, and nasal bridge skin to the lid margin, including the orbicularis oculi which was resected.", [["fascia", "ANATOMY", 29, 35], ["frontalis", "ANATOMY", 37, 46], ["nasal bridge skin", "ANATOMY", 52, 69], ["lid margin", "ANATOMY", 77, 87], ["orbicularis oculi", "ANATOMY", 103, 120], ["fascia", "TISSUE", 29, 35], ["nasal", "ORGAN", 52, 57], ["skin", "ORGAN", 65, 69], ["lid margin", "TISSUE", 77, 87], ["orbicularis oculi", "ORGAN", 103, 120], ["the underlying fascia, frontalis, and nasal bridge skin to the lid margin", "PROBLEM", 14, 87], ["fascia", "ANATOMY", 29, 35], ["frontalis", "ANATOMY", 37, 46], ["nasal", "ANATOMY", 52, 57], ["bridge", "ANATOMY_MODIFIER", 58, 64], ["skin", "ANATOMY", 65, 69], ["lid", "ANATOMY", 77, 80], ["margin", "OBSERVATION_MODIFIER", 81, 87], ["orbicularis oculi", "ANATOMY", 103, 120], ["resected", "OBSERVATION", 131, 139]]], ["Orbital septum and levators were left intact (Fig. 12) .", [["Orbital septum", "ANATOMY", 0, 14], ["levators", "ANATOMY", 19, 27], ["Orbital septum", "MULTI-TISSUE_STRUCTURE", 0, 14], ["septum", "ANATOMY_MODIFIER", 8, 14], ["left", "ANATOMY_MODIFIER", 33, 37], ["intact", "OBSERVATION", 38, 44]]], ["The extent of the defects was similar bilaterally and extended to the vertex with bare periosteum in the midline (Fig. 13) .", [["periosteum", "ANATOMY", 87, 97], ["midline", "ANATOMY", 105, 112], ["periosteum", "TISSUE", 87, 97], ["the defects", "PROBLEM", 14, 25], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["defects", "OBSERVATION", 18, 25], ["similar", "OBSERVATION_MODIFIER", 30, 37], ["bilaterally", "OBSERVATION_MODIFIER", 38, 49], ["vertex", "ANATOMY_MODIFIER", 70, 76], ["bare periosteum", "OBSERVATION", 82, 97], ["midline", "ANATOMY_MODIFIER", 105, 112]]], ["A week later, reconstruction was performed.", [["reconstruction", "TREATMENT", 14, 28]]], ["Scalp flaps were raised bilaterally (Fig. 14) .", [["Scalp", "ANATOMY", 0, 5], ["Scalp flaps", "PATHOLOGICAL_FORMATION", 0, 11], ["Scalp flaps", "TREATMENT", 0, 11], ["flaps", "OBSERVATION", 6, 11], ["bilaterally", "ANATOMY_MODIFIER", 24, 35]]], ["Both cheeks were advanced superiorly for lower eyelid reconstruction using nasolabial incisions (Fig. 15) .", [["cheeks", "ANATOMY", 5, 11], ["lower eyelid", "ANATOMY", 41, 53], ["nasolabial", "ANATOMY", 75, 85], ["cheeks", "ORGAN", 5, 11], ["eyelid", "ORGAN", 47, 53], ["lower eyelid reconstruction", "TREATMENT", 41, 68], ["nasolabial incisions", "TREATMENT", 75, 95], ["cheeks", "ANATOMY", 5, 11], ["lower eyelid", "ANATOMY", 41, 53], ["nasolabial", "ANATOMY", 75, 85], ["incisions", "OBSERVATION", 86, 95]]], ["A lateral canthopexy was performed bilaterally.", [["A lateral canthopexy", "TEST", 0, 20], ["bilaterally", "ANATOMY_MODIFIER", 35, 46]]], ["Palmaris tendon was used as slings for lower eyelid support bilaterally (Fig. 16) .", [["Palmaris tendon", "ANATOMY", 0, 15], ["eyelid", "ANATOMY", 45, 51], ["Palmaris tendon", "TISSUE", 0, 15], ["slings for lower eyelid support", "TREATMENT", 28, 59], ["tendon", "ANATOMY", 9, 15], ["lower eyelid", "ANATOMY", 39, 51], ["bilaterally", "ANATOMY_MODIFIER", 60, 71]]], ["The upper eyelids were reconstructed using compound grafts from the scrotum incorporating skin and cremasteric muscle.", [["upper eyelids", "ANATOMY", 4, 17], ["grafts", "ANATOMY", 52, 58], ["scrotum", "ANATOMY", 68, 75], ["skin", "ANATOMY", 90, 94], ["cremasteric muscle", "ANATOMY", 99, 117], ["upper eyelids", "ORGAN", 4, 17], ["grafts", "TISSUE", 52, 58], ["scrotum", "ORGANISM_SUBDIVISION", 68, 75], ["skin", "ORGAN", 90, 94], ["cremasteric muscle", "TISSUE", 99, 117], ["The upper eyelids", "TREATMENT", 0, 17], ["compound grafts", "TREATMENT", 43, 58], ["upper eyelids", "ANATOMY", 4, 17], ["compound grafts", "OBSERVATION", 43, 58], ["scrotum", "ANATOMY", 68, 75], ["skin", "ANATOMY", 90, 94], ["cremasteric muscle", "ANATOMY", 99, 117]]], ["Sural nerve grafts were coapted to the frontal nerve bilaterally (Fig. 17) and directly onto the cremasteric muscular aspect of the compound graft to neuratize and reinnervate this muscle for upper eyelid dynamic reconstruction in both upper eyelids (Fig. 18) .", [["Sural nerve grafts", "ANATOMY", 0, 18], ["frontal nerve", "ANATOMY", 39, 52], ["muscular", "ANATOMY", 109, 117], ["muscle", "ANATOMY", 181, 187], ["eyelid", "ANATOMY", 198, 204], ["upper eyelids", "ANATOMY", 236, 249], ["Sural nerve grafts", "TISSUE", 0, 18], ["frontal nerve", "MULTI-TISSUE_STRUCTURE", 39, 52], ["muscular", "ORGAN", 109, 117], ["graft", "TISSUE", 141, 146], ["muscle", "ORGAN", 181, 187], ["upper eyelid", "ORGANISM_SUBDIVISION", 192, 204], ["upper eyelids", "ORGANISM_SUBDIVISION", 236, 249], ["Sural nerve grafts", "TREATMENT", 0, 18], ["the compound graft", "TREATMENT", 128, 146], ["neuratize", "TREATMENT", 150, 159], ["upper eyelid dynamic reconstruction", "TREATMENT", 192, 227], ["nerve", "ANATOMY", 6, 11], ["grafts", "OBSERVATION", 12, 18], ["frontal nerve", "ANATOMY", 39, 52], ["bilaterally", "ANATOMY_MODIFIER", 53, 64], ["cremasteric muscular", "ANATOMY", 97, 117], ["compound graft", "OBSERVATION", 132, 146], ["muscle", "ANATOMY", 181, 187], ["upper eyelid", "ANATOMY", 192, 204], ["both", "ANATOMY_MODIFIER", 231, 235], ["upper eyelids", "ANATOMY", 236, 249]]], ["The cremasteric muscle is a thin layer of striated muscle found in the scrotum between the external and internal layers of spermatic fascia that functions to raise and lower the testes for temperature regulation.", [["cremasteric muscle", "ANATOMY", 4, 22], ["thin layer", "ANATOMY", 28, 38], ["striated muscle", "ANATOMY", 42, 57], ["scrotum", "ANATOMY", 71, 78], ["internal layers", "ANATOMY", 104, 119], ["spermatic fascia", "ANATOMY", 123, 139], ["testes", "ANATOMY", 178, 184], ["cremasteric muscle", "TISSUE", 4, 22], ["striated muscle", "TISSUE", 42, 57], ["scrotum", "ORGAN", 71, 78], ["internal layers", "TISSUE", 104, 119], ["spermatic fascia", "TISSUE", 123, 139], ["testes", "ORGAN", 178, 184], ["striated muscle", "PROBLEM", 42, 57], ["temperature regulation", "TREATMENT", 189, 211], ["cremasteric muscle", "ANATOMY", 4, 22], ["thin", "OBSERVATION_MODIFIER", 28, 32], ["layer", "OBSERVATION_MODIFIER", 33, 38], ["striated muscle", "ANATOMY", 42, 57], ["scrotum", "ANATOMY", 71, 78], ["external", "ANATOMY_MODIFIER", 91, 99], ["internal", "ANATOMY_MODIFIER", 104, 112], ["layers", "ANATOMY_MODIFIER", 113, 119], ["spermatic fascia", "ANATOMY", 123, 139], ["testes", "ANATOMY", 178, 184]]], ["It demonstrates a cremasteric reflex as well as contracts voluntarily.", [["a cremasteric reflex", "PROBLEM", 16, 36], ["cremasteric reflex", "OBSERVATION", 18, 36]]], ["It is supplied by the cremasteric artery, a branch of the inferior epigastric artery and the genitofemoral nerve, both of which were not dissected out.", [["cremasteric artery", "ANATOMY", 22, 40], ["inferior epigastric artery", "ANATOMY", 58, 84], ["genitofemoral nerve", "ANATOMY", 93, 112], ["cremasteric artery", "MULTI-TISSUE_STRUCTURE", 22, 40], ["inferior epigastric artery", "MULTI-TISSUE_STRUCTURE", 58, 84], ["genitofemoral nerve", "MULTI-TISSUE_STRUCTURE", 93, 112], ["cremasteric artery", "ANATOMY", 22, 40], ["branch", "ANATOMY_MODIFIER", 44, 50], ["inferior epigastric artery", "ANATOMY", 58, 84], ["genitofemoral nerve", "ANATOMY", 93, 112]]], ["Instead, this muscle was neuratized by the frontal nerve and sural nerve graft.", [["muscle", "ANATOMY", 14, 20], ["frontal nerve", "ANATOMY", 43, 56], ["sural nerve graft", "ANATOMY", 61, 78], ["muscle", "ORGAN", 14, 20], ["frontal nerve", "MULTI-TISSUE_STRUCTURE", 43, 56], ["sural nerve graft", "TISSUE", 61, 78], ["sural nerve graft", "TREATMENT", 61, 78], ["muscle", "ANATOMY", 14, 20], ["frontal nerve", "ANATOMY", 43, 56], ["sural nerve", "ANATOMY", 61, 72], ["graft", "OBSERVATION", 73, 78]]], ["This was based on the concept of muscle graft for dynamic facial reanimation first described by Noel Thompson in 1971 [4] and also Nassif et al. [5] The reason for using the scrotum as a donor site for the skin graft, along with the cremasteric muscle, was twofold.", [["muscle graft", "ANATOMY", 33, 45], ["facial", "ANATOMY", 58, 64], ["scrotum", "ANATOMY", 174, 181], ["skin", "ANATOMY", 206, 210], ["cremasteric muscle", "ANATOMY", 233, 251], ["muscle graft", "TISSUE", 33, 45], ["scrotum", "ORGAN", 174, 181], ["skin graft", "TISSUE", 206, 216], ["muscle", "ORGAN", 245, 251], ["muscle graft", "TREATMENT", 33, 45], ["dynamic facial reanimation", "TREATMENT", 50, 76], ["the scrotum", "PROBLEM", 170, 181], ["a donor site", "TREATMENT", 185, 197], ["the skin graft", "TREATMENT", 202, 216], ["muscle", "ANATOMY", 33, 39], ["graft", "OBSERVATION", 40, 45], ["scrotum", "ANATOMY", 174, 181], ["skin", "ANATOMY", 206, 210], ["graft", "OBSERVATION", 211, 216], ["cremasteric muscle", "ANATOMY", 233, 251]]], ["Firstly, as skin grafts were required for the upper eyelid reconstruction, a compound graft with the cremasteric muscle component would serve the secondary purpose of dynamic reconstruction for spontaneous eye closure.", [["skin grafts", "ANATOMY", 12, 23], ["eyelid", "ANATOMY", 52, 58], ["muscle", "ANATOMY", 113, 119], ["eye", "ANATOMY", 206, 209], ["skin grafts", "TISSUE", 12, 23], ["upper eyelid", "ORGANISM_SUBDIVISION", 46, 58], ["graft", "TISSUE", 86, 91], ["muscle", "ORGAN", 113, 119], ["eye", "ORGAN", 206, 209], ["skin grafts", "TREATMENT", 12, 23], ["the upper eyelid reconstruction", "TREATMENT", 42, 73], ["a compound graft", "TREATMENT", 75, 91], ["the cremasteric muscle component", "TREATMENT", 97, 129], ["dynamic reconstruction", "TREATMENT", 167, 189], ["spontaneous eye closure", "TREATMENT", 194, 217], ["skin", "ANATOMY", 12, 16], ["grafts", "OBSERVATION", 17, 23], ["upper eyelid", "ANATOMY", 46, 58], ["graft", "OBSERVATION", 86, 91], ["cremasteric muscle", "ANATOMY", 101, 119], ["eye", "ANATOMY", 206, 209], ["closure", "OBSERVATION", 210, 217]]], ["Secondly, with the frontal nerve identified and readily available post-debridement, coapting a nerve graft for the short distance to the muscle graft on each side seems an obvious reconstructive step.", [["frontal nerve", "ANATOMY", 19, 32], ["nerve", "ANATOMY", 95, 100], ["muscle", "ANATOMY", 137, 143], ["frontal nerve", "MULTI-TISSUE_STRUCTURE", 19, 32], ["nerve graft", "TISSUE", 95, 106], ["muscle graft", "TISSUE", 137, 149], ["debridement", "TREATMENT", 71, 82], ["a nerve graft", "TREATMENT", 93, 106], ["the short distance to the muscle graft", "TREATMENT", 111, 149], ["an obvious reconstructive step", "PROBLEM", 169, 199], ["frontal nerve", "ANATOMY", 19, 32], ["debridement", "OBSERVATION", 71, 82], ["nerve", "ANATOMY", 95, 100], ["graft", "OBSERVATION", 101, 106], ["muscle", "ANATOMY", 137, 143], ["graft", "OBSERVATION", 144, 149], ["obvious", "OBSERVATION_MODIFIER", 172, 179], ["reconstructive", "OBSERVATION", 180, 194]]], ["Further conventional technique, albeit more complex and time-consuming surgery using the platysma muscle to restore spontaneous blink, would still be possible by re-coaptation to the same nerve graft in the future and tunneling the muscle under the previous graft, so no bridges were burnt.", [["platysma muscle", "ANATOMY", 89, 104], ["nerve", "ANATOMY", 188, 193], ["muscle", "ANATOMY", 232, 238], ["platysma muscle", "TISSUE", 89, 104], ["nerve graft", "TISSUE", 188, 199], ["muscle", "ORGAN", 232, 238], ["graft", "TISSUE", 258, 263], ["Further conventional technique", "TEST", 0, 30], ["surgery", "TREATMENT", 71, 78], ["the platysma muscle", "TREATMENT", 85, 104], ["spontaneous blink", "PROBLEM", 116, 133], ["the same nerve graft", "TREATMENT", 179, 199], ["the previous graft", "TREATMENT", 245, 263], ["platysma muscle", "ANATOMY", 89, 104], ["nerve", "ANATOMY", 188, 193], ["graft", "OBSERVATION", 194, 199], ["muscle", "ANATOMY", 232, 238], ["graft", "OBSERVATION", 258, 263]]], ["With further lateral canthopexy procedures 6 months down the line, the patient could achieve closure of his eyelids even though spontaneous blink was not present.", [["eyelids", "ANATOMY", 108, 115], ["patient", "ORGANISM", 71, 78], ["eyelids", "ORGAN", 108, 115], ["patient", "SPECIES", 71, 78], ["further lateral canthopexy procedures", "TREATMENT", 5, 42], ["the line", "TREATMENT", 57, 65], ["closure of his eyelids", "TREATMENT", 93, 115], ["spontaneous blink", "PROBLEM", 128, 145], ["closure", "OBSERVATION", 93, 100], ["eyelids", "ANATOMY", 108, 115]]], ["However, the patient declined further surgery and was satisfied with the result having had no episodes of eye infections (Fig. 19 ).DiscussionThe most common trigger for periorbital NF is penetrating or surgical trauma.", [["eye", "ANATOMY", 106, 109], ["periorbital NF", "ANATOMY", 170, 184], ["eye infections", "DISEASE", 106, 120], ["NF", "DISEASE", 182, 184], ["trauma", "DISEASE", 212, 218], ["patient", "ORGANISM", 13, 20], ["eye", "ORGAN", 106, 109], ["patient", "SPECIES", 13, 20], ["further surgery", "TREATMENT", 30, 45], ["eye infections", "PROBLEM", 106, 120], ["periorbital NF", "PROBLEM", 170, 184], ["surgical trauma", "PROBLEM", 203, 218], ["eye", "ANATOMY", 106, 109], ["infections", "OBSERVATION", 110, 120], ["periorbital", "ANATOMY", 170, 181], ["penetrating", "OBSERVATION", 188, 199], ["surgical trauma", "OBSERVATION", 203, 218]]], ["Patients who are immunocompromised or with chronic conditions are also more at risk [1] .", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["immunocompromised", "PROBLEM", 17, 34], ["chronic conditions", "PROBLEM", 43, 61], ["immunocompromised", "OBSERVATION", 17, 34]]], ["Necrotizing fasciitis is divided into types 1 and 2.", [["Necrotizing fasciitis", "DISEASE", 0, 21], ["Necrotizing fasciitis", "PROBLEM", 0, 21], ["fasciitis", "OBSERVATION", 12, 21]]], ["Type 1 being polymicrobial is caused by both aerobic and anaerobic organisms and occurs in immunocompromised patients.", [["polymicrobial", "DISEASE", 13, 26], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["Type 1 being polymicrobial", "PROBLEM", 0, 26], ["both aerobic and anaerobic organisms", "PROBLEM", 40, 76], ["polymicrobial", "OBSERVATION", 13, 26], ["anaerobic organisms", "OBSERVATION", 57, 76]]], ["Type 2 is more common in periorbital necrotizing fasciitis and is usually due to Streptococci or Staphylococci, with \u03b2-haemolytic Streptococci A being the most common causative organism cultured.", [["periorbital necrotizing fasciitis", "ANATOMY", 25, 58], ["necrotizing fasciitis", "DISEASE", 37, 58], ["Staphylococci", "DISEASE", 97, 110], ["\u03b2-haemolytic Streptococci A", "CANCER", 117, 144], ["Type 2", "PROBLEM", 0, 6], ["periorbital necrotizing fasciitis", "PROBLEM", 25, 58], ["Streptococci", "PROBLEM", 81, 93], ["Staphylococci", "PROBLEM", 97, 110], ["\u03b2-haemolytic Streptococci", "PROBLEM", 117, 142], ["more common", "OBSERVATION_MODIFIER", 10, 21], ["periorbital", "ANATOMY", 25, 36], ["necrotizing", "OBSERVATION_MODIFIER", 37, 48], ["fasciitis", "OBSERVATION", 49, 58], ["Streptococci", "OBSERVATION", 81, 93], ["Staphylococci", "OBSERVATION", 97, 110], ["\u03b2-haemolytic Streptococci", "OBSERVATION", 117, 142]]], ["Periorbital necrotizing fasciitis can be divided into preseptal and post-septal.", [["necrotizing fasciitis", "DISEASE", 12, 33], ["Periorbital necrotizing fasciitis", "PROBLEM", 0, 33], ["necrotizing", "OBSERVATION_MODIFIER", 12, 23], ["fasciitis", "OBSERVATION", 24, 33], ["preseptal", "ANATOMY_MODIFIER", 54, 63], ["post-septal", "ANATOMY_MODIFIER", 68, 79]]], ["In pre-septal involvement, the septum is not breached and the aim is to preserve as much orbicularis as possible for function with a non-radical debridement only to healthy tissues and not beyond.", [["pre-septal", "ANATOMY", 3, 13], ["septum", "ANATOMY", 31, 37], ["orbicularis", "ANATOMY", 89, 100], ["tissues", "ANATOMY", 173, 180], ["septum", "MULTI-TISSUE_STRUCTURE", 31, 37], ["orbicularis", "ORGAN", 89, 100], ["tissues", "TISSUE", 173, 180], ["a non-radical debridement", "TREATMENT", 131, 156], ["septum", "ANATOMY", 31, 37], ["not", "UNCERTAINTY", 41, 44], ["breached", "OBSERVATION", 45, 53], ["debridement", "OBSERVATION", 145, 156]]], ["Lateral canthotomies may be required for access during debridement.", [["Lateral canthotomies", "TREATMENT", 0, 20], ["debridement", "TREATMENT", 55, 66], ["debridement", "OBSERVATION", 55, 66]]], ["Post-septal involvement is usually pre-determined on CT, if there is Diagnosis is mainly based on the clinical features with patients presenting with acute periorbital swelling associated with severe pain and pyrexia.", [["septal", "ANATOMY", 5, 11], ["periorbital", "ANATOMY", 156, 167], ["periorbital swelling", "DISEASE", 156, 176], ["pain", "DISEASE", 200, 204], ["pyrexia", "DISEASE", 209, 216], ["septal", "MULTI-TISSUE_STRUCTURE", 5, 11], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["Post-septal involvement", "PROBLEM", 0, 23], ["CT", "TEST", 53, 55], ["acute periorbital swelling", "PROBLEM", 150, 176], ["severe pain", "PROBLEM", 193, 204], ["pyrexia", "PROBLEM", 209, 216], ["septal", "ANATOMY_MODIFIER", 5, 11], ["involvement", "OBSERVATION", 12, 23], ["acute", "OBSERVATION_MODIFIER", 150, 155], ["periorbital", "ANATOMY", 156, 167], ["swelling", "OBSERVATION", 168, 176], ["severe", "OBSERVATION_MODIFIER", 193, 199], ["pain", "OBSERVATION", 200, 204], ["pyrexia", "OBSERVATION", 209, 216]]], ["Skin may appear erythematous showing appearance of gas while CT being useful for determining the extent of spread particularly if there has been postseptal extension.", [["Skin", "ANATOMY", 0, 4], ["Skin", "ORGAN", 0, 4], ["erythematous", "PROBLEM", 16, 28], ["appearance of gas", "PROBLEM", 37, 54], ["CT", "TEST", 61, 63], ["postseptal extension", "PROBLEM", 145, 165], ["erythematous", "OBSERVATION", 16, 28], ["gas", "OBSERVATION", 51, 54], ["spread", "OBSERVATION", 107, 113], ["postseptal", "OBSERVATION_MODIFIER", 145, 155], ["extension", "OBSERVATION_MODIFIER", 156, 165]]], ["The criteria for debridement and extent of debridement remain unclear.", [["debridement", "TREATMENT", 17, 28], ["debridement", "TREATMENT", 43, 54], ["debridement", "OBSERVATION", 17, 28], ["debridement", "OBSERVATION", 43, 54]]], ["The majority of cases identified by Lazzeri [6] and Amrith [7] involved surgical management.", [["surgical management", "TREATMENT", 72, 91]]], ["Medical management can be effective when early disease is restricted to the eyelids [8] .DiscussionReconstruction can be challenging and should be commenced as soon as possible to protect the orbital contents as well as mitigate the psychological sequela of disfigurement with the orbital area being a central area of focus in appearances.", [["eyelids", "ANATOMY", 76, 83], ["orbital", "ANATOMY", 192, 199], ["orbital area", "ANATOMY", 281, 293], ["disfigurement", "DISEASE", 258, 271], ["eyelids", "ORGAN", 76, 83], ["orbital", "ORGAN", 192, 199], ["Medical management", "TREATMENT", 0, 18], ["early disease", "PROBLEM", 41, 54], ["the psychological sequela of disfigurement", "PROBLEM", 229, 271], ["eyelids", "ANATOMY", 76, 83], ["orbital", "ANATOMY", 192, 199], ["disfigurement", "OBSERVATION", 258, 271], ["orbital", "ANATOMY", 281, 288], ["central", "OBSERVATION_MODIFIER", 302, 309], ["focus", "OBSERVATION", 318, 323]]], ["Our cases demonstrate in detail the devastating outcomes of periorbital necrotizing fasciitis, the importance of early presentation, intervention with emergency debridement, and reconstruction to restore the patients' form and function, as well as to protect vision.", [["periorbital necrotizing fasciitis", "ANATOMY", 60, 93], ["necrotizing fasciitis", "DISEASE", 72, 93], ["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 208, 216], ["periorbital necrotizing fasciitis", "PROBLEM", 60, 93], ["intervention", "TREATMENT", 133, 145], ["emergency debridement", "TREATMENT", 151, 172], ["reconstruction", "TREATMENT", 178, 192], ["devastating", "OBSERVATION_MODIFIER", 36, 47], ["periorbital", "ANATOMY", 60, 71], ["necrotizing", "OBSERVATION_MODIFIER", 72, 83], ["fasciitis", "OBSERVATION", 84, 93]]]], "5fbd3e0f19d7c2477dfff703432b02838726fe25": [["IntroductionAt the beginning of February 2020, only three cases of coronavirus disease 2019 (COVID- 19) were identified in Italy, all involving people who had recently travelled to China [1] .", [["coronavirus disease", "DISEASE", 67, 86], ["people", "ORGANISM", 144, 150], ["people", "SPECIES", 144, 150], ["coronavirus disease", "PROBLEM", 67, 86], ["coronavirus disease", "OBSERVATION", 67, 86]]], ["On February 20, 2020, a severe case of pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was diagnosed in Lombardy, Italy, in a man in his 30s without any history of possible exposure abroad [2] .", [["pneumonia", "DISEASE", 39, 48], ["acute respiratory syndrome coronavirus", "DISEASE", 63, 101], ["SARS-CoV-2", "ORGANISM", 105, 115], ["man", "ORGANISM", 156, 159], ["man", "SPECIES", 156, 159], ["severe acute respiratory syndrome coronavirus", "SPECIES", 56, 101], ["SARS-CoV-2", "SPECIES", 105, 115], ["pneumonia", "PROBLEM", 39, 48], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 56, 101], ["pneumonia", "OBSERVATION", 39, 48], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["respiratory syndrome", "OBSERVATION", 69, 89]]], ["Within 14 days, many other cases of COVID-19 in the surrounding area were diagnosed, including a substantial number of critically ill patients [3] .", [["area", "ANATOMY", 64, 68], ["critically ill", "DISEASE", 119, 133], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["COVID", "TEST", 36, 41], ["substantial", "OBSERVATION_MODIFIER", 97, 108]]], ["On March 9, 2020, the Italian Government implemented extraordinary measures to limit viral transmission restricting movement in the entire national territory to minimize potential contacts with infected people (www.gover no.it, 2020).", [["people", "ORGANISM", 203, 209], ["people", "SPECIES", 203, 209], ["extraordinary measures", "TREATMENT", 53, 75]]], ["At that time, the total cases in Italy were 10,149 and the deaths more than 630 (www. stati sta.com, 2020).", [["deaths", "DISEASE", 59, 65], ["the total cases", "TEST", 14, 29]]], ["Since then, a spread of COVID-19 was observed, especially in northern Italy, with a wide severity spectrum, ranging from asymptomatic disease, minor flulike symptoms to severe pneumopathies or multiorgan failure [3] .", [["multiorgan", "ANATOMY", 193, 203], ["pneumopathies", "DISEASE", 176, 189], ["multiorgan failure", "DISEASE", 193, 211], ["COVID-19", "DNA", 24, 32], ["COVID", "TEST", 24, 29], ["a wide severity spectrum", "PROBLEM", 82, 106], ["asymptomatic disease", "PROBLEM", 121, 141], ["minor flulike symptoms", "PROBLEM", 143, 165], ["severe pneumopathies", "PROBLEM", 169, 189], ["multiorgan failure", "PROBLEM", 193, 211], ["asymptomatic", "OBSERVATION_MODIFIER", 121, 133], ["disease", "OBSERVATION", 134, 141], ["severe", "OBSERVATION_MODIFIER", 169, 175], ["pneumopathies", "OBSERVATION", 176, 189], ["multiorgan failure", "OBSERVATION", 193, 211]]], ["Patients who are older and have comorbidities (diabetes, cardiovascular disease, cancer, immunosuppression, obesity, etc.) are the most likely to develop severe forms [5, 6] .", [["cardiovascular", "ANATOMY", 57, 71], ["cancer", "ANATOMY", 81, 87], ["diabetes", "DISEASE", 47, 55], ["cardiovascular disease", "DISEASE", 57, 79], ["cancer", "DISEASE", 81, 87], ["immunosuppression", "DISEASE", 89, 106], ["obesity", "DISEASE", 108, 115], ["Patients", "ORGANISM", 0, 8], ["cancer", "CANCER", 81, 87], ["Patients", "SPECIES", 0, 8], ["comorbidities (diabetes", "PROBLEM", 32, 55], ["cardiovascular disease", "PROBLEM", 57, 79], ["cancer", "PROBLEM", 81, 87], ["immunosuppression", "TREATMENT", 89, 106], ["obesity", "PROBLEM", 108, 115], ["cardiovascular", "ANATOMY", 57, 71], ["cancer", "OBSERVATION", 81, 87], ["most likely", "UNCERTAINTY", 131, 142]]], ["In Italy, as of May 13, 2020, there were 221,216 confirmed cases of COVID-19 and 30,911 related deaths (www. stati sta.com, 2020).IntroductionCOVID-19 pandemic imposed clinicians a unique set of challenges in the management of women needing periodical screening mammography, imaging, and/or needle biopsy for a suspect breast cancer.", [["breast cancer", "ANATOMY", 319, 332], ["COVID", "DISEASE", 68, 73], ["deaths", "DISEASE", 96, 102], ["breast cancer", "DISEASE", 319, 332], ["women", "ORGANISM", 227, 232], ["breast cancer", "CANCER", 319, 332], ["women", "SPECIES", 227, 232], ["COVID", "TEST", 68, 73], ["periodical screening mammography", "TEST", 241, 273], ["imaging", "TEST", 275, 282], ["needle biopsy", "TEST", 291, 304], ["breast cancer", "PROBLEM", 319, 332], ["breast", "ANATOMY", 319, 325], ["cancer", "OBSERVATION", 326, 332]]], ["Because of the combination of lockdown, need of social distancing, and reduced hospital resources, in many cases the routine outpatient breast imaging activity has been drastically reduced.", [["breast", "ANATOMY", 136, 142], ["breast", "ORGANISM_SUBDIVISION", 136, 142], ["the routine outpatient breast imaging activity", "TEST", 113, 159], ["breast", "ANATOMY", 136, 142], ["reduced", "OBSERVATION_MODIFIER", 181, 188]]], ["Therefore, it is crucial to define which women require urgent or nonreschedulable care, can wait reasonable time, or can wait until the pandemic is over [7, 8] .", [["women", "ORGANISM", 41, 46], ["women", "SPECIES", 41, 46], ["urgent or nonreschedulable care", "TREATMENT", 55, 86]]], ["A new paradigm has been introduced by the pandemic facing, on the one hand, with best oncological management, avoiding any potential loss of opportunity [9, 10] and, on the other, extra-protection from the risk of SARS-CoV-2 infection [11] .IntroductionIn this context, the Italian College of Breast Radiologists by the Italian Society of Medical Radiology (SIRM) provides recommendations for breast care provision and procedural prioritization, being aware that medical decisions must be currently taken balancing patient's individual and community safety.", [["breast", "ANATOMY", 393, 399], ["SARS-CoV-2 infection", "DISEASE", 214, 234], ["SARS-CoV-2", "ORGANISM", 214, 224], ["patient", "ORGANISM", 515, 522], ["patient", "SPECIES", 515, 522], ["SARS-CoV", "SPECIES", 214, 222], ["A new paradigm", "TREATMENT", 0, 14], ["best oncological management", "TREATMENT", 81, 108], ["SARS", "PROBLEM", 214, 218], ["CoV-2 infection", "PROBLEM", 219, 234], ["breast care provision", "TREATMENT", 393, 414], ["procedural prioritization", "TREATMENT", 419, 444], ["new", "OBSERVATION_MODIFIER", 2, 5], ["SARS", "OBSERVATION", 214, 218], ["Breast", "ANATOMY", 293, 299]]], ["These recommendations are limited to the diagnosis and management of breast malignant disease.", [["breast malignant disease", "ANATOMY", 69, 93], ["breast malignant disease", "DISEASE", 69, 93], ["breast malignant disease", "CANCER", 69, 93], ["management", "TREATMENT", 55, 65], ["breast malignant disease", "PROBLEM", 69, 93], ["breast", "ANATOMY", 69, 75], ["malignant", "OBSERVATION", 76, 85]]], ["Recommendations for oncologic imaging of whole-body staging/restaging are left to general oncologic imaging recommendations (www.esmo.org, 2020; www.asco.org, 2020) [11, 12] .Priority categories and suggested practiceThe response to this pandemic has led to a sudden disruption of routine medical care, including breast imaging workup in asymptomatic population, symptomatic patients, and management of cancer patients [7, 8] .", [["whole-body", "ANATOMY", 41, 51], ["breast", "ANATOMY", 313, 319], ["cancer", "ANATOMY", 403, 409], ["cancer", "DISEASE", 403, 409], ["breast", "ORGANISM_SUBDIVISION", 313, 319], ["patients", "ORGANISM", 375, 383], ["cancer", "CANCER", 403, 409], ["patients", "ORGANISM", 410, 418], ["patients", "SPECIES", 375, 383], ["patients", "SPECIES", 410, 418], ["oncologic imaging", "TEST", 20, 37], ["whole-body staging/restaging", "TEST", 41, 69], ["general oncologic imaging", "TEST", 82, 107], ["routine medical care", "TREATMENT", 281, 301], ["breast imaging workup", "TEST", 313, 334], ["cancer", "PROBLEM", 403, 409], ["breast", "ANATOMY", 313, 319], ["cancer", "OBSERVATION", 403, 409]]], ["Even early breast cancer can be a fatal disease if left untreated, so adequate surgery combined with appropriate perioperative therapies is essential to improve the outcome [9, 10] .", [["breast cancer", "ANATOMY", 11, 24], ["breast cancer", "DISEASE", 11, 24], ["breast cancer", "CANCER", 11, 24], ["early breast cancer", "PROBLEM", 5, 24], ["a fatal disease", "PROBLEM", 32, 47], ["adequate surgery", "TREATMENT", 70, 86], ["appropriate perioperative therapies", "TREATMENT", 101, 136], ["early", "OBSERVATION_MODIFIER", 5, 10], ["breast", "ANATOMY", 11, 17], ["cancer", "OBSERVATION", 18, 24], ["fatal", "OBSERVATION_MODIFIER", 34, 39]]], ["It is well known that early detection contributes to a decrease in specific breast cancer mortality [13] [14] [15] , and breast cancer outcomes are dependent on timely and high-quality multidisciplinary interventions [14] .", [["breast cancer", "ANATOMY", 76, 89], ["breast cancer", "ANATOMY", 121, 134], ["breast cancer", "DISEASE", 76, 89], ["breast cancer", "DISEASE", 121, 134], ["breast cancer", "CANCER", 76, 89], ["breast cancer", "CANCER", 121, 134], ["a decrease in specific breast cancer mortality", "PROBLEM", 53, 99], ["breast cancer outcomes", "PROBLEM", 121, 143], ["decrease", "OBSERVATION_MODIFIER", 55, 63], ["breast", "ANATOMY", 76, 82], ["cancer", "OBSERVATION", 83, 89], ["breast", "ANATOMY", 121, 127], ["cancer", "OBSERVATION", 128, 134]]], ["A short delay (e.g., 6-12 weeks) should not affect overall outcomes [9, 10] , while a diagnostic delay longer than 3 months potentially does [9, 10] .", [["A short delay", "PROBLEM", 0, 13], ["short", "OBSERVATION_MODIFIER", 2, 7]]], ["Triage may become necessary to justify which patients should undergo immediate care versus further delay.Priority categories and suggested practiceIn this context, the Italian College of Breast Radiologists by SIRM has defined the following recommendations:Priority categories and suggested practice1. patients having a scheduled or to-be-scheduled appointment for in-depth diagnostic breast imaging or needle biopsy should confirm the appointment or obtain a new one; 2. patients who have suspicious symptoms of breast cancer (in particular: new onset palpable nodule; skin or nipple retraction; orange peel skin; unilateral secretion from the nipple) should request non-deferrable tests at radiology services; 3. asymptomatic women performing annual mammographic follow-up after breast cancer treatment should preferably schedule the appointment within 1 year and 3 months from the previous check, compatibly with the local organizational conditions; 4. asymptomatic women who have not responded to the invitation for screening mammography after the onset of the pandemic or have been informed of the suspension of the screening activity should schedule the check preferably within 3 months from the date of the not performed check, compatibly with local organizational conditions.Priority categories and suggested practiceThese recommendations are driven by the common goal to preserve hospital resources for COVID-19 patients by deferring breast imaging procedures without compromising long-term outcomes for individual patients.", [["Breast", "ANATOMY", 187, 193], ["breast", "ANATOMY", 385, 391], ["breast cancer", "ANATOMY", 513, 526], ["palpable nodule", "ANATOMY", 553, 568], ["skin", "ANATOMY", 570, 574], ["nipple", "ANATOMY", 578, 584], ["skin", "ANATOMY", 609, 613], ["nipple", "ANATOMY", 645, 651], ["breast cancer", "ANATOMY", 781, 794], ["breast", "ANATOMY", 1443, 1449], ["breast cancer", "DISEASE", 513, 526], ["breast cancer", "DISEASE", 781, 794], ["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 302, 310], ["patients", "ORGANISM", 472, 480], ["breast cancer", "CANCER", 513, 526], ["skin", "ORGAN", 570, 574], ["nipple", "ORGAN", 578, 584], ["skin", "ORGAN", 609, 613], ["nipple", "ORGAN", 645, 651], ["women", "ORGANISM", 728, 733], ["breast cancer", "CANCER", 781, 794], ["women", "ORGANISM", 969, 974], ["patients", "ORGANISM", 1421, 1429], ["breast", "ORGANISM_SUBDIVISION", 1443, 1449], ["patients", "ORGANISM", 1524, 1532], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 302, 310], ["patients", "SPECIES", 472, 480], ["women", "SPECIES", 728, 733], ["women", "SPECIES", 969, 974], ["patients", "SPECIES", 1421, 1429], ["patients", "SPECIES", 1524, 1532], ["immediate care", "TREATMENT", 69, 83], ["diagnostic breast imaging", "TEST", 374, 399], ["needle biopsy", "TEST", 403, 416], ["suspicious symptoms", "PROBLEM", 490, 509], ["breast cancer", "PROBLEM", 513, 526], ["new onset palpable nodule", "PROBLEM", 543, 568], ["nipple retraction", "PROBLEM", 578, 595], ["orange peel skin", "PROBLEM", 597, 613], ["unilateral secretion", "PROBLEM", 615, 635], ["asymptomatic", "PROBLEM", 715, 727], ["breast cancer treatment", "TREATMENT", 781, 804], ["the previous check", "TEST", 880, 898], ["screening mammography", "TEST", 1020, 1041], ["the check", "TEST", 1156, 1165], ["COVID", "TREATMENT", 1412, 1417], ["breast imaging procedures", "TEST", 1443, 1468], ["Breast", "ANATOMY", 187, 193], ["breast", "ANATOMY", 385, 391], ["breast", "ANATOMY", 513, 519], ["cancer", "OBSERVATION", 520, 526], ["palpable", "OBSERVATION_MODIFIER", 553, 561], ["nodule", "OBSERVATION", 562, 568], ["skin", "ANATOMY", 570, 574], ["nipple", "ANATOMY", 578, 584], ["skin", "ANATOMY", 609, 613], ["nipple", "ANATOMY", 645, 651], ["breast", "ANATOMY", 781, 787], ["cancer", "OBSERVATION", 788, 794]]], ["The demands COVID-19 pandemic will put on healthcare institutions remain unpredictable and will have temporal and geographical variability.", [["The demands COVID", "TREATMENT", 0, 17], ["temporal and geographical variability", "PROBLEM", 101, 138], ["geographical variability", "OBSERVATION", 114, 138]]], ["Therefore, the risk of disease progression and compromised breast cancer-specific outcomes need to be weighed against viral exposure to patients and staff, considering each individual's comorbidities and age to predict risk of mortality because of COVID-19.", [["breast cancer", "ANATOMY", 59, 72], ["breast cancer", "DISEASE", 59, 72], ["breast cancer", "CANCER", 59, 72], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["disease progression", "PROBLEM", 23, 42], ["compromised breast cancer", "PROBLEM", 47, 72], ["each individual's comorbidities", "PROBLEM", 168, 199], ["COVID", "TEST", 248, 253], ["disease", "OBSERVATION", 23, 30], ["breast", "ANATOMY", 59, 65], ["cancer", "OBSERVATION", 66, 72]]], ["Lastly, these are only recommendations and are not intended to supersede individual physician judgment or institutional policies and guidelines.Priority categories and suggested practiceAll efforts should be made to avoid delayed diagnosis in patients considered at high priority, due to the potential impact on cancer outcome.", [["cancer", "ANATOMY", 312, 318], ["cancer", "DISEASE", 312, 318], ["patients", "ORGANISM", 243, 251], ["cancer", "CANCER", 312, 318], ["patients", "SPECIES", 243, 251], ["cancer outcome", "PROBLEM", 312, 326], ["cancer", "OBSERVATION", 312, 318]]], ["Suspicious symptoms, clinical or imaging findings are listed below: [24] ; 12. indication to breast and/or loco-regional lymph node needle biopsy [20] .Priority categories and suggested practiceMoreover, the multidisciplinary tumor board meetings should be restricted to one professional for each discipline of the core team [25] or, better, online performed involving all the members, for cases requiring multidisciplinary decision (e.g., B3 lesions diagnosed on image-guided breast biopsy, decision to perform or not breast magnetic resonance imaging (MRI) for local and contralateral staging; decision on type and frequency of imaging for monitoring the effect of neoadjuvant therapy, etc.).", [["breast", "ANATOMY", 93, 99], ["lymph node", "ANATOMY", 121, 131], ["tumor", "ANATOMY", 226, 231], ["B3 lesions", "ANATOMY", 440, 450], ["breast", "ANATOMY", 477, 483], ["breast", "ANATOMY", 519, 525], ["tumor", "DISEASE", 226, 231], ["breast", "CANCER", 93, 99], ["lymph node", "MULTI-TISSUE_STRUCTURE", 121, 131], ["tumor", "CANCER", 226, 231], ["breast biopsy", "MULTI-TISSUE_STRUCTURE", 477, 490], ["Suspicious symptoms", "PROBLEM", 0, 19], ["clinical or imaging findings", "TEST", 21, 49], ["loco-regional lymph node needle biopsy", "TREATMENT", 107, 145], ["B3 lesions", "PROBLEM", 440, 450], ["image-guided breast biopsy", "TEST", 464, 490], ["breast magnetic resonance imaging", "TEST", 519, 552], ["MRI", "TEST", 554, 557], ["local and contralateral staging", "TEST", 563, 594], ["imaging", "TEST", 630, 637], ["neoadjuvant therapy", "TREATMENT", 667, 686], ["breast", "ANATOMY", 93, 99], ["lymph node", "OBSERVATION", 121, 131], ["breast", "ANATOMY", 477, 483], ["biopsy", "OBSERVATION", 484, 490]]], ["In the context of current pandemic, multidisciplinary discussions should take into consideration both values and preferences of any individual patient as well as the local epidemiological condition, expected to strongly vary during the next months.Personal protective equipmentThe Italian College of Breast Radiologists by SIRM promotes the following precautions to protect both patients and healthcare workers (radiologists, radiographers, nurses, and reception staff) from infection or disease spread during breast imaging procedures, particularly mammography, breast ultrasound, breast MRI, and breast intervention procedures, such as biopsy.", [["Breast", "ANATOMY", 300, 306], ["breast", "ANATOMY", 510, 516], ["breast", "ANATOMY", 563, 569], ["breast", "ANATOMY", 582, 588], ["breast", "ANATOMY", 598, 604], ["infection", "DISEASE", 475, 484], ["patient", "ORGANISM", 143, 150], ["patients", "ORGANISM", 379, 387], ["breast", "ORGANISM_SUBDIVISION", 510, 516], ["breast", "ORGANISM_SUBDIVISION", 563, 569], ["breast", "ORGANISM_SUBDIVISION", 582, 588], ["breast", "ORGANISM_SUBDIVISION", 598, 604], ["patient", "SPECIES", 143, 150], ["patients", "SPECIES", 379, 387], ["Personal protective equipment", "TREATMENT", 248, 277], ["infection", "PROBLEM", 475, 484], ["disease spread", "PROBLEM", 488, 502], ["breast imaging procedures", "TEST", 510, 535], ["mammography", "TEST", 550, 561], ["breast ultrasound", "TEST", 563, 580], ["breast MRI", "TEST", 582, 592], ["breast intervention procedures", "TREATMENT", 598, 628], ["biopsy", "TEST", 638, 644], ["Breast", "ANATOMY", 300, 306], ["infection", "OBSERVATION", 475, 484], ["breast", "ANATOMY", 563, 569], ["breast", "ANATOMY", 582, 588], ["breast", "ANATOMY", 598, 604]]], ["The close proximity of both the patients' and healthcare workers' faces during these imaging procedures raises concern for droplet contamination in addition to blood spatter contamination, which may occur during image-guided interventions and spread by saliva while talking during imaging (https ://apps.who.int/, 2020).", [["blood", "ANATOMY", 160, 165], ["patients", "ORGANISM", 32, 40], ["blood", "ORGANISM_SUBSTANCE", 160, 165], ["saliva", "ORGANISM_SUBSTANCE", 253, 259], ["patients", "SPECIES", 32, 40], ["these imaging procedures", "TEST", 79, 103], ["droplet contamination", "PROBLEM", 123, 144], ["blood spatter contamination", "PROBLEM", 160, 187], ["image-guided interventions", "TREATMENT", 212, 238], ["imaging", "TEST", 281, 288], ["raises concern for", "UNCERTAINTY", 104, 122], ["droplet contamination", "OBSERVATION", 123, 144]]], ["Everyone involved is invited to follow the indications explained below during breast imaging procedures, avoiding inappropriate, unsolicited, or redundant examinations and being compliant with the established settings.Oncological/urgent outpatient, supposed SARS-CoV-2 negativeAll patients are considered at risk of SARS-CoV-2 infection.", [["breast", "ANATOMY", 78, 84], ["SARS", "DISEASE", 258, 262], ["SARS-CoV-2 infection", "DISEASE", 316, 336], ["breast", "ORGANISM_SUBDIVISION", 78, 84], ["patients", "ORGANISM", 281, 289], ["SARS-CoV-2", "ORGANISM", 316, 326], ["patients", "SPECIES", 281, 289], ["SARS-CoV-2", "SPECIES", 316, 326], ["breast imaging procedures", "TEST", 78, 103], ["redundant examinations", "TEST", 145, 167], ["CoV", "TEST", 263, 266], ["SARS", "PROBLEM", 316, 320], ["CoV", "PROBLEM", 321, 324], ["2 infection", "PROBLEM", 325, 336], ["SARS", "OBSERVATION", 316, 320], ["infection", "OBSERVATION", 327, 336]]], ["In the waiting room, the patient should be present alone without any accompanying caregiver; close adherence to physical distancing (at least 1 m) is required between each patient.", [["patient", "ORGANISM", 25, 32], ["patient", "ORGANISM", 172, 179], ["patient", "SPECIES", 25, 32], ["patient", "SPECIES", 172, 179]]], ["Patients with fever or respiratory symptoms (cough, dyspnoea, cold, sore throat) should be invited to go back home and contact the referring physician.", [["respiratory", "ANATOMY", 23, 34], ["fever", "DISEASE", 14, 19], ["respiratory symptoms", "DISEASE", 23, 43], ["cough", "DISEASE", 45, 50], ["dyspnoea", "DISEASE", 52, 60], ["sore throat", "DISEASE", 68, 79], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["fever", "PROBLEM", 14, 19], ["respiratory symptoms", "PROBLEM", 23, 43], ["cough", "PROBLEM", 45, 50], ["dyspnoea", "PROBLEM", 52, 60], ["cold, sore throat", "PROBLEM", 62, 79]]], ["Asymptomatic patients should be invited to sanitize their hands, using the appropriate devices set up at the entrance of the waiting room.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["the appropriate devices", "TREATMENT", 71, 94]]], ["Patients wearing gloves should be invited to replace them with new ones provided by the center.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["gloves", "TREATMENT", 17, 23]]], ["Patients must wear a surgical mask (provided by the center if the patient does not wear it at the arrival), and if wearing an FFP2 or FFP3 mask with filter, they should wear a surgical mask over.Oncological/urgent outpatient, supposed SARS-CoV-2 negativeAll staff having close or physical contact with patients undergoing breast imaging, including interventional procedures (breast biopsy), should wear surgical mask, visor or goggle protection, disposable gown, disposable cap, and disposable gloves.", [["breast", "ANATOMY", 322, 328], ["breast", "ANATOMY", 375, 381], ["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 66, 73], ["FFP2", "GENE_OR_GENE_PRODUCT", 126, 130], ["patients", "ORGANISM", 302, 310], ["breast", "ORGANISM_SUBDIVISION", 322, 328], ["breast biopsy", "MULTI-TISSUE_STRUCTURE", 375, 388], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 66, 73], ["patients", "SPECIES", 302, 310], ["a surgical mask", "TREATMENT", 19, 34], ["an FFP2 or FFP3 mask", "TREATMENT", 123, 143], ["filter", "TREATMENT", 149, 155], ["a surgical mask", "TREATMENT", 174, 189], ["CoV", "TEST", 240, 243], ["breast imaging", "TEST", 322, 336], ["interventional procedures", "TREATMENT", 348, 373], ["breast biopsy", "TEST", 375, 388], ["surgical mask", "TREATMENT", 403, 416], ["visor", "TREATMENT", 418, 423], ["goggle protection", "TREATMENT", 427, 444], ["disposable gown", "TREATMENT", 446, 461], ["disposable cap", "TREATMENT", 463, 477], ["disposable gloves", "TREATMENT", 483, 500], ["breast", "ANATOMY", 322, 328], ["breast", "ANATOMY", 375, 381]]], ["For breast ultrasound, the probe should be covered with a probe cover or glove.", [["breast", "ANATOMY", 4, 10], ["breast", "ORGANISM_SUBDIVISION", 4, 10], ["breast ultrasound", "TEST", 4, 21], ["the probe", "TREATMENT", 23, 32], ["a probe cover", "TREATMENT", 56, 69], ["breast", "ANATOMY", 4, 10]]], ["All the devices with direct contact to the patient (e.g., ultrasound probe cover, mammographic equipment, magnetic resonance breast coil) should be sanitized with a disinfectant before every patient.", [["breast", "ANATOMY", 125, 131], ["patient", "ORGANISM", 43, 50], ["patient", "ORGANISM", 191, 198], ["patient", "SPECIES", 43, 50], ["patient", "SPECIES", 191, 198], ["ultrasound probe", "TEST", 58, 74], ["magnetic resonance breast coil", "TREATMENT", 106, 136]]], ["The healthcare workers remaining 1 m from the patient may not wear special devices.SARS-CoV-2 infection under investigation (patients waiting for swab result)The patient must wear a surgical mask.", [["SARS-CoV-2 infection", "DISEASE", 83, 103], ["patient", "ORGANISM", 46, 53], ["SARS-CoV-2", "ORGANISM", 83, 93], ["patients", "ORGANISM", 125, 133], ["patient", "ORGANISM", 162, 169], ["patient", "SPECIES", 46, 53], ["patients", "SPECIES", 125, 133], ["patient", "SPECIES", 162, 169], ["special devices", "TREATMENT", 67, 82], ["SARS", "PROBLEM", 83, 87], ["swab result", "TEST", 146, 157], ["a surgical mask", "TREATMENT", 180, 195], ["infection", "OBSERVATION", 94, 103]]], ["All healthcare workers (radiologists, radiographers, and nurses) wear an FFP2 mask, visor or goggle protection, disposable gown, disposable cap, and disposable gloves.", [["an FFP2 mask", "TREATMENT", 70, 82], ["visor", "TREATMENT", 84, 89], ["goggle protection", "TREATMENT", 93, 110], ["disposable gown", "TREATMENT", 112, 127], ["disposable cap", "TREATMENT", 129, 143], ["disposable gloves", "TREATMENT", 149, 166]]], ["The ultrasound cover must be implemented with washable or plastic film on the keyboard and the ultrasound machine, not only for interventional procedures.", [["The ultrasound", "TEST", 0, 14], ["plastic film", "TEST", 58, 70], ["the ultrasound machine", "TEST", 91, 113], ["interventional procedures", "TREATMENT", 128, 153]]], ["The ultrasound probe cover must be changed for each patient to prevent potential transmission.", [["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["The ultrasound probe", "TREATMENT", 0, 20]]], ["Further sanitization of all the devices with which the patient comes into contact (e.g., ultrasound probe and machine, mammographic equipment, and magnetic resonance room) must be performed after undressing at the end procedure to be ready for next dressing.Patients positive for SARS-CoV-2 infectionThe patient must wear a surgical mask.", [["SARS-CoV-2 infection", "DISEASE", 280, 300], ["patient", "ORGANISM", 55, 62], ["Patients", "ORGANISM", 258, 266], ["SARS-CoV-2", "ORGANISM", 280, 290], ["patient", "ORGANISM", 304, 311], ["patient", "SPECIES", 55, 62], ["Patients", "SPECIES", 258, 266], ["patient", "SPECIES", 304, 311], ["SARS-CoV", "SPECIES", 280, 288], ["all the devices", "TREATMENT", 24, 39], ["ultrasound probe", "TEST", 89, 105], ["the end procedure", "TREATMENT", 210, 227], ["next dressing", "TREATMENT", 244, 257], ["SARS", "PROBLEM", 280, 284], ["CoV", "PROBLEM", 285, 288], ["2 infection", "PROBLEM", 289, 300], ["a surgical mask", "TREATMENT", 322, 337], ["infection", "OBSERVATION", 291, 300]]], ["All healthcare workers (radiologists, radiographers, and nurses) wear an FFP2 or FFP3 mask, visor or goggle protection, disposable waterproof gown, disposable cap, double disposable gloves.", [["an FFP2", "TREATMENT", 70, 77], ["FFP3 mask", "TREATMENT", 81, 90], ["visor", "TREATMENT", 92, 97], ["goggle protection", "TREATMENT", 101, 118], ["disposable waterproof gown", "TREATMENT", 120, 146], ["disposable cap", "TREATMENT", 148, 162], ["double disposable gloves", "TREATMENT", 164, 188]]], ["Complete coverage of the ultrasound machine and probe must be implemented, not only for interventional procedures.", [["the ultrasound machine", "TREATMENT", 21, 43], ["interventional procedures", "TREATMENT", 88, 113]]], ["The probe cover must be changed for each patient to prevent transmission of further infection.", [["infection", "DISEASE", 84, 93], ["patient", "ORGANISM", 41, 48], ["patient", "SPECIES", 41, 48], ["The probe", "TREATMENT", 0, 9], ["further infection", "PROBLEM", 76, 93], ["infection", "OBSERVATION", 84, 93]]], ["Further sanitization of all the area in which the patient comes into contact must be performed after undressing at the end procedure to be ready for next dressing.", [["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57], ["Further sanitization of all the area", "TREATMENT", 0, 36], ["the end procedure", "TREATMENT", 115, 132], ["next dressing", "TREATMENT", 149, 162]]], ["In cases where the patient cannot wear the surgical mask, healthcare workers must wear an FFP3 mask.Emotional aspects of cancer patients during COVID-19 pandemicAll the commotion of the COVID-19 pandemic is anxietyprovoking among both patients and practitioners.", [["cancer", "ANATOMY", 121, 127], ["cancer", "DISEASE", 121, 127], ["patient", "ORGANISM", 19, 26], ["cancer", "CANCER", 121, 127], ["patients", "ORGANISM", 128, 136], ["patients", "ORGANISM", 235, 243], ["patient", "SPECIES", 19, 26], ["patients", "SPECIES", 128, 136], ["patients", "SPECIES", 235, 243], ["the surgical mask", "TREATMENT", 39, 56], ["an FFP3 mask", "TREATMENT", 87, 99], ["cancer", "PROBLEM", 121, 127], ["COVID", "TEST", 144, 149], ["the COVID", "TREATMENT", 182, 191], ["cancer", "OBSERVATION", 121, 127]]], ["The aim of these recommendations is to share good clinical practice recommendations in this difficult contest, giving the clinicians the cornerstones to manage patients correctly and safely.", [["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 160, 168]]], ["Oncological patient is one of the most fragile during the pandemic.", [["patient", "ORGANISM", 12, 19], ["patient", "SPECIES", 12, 19], ["one of the most fragile", "OBSERVATION_MODIFIER", 23, 46]]], ["The significant psychological impact on oncological patients is compounded by multiple factors: knowledge that the individual is at higher risk of serious complication if infected by SARS-CoV-2, loneliness and isolation as a result of social distancing, and the underlying constant fear of the cancer [26] .", [["cancer", "ANATOMY", 294, 300], ["SARS", "DISEASE", 183, 187], ["loneliness", "DISEASE", 195, 205], ["cancer", "DISEASE", 294, 300], ["patients", "ORGANISM", 52, 60], ["cancer", "CANCER", 294, 300], ["patients", "SPECIES", 52, 60], ["serious complication", "PROBLEM", 147, 167], ["loneliness", "PROBLEM", 195, 205], ["isolation", "TREATMENT", 210, 219], ["the cancer", "PROBLEM", 290, 300], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["cancer", "OBSERVATION", 294, 300]]], ["Patient psychological well-being needs to be considered and often can be addressed with telemedicine/ phone visits.", [["Patient", "SPECIES", 0, 7]]], ["To reduce uncertainty feelings affecting both clinicians and patients, structured recommendations and the adequate psychological support are essential tools for healthcare workers to aid cancer patients to overcome this difficult moment [27, 28] .Conclusions and future directionsThis information should be used to provide radiologists with structured recommendations for breast care in both asymptomatic population and breast cancer patients during the COVID-19 pandemic.", [["cancer", "ANATOMY", 187, 193], ["breast", "ANATOMY", 372, 378], ["breast cancer", "ANATOMY", 420, 433], ["cancer", "DISEASE", 187, 193], ["breast cancer", "DISEASE", 420, 433], ["patients", "ORGANISM", 61, 69], ["cancer", "CANCER", 187, 193], ["patients", "ORGANISM", 194, 202], ["breast", "ORGANISM_SUBDIVISION", 372, 378], ["breast cancer", "CANCER", 420, 433], ["patients", "ORGANISM", 434, 442], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 194, 202], ["patients", "SPECIES", 434, 442], ["breast care", "TREATMENT", 372, 383], ["breast cancer", "PROBLEM", 420, 433], ["the COVID", "TEST", 450, 459], ["pandemic", "PROBLEM", 463, 471], ["breast", "ANATOMY", 372, 378], ["breast", "ANATOMY", 420, 426], ["cancer", "OBSERVATION", 427, 433]]], ["In particular, we recommend that diagnostic procedures in symptomatic patients and in patients with a suspicious finding should be confirmed according to local availability and resources.", [["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 86, 94], ["diagnostic procedures", "TEST", 33, 54], ["a suspicious finding", "PROBLEM", 100, 120]]], ["Breast cancer patient's follow-up and routine breast cancer screening should be performed with a delay of no more than 3 months from the scheduled date, compatibly with the local organizational conditions.", [["Breast cancer", "ANATOMY", 0, 13], ["breast cancer", "ANATOMY", 46, 59], ["Breast cancer", "DISEASE", 0, 13], ["breast cancer", "DISEASE", 46, 59], ["Breast cancer", "CANCER", 0, 13], ["patient", "ORGANISM", 14, 21], ["breast cancer", "CANCER", 46, 59], ["patient", "SPECIES", 14, 21], ["Breast cancer", "PROBLEM", 0, 13], ["routine breast cancer screening", "TEST", 38, 69], ["cancer", "OBSERVATION", 7, 13], ["breast", "ANATOMY", 46, 52], ["cancer", "OBSERVATION", 53, 59]]], ["All breast imaging procedures should be conducted wearing personal protective equipment precautions, following the measures of social distancing, and the sanitization of equipment and spaces to protect both patients and healthcare workers.", [["breast", "ANATOMY", 4, 10], ["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 207, 215], ["All breast imaging procedures", "TREATMENT", 0, 29], ["personal protective equipment precautions", "TREATMENT", 58, 99], ["breast", "ANATOMY", 4, 10]]], ["However, as the pandemic rapidly evolves, we are increasingly learning about viral transmission and its impact on the healthcare system.", [["viral transmission", "TREATMENT", 77, 95]]], ["It is our hope that this paper will help women, radiologists, and all other clinicians to provide the highestlevel care for their patients during this evolving pandemic.", [["women", "ORGANISM", 41, 46], ["patients", "ORGANISM", 130, 138], ["women", "SPECIES", 41, 46], ["patients", "SPECIES", 130, 138], ["the highestlevel care", "TREATMENT", 98, 119]]]], "PMC7223508": [["IntroductionLower respiratory tract infections (LRTI) are one of the major causes of morbidity and mortality in children in the preschool age group all over the world, especially in developing countries [1].", [["respiratory tract", "ANATOMY", 18, 35], ["respiratory tract infections", "DISEASE", 18, 46], ["LRTI", "DISEASE", 48, 52], ["IntroductionLower respiratory tract", "ORGANISM_SUBDIVISION", 0, 35], ["children", "ORGANISM", 112, 120], ["children", "SPECIES", 112, 120], ["IntroductionLower respiratory tract infections", "PROBLEM", 0, 46], ["morbidity", "PROBLEM", 85, 94], ["respiratory tract", "ANATOMY", 18, 35], ["infections", "OBSERVATION", 36, 46], ["morbidity", "OBSERVATION", 85, 94]]], ["In a meta-analysis conducted in 2013, the incidence of pneumonia in children under 5 years was 0.22 episodes per child per year [2].", [["pneumonia", "DISEASE", 55, 64], ["children", "ORGANISM", 68, 76], ["children", "SPECIES", 68, 76], ["pneumonia", "PROBLEM", 55, 64], ["pneumonia", "OBSERVATION", 55, 64]]], ["One hundred and fifty million new cases of pneumonia occur all over the world per year; 7\u201313% of these cases require hospitalization and LRTIs caused 19% of children deaths under 5 years [3].", [["pneumonia", "DISEASE", 43, 52], ["LRTIs", "DISEASE", 137, 142], ["deaths", "DISEASE", 166, 172], ["children", "ORGANISM", 157, 165], ["children", "SPECIES", 157, 165], ["pneumonia", "PROBLEM", 43, 52], ["LRTIs", "TREATMENT", 137, 142], ["pneumonia", "OBSERVATION", 43, 52]]], ["In the light of these data, LRTIs are particularly have been striking as a significant public problem due to its high mortality and morbidity rates in children under 5 years of age.IntroductionIn children, LRTIs can be caused by various microorganisms.", [["LRTIs", "DISEASE", 206, 211], ["LRTIs", "SIMPLE_CHEMICAL", 28, 33], ["children", "ORGANISM", 151, 159], ["children", "ORGANISM", 196, 204], ["children", "SPECIES", 151, 159], ["children", "SPECIES", 196, 204], ["LRTIs", "PROBLEM", 28, 33], ["a significant public problem", "PROBLEM", 73, 101], ["LRTIs", "PROBLEM", 206, 211], ["various microorganisms", "PROBLEM", 229, 251], ["LRTIs", "OBSERVATION", 28, 33], ["significant", "OBSERVATION_MODIFIER", 75, 86], ["LRTIs", "OBSERVATION", 206, 211]]], ["The most frequent viral causes of LRTIs, especially in children under 2 years, are respiratory syncytial virus (RSV), influenza virus, parainfluenza virus, and adenovirus [4].", [["LRTIs", "DISEASE", 34, 39], ["respiratory syncytial virus (RSV), influenza virus, parainfluenza virus", "DISEASE", 83, 154], ["children", "ORGANISM", 55, 63], ["respiratory syncytial virus", "ORGANISM", 83, 110], ["RSV", "ORGANISM", 112, 115], ["influenza virus", "ORGANISM", 118, 133], ["parainfluenza virus", "ORGANISM", 135, 154], ["adenovirus", "ORGANISM", 160, 170], ["children", "SPECIES", 55, 63], ["syncytial virus (RSV", "SPECIES", 95, 115], ["influenza virus, parainfluenza virus", "SPECIES", 118, 154], ["respiratory syncytial virus", "SPECIES", 83, 110], ["RSV", "SPECIES", 112, 115], ["parainfluenza virus", "SPECIES", 135, 154], ["adenovirus", "SPECIES", 160, 170], ["LRTIs", "PROBLEM", 34, 39], ["respiratory syncytial virus (RSV)", "PROBLEM", 83, 116], ["influenza virus", "PROBLEM", 118, 133], ["parainfluenza virus", "PROBLEM", 135, 154], ["adenovirus", "PROBLEM", 160, 170], ["most frequent", "OBSERVATION_MODIFIER", 4, 17], ["viral", "OBSERVATION_MODIFIER", 18, 23], ["LRTIs", "OBSERVATION", 34, 39], ["respiratory", "ANATOMY", 83, 94], ["syncytial virus", "OBSERVATION", 95, 110], ["parainfluenza virus", "OBSERVATION", 135, 154]]], ["RSV is the most common viral agent in childhood LRTIs [5].", [["LRTIs", "DISEASE", 48, 53], ["RSV", "ORGANISM", 0, 3], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["most common", "OBSERVATION_MODIFIER", 11, 22], ["LRTIs", "OBSERVATION", 48, 53]]], ["There is no proven treatment option other than adequate hydration and oxygenation for RSV infections [6].", [["RSV infections", "DISEASE", 86, 100], ["RSV", "ORGANISM", 86, 89], ["RSV", "SPECIES", 86, 89], ["treatment option", "TREATMENT", 19, 35], ["adequate hydration", "TREATMENT", 47, 65], ["RSV infections", "PROBLEM", 86, 100], ["no proven", "UNCERTAINTY", 9, 18], ["treatment", "OBSERVATION", 19, 28]]], ["Therefore, protection from RSV infections is crucial.", [["RSV infections", "DISEASE", 27, 41], ["RSV", "ORGANISM", 27, 30], ["RSV", "SPECIES", 27, 30], ["protection", "TREATMENT", 11, 21], ["RSV infections", "PROBLEM", 27, 41], ["RSV infections", "OBSERVATION", 27, 41]]], ["In recent years, efforts to develop vaccines against RSV infections have gained momentum.", [["RSV infections", "DISEASE", 53, 67], ["RSV", "ORGANISM", 53, 56], ["RSV", "SPECIES", 53, 56], ["RSV", "SPECIES", 53, 56], ["vaccines", "TREATMENT", 36, 44], ["RSV infections", "PROBLEM", 53, 67]]], ["Vaccine development efforts focus on early childhood vaccination or protection of babies by antibodies that are transplacentally transported to babies from immunized mothers.", [["babies", "ORGANISM", 82, 88], ["babies", "ORGANISM", 144, 150], ["antibodies", "PROTEIN", 92, 102], ["Vaccine", "TREATMENT", 0, 7], ["early childhood vaccination", "TREATMENT", 37, 64]]], ["While vaccine development studies are ongoing, it is important to understand RSV immunity to determine RSV Ig G antibody seropositivity rates in mother-infant pairs and to evaluate the transplacental antibody transfer kinetics.IntroductionFor this purpose, we investigated RSV antibody levels at birth and 6th month (only infant\u2019s antibody levels) of age and evaluated the factors related to antibody transfer ratio in 84 mother-infant pairs.Study population, definitions ::: Material and methodsThe patients who were admitted to Istanbul Faculty of Medicine, Department of Obstetrics and Gynecology for delivery between January 2016 and April 2016 were informed in detail for the study.Study population, definitions ::: Material and methodsWritten consent was obtained from the families who were interviewed and agreed to participate in the study.", [["RSV", "ORGANISM", 77, 80], ["RSV", "ORGANISM", 103, 106], ["Ig G antibody", "GENE_OR_GENE_PRODUCT", 107, 120], ["RSV", "ORGANISM", 273, 276], ["infant", "ORGANISM", 429, 435], ["patients", "ORGANISM", 500, 508], ["RSV Ig G antibody", "PROTEIN", 103, 120], ["RSV antibody", "PROTEIN", 273, 285], ["infant", "SPECIES", 322, 328], ["infant", "SPECIES", 429, 435], ["patients", "SPECIES", 500, 508], ["RSV", "SPECIES", 77, 80], ["RSV", "SPECIES", 103, 106], ["RSV", "SPECIES", 273, 276], ["vaccine development studies", "TEST", 6, 33], ["RSV Ig G antibody seropositivity rates", "TEST", 103, 141], ["RSV antibody levels", "TEST", 273, 292], ["infant\u2019s antibody levels", "TEST", 322, 346], ["the factors", "PROBLEM", 369, 380], ["antibody transfer ratio", "TEST", 392, 415], ["the study", "TEST", 677, 686], ["the study", "TEST", 838, 847]]], ["Family contact information, gestation week, type of delivery, gravidity, parity, number of school-aged siblings, household members, and smokers at home were asked to parents.Study population, definitions ::: Material and methodsInfants that were born between 37 + 0/7 and 38 + 6/7 weeks of gestation were defined as early term, those that were born between 39 + 0/7 and 40 + 6/7 weeks of gestation were defined as full term, and that those were born between 41+ 0/7 and 41 6/7 weeks of gestation were defined as late term [7].Study population, definitions ::: Material and methodsInfants were divided into 3 groups according to their birth weights: small for gestational age (SGA), appropriate for gestational age (AGA), and large for gestational age (LGA).", [["Infants", "ORGANISM", 228, 235], ["Infants", "ORGANISM", 580, 587], ["Infants", "SPECIES", 228, 235], ["Infants", "SPECIES", 580, 587], ["Material and methods", "TREATMENT", 560, 580], ["small", "OBSERVATION_MODIFIER", 649, 654], ["large", "OBSERVATION_MODIFIER", 725, 730]]], ["According to the fetal birth weight percentiles, infants were defined as SGA if their birth weight were less than 10th percentile, AGA if their birth weight were between 10 and 90 percentile, and LGA if their birth weight were above 90th percentile [8].Sampling ::: Material and methodsBefore delivery, when vascular access was opening, 2-mL blood sample was taken from the mothers.", [["fetal", "ANATOMY", 17, 22], ["vascular", "ANATOMY", 308, 316], ["blood sample", "ANATOMY", 342, 354], ["fetal", "ANATOMICAL_SYSTEM", 17, 22], ["infants", "ORGANISM", 49, 56], ["vascular", "MULTI-TISSUE_STRUCTURE", 308, 316], ["blood", "ORGANISM_SUBSTANCE", 342, 347], ["infants", "SPECIES", 49, 56], ["the fetal birth weight percentiles", "TEST", 13, 47], ["SGA", "TEST", 73, 76], ["their birth weight", "TEST", 80, 98], ["AGA", "TEST", 131, 134], ["their birth weight", "TEST", 138, 156], ["their birth weight", "TEST", 203, 221], ["delivery", "TREATMENT", 293, 301], ["blood sample", "TEST", 342, 354]]], ["Babies\u2019 blood samples (2 ml) were taken via umbilical cord immediately after birth.", [["blood samples", "ANATOMY", 8, 21], ["umbilical cord", "ANATOMY", 44, 58], ["Babies", "ORGANISM", 0, 6], ["blood samples", "ORGANISM_SUBSTANCE", 8, 21], ["umbilical cord", "ORGAN", 44, 58], ["Babies", "SPECIES", 0, 6], ["blood samples", "TEST", 8, 21], ["umbilical cord", "ANATOMY", 44, 58]]], ["Blood samples were stored at \u2013 70 \u00b0C until processing after they were rapidly centrifuged at 3000\u20133500 rpm for 15 min.Sampling ::: Material and methodsSix months after birth, the parents whom could be reached were reinterviewed.", [["Blood samples", "ANATOMY", 0, 13], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["Blood samples", "TEST", 0, 13]]], ["And control blood samples were taken after informed consents were obtained.", [["blood samples", "ANATOMY", 12, 25], ["blood samples", "ORGANISM_SUBSTANCE", 12, 25], ["control blood samples", "TEST", 4, 25]]], ["Blood samples were stored at \u2013 70 \u00b0C until processing after they were rapidly centrifuged at 3000\u20133500 rpm for 15 min, and 2 mL of blood samples were taken from infants.Detection of RSV antibody levels in serum samples ::: Material and methodsIn our study, anti-RSV Ig G antibody levels in serum samples were determined by ELISA method in the Department of Virology and Basic Immunology of Istanbul University Istanbul Medical Faculty.", [["Blood samples", "ANATOMY", 0, 13], ["blood samples", "ANATOMY", 131, 144], ["serum samples", "ANATOMY", 205, 218], ["serum samples", "ANATOMY", 290, 303], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["blood samples", "ORGANISM_SUBSTANCE", 131, 144], ["infants", "ORGANISM", 161, 168], ["RSV", "ORGANISM", 182, 185], ["serum samples", "ORGANISM_SUBSTANCE", 205, 218], ["anti-RSV Ig G antibody", "GENE_OR_GENE_PRODUCT", 257, 279], ["serum samples", "ORGANISM_SUBSTANCE", 290, 303], ["RSV antibody", "PROTEIN", 182, 194], ["anti-RSV Ig G antibody", "PROTEIN", 257, 279], ["infants", "SPECIES", 161, 168], ["RSV", "SPECIES", 182, 185], ["anti-RSV", "SPECIES", 257, 265], ["Blood samples", "TEST", 0, 13], ["blood samples", "TEST", 131, 144], ["Detection of RSV antibody levels", "TEST", 169, 201], ["serum samples", "TEST", 205, 218], ["our study", "TEST", 246, 255], ["anti-RSV Ig G antibody levels", "TEST", 257, 286], ["serum samples", "TEST", 290, 303], ["RSV antibody", "OBSERVATION", 182, 194]]], ["The ELISA test was performed automatically on a Triturus (Grifols, Spain, Serial No. 053-195-1484) instrument using the Serion ELISA classic (Viron/Serion, Germany, Catalog No. 13.13 / 09-1) kit.Detection of RSV antibody levels in serum samples ::: Material and methodsSerum samples were thawed at \u2212 70 \u00b0C to + 4 \u00b0C the day before the testing began.", [["serum samples", "ANATOMY", 231, 244], ["Serum samples", "ANATOMY", 269, 282], ["RSV", "ORGANISM", 208, 211], ["serum samples", "ORGANISM_SUBSTANCE", 231, 244], ["Serum samples", "ORGANISM_SUBSTANCE", 269, 282], ["RSV antibody", "PROTEIN", 208, 220], ["RSV", "SPECIES", 208, 211], ["The ELISA test", "TEST", 0, 14], ["Detection of RSV antibody levels", "TEST", 195, 227], ["serum samples", "TEST", 231, 244], ["Serum samples", "TEST", 269, 282], ["the testing", "TEST", 331, 342], ["RSV antibody", "OBSERVATION", 208, 220]]], ["Patient specimens and control sera were identified in the Triturus analyzer.", [["specimens", "ANATOMY", 8, 17], ["sera", "ANATOMY", 30, 34], ["Patient", "ORGANISM", 0, 7], ["sera", "ORGANISM_SUBSTANCE", 30, 34], ["Triturus", "ORGANISM", 58, 66], ["Patient", "SPECIES", 0, 7], ["Patient specimens and control sera", "TEST", 0, 34], ["Triturus", "ANATOMY", 58, 66]]], ["At the end of the study, the optical densimeter values obtained for the blank, control sera, and patient samples were manually entered into the \u201cSerion activity 11\u201d program.", [["sera", "ANATOMY", 87, 91], ["samples", "ANATOMY", 105, 112], ["sera", "ORGANISM_SUBSTANCE", 87, 91], ["patient", "ORGANISM", 97, 104], ["patient", "SPECIES", 97, 104], ["the study", "TEST", 14, 23], ["the optical densimeter values", "TEST", 25, 54], ["the blank, control sera", "TEST", 68, 91]]], ["Patient results from the Serion activity 11 program were quantified as \u201cIU/mL.\u201d", [["Patient", "SPECIES", 0, 7]]], ["This program interprets the quantitative measurements as negative, intermediate, and positive according to the cut-off values given in the certificate.Statistical analysis ::: Material and methodsStatistical analysis was performed with SPSS version 21.0 (IBM, Armonk, NY).The Kolmogorov-Smirnov test was used for analyzing the distributions of variables.", [["the quantitative measurements", "TEST", 24, 53], ["Statistical analysis", "TEST", 196, 216], ["SPSS version", "TEST", 236, 248], ["The Kolmogorov-Smirnov test", "TEST", 272, 299]]], ["Categorical variables were reported as numbers and percentages.", [["Categorical variables", "TEST", 0, 21]]], ["Continuous variables with normal distribution were given as mean \u00b1 standard deviation (SD) while those with non-normal distribution were presented as median (minimum-maximum).", [["mean \u00b1 standard deviation (SD)", "PROBLEM", 60, 90], ["normal", "OBSERVATION", 26, 32]]], ["Categorical data were compared by the \u03c72 test and Fisher\u2019s exact test.", [["Categorical data", "TEST", 0, 16]]], ["Normally distributed continuous variables were compared by Student\u2019s T test.", [["Student\u2019s T test", "TEST", 59, 75]]], ["Mann-Whitney U test or Kruskal Wallis test were used for continuous variables, which are not normally distributed according to number of groups.", [["Whitney U test", "TEST", 5, 19], ["Kruskal Wallis test", "TEST", 23, 42]]], ["In all analyses, a value of p < 0.05 was considered as statistically significant.Ethics statement ::: Material and methodsOur study was found to be ethically acceptable by Istanbul University Istanbul Faculty of Medicine Clinical Research Ethics Committee (2015/1816).", [["a value", "TEST", 17, 24], ["Our study", "TEST", 122, 131]]], ["Written informed consent was obtained from all of the participants\u2019 parents.ResultsSociodemographic characteristics of the cases and schematic representation of patient group are shown in Table 1 and Figure 1.", [["patient", "ORGANISM", 161, 168], ["participants", "SPECIES", 54, 66], ["patient", "SPECIES", 161, 168]]], ["Anti-RSV IgG antibodies of the mothers were positive in 46.5%, negative in 45.7%, and borderline in 7.9%.", [["RSV", "ORGANISM", 5, 8], ["mothers", "ORGANISM", 31, 38], ["Anti-RSV IgG antibodies", "PROTEIN", 0, 23], ["RSV", "SPECIES", 5, 8], ["RSV", "SPECIES", 5, 8], ["Anti-RSV IgG antibodies", "TEST", 0, 23]]], ["Anti-RSV IgG antibodies of infants at birth were positive in 61.5%, negative in 35.4%, and borderline in 3.1%.", [["RSV", "ORGANISM", 5, 8], ["infants", "ORGANISM", 27, 34], ["Anti-RSV IgG antibodies", "PROTEIN", 0, 23], ["RSV", "SPECIES", 5, 8], ["infants", "SPECIES", 27, 34], ["RSV", "SPECIES", 5, 8], ["Anti-RSV IgG antibodies", "TEST", 0, 23], ["borderline", "OBSERVATION_MODIFIER", 91, 101]]], ["At the sixth month, anti-RSV antibodies were negative in all infants.", [["anti-RSV antibodies", "GENE_OR_GENE_PRODUCT", 20, 39], ["infants", "ORGANISM", 61, 68], ["anti-RSV antibodies", "PROTEIN", 20, 39], ["infants", "SPECIES", 61, 68], ["anti-RSV", "SPECIES", 20, 28], ["anti-RSV antibodies", "TEST", 20, 39], ["negative", "OBSERVATION", 45, 53]]], ["Median of the anti-RSV antibody levels of the mothers and infants at birth were 12.08 IU/ml (1.21\u2013119.27) and 13.78 IU/ml (3.99\u2013108.6), respectively.", [["anti-RSV antibody", "GENE_OR_GENE_PRODUCT", 14, 31], ["mothers", "ORGANISM", 46, 53], ["infants", "ORGANISM", 58, 65], ["anti-RSV antibody", "PROTEIN", 14, 31], ["infants", "SPECIES", 58, 65], ["anti-RSV", "SPECIES", 14, 22], ["the anti-RSV antibody levels", "TEST", 10, 38]]], ["Mean anti-RSV antibody levels of infants at 6th month were 3.42 \u00b1 0.43 IU/ml (Table 2).", [["anti-RSV antibody", "GENE_OR_GENE_PRODUCT", 5, 22], ["infants", "ORGANISM", 33, 40], ["anti-RSV antibody", "PROTEIN", 5, 22], ["infants", "SPECIES", 33, 40], ["anti-RSV", "SPECIES", 5, 13], ["Mean anti-RSV antibody levels", "TEST", 0, 29], ["infants", "TEST", 33, 40]]], ["Anti-RSV IgG antibody levels of the mothers and infants (at birth and 6th month) are shown in Figure 2.ResultsMedian ratio of cord antibody level to maternal antibody level was 1.22 (0.14\u20136.05).In order to investigate the affecting factors to the transfer of antibodies from mother to baby, \u201cthe ratio of cord antibody level to maternal antibody level\u201d was compared according to gender, type of delivery, gestation week, birth weight, and the number of gravidity and parity.", [["cord", "ANATOMY", 126, 130], ["cord", "ANATOMY", 305, 309], ["RSV", "ORGANISM", 5, 8], ["mothers", "ORGANISM", 36, 43], ["infants", "ORGANISM", 48, 55], ["cord", "ORGAN", 126, 130], ["baby", "ORGANISM", 285, 289], ["cord", "ORGAN", 305, 309], ["RSV IgG antibody", "PROTEIN", 5, 21], ["cord antibody", "PROTEIN", 126, 139], ["antibodies", "PROTEIN", 259, 269], ["cord antibody", "PROTEIN", 305, 318], ["maternal antibody", "PROTEIN", 328, 345], ["RSV", "SPECIES", 5, 8], ["infants", "SPECIES", 48, 55], ["RSV", "SPECIES", 5, 8], ["Anti-RSV IgG antibody levels", "TEST", 0, 28], ["Median ratio", "TEST", 110, 122], ["cord antibody level", "TEST", 126, 145], ["maternal antibody level", "TEST", 149, 172], ["the affecting factors", "PROBLEM", 218, 239], ["cord antibody level", "TEST", 305, 324], ["maternal antibody level", "TEST", 328, 351], ["birth weight", "TEST", 421, 433], ["cord", "ANATOMY", 126, 130], ["cord", "ANATOMY", 305, 309]]], ["Median ratio that was detected in AGA infants was statistically higher than the median ratio detected in SGA or LGA infants (Table 3).ResultsAnti-RSV antibody levels of infants at birth and 6th month were compared according to factors may affect the antibody levels.", [["infants", "ORGANISM", 38, 45], ["RSV", "ORGANISM", 146, 149], ["infants", "ORGANISM", 169, 176], ["RSV antibody", "PROTEIN", 146, 158], ["infants", "SPECIES", 38, 45], ["infants", "SPECIES", 116, 123], ["infants", "SPECIES", 169, 176], ["RSV", "SPECIES", 146, 149], ["Median ratio", "TEST", 0, 12], ["ResultsAnti-RSV antibody levels", "TEST", 134, 165], ["the antibody levels", "TEST", 246, 265]]], ["There were no significant differences at birth and at 6th month between groups for each factor (Tables 4 and 5).ResultsThere was a statistically significant and strong correlation between anti-RSV antibody levels of mothers and infants at birth (p: 0.0001, r: 0.667) and anti-RSV antibody levels of infants at birth and at 6 months of age (p: 0.0001, r: 0.343) (Fig. 3 a and b).DiscussionIn this prospective study, we reported an effective anti-RSV antibody transfer from mother to infant.", [["anti-RSV antibody", "GENE_OR_GENE_PRODUCT", 188, 205], ["mothers", "ORGANISM", 216, 223], ["infants", "ORGANISM", 228, 235], ["anti-RSV antibody", "GENE_OR_GENE_PRODUCT", 271, 288], ["infants", "ORGANISM", 299, 306], ["infant", "ORGANISM", 482, 488], ["anti-RSV antibody", "PROTEIN", 188, 205], ["anti-RSV antibody", "PROTEIN", 271, 288], ["anti-RSV antibody", "PROTEIN", 440, 457], ["infants", "SPECIES", 228, 235], ["infants", "SPECIES", 299, 306], ["infant", "SPECIES", 482, 488], ["anti-RSV", "SPECIES", 440, 448], ["significant differences at birth", "PROBLEM", 14, 46], ["anti-RSV antibody levels", "TEST", 188, 212], ["anti-RSV antibody levels", "TEST", 271, 295], ["this prospective study", "TEST", 391, 413], ["an effective anti-RSV antibody transfer", "TREATMENT", 427, 466], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37]]], ["In addition, we have showed that the antibody transmission rate is optimal in AGA infants.", [["infants", "ORGANISM", 82, 89], ["infants", "SPECIES", 82, 89], ["the antibody transmission rate", "TEST", 33, 63]]], ["To our best knowledge, it is the first study reporting that anti-RSV antibody transmission rate may be negatively affected in SGA and LGA infants.DiscussionIn accordance with our results, Chu et al. [9] found the median ratio of cord antibody level to maternal antibody level to be 1.01 and baseline demographic features like age and gender had no effect on it.", [["cord", "ANATOMY", 229, 233], ["anti-RSV antibody", "GENE_OR_GENE_PRODUCT", 60, 77], ["infants", "ORGANISM", 138, 145], ["cord", "ORGAN", 229, 233], ["anti-RSV antibody", "PROTEIN", 60, 77], ["cord antibody", "PROTEIN", 229, 242], ["infants", "SPECIES", 138, 145], ["anti-RSV", "SPECIES", 60, 68], ["the first study", "TEST", 29, 44], ["anti-RSV antibody transmission rate", "TEST", 60, 95], ["the median ratio", "TEST", 209, 225], ["cord antibody level", "TEST", 229, 248], ["maternal antibody level", "TEST", 252, 275], ["cord", "ANATOMY", 229, 233]]], ["In another study, it is reported that increasing number of maternal parity and female gender were related with increased antibody transfer [10].", [["another study", "TEST", 3, 16], ["increased antibody transfer", "PROBLEM", 111, 138], ["increasing", "OBSERVATION_MODIFIER", 38, 48], ["number", "OBSERVATION_MODIFIER", 49, 55]]], ["Furthermore, Okoko et al. [11] suggested that low birth weight and prematurity were associated with lower antibody transfer rate for various viruses including RSV.DiscussionThere are a limited number of studies investigating the effect of weight for gestational age on antibody transfer rate.", [["birth weight", "DISEASE", 50, 62], ["prematurity", "DISEASE", 67, 78], ["RSV", "ORGANISM", 159, 162], ["RSV", "SPECIES", 159, 162], ["low birth weight", "PROBLEM", 46, 62], ["prematurity", "PROBLEM", 67, 78], ["lower antibody transfer rate", "PROBLEM", 100, 128], ["various viruses", "PROBLEM", 133, 148], ["RSV", "PROBLEM", 159, 162], ["antibody transfer rate", "TREATMENT", 269, 291], ["prematurity", "OBSERVATION", 67, 78]]], ["Yeung et al. [12] reported that IgG levels were lower in \u201csmall for dates\u201d infants.", [["IgG", "GENE_OR_GENE_PRODUCT", 32, 35], ["infants", "ORGANISM", 75, 82], ["IgG", "PROTEIN", 32, 35], ["infants", "SPECIES", 75, 82], ["IgG levels", "TEST", 32, 42]]], ["It has been reported that transfer rate of all IgG subtypes was negatively affected in premature AGA infants and term SGA infants.", [["IgG", "GENE_OR_GENE_PRODUCT", 47, 50], ["infants", "ORGANISM", 101, 108], ["infants", "ORGANISM", 122, 129], ["IgG subtypes", "PROTEIN", 47, 59], ["infants", "SPECIES", 101, 108], ["infants", "SPECIES", 122, 129]]], ["In contrast, Addy et al. [13] reported that AGA and SGA infants had similar IgG levels.", [["AGA", "SIMPLE_CHEMICAL", 44, 47], ["infants", "ORGANISM", 56, 63], ["IgG", "GENE_OR_GENE_PRODUCT", 76, 79], ["IgG", "PROTEIN", 76, 79], ["infants", "SPECIES", 56, 63], ["AGA", "TEST", 44, 47], ["similar IgG levels", "PROBLEM", 68, 86]]], ["The conflicting results found in the studies may be related to underlying conditions of the inappropriate birth weights for gestational age.", [["the studies", "TEST", 33, 44], ["underlying conditions", "PROBLEM", 63, 84], ["may be related to", "UNCERTAINTY", 45, 62]]], ["The inappropriate birth weight for gestational age can be caused by many conditions associated with the fetus, placenta, or mother, such as hypertension, diabetes, and various placental pathologies.", [["fetus", "ANATOMY", 104, 109], ["placenta", "ANATOMY", 111, 119], ["placental", "ANATOMY", 176, 185], ["hypertension", "DISEASE", 140, 152], ["diabetes", "DISEASE", 154, 162], ["placental pathologies", "DISEASE", 176, 197], ["fetus", "ORGANISM_SUBDIVISION", 104, 109], ["placenta", "MULTI-TISSUE_STRUCTURE", 111, 119], ["placental", "ORGAN", 176, 185], ["hypertension", "PROBLEM", 140, 152], ["diabetes", "PROBLEM", 154, 162], ["various placental pathologies", "PROBLEM", 168, 197], ["placenta", "ANATOMY", 111, 119], ["hypertension", "OBSERVATION", 140, 152], ["diabetes", "OBSERVATION", 154, 162], ["placental", "ANATOMY", 176, 185], ["pathologies", "OBSERVATION", 186, 197]]], ["In order to be able to make more accurate statements about this subject, prospective studies are needed by evaluating the conditions causing inappropriate birth weights for gestational age.DiscussionThe maternal antibody positivity rate in our study was lower than the literature.", [["prospective studies", "TEST", 73, 92], ["The maternal antibody positivity rate", "TEST", 199, 236], ["our study", "TEST", 240, 249]]], ["Hac\u0131mustafaoglu et al. [16] found that 83% of mothers had anti-RSV IgG antibody positivity in a study conducted in Turkey.", [["mothers", "ORGANISM", 46, 53], ["anti-RSV IgG antibody", "PROTEIN", 58, 79], ["anti-RSV", "SPECIES", 58, 66], ["anti-RSV IgG antibody", "TEST", 58, 79], ["a study", "TEST", 94, 101]]], ["The rate reported by Hac\u0131mustafaoglu et al. is also lower than the ones in the literature, suggesting that antibody positivity rates may be affected by geographical and climatic characteristics.", [["The rate", "TEST", 0, 8], ["antibody positivity rates", "PROBLEM", 107, 132], ["lower", "OBSERVATION_MODIFIER", 52, 57], ["climatic characteristics", "OBSERVATION", 169, 193]]], ["Supporting to this idea, in a cohort study conducted in Gambia and the USA at the same time, a significant difference in anti-RSV IgG antibody levels was found in infants between the countries [17].DiscussionIn our study group, 61.5% of infants had positive anti-RSV IgG antibodies at the time of birth.", [["anti-RSV IgG antibody", "GENE_OR_GENE_PRODUCT", 121, 142], ["infants", "ORGANISM", 163, 170], ["infants", "ORGANISM", 237, 244], ["anti-RSV IgG antibody", "PROTEIN", 121, 142], ["anti-RSV IgG antibodies", "PROTEIN", 258, 281], ["infants", "SPECIES", 163, 170], ["infants", "SPECIES", 237, 244], ["anti-RSV", "SPECIES", 121, 129], ["anti-RSV", "SPECIES", 258, 266], ["a cohort study", "TEST", 28, 42], ["a significant difference", "PROBLEM", 93, 117], ["anti-RSV IgG antibody levels", "TEST", 121, 149], ["our study group", "TEST", 211, 226], ["positive anti-RSV IgG antibodies", "PROBLEM", 249, 281], ["significant", "OBSERVATION_MODIFIER", 95, 106], ["difference", "OBSERVATION_MODIFIER", 107, 117]]], ["Forster et al. [18] reported that 99% anti-RSV IgG positivity was detected in cord blood in a group of infants with an allergic disease history.", [["cord blood", "ANATOMY", 78, 88], ["allergic disease", "DISEASE", 119, 135], ["anti-RSV", "ORGANISM", 38, 46], ["IgG", "GENE_OR_GENE_PRODUCT", 47, 50], ["cord blood", "ORGANISM_SUBSTANCE", 78, 88], ["infants", "ORGANISM", 103, 110], ["IgG", "PROTEIN", 47, 50], ["infants", "SPECIES", 103, 110], ["anti-RSV", "SPECIES", 38, 46], ["anti-RSV IgG positivity", "TEST", 38, 61], ["cord blood", "TEST", 78, 88], ["an allergic disease history", "PROBLEM", 116, 143], ["cord", "ANATOMY", 78, 82], ["allergic disease", "OBSERVATION", 119, 135]]], ["In another study, Hac\u0131mustafaoglu et al. [16] reported that anti-RSV IgG antibody positivity was detected in 83% of mothers and infants in their study.", [["anti-RSV", "ORGANISM", 60, 68], ["IgG", "GENE_OR_GENE_PRODUCT", 69, 72], ["mothers", "ORGANISM", 116, 123], ["infants", "ORGANISM", 128, 135], ["anti-RSV IgG antibody", "PROTEIN", 60, 81], ["infants", "SPECIES", 128, 135], ["anti-RSV", "SPECIES", 60, 68], ["another study", "TEST", 3, 16], ["anti-RSV IgG antibody positivity", "TEST", 60, 92], ["their study", "TEST", 139, 150]]], ["These high seropositivity rates reported in the literature are inconsistent with our results.", [["These high seropositivity rates", "PROBLEM", 0, 31], ["high", "OBSERVATION_MODIFIER", 6, 10], ["seropositivity", "OBSERVATION", 11, 25]]], ["The high seropositivity rate reported by Forster et al. [18] was thought to be related to their patient group\u2019s atopic characteristics.", [["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 96, 103], ["The high seropositivity rate", "PROBLEM", 0, 28], ["high", "OBSERVATION_MODIFIER", 4, 8]]], ["The low antibody positivity rate reported in our maternal group may have caused to the low antibody positivity rate in infant group at birth.DiscussionAll blood samples we collected at sixth month had negative anti- RSV Ig G antibody levels.", [["blood samples", "ANATOMY", 155, 168], ["blood samples", "ORGANISM_SUBSTANCE", 155, 168], ["RSV", "ORGANISM", 216, 219], ["Ig G antibody", "GENE_OR_GENE_PRODUCT", 220, 233], ["RSV Ig G antibody", "PROTEIN", 216, 233], ["infant", "SPECIES", 119, 125], ["RSV", "SPECIES", 216, 219], ["The low antibody positivity rate", "PROBLEM", 0, 32], ["the low antibody positivity rate", "PROBLEM", 83, 115], ["All blood samples", "TEST", 151, 168], ["RSV Ig G antibody levels", "TEST", 216, 240], ["low", "OBSERVATION_MODIFIER", 4, 7], ["antibody positivity", "OBSERVATION", 8, 27]]], ["Arankalle et al. [19] found that only 0.7% of babies who were all positive for RSV antibodies at birth were positive for anti-RSV antibodies at the sixth month.", [["babies", "ORGANISM", 46, 52], ["RSV", "ORGANISM", 79, 82], ["RSV antibodies", "PROTEIN", 79, 93], ["anti-RSV antibodies", "PROTEIN", 121, 140], ["RSV", "SPECIES", 79, 82], ["anti-RSV", "SPECIES", 121, 129], ["RSV antibodies", "PROBLEM", 79, 93], ["anti-RSV antibodies", "PROBLEM", 121, 140]]], ["In another study, the infants\u2019 anti-RSV IgG antibody positivity rate at sixth month was reported as 16% [20].", [["infants", "ORGANISM", 22, 29], ["anti-RSV", "ORGANISM", 31, 39], ["anti-RSV IgG antibody", "PROTEIN", 31, 52], ["infants", "SPECIES", 22, 29], ["anti-RSV", "SPECIES", 31, 39], ["another study", "TEST", 3, 16], ["the infants\u2019 anti-RSV IgG antibody positivity rate", "TEST", 18, 68]]], ["Cox et al. [21] found that maternal antibodies began to diminish at 2nd month and the lowest anti-RSV IgG antibody levels were detected at 6th\u20138th month.", [["IgG", "GENE_OR_GENE_PRODUCT", 102, 105], ["maternal antibodies", "PROTEIN", 27, 46], ["anti-RSV IgG antibody", "PROTEIN", 93, 114], ["anti-RSV", "SPECIES", 93, 101], ["Cox et al.", "TEST", 0, 10], ["maternal antibodies", "PROBLEM", 27, 46], ["the lowest anti-RSV IgG antibody levels", "TEST", 82, 121]]], ["In a similar study, the lowest anti-RSV IgG antibody levels were detected at 5th\u20136th month [17].", [["IgG", "GENE_OR_GENE_PRODUCT", 40, 43], ["anti-RSV IgG antibody", "PROTEIN", 31, 52], ["anti-RSV", "SPECIES", 31, 39], ["a similar study", "TEST", 3, 18], ["the lowest anti-RSV IgG antibody levels", "TEST", 20, 59]]], ["Although there are conflicting reports about the positivity rates at 6th month in the literature, all studies agree that the lowest antibody levels are detected around 5th\u20137th month.DiscussionIn accordance with our results, Bhattarakosol et al. [22] reported that they found no relationship between gender and RSV seropositivity.", [["RSV", "ORGANISM", 310, 313], ["RSV", "SPECIES", 310, 313], ["the positivity rates", "PROBLEM", 45, 65], ["all studies", "TEST", 98, 109], ["the lowest antibody levels", "TEST", 121, 147], ["RSV seropositivity", "PROBLEM", 310, 328]]], ["Chu et al. [9] reported that the only variable associated with antibody levels at birth was maternal education.", [["antibody levels", "PROBLEM", 63, 78]]], ["In another study, it is reported that low birth weight and prematurity were associated with low antibody levels of infant [23].", [["birth weight", "DISEASE", 42, 54], ["prematurity", "DISEASE", 59, 70], ["infant", "SPECIES", 115, 121], ["another study", "TEST", 3, 16], ["low birth weight", "PROBLEM", 38, 54], ["prematurity", "PROBLEM", 59, 70], ["low antibody levels", "PROBLEM", 92, 111], ["prematurity", "OBSERVATION", 59, 70]]], ["Le Saux et al. [24] found that having at least one child at home was associated with high levels of RSV antibodies at birth.DiscussionIn our study, there was a statistically significant correlation between cord and maternal antibody level and this correlation suggests that raising maternal antibody levels through maternal inoculation could be a logical strategy for protecting infants from RSV infections.DiscussionThe most important limitation of our study was that the entire patient group consisted of term babies.", [["cord", "ANATOMY", 206, 210], ["RSV infections", "DISEASE", 392, 406], ["child", "ORGANISM", 51, 56], ["RSV", "ORGANISM", 100, 103], ["cord", "ORGAN", 206, 210], ["infants", "ORGANISM", 379, 386], ["RSV", "ORGANISM", 392, 395], ["patient", "ORGANISM", 480, 487], ["babies", "ORGANISM", 512, 518], ["RSV antibodies", "PROTEIN", 100, 114], ["infants", "SPECIES", 379, 386], ["patient", "SPECIES", 480, 487], ["RSV", "SPECIES", 100, 103], ["RSV", "SPECIES", 392, 395], ["high levels of RSV antibodies", "PROBLEM", 85, 114], ["our study", "TEST", 137, 146], ["a statistically significant correlation between cord and maternal antibody level", "PROBLEM", 158, 238], ["maternal antibody levels", "PROBLEM", 282, 306], ["maternal inoculation", "PROBLEM", 315, 335], ["a logical strategy", "TREATMENT", 345, 363], ["RSV infections", "PROBLEM", 392, 406], ["our study", "TEST", 450, 459], ["RSV antibodies", "OBSERVATION", 100, 114], ["cord", "ANATOMY", 206, 210], ["RSV infections", "OBSERVATION", 392, 406]]], ["As preterm infants are more susceptible to RSV infections, there is a particular need for studies in this population.ConclusionsThe vaccine development efforts against RSV have accelerated in recent years because of its important effect on public health.", [["RSV infections", "DISEASE", 43, 57], ["RSV", "DISEASE", 168, 171], ["infants", "ORGANISM", 11, 18], ["RSV", "ORGANISM", 43, 46], ["RSV", "ORGANISM", 168, 171], ["infants", "SPECIES", 11, 18], ["RSV", "SPECIES", 43, 46], ["RSV", "SPECIES", 168, 171], ["RSV infections", "PROBLEM", 43, 57], ["studies", "TEST", 90, 97], ["The vaccine", "TREATMENT", 128, 139], ["RSV", "PROBLEM", 168, 171], ["RSV infections", "OBSERVATION", 43, 57]]], ["A significant positive correlation between maternal antibody levels and infants\u2019 antibody levels at birth that we have reported in this study suggests that maternal vaccination strategies may be logical.", [["infants", "ORGANISM", 72, 79], ["infants", "SPECIES", 72, 79], ["A significant positive correlation", "PROBLEM", 0, 34], ["maternal antibody levels", "TEST", 43, 67], ["infants\u2019 antibody levels", "TEST", 72, 96], ["this study", "TEST", 131, 141], ["maternal vaccination strategies", "TREATMENT", 156, 187], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["positive", "OBSERVATION", 14, 22]]], ["We have pointed out that antibody transfer rate was highest in AGA infants.", [["infants", "SPECIES", 67, 74], ["antibody transfer rate", "TEST", 25, 47]]], ["It should be kept in mind that maternal vaccination strategies may be less effective in LGA and SGA infants.", [["infants", "ORGANISM", 100, 107], ["infants", "SPECIES", 100, 107], ["maternal vaccination strategies", "TREATMENT", 31, 62]]], ["Further prospective studies are needed to investigate the effect of birth weight on antibody transfer rate.", [["Further prospective studies", "TEST", 0, 27], ["birth weight", "TEST", 68, 80], ["antibody transfer rate", "TREATMENT", 84, 106]]]], "PMC7340760": [["IntroductionIn late December 2019, a case of unidentified pneumonia was reported in Wuhan, Hubei Province, People\u2019s Republic of China (PRC).", [["pneumonia", "DISEASE", 58, 67], ["unidentified pneumonia", "PROBLEM", 45, 67], ["pneumonia", "OBSERVATION", 58, 67]]], ["Its clinical characteristics were very similar to those of viral pneumonia.", [["pneumonia", "DISEASE", 65, 74], ["viral pneumonia", "PROBLEM", 59, 74], ["viral", "OBSERVATION_MODIFIER", 59, 64], ["pneumonia", "OBSERVATION", 65, 74]]], ["After analysis of respiratory samples, the experts at the PRC centers for Disease Control declared that the pneumonia, later known as novel coronavirus pneumonia, was caused by a novel coronavirus [1].", [["respiratory samples", "ANATOMY", 18, 37], ["pneumonia", "DISEASE", 108, 117], ["coronavirus pneumonia", "DISEASE", 140, 161], ["coronavirus", "DISEASE", 185, 196], ["coronavirus", "ORGANISM", 140, 151], ["respiratory samples", "TEST", 18, 37], ["Disease Control", "TREATMENT", 74, 89], ["the pneumonia", "PROBLEM", 104, 117], ["novel coronavirus pneumonia", "PROBLEM", 134, 161], ["a novel coronavirus", "PROBLEM", 177, 196], ["respiratory", "ANATOMY", 18, 29], ["pneumonia", "OBSERVATION", 108, 117], ["coronavirus", "OBSERVATION_MODIFIER", 140, 151], ["pneumonia", "OBSERVATION", 152, 161]]], ["WHO declared coronavirus disease 2019 (COVID-19) as a Public Health Emergency of International Concern on January 30, 2020 [2].", [["coronavirus disease", "DISEASE", 13, 32], ["coronavirus", "ORGANISM", 13, 24], ["coronavirus disease", "PROBLEM", 13, 32], ["coronavirus disease", "OBSERVATION", 13, 32]]], ["More than 180 countries have reported laboratory-confirmed cases of COVID-19 on all continents except Antarctica [3].", [["COVID", "DISEASE", 68, 73], ["COVID", "TEST", 68, 73]]], ["As of May 23, 2020, COVID-19 has been confirmed in over 5 million individuals worldwide and has resulted in more than 340,290 deaths [4].", [["COVID-19", "CHEMICAL", 20, 28], ["deaths", "DISEASE", 126, 132], ["COVID", "TEST", 20, 25]]], ["In India, the numbers stand at 1,24,794 active cases and 3726 deaths and are still rising.", [["deaths", "DISEASE", 62, 68]]]], "75e701c7f4cd0a33dc6e4dd6d56093f194f972bf": [["INTRODUCTIONIn the cytosol of bacteria, the degradation of proteins and polypeptides is performed by LON and CLPP (caseinolytic peptidase P), among other proteases (1) .", [["cytosol", "ANATOMY", 19, 26], ["cytosol", "CELLULAR_COMPONENT", 19, 26], ["LON", "SIMPLE_CHEMICAL", 101, 104], ["CLPP", "SIMPLE_CHEMICAL", 109, 113], ["caseinolytic peptidase P", "GENE_OR_GENE_PRODUCT", 115, 139], ["LON", "PROTEIN", 101, 104], ["CLPP", "PROTEIN", 109, 113], ["caseinolytic peptidase P", "PROTEIN", 115, 139], ["proteases", "PROTEIN", 154, 163], ["bacteria", "PROBLEM", 30, 38], ["the degradation of proteins and polypeptides", "PROBLEM", 40, 84], ["CLPP (caseinolytic peptidase P)", "TREATMENT", 109, 140], ["bacteria", "OBSERVATION", 30, 38]]], ["These two enzymes show high phylogenetic conservation, but their complementary roles are not understood.", [["These two enzymes", "TEST", 0, 17], ["high phylogenetic conservation", "PROBLEM", 23, 53], ["high phylogenetic conservation", "OBSERVATION", 23, 53]]], ["Mitochondrial LONP1 contains domains with protease and ATPase activity on the same polypeptide, and is considered as the main factor for proteolysis of soluble substrates in the matrix compartment.", [["Mitochondrial", "ANATOMY", 0, 13], ["matrix compartment", "ANATOMY", 178, 196], ["Mitochondrial", "CELLULAR_COMPONENT", 0, 13], ["ATPase", "GENE_OR_GENE_PRODUCT", 55, 61], ["matrix compartment", "CELLULAR_COMPONENT", 178, 196], ["LONP1", "PROTEIN", 14, 19], ["protease", "PROTEIN", 42, 50], ["ATPase", "PROTEIN", 55, 61], ["Mitochondrial LONP1", "TEST", 0, 19], ["protease", "TREATMENT", 42, 50], ["ATPase activity", "TREATMENT", 55, 70], ["proteolysis of soluble substrates in the matrix compartment", "PROBLEM", 137, 196], ["domains", "OBSERVATION_MODIFIER", 29, 36], ["matrix", "ANATOMY_MODIFIER", 178, 184]]], ["Furthermore, mutant LON/PIM1 yeast strains also exhibit defects in mitochondrial DNA (mtDNA) (2) .", [["mitochondrial", "ANATOMY", 67, 80], ["LON", "GENE_OR_GENE_PRODUCT", 20, 23], ["PIM1", "GENE_OR_GENE_PRODUCT", 24, 28], ["mitochondrial DNA", "CELLULAR_COMPONENT", 67, 84], ["mtDNA", "CELLULAR_COMPONENT", 86, 91], ["LON", "PROTEIN", 20, 23], ["PIM1", "PROTEIN", 24, 28], ["mitochondrial DNA", "DNA", 67, 84], ["yeast", "SPECIES", 29, 34], ["yeast", "SPECIES", 29, 34], ["mutant LON/PIM1 yeast strains", "PROBLEM", 13, 42], ["defects in mitochondrial DNA", "PROBLEM", 56, 84], ["defects", "OBSERVATION", 56, 63], ["mitochondrial DNA", "OBSERVATION", 67, 84]]], ["In contrast, mitochondrial CLPP lacks ATPase activity and each subunit contains only the domain for digestion of small peptides without ATP requirement.", [["mitochondrial", "ANATOMY", 13, 26], ["ATP", "CHEMICAL", 136, 139], ["ATP", "CHEMICAL", 136, 139], ["mitochondrial", "CELLULAR_COMPONENT", 13, 26], ["ATPase", "GENE_OR_GENE_PRODUCT", 38, 44], ["ATP", "SIMPLE_CHEMICAL", 136, 139], ["mitochondrial CLPP", "PROTEIN", 13, 31], ["ATPase", "PROTEIN", 38, 44], ["mitochondrial CLPP", "TEST", 13, 31], ["ATPase activity", "PROBLEM", 38, 53], ["small peptides", "PROBLEM", 113, 127], ["ATP requirement", "PROBLEM", 136, 151], ["mitochondrial CLPP", "OBSERVATION", 13, 31], ["ATPase activity", "OBSERVATION", 38, 53], ["small peptides", "OBSERVATION", 113, 127], ["without", "UNCERTAINTY", 128, 135], ["ATP requirement", "OBSERVATION", 136, 151]]], ["Through association with the ATPase and chaperone CLPX, activation of CLPP as serine protease occurs for the ATP-dependent digestion of larger proteins (2) .", [["ATP", "CHEMICAL", 109, 112], ["serine", "CHEMICAL", 78, 84], ["ATP", "CHEMICAL", 109, 112], ["ATPase", "GENE_OR_GENE_PRODUCT", 29, 35], ["CLPX", "GENE_OR_GENE_PRODUCT", 50, 54], ["CLPP", "GENE_OR_GENE_PRODUCT", 70, 74], ["serine", "AMINO_ACID", 78, 84], ["ATP", "SIMPLE_CHEMICAL", 109, 112], ["ATPase", "PROTEIN", 29, 35], ["chaperone CLPX", "PROTEIN", 40, 54], ["CLPP", "PROTEIN", 70, 74], ["serine protease", "PROTEIN", 78, 93], ["the ATPase", "TREATMENT", 25, 35], ["chaperone CLPX", "TREATMENT", 40, 54], ["activation of CLPP", "TREATMENT", 56, 74], ["serine protease", "TREATMENT", 78, 93], ["the ATP", "TEST", 105, 112]]], ["Both CLPP and CLPX have been studied intensively in Escherichia coli (E. coli) and other prokaryotes (3) .", [["CLPP", "CHEMICAL", 5, 9], ["CLPX", "CHEMICAL", 14, 18], ["CLPP", "GENE_OR_GENE_PRODUCT", 5, 9], ["CLPX", "GENE_OR_GENE_PRODUCT", 14, 18], ["Escherichia coli", "ORGANISM", 52, 68], ["E. coli", "ORGANISM", 70, 77], ["CLPP", "PROTEIN", 5, 9], ["CLPX", "PROTEIN", 14, 18], ["Escherichia coli", "SPECIES", 52, 68], ["E. coli", "SPECIES", 70, 77], ["Escherichia coli", "SPECIES", 52, 68], ["E. coli", "SPECIES", 70, 77], ["Both CLPP", "PROBLEM", 0, 9], ["CLPX", "PROBLEM", 14, 18], ["Escherichia coli (E. coli", "PROBLEM", 52, 77], ["CLPP", "OBSERVATION", 5, 9], ["CLPX", "OBSERVATION", 14, 18], ["Escherichia coli", "OBSERVATION", 52, 68], ["E. coli", "OBSERVATION", 70, 77]]], ["Purification and structural biology studies showed that hexameric rings of the ATPase CLPX or specific other AAA+ (ATPases Associated with diverse cellular Activities) proteins of the HSP100 family (CLPA, CLPC) (4,5) depend on ATP in order to bind two heptameric CLPP rings at either end, thus forming a barrel-shaped CLPP proteolytic chamber.", [["cellular", "ANATOMY", 147, 155], ["ATP", "CHEMICAL", 227, 230], ["ATP", "CHEMICAL", 227, 230], ["ATPase", "GENE_OR_GENE_PRODUCT", 79, 85], ["AAA+", "GENE_OR_GENE_PRODUCT", 109, 113], ["cellular", "CELL", 147, 155], ["HSP100", "GENE_OR_GENE_PRODUCT", 184, 190], ["ATP", "SIMPLE_CHEMICAL", 227, 230], ["CLPP", "SIMPLE_CHEMICAL", 318, 322], ["ATPase CLPX", "PROTEIN", 79, 90], ["AAA", "PROTEIN", 109, 112], ["ATPases", "PROTEIN", 115, 122], ["diverse cellular Activities) proteins", "PROTEIN", 139, 176], ["HSP100 family", "PROTEIN", 184, 197], ["CLPA", "PROTEIN", 199, 203], ["CLPC", "PROTEIN", 205, 209], ["heptameric CLPP rings", "PROTEIN", 252, 273], ["structural biology studies", "TEST", 17, 43], ["the ATPase CLPX", "PROBLEM", 75, 90], ["ATP", "TREATMENT", 227, 230], ["heptameric CLPP rings", "TREATMENT", 252, 273], ["a barrel-shaped CLPP proteolytic chamber", "TREATMENT", 302, 342], ["AAA", "OBSERVATION", 109, 112], ["CLPP rings", "OBSERVATION", 263, 273], ["shaped", "OBSERVATION_MODIFIER", 311, 317], ["CLPP", "OBSERVATION", 318, 322], ["proteolytic chamber", "OBSERVATION", 323, 342]]], ["Unfolded substrates are translocated by CLPX into this cylinder to be cleaved in fragments with an average product length of 10 residues.", [["fragments", "ANATOMY", 81, 90], ["CLPX", "GENE_OR_GENE_PRODUCT", 40, 44], ["CLPX", "PROTEIN", 40, 44], ["Unfolded substrates", "PROBLEM", 0, 19], ["CLPX", "OBSERVATION", 40, 44], ["fragments", "OBSERVATION_MODIFIER", 81, 90], ["average", "OBSERVATION_MODIFIER", 99, 106], ["product", "OBSERVATION_MODIFIER", 107, 114], ["length", "OBSERVATION_MODIFIER", 115, 121]]], ["These products are further degraded to free amino acids by exopeptidases (3) .", [["amino acids", "CHEMICAL", 44, 55], ["amino acids", "CHEMICAL", 44, 55], ["amino acids", "AMINO_ACID", 44, 55], ["free amino acids", "TEST", 39, 55]]], ["CLPX determines substrate specificity of the complex.", [["CLPX", "CHEMICAL", 0, 4], ["CLPX", "SIMPLE_CHEMICAL", 0, 4], ["CLPX", "PROTEIN", 0, 4], ["complex", "OBSERVATION_MODIFIER", 45, 52]]], ["CLPX was found to recognize specific unstructured peptide sequences and usually unfold the corresponding proteins.", [["CLPX", "CHEMICAL", 0, 4], ["CLPX", "GENE_OR_GENE_PRODUCT", 0, 4], ["CLPX", "PROTEIN", 0, 4], ["CLPX", "PROBLEM", 0, 4], ["specific unstructured peptide sequences", "PROBLEM", 28, 67]]], ["The unstructured domains are named degrons, such as the C-motif 1/ssrA tag (6) .", [["C-motif 1", "DNA", 56, 65], ["ssrA tag", "PROTEIN", 66, 74]]], ["Degrons are thought to be exposed, e.g. in nascent peptides on stalled ribosomes, as well as in unassembled subunits of ribosomes and other macromolecular complexes (3) .", [["ribosomes", "ANATOMY", 71, 80], ["ribosomes", "ANATOMY", 120, 129], ["ribosomes", "CELLULAR_COMPONENT", 71, 80], ["ribosomes", "CELLULAR_COMPONENT", 120, 129], ["ribosomes", "PROTEIN", 120, 129], ["macromolecular complexes", "PROTEIN", 140, 164], ["thought to be", "UNCERTAINTY", 12, 25], ["nascent peptides", "OBSERVATION", 43, 59], ["macromolecular complexes", "OBSERVATION", 140, 164]]], ["Individual repair proteins like RecN are synthesized at high levels during cell stress, but efficiently removed by the CLPXP protein complex upon return to the unstressed state, to avoid deleterious effects (7, 8) .", [["cell", "ANATOMY", 75, 79], ["RecN", "GENE_OR_GENE_PRODUCT", 32, 36], ["cell", "CELL", 75, 79], ["CLPXP", "GENE_OR_GENE_PRODUCT", 119, 124], ["repair proteins", "PROTEIN", 11, 26], ["RecN", "PROTEIN", 32, 36], ["CLPXP protein complex", "PROTEIN", 119, 140], ["Individual repair proteins", "TREATMENT", 0, 26], ["deleterious effects", "PROBLEM", 187, 206], ["repair", "OBSERVATION", 11, 17]]], ["Similarly, a degron in sigmaS, the master regulator of general stress response in E. coli, is responsible for CLPXP recognition and degradation in growing cells (9) .", [["cells", "ANATOMY", 155, 160], ["sigmaS", "GENE_OR_GENE_PRODUCT", 23, 29], ["E. coli", "ORGANISM", 82, 89], ["CLPXP", "GENE_OR_GENE_PRODUCT", 110, 115], ["cells", "CELL", 155, 160], ["sigmaS", "PROTEIN", 23, 29], ["CLPXP", "PROTEIN", 110, 115], ["growing cells", "CELL_TYPE", 147, 160], ["E. coli", "SPECIES", 82, 89], ["E. coli", "SPECIES", 82, 89], ["a degron in sigmaS", "PROBLEM", 11, 29], ["general stress response", "PROBLEM", 55, 78], ["E. coli", "PROBLEM", 82, 89], ["CLPXP recognition", "PROBLEM", 110, 127], ["degradation in growing cells", "PROBLEM", 132, 160], ["degron", "OBSERVATION", 13, 19], ["stress response", "OBSERVATION", 63, 78], ["E. coli", "OBSERVATION", 82, 89], ["responsible for", "UNCERTAINTY", 94, 109], ["growing cells", "OBSERVATION", 147, 160]]], ["With a slightly different mechanism, the degron in RseA ensures its degradation by CLPXP in times of cell stress, thus derepressing the sigmaE factor to induce genes responsible for the envelope stress response (10) .", [["cell", "ANATOMY", 101, 105], ["RseA", "CHEMICAL", 51, 55], ["RseA", "SIMPLE_CHEMICAL", 51, 55], ["CLPXP", "GENE_OR_GENE_PRODUCT", 83, 88], ["cell", "CELL", 101, 105], ["sigmaE factor", "GENE_OR_GENE_PRODUCT", 136, 149], ["RseA", "PROTEIN", 51, 55], ["CLPXP", "PROTEIN", 83, 88], ["sigmaE factor", "PROTEIN", 136, 149], ["a slightly different mechanism", "PROBLEM", 5, 35], ["the degron in RseA", "PROBLEM", 37, 55], ["cell stress", "PROBLEM", 101, 112], ["the sigmaE factor", "PROBLEM", 132, 149], ["the envelope stress response", "PROBLEM", 182, 210], ["slightly different", "OBSERVATION_MODIFIER", 7, 25]]], ["Interestingly, CLPXP-mediated degradation of the bacteriophage repressor and of the O protein as an initiator of phage DNA replication (11, 12) vary with growth conditions and thus modulate the bacteriophage lysis-versuslysogenization decisions, i.e. bacterial immunity.INTRODUCTIONEukaryotic cells contain CLPP and CLPX orthologs in the mitochondrial matrix.", [["cells", "ANATOMY", 293, 298], ["mitochondrial matrix", "ANATOMY", 338, 358], ["CLPXP", "CHEMICAL", 15, 20], ["CLPXP", "GENE_OR_GENE_PRODUCT", 15, 20], ["DNA", "CELLULAR_COMPONENT", 119, 122], ["INTRODUCTIONEukaryotic cells", "CELL", 270, 298], ["CLPP", "GENE_OR_GENE_PRODUCT", 307, 311], ["CLPX", "GENE_OR_GENE_PRODUCT", 316, 320], ["mitochondrial matrix", "CELLULAR_COMPONENT", 338, 358], ["CLPXP", "PROTEIN", 15, 20], ["bacteriophage repressor", "PROTEIN", 49, 72], ["O protein", "PROTEIN", 84, 93], ["CLPP", "PROTEIN", 307, 311], ["CLPX orthologs", "PROTEIN", 316, 330], ["CLPXP", "TREATMENT", 15, 20], ["the bacteriophage repressor", "TREATMENT", 45, 72], ["the O protein", "TREATMENT", 80, 93], ["phage DNA replication", "TREATMENT", 113, 134], ["growth conditions", "PROBLEM", 154, 171], ["the bacteriophage lysis", "TREATMENT", 190, 213], ["INTRODUCTIONEukaryotic cells", "TREATMENT", 270, 298], ["CLPP", "PROBLEM", 307, 311], ["CLPX orthologs in the mitochondrial matrix", "PROBLEM", 316, 358], ["bacterial immunity", "OBSERVATION", 251, 269], ["CLPP", "OBSERVATION", 307, 311], ["CLPX orthologs", "OBSERVATION", 316, 330], ["mitochondrial matrix", "OBSERVATION", 338, 358]]], ["Contrary to the vast knowledge about CLPP structure and biochemistry in prokaryotes, relatively little is known about the biological role of CLPP in eukaryotes.", [["CLPP", "SIMPLE_CHEMICAL", 37, 41], ["CLPP", "GENE_OR_GENE_PRODUCT", 141, 145], ["CLPP", "PROTEIN", 141, 145], ["CLPP structure", "PROBLEM", 37, 51], ["CLPP", "OBSERVATION", 141, 145]]], ["In good agreement with a CLPP role in cell stress and protein quality control, its expression is induced by stressors in eukaryotes as in prokaryotes (13) (14) (15) .", [["cell", "ANATOMY", 38, 42], ["cell", "CELL", 38, 42], ["a CLPP role", "TREATMENT", 23, 34], ["cell stress", "TREATMENT", 38, 49], ["protein quality control", "TREATMENT", 54, 77], ["cell stress", "OBSERVATION", 38, 49]]], ["Recent data showed a surprising increase in healthy lifespan due to a deletion of the gene encoding CLPP in the filamentous fungus Podospora anserina (16) .", [["CLPP", "GENE_OR_GENE_PRODUCT", 100, 104], ["filamentous fungus Podospora anserina", "ORGANISM", 112, 149], ["CLPP", "PROTEIN", 100, 104], ["Podospora anserina", "SPECIES", 131, 149], ["Podospora anserina", "SPECIES", 131, 149], ["Recent data", "TEST", 0, 11], ["a deletion", "PROBLEM", 68, 78], ["the gene encoding CLPP", "PROBLEM", 82, 104], ["the filamentous fungus Podospora anserina", "PROBLEM", 108, 149], ["increase", "OBSERVATION_MODIFIER", 32, 40], ["CLPP", "OBSERVATION_MODIFIER", 100, 104], ["filamentous fungus", "OBSERVATION", 112, 130], ["Podospora anserina", "OBSERVATION", 131, 149]]], ["In Caenorhabditis elegans, the loss of CLPP modulates mitochondrial unfolded protein responses (17, 18) .", [["mitochondrial", "ANATOMY", 54, 67], ["Caenorhabditis elegans", "ORGANISM", 3, 25], ["CLPP", "GENE_OR_GENE_PRODUCT", 39, 43], ["mitochondrial", "CELLULAR_COMPONENT", 54, 67], ["CLPP", "PROTEIN", 39, 43], ["Caenorhabditis elegans", "SPECIES", 3, 25], ["Caenorhabditis elegans", "SPECIES", 3, 25], ["Caenorhabditis elegans", "PROBLEM", 3, 25], ["the loss of CLPP modulates mitochondrial unfolded protein responses", "PROBLEM", 27, 94], ["Caenorhabditis elegans", "OBSERVATION", 3, 25], ["loss", "OBSERVATION_MODIFIER", 31, 35], ["unfolded", "OBSERVATION_MODIFIER", 68, 76], ["protein responses", "OBSERVATION", 77, 94]]], ["Mammalian studies reported the accumulation of unfolded proteins in the mitochondrial matrix to induce the expression of CLPP in parallel to mitochondrial chaperones such as mtHSP60, mtHSP10 and mtDNAJ, and in dependence on the transcription factors CHOP and C/EBPbeta (13, 19, 20) .", [["mitochondrial matrix", "ANATOMY", 72, 92], ["mitochondrial", "ANATOMY", 141, 154], ["mitochondrial matrix", "CELLULAR_COMPONENT", 72, 92], ["CLPP", "GENE_OR_GENE_PRODUCT", 121, 125], ["mitochondrial", "CELLULAR_COMPONENT", 141, 154], ["mtHSP60", "GENE_OR_GENE_PRODUCT", 174, 181], ["mtHSP10", "GENE_OR_GENE_PRODUCT", 183, 190], ["mtDNAJ", "GENE_OR_GENE_PRODUCT", 195, 201], ["CHOP", "GENE_OR_GENE_PRODUCT", 250, 254], ["C/EBPbeta", "GENE_OR_GENE_PRODUCT", 259, 268], ["unfolded proteins", "PROTEIN", 47, 64], ["CLPP", "PROTEIN", 121, 125], ["mitochondrial chaperones", "PROTEIN", 141, 165], ["mtHSP60", "PROTEIN", 174, 181], ["mtHSP10", "PROTEIN", 183, 190], ["mtDNAJ", "PROTEIN", 195, 201], ["transcription factors", "PROTEIN", 228, 249], ["CHOP", "PROTEIN", 250, 254], ["C", "PROTEIN", 259, 260], ["EBPbeta", "PROTEIN", 261, 268], ["Mammalian studies", "TEST", 0, 17], ["unfolded proteins", "PROBLEM", 47, 64], ["the mitochondrial matrix", "TREATMENT", 68, 92], ["CLPP", "PROBLEM", 121, 125], ["CHOP", "TEST", 250, 254], ["C/EBPbeta", "TEST", 259, 268], ["unfolded proteins", "OBSERVATION", 47, 64], ["mitochondrial matrix", "OBSERVATION", 72, 92], ["CLPP", "OBSERVATION", 121, 125]]], ["Human CLPXP was found to constitute a bona fide ATP-dependent protease and assemble similarly as E. coli CLPXP, but to differ in substrate selection (21) .INTRODUCTIONIn humans, recessive CLPP missense and splice-donor mutations are the cause of ovarian failure and sensorineural deafness in Perrault syndrome, as reported during the preparation of our CLPP-null-mouse manuscript (22) .", [["ovarian", "ANATOMY", 246, 253], ["ATP", "CHEMICAL", 48, 51], ["ovarian failure", "DISEASE", 246, 261], ["sensorineural deafness", "DISEASE", 266, 288], ["Perrault syndrome", "DISEASE", 292, 309], ["ATP", "CHEMICAL", 48, 51], ["Human", "ORGANISM", 0, 5], ["CLPXP", "GENE_OR_GENE_PRODUCT", 6, 11], ["ATP", "SIMPLE_CHEMICAL", 48, 51], ["E. coli", "ORGANISM", 97, 104], ["CLPXP", "GENE_OR_GENE_PRODUCT", 105, 110], ["humans", "ORGANISM", 170, 176], ["CLPP", "GENE_OR_GENE_PRODUCT", 188, 192], ["ovarian", "ORGAN", 246, 253], ["CLPP", "GENE_OR_GENE_PRODUCT", 353, 357], ["mouse", "ORGANISM", 363, 368], ["Human CLPXP", "PROTEIN", 0, 11], ["bona fide ATP-dependent protease", "PROTEIN", 38, 70], ["CLPXP", "PROTEIN", 105, 110], ["CLPP", "DNA", 353, 357], ["Human", "SPECIES", 0, 5], ["E. coli", "SPECIES", 97, 104], ["humans", "SPECIES", 170, 176], ["mouse", "SPECIES", 363, 368], ["Human", "SPECIES", 0, 5], ["E. coli", "SPECIES", 97, 104], ["humans", "SPECIES", 170, 176], ["Human CLPXP", "TREATMENT", 0, 11], ["dependent protease", "PROBLEM", 52, 70], ["E. coli CLPXP", "PROBLEM", 97, 110], ["recessive CLPP missense and splice", "PROBLEM", 178, 212], ["donor mutations", "PROBLEM", 213, 228], ["ovarian failure", "PROBLEM", 246, 261], ["sensorineural deafness", "PROBLEM", 266, 288], ["Perrault syndrome", "PROBLEM", 292, 309], ["our CLPP", "TEST", 349, 357], ["coli CLPXP", "OBSERVATION", 100, 110], ["CLPP missense", "OBSERVATION", 188, 201], ["ovarian", "ANATOMY", 246, 253], ["failure", "OBSERVATION", 254, 261], ["sensorineural", "OBSERVATION_MODIFIER", 266, 279], ["deafness", "OBSERVATION", 280, 288], ["Perrault syndrome", "OBSERVATION", 292, 309]]], ["An additional role of CLPP in neurodegenerative diseases is suggested by several observations.", [["CLPP", "CHEMICAL", 22, 26], ["neurodegenerative diseases", "DISEASE", 30, 56], ["CLPP", "GENE_OR_GENE_PRODUCT", 22, 26], ["CLPP", "PROTEIN", 22, 26], ["CLPP", "PROBLEM", 22, 26], ["neurodegenerative diseases", "PROBLEM", 30, 56], ["CLPP", "OBSERVATION", 22, 26], ["neurodegenerative diseases", "OBSERVATION", 30, 56]]], ["CLPP mRNA and protein levels are down-regulated in response to a dominant negative mutation of mtHSP60 that results in a clinical manifestation as spastic paraplegia (23, 24) .", [["spastic paraplegia", "DISEASE", 147, 165], ["CLPP", "GENE_OR_GENE_PRODUCT", 0, 4], ["mtHSP60", "GENE_OR_GENE_PRODUCT", 95, 102], ["CLPP mRNA", "RNA", 0, 9], ["mtHSP60", "PROTEIN", 95, 102], ["CLPP mRNA", "TEST", 0, 9], ["protein levels", "TEST", 14, 28], ["a dominant negative mutation of mtHSP60", "PROBLEM", 63, 102], ["spastic paraplegia", "PROBLEM", 147, 165], ["spastic", "OBSERVATION_MODIFIER", 147, 154], ["paraplegia", "OBSERVATION", 155, 165]]], ["A progressive increase of CLPP protein levels due to the disturbed assembly of mitochondrial iron-sulfur clusters results from frataxin deficiency in Friedreich's ataxia (25) .", [["mitochondrial", "ANATOMY", 79, 92], ["frataxin deficiency", "DISEASE", 127, 146], ["Friedreich's ataxia", "DISEASE", 150, 169], ["CLPP", "GENE_OR_GENE_PRODUCT", 26, 30], ["mitochondrial", "CELLULAR_COMPONENT", 79, 92], ["frataxin", "GENE_OR_GENE_PRODUCT", 127, 135], ["CLPP", "PROTEIN", 26, 30], ["mitochondrial iron-sulfur clusters", "PROTEIN", 79, 113], ["frataxin", "PROTEIN", 127, 135], ["A progressive increase of CLPP protein levels", "PROBLEM", 0, 45], ["mitochondrial iron-sulfur clusters", "PROBLEM", 79, 113], ["frataxin deficiency", "PROBLEM", 127, 146], ["Friedreich's ataxia", "PROBLEM", 150, 169], ["progressive", "OBSERVATION_MODIFIER", 2, 13], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["CLPP protein levels", "OBSERVATION", 26, 45], ["mitochondrial iron-sulfur clusters", "OBSERVATION", 79, 113], ["frataxin deficiency", "OBSERVATION", 127, 146]]], ["CLPXP or other mitochondrial proteases, as HTRA2, PARL, the SPG7/AFG3L2 subunits of the m-AAA complex, as well as OPA1, were also implicated in age-associated neurodegeneration syndromes (26) such as Parkinson's disease (27) (28) (29) , spinocerebellar ataxia (30, 31) , spastic ataxia-neuropathy syndrome (32) , spastic paraplegia (33) and optic atrophy (34) , multiple diseases with established pathology regarding respiration, lipid organelles, protein aggregates and neuroinflammation.", [["mitochondrial", "ANATOMY", 15, 28], ["spinocerebellar", "ANATOMY", 237, 252], ["lipid organelles", "ANATOMY", 430, 446], ["neurodegeneration", "DISEASE", 159, 176], ["Parkinson's disease", "DISEASE", 200, 219], ["spinocerebellar ataxia", "DISEASE", 237, 259], ["spastic ataxia-neuropathy syndrome", "DISEASE", 271, 305], ["spastic paraplegia", "DISEASE", 313, 331], ["optic atrophy", "DISEASE", 341, 354], ["neuroinflammation", "DISEASE", 471, 488], ["CLPXP", "GENE_OR_GENE_PRODUCT", 0, 5], ["mitochondrial", "CELLULAR_COMPONENT", 15, 28], ["HTRA2", "GENE_OR_GENE_PRODUCT", 43, 48], ["PARL", "GENE_OR_GENE_PRODUCT", 50, 54], ["SPG7", "GENE_OR_GENE_PRODUCT", 60, 64], ["AFG3L2", "GENE_OR_GENE_PRODUCT", 65, 71], ["m-AAA complex", "GENE_OR_GENE_PRODUCT", 88, 101], ["OPA1", "GENE_OR_GENE_PRODUCT", 114, 118], ["Parkinson's disease", "CANCER", 200, 219], ["lipid organelles", "CELLULAR_COMPONENT", 430, 446], ["CLPXP", "PROTEIN", 0, 5], ["mitochondrial proteases", "PROTEIN", 15, 38], ["HTRA2", "PROTEIN", 43, 48], ["PARL", "PROTEIN", 50, 54], ["SPG7", "PROTEIN", 60, 64], ["AFG3L2 subunits", "PROTEIN", 65, 80], ["AAA complex", "PROTEIN", 90, 101], ["OPA1", "PROTEIN", 114, 118], ["CLPXP", "PROBLEM", 0, 5], ["other mitochondrial proteases", "PROBLEM", 9, 38], ["HTRA2", "TEST", 43, 48], ["PARL", "TEST", 50, 54], ["the SPG7", "TEST", 56, 64], ["OPA1", "PROBLEM", 114, 118], ["neurodegeneration syndromes", "PROBLEM", 159, 186], ["Parkinson's disease", "PROBLEM", 200, 219], ["spinocerebellar ataxia", "PROBLEM", 237, 259], ["spastic ataxia", "PROBLEM", 271, 285], ["neuropathy syndrome", "PROBLEM", 286, 305], ["spastic paraplegia", "PROBLEM", 313, 331], ["optic atrophy", "PROBLEM", 341, 354], ["multiple diseases", "PROBLEM", 362, 379], ["lipid organelles", "TEST", 430, 446], ["protein aggregates", "PROBLEM", 448, 466], ["neuroinflammation", "PROBLEM", 471, 488], ["mitochondrial proteases", "OBSERVATION", 15, 38], ["AAA", "ANATOMY", 90, 93], ["neurodegeneration syndromes", "OBSERVATION", 159, 186], ["spinocerebellar ataxia", "ANATOMY", 237, 259], ["spastic", "OBSERVATION_MODIFIER", 271, 278], ["ataxia", "OBSERVATION", 279, 285], ["neuropathy syndrome", "OBSERVATION", 286, 305], ["spastic", "OBSERVATION_MODIFIER", 313, 320], ["paraplegia", "OBSERVATION", 321, 331], ["optic", "OBSERVATION_MODIFIER", 341, 346], ["atrophy", "OBSERVATION", 347, 354], ["multiple", "OBSERVATION_MODIFIER", 362, 370], ["diseases", "OBSERVATION", 371, 379], ["protein aggregates", "OBSERVATION", 448, 466], ["neuroinflammation", "OBSERVATION", 471, 488]]], ["Thus, the mitochondrial protein quality control system and in particular CLPXP has an important impact on fertility, survival and neural aging (35) (36) (37) .INTRODUCTIONWe endeavored to understand CLPP functions in the mitochondria and in the stress response of mammalian cells, investigating for the first time the Clpp gene ablation effects in mouse and characterizing CLPP-dependent phenotypes, histological, biochemical, cellular and molecular anomalies.", [["mitochondrial", "ANATOMY", 10, 23], ["neural", "ANATOMY", 130, 136], ["mitochondria", "ANATOMY", 221, 233], ["cells", "ANATOMY", 274, 279], ["cellular", "ANATOMY", 427, 435], ["mitochondrial", "CELLULAR_COMPONENT", 10, 23], ["CLPXP", "GENE_OR_GENE_PRODUCT", 73, 78], ["CLPP", "GENE_OR_GENE_PRODUCT", 199, 203], ["mitochondria", "CELLULAR_COMPONENT", 221, 233], ["mammalian cells", "CELL", 264, 279], ["Clpp", "GENE_OR_GENE_PRODUCT", 318, 322], ["mouse", "ORGANISM", 348, 353], ["CLPP", "GENE_OR_GENE_PRODUCT", 373, 377], ["cellular", "CELL", 427, 435], ["CLPXP", "PROTEIN", 73, 78], ["CLPP", "PROTEIN", 199, 203], ["mammalian cells", "CELL_TYPE", 264, 279], ["Clpp gene", "DNA", 318, 327], ["mouse", "SPECIES", 348, 353], ["mouse", "SPECIES", 348, 353], ["the mitochondrial protein quality control system", "PROBLEM", 6, 54], ["CLPP functions", "PROBLEM", 199, 213], ["the Clpp gene ablation", "TREATMENT", 314, 336], ["CLPP-dependent phenotypes", "PROBLEM", 373, 398], ["histological, biochemical, cellular and molecular anomalies", "PROBLEM", 400, 459], ["mammalian cells", "OBSERVATION", 264, 279], ["ablation", "OBSERVATION", 328, 336], ["dependent phenotypes", "OBSERVATION", 378, 398], ["molecular anomalies", "OBSERVATION", 440, 459]]], ["Early, severe and tissue-specific pathologies were observed, which represent a quite faithful model of the human Perrault syndrome.", [["tissue", "ANATOMY", 18, 24], ["Perrault syndrome", "DISEASE", 113, 130], ["tissue", "TISSUE", 18, 24], ["human", "ORGANISM", 107, 112], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 107, 112], ["Early, severe and tissue-specific pathologies", "PROBLEM", 0, 45], ["the human Perrault syndrome", "PROBLEM", 103, 130], ["severe", "OBSERVATION_MODIFIER", 7, 13], ["tissue", "ANATOMY", 18, 24], ["specific", "OBSERVATION_MODIFIER", 25, 33], ["pathologies", "OBSERVATION", 34, 45], ["human Perrault syndrome", "OBSERVATION", 107, 130]]], ["Ovarian dysgenesis was explained by follicular differentiation failure, and in addition testis pathology due to spermatic differentiation failure was documented, resulting in complete female and male infertility in mice.", [["Ovarian", "ANATOMY", 0, 7], ["follicular", "ANATOMY", 36, 46], ["testis", "ANATOMY", 88, 94], ["spermatic", "ANATOMY", 112, 121], ["Ovarian dysgenesis", "DISEASE", 0, 18], ["infertility", "DISEASE", 200, 211], ["Ovarian", "ORGAN", 0, 7], ["testis", "ORGAN", 88, 94], ["mice", "ORGANISM", 215, 219], ["mice", "SPECIES", 215, 219], ["mice", "SPECIES", 215, 219], ["Ovarian dysgenesis", "PROBLEM", 0, 18], ["follicular differentiation failure", "PROBLEM", 36, 70], ["testis pathology", "TEST", 88, 104], ["spermatic differentiation failure", "PROBLEM", 112, 145], ["dysgenesis", "OBSERVATION", 8, 18], ["follicular differentiation failure", "OBSERVATION", 36, 70], ["spermatic", "ANATOMY", 112, 121], ["differentiation failure", "OBSERVATION", 122, 145]]], ["Severe tissue-specific pathology was also observed for auditory responses in analogy to Perrault syndrome.", [["tissue", "ANATOMY", 7, 13], ["Perrault syndrome", "DISEASE", 88, 105], ["tissue", "TISSUE", 7, 13], ["Severe tissue-specific pathology", "PROBLEM", 0, 32], ["auditory responses", "PROBLEM", 55, 73], ["Perrault syndrome", "PROBLEM", 88, 105], ["tissue", "ANATOMY", 7, 13], ["specific", "OBSERVATION_MODIFIER", 14, 22], ["pathology", "OBSERVATION", 23, 32]]], ["The underlying chain of molecular events was assessed by hypothesis-driven and unbiased expression studies, demonstrating ubiquitous effects for the transcriptional up-regulation of other mitochondrial chaperones, the CLPX accumulation in spite of mRNA downregulation, the mtDNA accumulation, the induction of an inflammatory transcriptome signature and the growth impairment.", [["mitochondrial", "ANATOMY", 188, 201], ["growth impairment", "DISEASE", 358, 375], ["mitochondrial", "CELLULAR_COMPONENT", 188, 201], ["CLPX", "GENE_OR_GENE_PRODUCT", 218, 222], ["mtDNA", "CELLULAR_COMPONENT", 273, 278], ["mitochondrial chaperones", "PROTEIN", 188, 212], ["CLPX", "PROTEIN", 218, 222], ["molecular events", "PROBLEM", 24, 40], ["unbiased expression studies", "TEST", 79, 106], ["other mitochondrial chaperones", "TREATMENT", 182, 212], ["the CLPX accumulation", "PROBLEM", 214, 235], ["mRNA downregulation", "PROBLEM", 248, 267], ["the mtDNA accumulation", "PROBLEM", 269, 291], ["an inflammatory transcriptome signature", "PROBLEM", 310, 349], ["the growth impairment", "PROBLEM", 354, 375], ["chain", "OBSERVATION_MODIFIER", 15, 20], ["mRNA downregulation", "OBSERVATION", 248, 267], ["mtDNA accumulation", "OBSERVATION", 273, 291], ["inflammatory", "OBSERVATION_MODIFIER", 313, 325], ["growth", "OBSERVATION_MODIFIER", 358, 364]]], ["In contrast, the respiratory dysfunction was marginal.", [["respiratory", "ANATOMY", 17, 28], ["respiratory dysfunction", "DISEASE", 17, 40], ["the respiratory dysfunction", "PROBLEM", 13, 40], ["respiratory dysfunction", "OBSERVATION", 17, 40], ["marginal", "OBSERVATION_MODIFIER", 45, 53]]], ["Thus, the absence of CLPP is compensated well by most tissues although light inflammatory stress is triggered by the mitochondrial quality control failure.", [["tissues", "ANATOMY", 54, 61], ["mitochondrial", "ANATOMY", 117, 130], ["CLPP", "GENE_OR_GENE_PRODUCT", 21, 25], ["tissues", "TISSUE", 54, 61], ["mitochondrial", "CELLULAR_COMPONENT", 117, 130], ["CLPP", "PROTEIN", 21, 25], ["CLPP", "PROBLEM", 21, 25], ["light inflammatory stress", "PROBLEM", 71, 96], ["the mitochondrial quality control failure", "PROBLEM", 113, 154], ["CLPP", "OBSERVATION", 21, 25], ["compensated", "OBSERVATION", 29, 40], ["most tissues", "OBSERVATION_MODIFIER", 49, 61], ["inflammatory", "OBSERVATION", 77, 89], ["mitochondrial quality control failure", "OBSERVATION", 117, 154]]], ["Profound early pathology occurs in gonad cells that are characterized by physiological dramatic reductions of mitochondrial numbers, underscoring the importance of CLPP for the degradation of mitochondrial components.Two independent founder lines with successful Clpp gene ablation show widespread CLPX protein increaseTo characterize the role of CLPP in a mammalian system, we undertook the established approach through constitutive mouse mutants (38) .", [["gonad cells", "ANATOMY", 35, 46], ["mitochondrial", "ANATOMY", 110, 123], ["mitochondrial", "ANATOMY", 192, 205], ["gonad cells", "CELL", 35, 46], ["mitochondrial", "CELLULAR_COMPONENT", 110, 123], ["CLPP", "GENE_OR_GENE_PRODUCT", 164, 168], ["mitochondrial", "CELLULAR_COMPONENT", 192, 205], ["founder lines", "CELL", 233, 246], ["Clpp", "GENE_OR_GENE_PRODUCT", 263, 267], ["CLPX", "GENE_OR_GENE_PRODUCT", 298, 302], ["CLPP", "GENE_OR_GENE_PRODUCT", 347, 351], ["mouse", "ORGANISM", 434, 439], ["gonad cells", "CELL_TYPE", 35, 46], ["CLPP", "PROTEIN", 164, 168], ["Clpp gene", "DNA", 263, 272], ["CLPX protein", "PROTEIN", 298, 310], ["CLPP", "PROTEIN", 347, 351], ["mouse", "SPECIES", 434, 439], ["mouse", "SPECIES", 434, 439], ["Profound early pathology", "PROBLEM", 0, 24], ["gonad cells", "PROBLEM", 35, 46], ["physiological dramatic reductions of mitochondrial numbers", "PROBLEM", 73, 131], ["CLPP", "PROBLEM", 164, 168], ["the degradation of mitochondrial components", "PROBLEM", 173, 216], ["successful Clpp gene ablation", "TREATMENT", 252, 281], ["widespread CLPX protein increase", "PROBLEM", 287, 319], ["CLPP", "PROBLEM", 347, 351], ["early", "OBSERVATION_MODIFIER", 9, 14], ["pathology", "OBSERVATION", 15, 24], ["gonad cells", "OBSERVATION", 35, 46], ["dramatic", "OBSERVATION_MODIFIER", 87, 95], ["reductions", "OBSERVATION_MODIFIER", 96, 106], ["mitochondrial numbers", "OBSERVATION", 110, 131], ["mitochondrial components", "OBSERVATION", 192, 216], ["founder lines", "OBSERVATION", 233, 246], ["widespread", "OBSERVATION_MODIFIER", 287, 297], ["CLPX protein", "OBSERVATION", 298, 310], ["increase", "OBSERVATION_MODIFIER", 311, 319], ["CLPP", "OBSERVATION", 347, 351]]], ["The murine Clpp gene was already characterized and shown to be highly expressed in skeletal muscle, heart and liver, encoding a mature protein of 34 kDa in size (39) .", [["skeletal muscle", "ANATOMY", 83, 98], ["heart", "ANATOMY", 100, 105], ["liver", "ANATOMY", 110, 115], ["murine", "ORGANISM", 4, 10], ["Clpp", "GENE_OR_GENE_PRODUCT", 11, 15], ["skeletal muscle", "TISSUE", 83, 98], ["heart", "ORGAN", 100, 105], ["liver", "ORGAN", 110, 115], ["murine Clpp gene", "DNA", 4, 20], ["mature protein", "PROTEIN", 128, 142], ["34 kDa", "PROTEIN", 146, 152], ["murine", "SPECIES", 4, 10], ["The murine Clpp gene", "TEST", 0, 20], ["Clpp gene", "OBSERVATION", 11, 20], ["skeletal muscle", "ANATOMY", 83, 98], ["heart", "ANATOMY", 100, 105], ["liver", "ANATOMY", 110, 115], ["34 kDa", "OBSERVATION_MODIFIER", 146, 152], ["size", "OBSERVATION_MODIFIER", 156, 160]]], ["Mouse embryonal stem cells with insertions of the genetrap construct within the Clpp gene were commercially available from the Texas Institute for Genomic Medicine (TIGM).", [["embryonal stem cells", "ANATOMY", 6, 26], ["Mouse", "ORGANISM", 0, 5], ["embryonal stem cells", "CELL", 6, 26], ["Clpp", "GENE_OR_GENE_PRODUCT", 80, 84], ["Mouse embryonal stem cells", "CELL_TYPE", 0, 26], ["genetrap construct", "DNA", 50, 68], ["Clpp gene", "DNA", 80, 89], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse embryonal stem cells", "PROBLEM", 0, 26], ["the genetrap construct", "TREATMENT", 46, 68], ["Genomic Medicine", "TREATMENT", 147, 163], ["embryonal stem cells", "OBSERVATION", 6, 26]]], ["Embryonal stem cell lines IST11134F10 (line F) and IST13563G11 (line G) with GeneTrap insertions in heterozygous state at Clpp intron 1 and 2, respectively (Fig. 1A) , were obtained and a reduction in Clpp transcript levels to 50% was demonstrated by real-time RT -PCR (data not shown).", [["Embryonal stem cell lines", "ANATOMY", 0, 25], ["Embryonal stem cell lines IST11134F10", "CELL", 0, 37], ["line F", "CELL", 39, 45], ["IST13563G11", "CELL", 51, 62], ["line G", "GENE_OR_GENE_PRODUCT", 64, 70], ["Clpp intron 1", "GENE_OR_GENE_PRODUCT", 122, 135], ["Clpp", "GENE_OR_GENE_PRODUCT", 201, 205], ["Embryonal stem cell lines", "CELL_LINE", 0, 25], ["IST11134F10", "CELL_LINE", 26, 37], ["IST13563G11", "DNA", 51, 62], ["GeneTrap insertions", "DNA", 77, 96], ["Clpp intron 1", "DNA", 122, 135], ["Clpp transcript", "RNA", 201, 216], ["Embryonal stem cell lines", "TREATMENT", 0, 25], ["IST13563G11 (line G", "TREATMENT", 51, 70], ["GeneTrap insertions", "TREATMENT", 77, 96], ["heterozygous state", "PROBLEM", 100, 118], ["Clpp intron", "TREATMENT", 122, 133], ["a reduction", "TREATMENT", 186, 197], ["Clpp transcript levels", "TEST", 201, 223], ["stem cell lines", "OBSERVATION", 10, 25], ["heterozygous", "OBSERVATION", 100, 112]]], ["Heterozygous breeders from each founder line were purchased and mated to study the Clpp 2/2 mutant and the littermate control offspring in comparison.", [["Clpp 2/2 mutant", "ORGANISM", 83, 98], ["Clpp 2/2 mutant", "PROTEIN", 83, 98], ["Heterozygous breeders", "PROBLEM", 0, 21], ["the Clpp", "TEST", 79, 87]]], ["Almost complete absence of Clpp transcripts due to the GeneTrap insertion was observed in all tissues studied from Clpp 2/2 animals (Fig. 1B) .", [["tissues", "ANATOMY", 94, 101], ["Clpp", "GENE_OR_GENE_PRODUCT", 27, 31], ["GeneTrap", "GENE_OR_GENE_PRODUCT", 55, 63], ["tissues", "TISSUE", 94, 101], ["Clpp transcripts", "RNA", 27, 43], ["GeneTrap insertion", "DNA", 55, 73], ["Clpp transcripts", "PROBLEM", 27, 43], ["the GeneTrap insertion", "TREATMENT", 51, 73], ["Clpp", "TEST", 115, 119], ["Clpp transcripts", "OBSERVATION", 27, 43], ["all tissues", "ANATOMY", 90, 101]]], ["The absence of CLPP protein was also confirmed in four representative tissues, i.e. liver (chosen for high mitochondrial content), testis (maximal mitochondrial fusion within sperm midpiece), ovary (progressive failure in Perrault syndrome), brain (neural tissue with high respiration and complex mitochondrial distribution) and heart (high respiration and mitochondria surrounding muscular contractile apparatus) (Fig. 1C) .Two independent founder lines with successful Clpp gene ablation show widespread CLPX protein increaseCLPP deficiency resulted in the accumulation of its direct interactor protein CLPX, in comparison with usually low CLPX levels observed in the corresponding wild-type (WT) tissues ( Fig. 1C and Supplementary Material, Fig. S1 ).", [["tissues", "ANATOMY", 70, 77], ["liver", "ANATOMY", 84, 89], ["mitochondrial", "ANATOMY", 107, 120], ["testis", "ANATOMY", 131, 137], ["mitochondrial", "ANATOMY", 147, 160], ["sperm midpiece", "ANATOMY", 175, 189], ["ovary", "ANATOMY", 192, 197], ["brain", "ANATOMY", 242, 247], ["neural tissue", "ANATOMY", 249, 262], ["mitochondrial", "ANATOMY", 297, 310], ["heart", "ANATOMY", 329, 334], ["mitochondria", "ANATOMY", 357, 369], ["muscular", "ANATOMY", 382, 390], ["tissues", "ANATOMY", 699, 706], ["Perrault syndrome", "DISEASE", 222, 239], ["CLPP", "GENE_OR_GENE_PRODUCT", 15, 19], ["tissues", "TISSUE", 70, 77], ["liver", "ORGAN", 84, 89], ["mitochondrial", "CELLULAR_COMPONENT", 107, 120], ["testis", "ORGAN", 131, 137], ["mitochondrial", "CELLULAR_COMPONENT", 147, 160], ["sperm midpiece", "MULTI-TISSUE_STRUCTURE", 175, 189], ["ovary", "ORGAN", 192, 197], ["brain", "ORGAN", 242, 247], ["neural tissue", "TISSUE", 249, 262], ["mitochondrial", "CELLULAR_COMPONENT", 297, 310], ["heart", "ORGAN", 329, 334], ["mitochondria", "CELLULAR_COMPONENT", 357, 369], ["founder lines", "CELL", 441, 454], ["Clpp", "GENE_OR_GENE_PRODUCT", 471, 475], ["CLPX", "GENE_OR_GENE_PRODUCT", 506, 510], ["increaseCLPP", "GENE_OR_GENE_PRODUCT", 519, 531], ["CLPX", "GENE_OR_GENE_PRODUCT", 605, 609], ["CLPX", "GENE_OR_GENE_PRODUCT", 642, 646], ["tissues", "TISSUE", 699, 706], ["S1", "GENE_OR_GENE_PRODUCT", 750, 752], ["CLPP protein", "PROTEIN", 15, 27], ["Clpp gene", "DNA", 471, 480], ["CLPX protein", "PROTEIN", 506, 518], ["increaseCLPP", "PROTEIN", 519, 531], ["interactor protein", "PROTEIN", 586, 604], ["CLPX", "PROTEIN", 605, 609], ["CLPX", "PROTEIN", 642, 646], ["S1", "PROTEIN", 750, 752], ["CLPP protein", "PROBLEM", 15, 27], ["high mitochondrial content)", "PROBLEM", 102, 129], ["testis (maximal mitochondrial fusion", "TREATMENT", 131, 167], ["ovary (progressive failure in Perrault syndrome", "PROBLEM", 192, 239], ["brain (neural tissue", "PROBLEM", 242, 262], ["high respiration and complex mitochondrial distribution) and heart (high respiration", "PROBLEM", 268, 352], ["successful Clpp gene ablation", "TREATMENT", 460, 489], ["widespread CLPX protein increaseCLPP deficiency", "PROBLEM", 495, 542], ["its direct interactor protein CLPX", "PROBLEM", 575, 609], ["usually low CLPX levels", "PROBLEM", 630, 653], ["Supplementary Material", "TREATMENT", 721, 743], ["CLPP protein", "OBSERVATION", 15, 27], ["liver", "ANATOMY", 84, 89], ["testis", "ANATOMY", 131, 137], ["mitochondrial fusion", "OBSERVATION", 147, 167], ["ovary", "ANATOMY", 192, 197], ["progressive", "OBSERVATION_MODIFIER", 199, 210], ["failure", "OBSERVATION", 211, 218], ["Perrault syndrome", "OBSERVATION", 222, 239], ["brain", "ANATOMY", 242, 247], ["neural tissue", "ANATOMY", 249, 262], ["high respiration", "OBSERVATION", 268, 284], ["mitochondrial distribution", "OBSERVATION", 297, 323], ["heart", "ANATOMY", 329, 334], ["high respiration", "OBSERVATION", 336, 352], ["founder lines", "OBSERVATION", 441, 454], ["widespread", "OBSERVATION_MODIFIER", 495, 505], ["CLPX protein", "OBSERVATION", 506, 518], ["increaseCLPP deficiency", "OBSERVATION", 519, 542], ["accumulation", "OBSERVATION_MODIFIER", 559, 571], ["protein CLPX", "OBSERVATION", 597, 609]]], ["This CLPX increase was consistently observed in all tissues by the Sigma antibody against the N-terminal amino acids 40 -132 of CLPX (Fig. 1C ) and by the Abgent antibody against the C-terminal amino acids 452-481 of CLPX (Supplementary Material, Fig. S1 ).", [["tissues", "ANATOMY", 52, 59], ["amino acids 40 -132", "CHEMICAL", 105, 124], ["amino acids 452-481", "CHEMICAL", 194, 213], ["amino acids", "CHEMICAL", 105, 116], ["amino acids", "CHEMICAL", 194, 205], ["CLPX", "GENE_OR_GENE_PRODUCT", 5, 9], ["tissues", "TISSUE", 52, 59], ["Sigma antibody", "GENE_OR_GENE_PRODUCT", 67, 81], ["amino acids", "AMINO_ACID", 105, 116], ["amino acids", "AMINO_ACID", 194, 205], ["S1", "GENE_OR_GENE_PRODUCT", 252, 254], ["CLPX", "PROTEIN", 5, 9], ["Sigma antibody", "PROTEIN", 67, 81], ["N-terminal amino acids 40 -132", "PROTEIN", 94, 124], ["CLPX", "PROTEIN", 128, 132], ["Fig. 1C", "PROTEIN", 134, 141], ["Abgent antibody", "PROTEIN", 155, 170], ["C-terminal amino acids 452-481", "PROTEIN", 183, 213], ["CLPX", "PROTEIN", 217, 221], ["S1", "PROTEIN", 252, 254], ["This CLPX increase", "PROBLEM", 0, 18], ["the Sigma antibody", "TEST", 63, 81], ["the N-terminal amino acids", "TEST", 90, 116], ["CLPX", "TEST", 128, 132], ["the Abgent antibody", "TEST", 151, 170], ["the C-terminal amino acids", "TEST", 179, 205], ["CLPX", "PROBLEM", 217, 221], ["increase", "OBSERVATION_MODIFIER", 10, 18]]], ["The relevance of additional bands with CLPX immunoreactivity cannot be interpreted in absence of a CLPX-knock-out tissue, but it is important to note that two isoforms of Clpx mRNA were previously described in testis (40) .", [["tissue", "ANATOMY", 114, 120], ["testis", "ANATOMY", 210, 216], ["CLPX", "GENE_OR_GENE_PRODUCT", 39, 43], ["CLPX", "GENE_OR_GENE_PRODUCT", 99, 103], ["tissue", "TISSUE", 114, 120], ["Clpx", "GENE_OR_GENE_PRODUCT", 171, 175], ["testis", "ORGAN", 210, 216], ["CLPX", "PROTEIN", 39, 43], ["CLPX", "PROTEIN", 99, 103], ["Clpx mRNA", "RNA", 171, 180], ["additional bands", "PROBLEM", 17, 33], ["CLPX immunoreactivity", "PROBLEM", 39, 60], ["a CLPX", "TEST", 97, 103], ["Clpx mRNA", "PROBLEM", 171, 180], ["out tissue", "OBSERVATION_MODIFIER", 110, 120], ["Clpx mRNA", "OBSERVATION", 171, 180]]], ["Similar amounts and parallel regulation of CLPP and CLPX would be expected in view of their cooperative functions and of previous proteomic data reporting similar intermediate levels in 14 mouse tissues (41) , but previous reports on Clpp mRNA showed the levels to vary between tissues (39, 40, 42) .", [["tissues", "ANATOMY", 195, 202], ["tissues", "ANATOMY", 278, 285], ["CLPP", "GENE_OR_GENE_PRODUCT", 43, 47], ["CLPX", "GENE_OR_GENE_PRODUCT", 52, 56], ["mouse", "ORGANISM", 189, 194], ["tissues", "TISSUE", 195, 202], ["Clpp", "GENE_OR_GENE_PRODUCT", 234, 238], ["tissues", "TISSUE", 278, 285], ["CLPP", "PROTEIN", 43, 47], ["CLPX", "PROTEIN", 52, 56], ["Clpp mRNA", "RNA", 234, 243], ["mouse", "SPECIES", 189, 194], ["mouse", "SPECIES", 189, 194], ["CLPP and CLPX", "TREATMENT", 43, 56], ["previous proteomic data", "TEST", 121, 144], ["Clpp mRNA", "TEST", 234, 243], ["the levels", "TEST", 251, 261], ["amounts", "OBSERVATION_MODIFIER", 8, 15], ["CLPP", "OBSERVATION", 43, 47], ["CLPX", "OBSERVATION", 52, 56]]], ["In conclusion, we observed an inverse correlation between CLPP and CLPX levels in the null mouse, suggesting that Figure 1 .", [["CLPP", "GENE_OR_GENE_PRODUCT", 58, 62], ["CLPX", "GENE_OR_GENE_PRODUCT", 67, 71], ["mouse", "ORGANISM", 91, 96], ["CLPP", "PROTEIN", 58, 62], ["CLPX", "PROTEIN", 67, 71], ["mouse", "SPECIES", 91, 96], ["mouse", "SPECIES", 91, 96], ["CLPP", "TEST", 58, 62], ["CLPX levels", "TEST", 67, 78], ["null mouse", "OBSERVATION", 86, 96]]], ["Two independent founder lines with CLPP null mutation show CLPX protein accumulation.", [["CLPP", "GENE_OR_GENE_PRODUCT", 35, 39], ["CLPX", "GENE_OR_GENE_PRODUCT", 59, 63], ["CLPX", "PROTEIN", 59, 63], ["CLPP null mutation", "TEST", 35, 53], ["CLPX protein accumulation", "PROBLEM", 59, 84], ["founder lines", "OBSERVATION", 16, 29], ["CLPX protein accumulation", "OBSERVATION", 59, 84]]], ["(A) Scheme of the Clpp gene exon-intron structure, coding region (broad bar from ATG) and of the two independent gene-trap insertion sites F (left arrow) and G (arrow further right).", [["Clpp", "GENE_OR_GENE_PRODUCT", 18, 22], ["Clpp gene exon-intron structure", "DNA", 18, 49], ["coding region", "DNA", 51, 64], ["ATG", "DNA", 81, 84], ["gene-trap insertion sites", "DNA", 113, 138], ["F", "DNA", 139, 140], ["G", "DNA", 158, 159], ["the Clpp gene exon-intron structure", "PROBLEM", 14, 49], ["ATG)", "TREATMENT", 81, 85], ["the two independent gene-trap insertion sites", "TREATMENT", 93, 138], ["left", "ANATOMY_MODIFIER", 142, 146], ["right", "ANATOMY_MODIFIER", 175, 180]]], ["(B) Absence of Clpp transcript in brain hemispheres of 5-month-old line G Clpp 2/2 homozygotes.", [["brain hemispheres", "ANATOMY", 34, 51], ["Clpp", "GENE_OR_GENE_PRODUCT", 15, 19], ["brain hemispheres", "MULTI-TISSUE_STRUCTURE", 34, 51], ["G Clpp 2/2", "CELL", 72, 82], ["Clpp transcript", "RNA", 15, 30], ["Clpp transcript in brain hemispheres", "PROBLEM", 15, 51], ["old line G Clpp 2/2 homozygotes", "PROBLEM", 63, 94], ["Clpp transcript", "OBSERVATION", 15, 30], ["brain", "ANATOMY", 34, 39], ["hemispheres", "ANATOMY_MODIFIER", 40, 51], ["Clpp", "OBSERVATION_MODIFIER", 74, 78], ["2/2 homozygotes", "OBSERVATION", 79, 94]]], ["The picture represents RT -PCR products with primers situated in exons 5/6 or 3/4, respectively, with lanes for three Clpp 2/2 versus three WT animals.", [["RT -PCR products", "DNA", 23, 39], ["exons", "DNA", 65, 70], ["RT -PCR products", "TREATMENT", 23, 39], ["primers", "PROBLEM", 45, 52], ["Clpp", "TEST", 118, 122], ["PCR products", "OBSERVATION", 27, 39]]], ["Gapdh served as a loading control.", [["Gapdh", "GENE_OR_GENE_PRODUCT", 0, 5], ["Gapdh", "DNA", 0, 5], ["Gapdh", "TREATMENT", 0, 5], ["a loading control", "TREATMENT", 16, 33]]], ["(C) Absent levels of anti-CLPP immunoreactivity contrasted with elevated levels of anti-CLPX immunoreactivity (antibody HPA040262 from Sigma) in western blots of all tissues from 5-month-old three line G Clpp 2/2 homozygotes versus three WT animals.", [["tissues", "ANATOMY", 166, 173], ["anti-CLPP", "GENE_OR_GENE_PRODUCT", 21, 30], ["anti-CLPX", "GENE_OR_GENE_PRODUCT", 83, 92], ["tissues", "TISSUE", 166, 173], ["G Clpp 2/2", "CELL", 202, 212], ["anti-CLPP", "PROTEIN", 21, 30], ["anti-CLPX", "PROTEIN", 83, 92], ["antibody HPA040262", "PROTEIN", 111, 129], ["Absent levels of anti-CLPP immunoreactivity", "PROBLEM", 4, 47], ["elevated levels", "PROBLEM", 64, 79], ["anti-CLPX immunoreactivity", "PROBLEM", 83, 109], ["antibody", "TEST", 111, 119], ["all tissues", "ANATOMY", 162, 173]]], ["Porin represents a loading control of mitochondrial mass.", [["mitochondrial mass", "ANATOMY", 38, 56], ["Porin", "CHEMICAL", 0, 5], ["Porin", "GENE_OR_GENE_PRODUCT", 0, 5], ["mitochondrial", "CELLULAR_COMPONENT", 38, 51], ["Porin", "PROTEIN", 0, 5], ["Porin", "TREATMENT", 0, 5], ["mitochondrial mass", "PROBLEM", 38, 56], ["mitochondrial", "ANATOMY", 38, 51], ["mass", "OBSERVATION", 52, 56]]], ["CLPX turnover depends directly on CLPP, while indirect effects or an up-regulation of CLPX translation in response to the CLPP deletion cannot be excluded.Two independent founder lines with successful Clpp gene ablation show widespread CLPX protein increaseClpp 2/2 animals exhibit phenotypes of impaired survival and hearing, absent fertility, resistance to ulcerative dermatitis, growth retardation and motor activity reductionTwo independent founder lines with successful Clpp gene ablation show widespread CLPX protein increaseTo test the consequences of the absence of mitochondrial CLPP for the organism, the animals were aged and all obvious phenotypes documented.", [["mitochondrial", "ANATOMY", 574, 587], ["impaired survival and hearing", "DISEASE", 296, 325], ["ulcerative dermatitis", "DISEASE", 359, 380], ["growth retardation", "DISEASE", 382, 400], ["CLPX", "GENE_OR_GENE_PRODUCT", 0, 4], ["CLPP", "GENE_OR_GENE_PRODUCT", 34, 38], ["CLPX", "GENE_OR_GENE_PRODUCT", 86, 90], ["CLPP", "GENE_OR_GENE_PRODUCT", 122, 126], ["founder lines", "CELL", 171, 184], ["Clpp", "GENE_OR_GENE_PRODUCT", 201, 205], ["CLPX", "GENE_OR_GENE_PRODUCT", 236, 240], ["Clpp", "GENE_OR_GENE_PRODUCT", 475, 479], ["CLPX", "GENE_OR_GENE_PRODUCT", 510, 514], ["mitochondrial", "CELLULAR_COMPONENT", 574, 587], ["CLPP", "GENE_OR_GENE_PRODUCT", 588, 592], ["CLPX", "PROTEIN", 0, 4], ["CLPP", "PROTEIN", 34, 38], ["CLPX", "PROTEIN", 86, 90], ["CLPP deletion", "DNA", 122, 135], ["Clpp gene", "DNA", 201, 210], ["CLPX protein", "PROTEIN", 236, 248], ["Clpp gene", "DNA", 475, 484], ["CLPX protein", "PROTEIN", 510, 522], ["mitochondrial CLPP", "PROTEIN", 574, 592], ["an up-regulation of CLPX translation", "TREATMENT", 66, 102], ["the CLPP deletion", "PROBLEM", 118, 135], ["successful Clpp gene ablation", "TREATMENT", 190, 219], ["widespread CLPX protein increaseClpp", "PROBLEM", 225, 261], ["impaired survival", "PROBLEM", 296, 313], ["hearing", "PROBLEM", 318, 325], ["absent fertility", "PROBLEM", 327, 343], ["ulcerative dermatitis", "PROBLEM", 359, 380], ["growth retardation", "PROBLEM", 382, 400], ["motor activity reduction", "TREATMENT", 405, 429], ["successful Clpp gene ablation", "TREATMENT", 464, 493], ["widespread CLPX protein increase", "PROBLEM", 499, 531], ["mitochondrial CLPP", "PROBLEM", 574, 592], ["the organism", "PROBLEM", 597, 609], ["all obvious phenotypes", "PROBLEM", 637, 659], ["CLPP deletion", "OBSERVATION", 122, 135], ["cannot be excluded", "UNCERTAINTY", 136, 154], ["founder lines", "OBSERVATION", 171, 184], ["impaired", "OBSERVATION_MODIFIER", 296, 304], ["survival", "OBSERVATION", 305, 313], ["ulcerative", "OBSERVATION_MODIFIER", 359, 369], ["dermatitis", "OBSERVATION", 370, 380], ["widespread", "OBSERVATION_MODIFIER", 499, 509], ["CLPX protein", "OBSERVATION", 510, 522], ["increase", "OBSERVATION_MODIFIER", 523, 531], ["mitochondrial CLPP", "OBSERVATION", 574, 592]]], ["The significant underrepresentation of pups with a Clpp 2/2 genotype born from heterozygous matings indicated a reduced intrauterine survival (Supplementary Material, Table S1 ).", [["intrauterine", "ANATOMY", 120, 132], ["pups", "ORGANISM_SUBDIVISION", 39, 43], ["Clpp 2/2", "GENE_OR_GENE_PRODUCT", 51, 59], ["a Clpp", "PROBLEM", 49, 55], ["heterozygous matings", "PROBLEM", 79, 99], ["a reduced intrauterine survival", "PROBLEM", 110, 141], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["reduced", "OBSERVATION_MODIFIER", 112, 119], ["intrauterine survival", "OBSERVATION", 120, 141]]], ["Clpp 2/2 males and females of both lines were completely infertile ( Fig. 2A) , with reduced macroscopic size of testes and ovaries already at age 3 months.", [["lines", "ANATOMY", 35, 40], ["testes", "ANATOMY", 113, 119], ["ovaries", "ANATOMY", 124, 131], ["Clpp", "GENE_OR_GENE_PRODUCT", 0, 4], ["lines", "CELL", 35, 40], ["testes", "ORGAN", 113, 119], ["ovaries", "ORGAN", 124, 131], ["Clpp", "PROBLEM", 0, 4], ["reduced macroscopic size of testes and ovaries", "PROBLEM", 85, 131], ["both lines", "OBSERVATION", 30, 40], ["reduced", "OBSERVATION_MODIFIER", 85, 92], ["macroscopic", "OBSERVATION_MODIFIER", 93, 104], ["size", "OBSERVATION_MODIFIER", 105, 109], ["testes", "ANATOMY", 113, 119], ["ovaries", "ANATOMY", 124, 131]]], ["Following the animals during our study to their current age of maximally 400 days, death from natural causes during postnatal life was significantly more frequent in the cohort of Clpp 2/2 mice in comparison with their littermate controls (Supplementary Material, Fig. S2 ).Two independent founder lines with successful Clpp gene ablation show widespread CLPX protein increaseTo assess manifestation of sensorineural deafness as in human Perrault syndrome, the motor startle response after sudden very loud acoustic stimuli was recorded on an accelerometer.", [["death", "DISEASE", 83, 88], ["sensorineural deafness", "DISEASE", 403, 425], ["Perrault syndrome", "DISEASE", 438, 455], ["Clpp 2/2 mice", "ORGANISM", 180, 193], ["founder lines", "CELL", 290, 303], ["Clpp", "GENE_OR_GENE_PRODUCT", 320, 324], ["CLPX", "GENE_OR_GENE_PRODUCT", 355, 359], ["human", "ORGANISM", 432, 437], ["S2", "PROTEIN", 269, 271], ["Clpp gene", "DNA", 320, 329], ["CLPX protein", "PROTEIN", 355, 367], ["mice", "SPECIES", 189, 193], ["human", "SPECIES", 432, 437], ["mice", "SPECIES", 189, 193], ["human", "SPECIES", 432, 437], ["our study", "TEST", 29, 38], ["death", "PROBLEM", 83, 88], ["successful Clpp gene ablation", "TREATMENT", 309, 338], ["widespread CLPX protein increase", "PROBLEM", 344, 376], ["sensorineural deafness", "PROBLEM", 403, 425], ["human Perrault syndrome", "PROBLEM", 432, 455], ["sudden very loud acoustic stimuli", "PROBLEM", 490, 523], ["founder lines", "OBSERVATION", 290, 303], ["widespread", "OBSERVATION_MODIFIER", 344, 354], ["CLPX protein", "OBSERVATION", 355, 367], ["increase", "OBSERVATION_MODIFIER", 368, 376], ["sensorineural", "OBSERVATION_MODIFIER", 403, 416], ["deafness", "OBSERVATION", 417, 425]]], ["While WT mice with C57BL/6 background also become deaf toward the end of their natural life span, much earlier deficits were demonstrable with high significance in Clpp 2/2 mice at ages 12-18 months (Fig. 2B ).", [["WT mice", "ORGANISM", 6, 13], ["C57BL/6 background", "ORGANISM", 19, 37], ["Clpp 2/2 mice", "ORGANISM", 164, 177], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 173, 177], ["mice", "SPECIES", 9, 13], ["deaf", "PROBLEM", 50, 54], ["much earlier deficits", "PROBLEM", 98, 119], ["Clpp", "TEST", 164, 168]]], ["Additional tests involving detection thresholds, wave-length differences including ultrasounds, young animals and sex differences remain to be performed.Two independent founder lines with successful Clpp gene ablation show widespread CLPX protein increaseIntriguingly, matched WT control mice underwent euthanasia for ulcerative dermatitis, which is a skin condition well known to occur spontaneously at age 6 -20 months in 5% of all mice with C57BL/6 background (43) (44) (45) , much more frequently than Clpp 2/2 mice.", [["ulcerative", "ANATOMY", 318, 328], ["skin", "ANATOMY", 352, 356], ["ulcerative dermatitis", "DISEASE", 318, 339], ["founder lines", "CELL", 169, 182], ["Clpp", "GENE_OR_GENE_PRODUCT", 199, 203], ["CLPX", "GENE_OR_GENE_PRODUCT", 234, 238], ["mice", "ORGANISM", 288, 292], ["skin", "ORGAN", 352, 356], ["mice", "ORGANISM", 434, 438], ["C57BL/6 background", "ORGANISM", 444, 462], ["Clpp 2/2 mice", "ORGANISM", 506, 519], ["Clpp gene", "DNA", 199, 208], ["CLPX protein", "PROTEIN", 234, 246], ["mice", "SPECIES", 288, 292], ["mice", "SPECIES", 434, 438], ["mice", "SPECIES", 515, 519], ["mice", "SPECIES", 288, 292], ["mice", "SPECIES", 434, 438], ["mice", "SPECIES", 515, 519], ["Additional tests", "TEST", 0, 16], ["detection thresholds", "TEST", 27, 47], ["wave-length differences", "PROBLEM", 49, 72], ["ultrasounds", "TEST", 83, 94], ["successful Clpp gene ablation", "TREATMENT", 188, 217], ["widespread CLPX protein increaseIntriguingly", "PROBLEM", 223, 267], ["euthanasia", "TREATMENT", 303, 313], ["ulcerative dermatitis", "PROBLEM", 318, 339], ["a skin condition", "PROBLEM", 350, 366], ["founder lines", "OBSERVATION", 169, 182], ["widespread", "OBSERVATION_MODIFIER", 223, 233], ["CLPX protein", "OBSERVATION", 234, 246], ["ulcerative dermatitis", "OBSERVATION", 318, 339], ["skin", "ANATOMY", 352, 356], ["condition", "OBSERVATION", 357, 366]]], ["This resistance to inflammatory skin pathology occurred in Clpp 2/2 mice in spite of sharing the same individually ventilated cages and showing the same pathogen-free status during health monitoring as WT mice.", [["skin", "ANATOMY", 32, 36], ["skin", "ORGAN", 32, 36], ["Clpp 2/2 mice", "ORGANISM", 59, 72], ["mice", "ORGANISM", 205, 209], ["mice", "SPECIES", 68, 72], ["mice", "SPECIES", 205, 209], ["mice", "SPECIES", 68, 72], ["mice", "SPECIES", 205, 209], ["inflammatory skin pathology", "PROBLEM", 19, 46], ["Clpp", "TEST", 59, 63], ["ventilated cages", "TREATMENT", 115, 131], ["health monitoring", "TEST", 181, 198], ["inflammatory", "OBSERVATION_MODIFIER", 19, 31], ["skin", "ANATOMY", 32, 36], ["pathology", "OBSERVATION", 37, 46], ["Clpp", "OBSERVATION_MODIFIER", 59, 63], ["2/2 mice", "OBSERVATION_MODIFIER", 64, 72]]], ["An effort to quantify this effect examined 20 Clpp 2/2 mice versus 25 matched WT controls.", [["mice", "ORGANISM", 55, 59], ["mice", "SPECIES", 55, 59]]], ["Ulcerative dermatitis was observed in one Clpp 2/2 animal versus nine WT mice, while the related skin pathology alopecia showed similar frequency during aging, with nine Clpp 2/2 versus eight WT mice being affected (Fig. 2C) .Two independent founder lines with successful Clpp gene ablation show widespread CLPX protein increaseClpp 2/2 body weight appeared normal until weaning, but later a reduced weight gain was observed throughout adult life (Fig. 2D) to such a degree that the genotype was obvious from visual inspection.", [["skin", "ANATOMY", 97, 101], ["body", "ANATOMY", 337, 341], ["Ulcerative dermatitis", "DISEASE", 0, 21], ["alopecia", "DISEASE", 112, 120], ["weight gain", "DISEASE", 400, 411], ["mice", "ORGANISM", 73, 77], ["skin", "ORGAN", 97, 101], ["mice", "ORGANISM", 195, 199], ["founder lines", "CELL", 242, 255], ["Clpp", "GENE_OR_GENE_PRODUCT", 272, 276], ["CLPX", "GENE_OR_GENE_PRODUCT", 307, 311], ["body", "ORGANISM_SUBDIVISION", 337, 341], ["Clpp gene", "DNA", 272, 281], ["CLPX protein", "PROTEIN", 307, 319], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 195, 199], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 195, 199], ["Ulcerative dermatitis", "PROBLEM", 0, 21], ["the related skin pathology alopecia", "PROBLEM", 85, 120], ["nine Clpp", "TEST", 165, 174], ["successful Clpp gene ablation", "TREATMENT", 261, 290], ["widespread CLPX protein increaseClpp", "PROBLEM", 296, 332], ["body weight", "TEST", 337, 348], ["a reduced weight gain", "PROBLEM", 390, 411], ["visual inspection", "TEST", 509, 526], ["dermatitis", "OBSERVATION", 11, 21], ["one Clpp", "OBSERVATION_MODIFIER", 38, 46], ["skin", "ANATOMY", 97, 101], ["pathology", "OBSERVATION", 102, 111], ["founder lines", "OBSERVATION", 242, 255], ["widespread", "OBSERVATION_MODIFIER", 296, 306], ["CLPX", "OBSERVATION", 307, 311], ["normal", "OBSERVATION", 358, 364]]], ["This effect was significant for males and females of both founder lines.", [["founder lines", "CELL_LINE", 58, 71], ["males", "PROBLEM", 32, 37], ["founder lines", "OBSERVATION", 58, 71]]], ["Body length assessment was more dependent on variant investigator's precision and animal compliance, but reflected essentially the same observation (Supplementary Material, Fig. S3 ).Two independent founder lines with successful Clpp gene ablation show widespread CLPX protein increaseAnalysis of spontaneous motor activity in the open field paradigm at the age of 6 months showed a significant reduction in horizontal activity (HACT), movement number (MOVNO), vertical activity (VACT) (Fig. 2E ) as well as total distance, movement time, stereotype count, margin distance and center distance (data not shown).", [["Body", "ANATOMY", 0, 4], ["Body", "ORGANISM_SUBDIVISION", 0, 4], ["founder lines", "CELL", 199, 212], ["Clpp", "GENE_OR_GENE_PRODUCT", 229, 233], ["CLPX", "GENE_OR_GENE_PRODUCT", 264, 268], ["Clpp gene", "DNA", 229, 238], ["CLPX protein", "PROTEIN", 264, 276], ["Body length assessment", "TEST", 0, 22], ["successful Clpp gene ablation", "TREATMENT", 218, 247], ["widespread CLPX protein increase", "PROBLEM", 253, 285], ["spontaneous motor activity", "PROBLEM", 297, 323], ["a significant reduction in horizontal activity (HACT)", "PROBLEM", 381, 434], ["movement time", "TEST", 524, 537], ["stereotype count", "TEST", 539, 555], ["center distance (data", "TEST", 577, 598], ["more dependent", "OBSERVATION_MODIFIER", 27, 41], ["founder lines", "OBSERVATION", 199, 212], ["widespread", "OBSERVATION_MODIFIER", 253, 263], ["CLPX protein", "OBSERVATION", 264, 276], ["increase", "OBSERVATION_MODIFIER", 277, 285], ["spontaneous", "OBSERVATION_MODIFIER", 297, 308], ["motor activity", "OBSERVATION", 309, 323], ["significant", "OBSERVATION_MODIFIER", 383, 394], ["reduction", "OBSERVATION_MODIFIER", 395, 404], ["horizontal activity", "OBSERVATION", 408, 427]]], ["Analysis of induced motor activity and coordination on a Rotarod showed a trend toward better performance of Clpp 2/2 mice (Fig. 2F) , suggesting that they either lack the spontaneity to jump off the rotating wheel or that the weight reduction facilitated performance.Two independent founder lines with successful Clpp gene ablation show widespread CLPX protein increaseTo complement these data on Clpp 2/2 animals at the level of cultured Clpp 2/2 cells, murine embryonal fibroblast (MEF) lines were established from three Clpp 2/2 and three WT animals and their growth curves compared.", [["Clpp 2/2 cells", "ANATOMY", 440, 454], ["embryonal fibroblast (MEF) lines", "ANATOMY", 463, 495], ["Clpp 2/2 mice", "ORGANISM", 109, 122], ["founder lines", "CELL", 284, 297], ["Clpp", "GENE_OR_GENE_PRODUCT", 314, 318], ["CLPX", "GENE_OR_GENE_PRODUCT", 349, 353], ["Clpp 2/2 animals", "ORGANISM", 398, 414], ["Clpp 2/2 cells", "CELL", 440, 454], ["murine", "ORGANISM", 456, 462], ["embryonal fibroblast (MEF) lines", "CELL", 463, 495], ["Clpp 2/2", "CELL", 524, 532], ["Clpp gene", "DNA", 314, 323], ["CLPX protein", "PROTEIN", 349, 361], ["cultured Clpp 2/2 cells", "CELL_LINE", 431, 454], ["murine embryonal fibroblast (MEF) lines", "CELL_LINE", 456, 495], ["mice", "SPECIES", 118, 122], ["murine", "SPECIES", 456, 462], ["induced motor activity", "PROBLEM", 12, 34], ["a Rotarod", "TEST", 55, 64], ["Clpp", "TEST", 109, 113], ["the weight reduction", "TREATMENT", 223, 243], ["successful Clpp gene ablation", "TREATMENT", 303, 332], ["widespread CLPX protein", "PROBLEM", 338, 361], ["these data", "TEST", 384, 394], ["Clpp", "TEST", 398, 402], ["Clpp", "TEST", 440, 444], ["murine embryonal fibroblast (MEF) lines", "TREATMENT", 456, 495], ["Clpp", "TEST", 524, 528], ["their growth curves", "TEST", 558, 577], ["motor activity", "OBSERVATION", 20, 34], ["founder lines", "OBSERVATION", 284, 297], ["Clpp", "OBSERVATION_MODIFIER", 440, 444], ["2/2 cells", "OBSERVATION", 445, 454], ["embryonal fibroblast", "OBSERVATION", 463, 483]]], ["Clpp 2/2 lines showed decreased population doubling values and reached replicative senescence earlier (Fig. 2G) .Two independent founder lines with successful Clpp gene ablation show widespread CLPX protein increaseThese data indicate that CLPP deficiency causes moderate reductions of survival, general growth and motor activity, a complete loss of fertility and hearing responses, as well as a remarkable protection against ulcerative dermatitis.", [["Clpp 2/2 lines", "ANATOMY", 0, 14], ["ulcerative", "ANATOMY", 426, 436], ["CLPP", "CHEMICAL", 240, 244], ["ulcerative dermatitis", "DISEASE", 426, 447], ["Clpp 2/2 lines", "CELL", 0, 14], ["founder lines", "CELL", 129, 142], ["Clpp", "GENE_OR_GENE_PRODUCT", 159, 163], ["CLPX", "GENE_OR_GENE_PRODUCT", 194, 198], ["CLPP", "GENE_OR_GENE_PRODUCT", 240, 244], ["Clpp 2/2 lines", "CELL_LINE", 0, 14], ["Clpp gene", "DNA", 159, 168], ["CLPX protein", "PROTEIN", 194, 206], ["CLPP", "PROTEIN", 240, 244], ["Clpp 2/2 lines", "PROBLEM", 0, 14], ["decreased population doubling values", "PROBLEM", 22, 58], ["replicative senescence", "PROBLEM", 71, 93], ["successful Clpp gene ablation", "TREATMENT", 148, 177], ["widespread CLPX protein increase", "PROBLEM", 183, 215], ["These data", "TEST", 215, 225], ["CLPP deficiency", "PROBLEM", 240, 255], ["moderate reductions of survival", "PROBLEM", 263, 294], ["general growth and motor activity", "PROBLEM", 296, 329], ["a complete loss of fertility", "PROBLEM", 331, 359], ["hearing responses", "PROBLEM", 364, 381], ["ulcerative dermatitis", "PROBLEM", 426, 447], ["decreased", "OBSERVATION_MODIFIER", 22, 31], ["population", "OBSERVATION_MODIFIER", 32, 42], ["founder lines", "OBSERVATION", 129, 142], ["widespread", "OBSERVATION_MODIFIER", 183, 193], ["CLPX protein", "OBSERVATION", 194, 206], ["increase", "OBSERVATION_MODIFIER", 207, 215], ["CLPP deficiency", "OBSERVATION", 240, 255], ["moderate", "OBSERVATION_MODIFIER", 263, 271], ["reductions", "OBSERVATION_MODIFIER", 272, 282], ["motor activity", "OBSERVATION", 315, 329], ["ulcerative", "OBSERVATION_MODIFIER", 426, 436], ["dermatitis", "OBSERVATION", 437, 447]]], ["Since CLPP mutations were recently identified as the cause of human Perrault syndrome, it is interesting to note that short stature and neurologic abnormalities were discussed by several authors as potential signs of this disorder in addition to the female infertility and sensorineural deafness (46, 47) .Respiration in Clpp 2/2 tissues shows mild reductionThe bioenergetic deficit in skeletal muscle was studied to determine whether it explained the reduced motor activity of Clpp 2/2 mice.", [["neurologic", "ANATOMY", 136, 146], ["Clpp 2/2 tissues", "ANATOMY", 321, 337], ["skeletal muscle", "ANATOMY", 386, 401], ["Perrault syndrome", "DISEASE", 68, 85], ["stature", "DISEASE", 124, 131], ["neurologic abnormalities", "DISEASE", 136, 160], ["infertility", "DISEASE", 257, 268], ["sensorineural deafness", "DISEASE", 273, 295], ["CLPP", "GENE_OR_GENE_PRODUCT", 6, 10], ["human", "ORGANISM", 62, 67], ["Clpp 2/2 tissues", "TISSUE", 321, 337], ["skeletal muscle", "ORGAN", 386, 401], ["Clpp 2/2 mice", "ORGANISM", 478, 491], ["CLPP", "PROTEIN", 6, 10], ["human", "SPECIES", 62, 67], ["mice", "SPECIES", 487, 491], ["human", "SPECIES", 62, 67], ["CLPP mutations", "PROBLEM", 6, 20], ["human Perrault syndrome", "PROBLEM", 62, 85], ["short stature and neurologic abnormalities", "PROBLEM", 118, 160], ["this disorder", "PROBLEM", 217, 230], ["the female infertility", "PROBLEM", 246, 268], ["sensorineural deafness", "PROBLEM", 273, 295], ["Respiration in Clpp", "TEST", 306, 325], ["mild reduction", "PROBLEM", 344, 358], ["The bioenergetic deficit in skeletal muscle", "PROBLEM", 358, 401], ["infertility", "OBSERVATION", 257, 268], ["sensorineural deafness", "OBSERVATION", 273, 295], ["mild", "OBSERVATION_MODIFIER", 344, 348], ["reduction", "OBSERVATION", 349, 358], ["bioenergetic", "OBSERVATION_MODIFIER", 362, 374], ["deficit", "OBSERVATION", 375, 382], ["skeletal muscle", "ANATOMY", 386, 401]]], ["The histological assessment of respiratory activity markers (COX, SDH and NADH) in type I muscle fibers, which are specialized in slow contractions maintained over long periods due to mitochondrial abundance and high oxidative/low glycolytic capacity, showed a slightly decreased size of these muscle cells (Supplementary Material, Fig. S4A ).", [["respiratory", "ANATOMY", 31, 42], ["muscle fibers", "ANATOMY", 90, 103], ["mitochondrial", "ANATOMY", 184, 197], ["muscle cells", "ANATOMY", 294, 306], ["NADH", "CHEMICAL", 74, 78], ["COX", "GENE_OR_GENE_PRODUCT", 61, 64], ["SDH", "GENE_OR_GENE_PRODUCT", 66, 69], ["NADH", "SIMPLE_CHEMICAL", 74, 78], ["muscle fibers", "CELL", 90, 103], ["mitochondrial", "CELLULAR_COMPONENT", 184, 197], ["muscle cells", "CELL", 294, 306], ["respiratory activity markers", "PROTEIN", 31, 59], ["COX", "PROTEIN", 61, 64], ["SDH", "PROTEIN", 66, 69], ["NADH", "PROTEIN", 74, 78], ["muscle cells", "CELL_TYPE", 294, 306], ["The histological assessment", "TEST", 0, 27], ["respiratory activity markers (COX, SDH and NADH) in type I muscle fibers", "PROBLEM", 31, 103], ["slow contractions", "PROBLEM", 130, 147], ["mitochondrial abundance", "PROBLEM", 184, 207], ["high oxidative/low glycolytic capacity", "PROBLEM", 212, 250], ["a slightly decreased size of these muscle cells", "PROBLEM", 259, 306], ["respiratory activity", "OBSERVATION", 31, 51], ["muscle fibers", "ANATOMY", 90, 103], ["slightly", "OBSERVATION_MODIFIER", 261, 269], ["decreased", "OBSERVATION_MODIFIER", 270, 279], ["size", "OBSERVATION_MODIFIER", 280, 284], ["muscle cells", "ANATOMY", 294, 306]]], ["However, signs of marked compensatory mitochondrial proliferation such as ragged red fibers or increased lipid droplets were not detected.", [["mitochondrial", "ANATOMY", 38, 51], ["red fibers", "ANATOMY", 81, 91], ["lipid droplets", "ANATOMY", 105, 119], ["mitochondrial", "CELLULAR_COMPONENT", 38, 51], ["red fibers", "CELLULAR_COMPONENT", 81, 91], ["lipid droplets", "CELLULAR_COMPONENT", 105, 119], ["marked compensatory mitochondrial proliferation", "PROBLEM", 18, 65], ["ragged red fibers", "PROBLEM", 74, 91], ["increased lipid droplets", "PROBLEM", 95, 119], ["signs of", "UNCERTAINTY", 9, 17], ["marked", "OBSERVATION_MODIFIER", 18, 24], ["compensatory", "OBSERVATION_MODIFIER", 25, 37], ["mitochondrial proliferation", "OBSERVATION", 38, 65], ["ragged", "OBSERVATION_MODIFIER", 74, 80], ["red fibers", "OBSERVATION", 81, 91], ["increased", "OBSERVATION_MODIFIER", 95, 104], ["lipid droplets", "OBSERVATION", 105, 119]]], ["In the subsarcolemmal space an increased number of enlarged mitochondria, which displayed also irregular cristae membrane organization, was detected upon negative stain electron microscopy.", [["subsarcolemmal space", "ANATOMY", 7, 27], ["mitochondria", "ANATOMY", 60, 72], ["cristae membrane", "ANATOMY", 105, 121], ["subsarcolemmal space", "CELLULAR_COMPONENT", 7, 27], ["mitochondria", "CELLULAR_COMPONENT", 60, 72], ["cristae membrane", "CELLULAR_COMPONENT", 105, 121], ["enlarged mitochondria", "PROBLEM", 51, 72], ["irregular cristae membrane organization", "PROBLEM", 95, 134], ["subsarcolemmal", "ANATOMY_MODIFIER", 7, 21], ["increased", "OBSERVATION_MODIFIER", 31, 40], ["number", "OBSERVATION_MODIFIER", 41, 47], ["enlarged", "OBSERVATION_MODIFIER", 51, 59], ["mitochondria", "OBSERVATION", 60, 72], ["irregular", "OBSERVATION_MODIFIER", 95, 104], ["cristae membrane organization", "OBSERVATION", 105, 134]]], ["Electron dense granules or paracrystalline structures were not observed (Supplementary Material, Fig. S4B ).", [["granules", "ANATOMY", 15, 23], ["paracrystalline structures", "ANATOMY", 27, 53], ["granules", "CELLULAR_COMPONENT", 15, 23], ["Electron dense granules or paracrystalline structures", "PROBLEM", 0, 53], ["dense", "OBSERVATION_MODIFIER", 9, 14], ["granules", "OBSERVATION", 15, 23], ["paracrystalline structures", "OBSERVATION", 27, 53]]], ["Thus, only mild signs of mitochondrial dysfunction and compensatory effects were observed.", [["mitochondrial", "ANATOMY", 25, 38], ["mitochondrial dysfunction", "DISEASE", 25, 50], ["mitochondrial", "CELLULAR_COMPONENT", 25, 38], ["mitochondrial dysfunction", "PROBLEM", 25, 50], ["compensatory effects", "PROBLEM", 55, 75], ["mild", "OBSERVATION_MODIFIER", 11, 15], ["mitochondrial dysfunction", "OBSERVATION", 25, 50], ["compensatory effects", "OBSERVATION", 55, 75]]], ["Similar unspecific changes are known to occur after the administration of mitochondrial toxins (48) .", [["mitochondrial", "ANATOMY", 74, 87], ["mitochondrial", "CELLULAR_COMPONENT", 74, 87], ["Similar unspecific changes", "PROBLEM", 0, 26], ["mitochondrial toxins", "PROBLEM", 74, 94], ["unspecific", "OBSERVATION", 8, 18]]], ["Light and electron microscopy analysis of the liver and the brain did not reveal any obvious anomalies (data not shown).Respiration in Clpp 2/2 tissues shows mild reductionTo assess the bioenergetic competence of Clpp 2/2 mitochondria by respirometry, mitochondria were isolated from skeletal and heart muscle in comparison with the brain.", [["liver", "ANATOMY", 46, 51], ["brain", "ANATOMY", 60, 65], ["Clpp 2/2 tissues", "ANATOMY", 135, 151], ["Clpp 2/2 mitochondria", "ANATOMY", 213, 234], ["mitochondria", "ANATOMY", 252, 264], ["skeletal", "ANATOMY", 284, 292], ["heart muscle", "ANATOMY", 297, 309], ["brain", "ANATOMY", 333, 338], ["liver", "ORGAN", 46, 51], ["brain", "ORGAN", 60, 65], ["Clpp 2/2 tissues", "TISSUE", 135, 151], ["Clpp 2/2", "ORGANISM_SUBSTANCE", 213, 221], ["mitochondria", "CELLULAR_COMPONENT", 222, 234], ["mitochondria", "CELLULAR_COMPONENT", 252, 264], ["skeletal", "TISSUE", 284, 292], ["heart muscle", "TISSUE", 297, 309], ["brain", "ORGAN", 333, 338], ["Light and electron microscopy analysis of the liver and the brain", "TEST", 0, 65], ["any obvious anomalies", "PROBLEM", 81, 102], ["Respiration in Clpp", "TEST", 120, 139], ["mild reduction", "PROBLEM", 158, 172], ["Clpp", "PROBLEM", 213, 217], ["liver", "ANATOMY", 46, 51], ["brain", "ANATOMY", 60, 65], ["anomalies", "OBSERVATION", 93, 102], ["mild", "OBSERVATION_MODIFIER", 158, 162], ["reduction", "OBSERVATION", 163, 172], ["Clpp", "OBSERVATION", 213, 217], ["skeletal", "ANATOMY", 284, 292], ["heart muscle", "ANATOMY", 297, 309], ["brain", "ANATOMY", 333, 338]]], ["At the age of 4 months, the respiratory rates were mostly unchanged.", [["respiratory", "ANATOMY", 28, 39], ["the respiratory rates", "TEST", 24, 45], ["respiratory", "ANATOMY", 28, 39], ["mostly", "OBSERVATION_MODIFIER", 51, 57], ["unchanged", "OBSERVATION", 58, 67]]], ["Only for the complex I-dependent state 3 respiration, a trend for a slight reduction was observed in heart muscle (Supplementary Material, Fig. S4C ).", [["heart muscle", "ANATOMY", 101, 113], ["heart muscle", "TISSUE", 101, 113], ["complex I", "PROTEIN", 13, 22], ["a slight reduction", "PROBLEM", 66, 84], ["slight", "OBSERVATION_MODIFIER", 68, 74], ["reduction", "OBSERVATION", 75, 84], ["heart muscle", "ANATOMY", 101, 113]]], ["To study assembly/stability of Clpp 2/2 OXPHOS complexes and supercomplexes, heart muscle, liver and brain mitochondria were analyzed by blue native electrophoresis.", [["heart muscle", "ANATOMY", 77, 89], ["liver", "ANATOMY", 91, 96], ["brain mitochondria", "ANATOMY", 101, 119], ["Clpp 2/2 OXPHOS", "GENE_OR_GENE_PRODUCT", 31, 46], ["heart muscle", "MULTI-TISSUE_STRUCTURE", 77, 89], ["liver", "ORGAN", 91, 96], ["brain mitochondria", "MULTI-TISSUE_STRUCTURE", 101, 119], ["Clpp", "PROTEIN", 31, 35], ["OXPHOS complexes", "PROTEIN", 40, 56], ["Clpp", "PROBLEM", 31, 35], ["OXPHOS complexes and supercomplexes, heart muscle, liver and brain mitochondria", "PROBLEM", 40, 119], ["blue native electrophoresis", "PROBLEM", 137, 164], ["OXPHOS complexes", "OBSERVATION", 40, 56], ["heart muscle", "ANATOMY", 77, 89], ["liver", "ANATOMY", 91, 96], ["brain mitochondria", "ANATOMY", 101, 119]]], ["Mitochondrial complexes in Clpp 2/2 brain appeared normal (Supplementary Material, Fig. S4D , left lanes), while a decrease in respiratory supercomplexes was observed in the heart and the liver (Supplementary Material, Fig. S4D , central and right lanes).", [["Mitochondrial", "ANATOMY", 0, 13], ["Clpp 2/2 brain", "ANATOMY", 27, 41], ["respiratory", "ANATOMY", 127, 138], ["heart", "ANATOMY", 174, 179], ["liver", "ANATOMY", 188, 193], ["right lanes", "ANATOMY", 242, 253], ["Mitochondrial", "CELLULAR_COMPONENT", 0, 13], ["brain", "ORGAN", 36, 41], ["heart", "ORGAN", 174, 179], ["liver", "ORGAN", 188, 193], ["Mitochondrial complexes", "PROTEIN", 0, 23], ["respiratory supercomplexes", "PROTEIN", 127, 153], ["Mitochondrial complexes", "TEST", 0, 23], ["Clpp", "TEST", 27, 31], ["a decrease in respiratory supercomplexes", "PROBLEM", 113, 153], ["central and right lanes", "TREATMENT", 230, 253], ["complexes", "OBSERVATION", 14, 23], ["Clpp", "OBSERVATION", 27, 31], ["2/2", "ANATOMY_MODIFIER", 32, 35], ["brain", "ANATOMY", 36, 41], ["normal", "OBSERVATION", 51, 57], ["left", "ANATOMY_MODIFIER", 94, 98], ["decrease", "OBSERVATION_MODIFIER", 115, 123], ["respiratory supercomplexes", "OBSERVATION", 127, 153], ["heart", "ANATOMY", 174, 179], ["liver", "ANATOMY", 188, 193], ["right", "ANATOMY_MODIFIER", 242, 247]]], ["Heme stain for complex IV revealed 60% residual monomeric complex IV in mutant liver mitochondria as measured by densitometry (data not shown).", [["liver mitochondria", "ANATOMY", 79, 97], ["Heme stain for complex IV", "GENE_OR_GENE_PRODUCT", 0, 25], ["monomeric complex IV", "GENE_OR_GENE_PRODUCT", 48, 68], ["liver", "ORGAN", 79, 84], ["mitochondria", "ORGANISM_SUBSTANCE", 85, 97], ["complex IV", "PROTEIN", 15, 25], ["monomeric complex IV", "PROTEIN", 48, 68], ["Heme stain", "TEST", 0, 10], ["complex IV", "TEST", 15, 25], ["60% residual monomeric complex IV in mutant liver mitochondria", "PROBLEM", 35, 97], ["liver", "ANATOMY", 79, 84]]], ["These data indicate that Clpp 2/2 mitochondria have only minor respiratory dysfunction in muscle and liver tissue, whereas they are normal in the brain at young adult ages.4874Human Molecular Genetics, 2013, Vol.", [["Clpp 2/2 mitochondria", "ANATOMY", 25, 46], ["respiratory", "ANATOMY", 63, 74], ["muscle", "ANATOMY", 90, 96], ["liver tissue", "ANATOMY", 101, 113], ["brain", "ANATOMY", 146, 151], ["respiratory dysfunction", "DISEASE", 63, 86], ["Clpp 2/2", "GENE_OR_GENE_PRODUCT", 25, 33], ["mitochondria", "CELLULAR_COMPONENT", 34, 46], ["muscle", "ORGAN", 90, 96], ["liver tissue", "TISSUE", 101, 113], ["brain", "ORGAN", 146, 151], ["Human", "ORGANISM", 176, 181], ["Human", "SPECIES", 176, 181], ["These data", "TEST", 0, 10], ["Clpp 2/2 mitochondria", "PROBLEM", 25, 46], ["minor respiratory dysfunction in muscle and liver tissue", "PROBLEM", 57, 113], ["Clpp", "OBSERVATION", 25, 29], ["minor", "OBSERVATION_MODIFIER", 57, 62], ["respiratory dysfunction", "OBSERVATION", 63, 86], ["muscle", "ANATOMY", 90, 96], ["liver", "ANATOMY", 101, 106], ["tissue", "ANATOMY_MODIFIER", 107, 113], ["normal", "OBSERVATION", 132, 138], ["brain", "ANATOMY", 146, 151]]], ["22, No. 24Selective death of spermatids and follicular granulosa cells in Clpp 2/2 miceThe mild changes in bioenergetic parameters were in stark contrast with the substantial retardation of general growth and in particular with the complete infertility of Clpp 2/2 animals.", [["spermatids", "ANATOMY", 29, 39], ["follicular granulosa cells", "ANATOMY", 44, 70], ["infertility", "DISEASE", 241, 252], ["spermatids", "CELL", 29, 39], ["follicular granulosa cells", "CELL", 44, 70], ["Clpp 2/2", "ORGANISM", 74, 82], ["mice", "ORGANISM", 83, 87], ["spermatids", "CELL_TYPE", 29, 39], ["follicular granulosa cells", "CELL_TYPE", 44, 70], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 83, 87], ["spermatids", "PROBLEM", 29, 39], ["follicular granulosa cells", "PROBLEM", 44, 70], ["Clpp", "TEST", 74, 78], ["The mild changes in bioenergetic parameters", "PROBLEM", 87, 130], ["general growth", "PROBLEM", 190, 204], ["follicular granulosa cells", "OBSERVATION", 44, 70], ["mild", "OBSERVATION_MODIFIER", 91, 95], ["changes", "OBSERVATION", 96, 103], ["bioenergetic parameters", "OBSERVATION", 107, 130], ["substantial", "OBSERVATION_MODIFIER", 163, 174], ["retardation", "OBSERVATION", 175, 186], ["growth", "OBSERVATION_MODIFIER", 198, 204], ["Clpp", "OBSERVATION", 256, 260]]], ["Therefore, more detailed analyses focused on testis and ovary tissue.", [["testis", "ANATOMY", 45, 51], ["ovary tissue", "ANATOMY", 56, 68], ["testis", "TISSUE", 45, 51], ["ovary tissue", "TISSUE", 56, 68], ["detailed analyses", "TEST", 16, 33], ["ovary tissue", "PROBLEM", 56, 68], ["testis", "ANATOMY", 45, 51], ["ovary", "ANATOMY", 56, 61]]], ["Light microscopy analysis of hematoxylin and eosin (H and E) stained seminiferous tubules demonstrated a complete absence of spermatids and mature spermatozoa in the testis from both Clpp 2/2 lines, together with spongiform changes of the seminiferous epithelium and a decrease in the number of dividing cells at the age of 6 months (Fig. 3A) .", [["seminiferous tubules", "ANATOMY", 69, 89], ["spermatids", "ANATOMY", 125, 135], ["spermatozoa", "ANATOMY", 147, 158], ["testis", "ANATOMY", 166, 172], ["Clpp 2/2 lines", "ANATOMY", 183, 197], ["seminiferous epithelium", "ANATOMY", 239, 262], ["cells", "ANATOMY", 304, 309], ["hematoxylin", "CHEMICAL", 29, 40], ["eosin", "CHEMICAL", 45, 50], ["hematoxylin", "SIMPLE_CHEMICAL", 29, 40], ["seminiferous tubules", "MULTI-TISSUE_STRUCTURE", 69, 89], ["spermatids", "CELLULAR_COMPONENT", 125, 135], ["spermatozoa", "CELLULAR_COMPONENT", 147, 158], ["testis", "ORGAN", 166, 172], ["Clpp 2/2 lines", "CELL", 183, 197], ["seminiferous epithelium", "TISSUE", 239, 262], ["cells", "CELL", 304, 309], ["mature spermatozoa", "CELL_TYPE", 140, 158], ["Clpp 2/2 lines", "CELL_LINE", 183, 197], ["dividing cells", "CELL_TYPE", 295, 309], ["Light microscopy analysis", "TEST", 0, 25], ["hematoxylin", "TEST", 29, 40], ["eosin (H and E) stained seminiferous tubules", "TEST", 45, 89], ["spermatids", "PROBLEM", 125, 135], ["mature spermatozoa in the testis", "PROBLEM", 140, 172], ["spongiform changes", "PROBLEM", 213, 231], ["the seminiferous epithelium", "PROBLEM", 235, 262], ["mature spermatozoa", "OBSERVATION", 140, 158], ["testis", "ANATOMY", 166, 172], ["both", "OBSERVATION_MODIFIER", 178, 182], ["Clpp", "OBSERVATION_MODIFIER", 183, 187], ["2/2 lines", "OBSERVATION", 188, 197], ["spongiform", "OBSERVATION", 213, 223], ["seminiferous", "ANATOMY_MODIFIER", 239, 251], ["epithelium", "ANATOMY_MODIFIER", 252, 262], ["decrease", "OBSERVATION_MODIFIER", 269, 277], ["number", "OBSERVATION_MODIFIER", 285, 291], ["dividing cells", "OBSERVATION", 295, 309]]], ["Upon electron microscopical analysis, a severe destruction of the cellular organization was evident, and there were no acrosomes and axonemes in Clpp 2/2 testes at age 3 months, while they were readily detectable in WT testes (Fig. 3B ).", [["cellular", "ANATOMY", 66, 74], ["acrosomes", "ANATOMY", 119, 128], ["axonemes", "ANATOMY", 133, 141], ["Clpp 2/2 testes", "ANATOMY", 145, 160], ["testes", "ANATOMY", 219, 225], ["cellular", "CELL", 66, 74], ["axonemes", "CELLULAR_COMPONENT", 133, 141], ["testes", "ORGAN", 154, 160], ["testes", "ORGAN", 219, 225], ["electron microscopical analysis", "TEST", 5, 36], ["a severe destruction of the cellular organization", "PROBLEM", 38, 87], ["acrosomes", "PROBLEM", 119, 128], ["severe", "OBSERVATION_MODIFIER", 40, 46], ["destruction", "OBSERVATION", 47, 58], ["cellular organization", "OBSERVATION", 66, 87], ["no", "UNCERTAINTY", 116, 118], ["acrosomes", "OBSERVATION_MODIFIER", 119, 128], ["testes", "ANATOMY", 219, 225]]], ["However, obvious structural pathology of mitochondria was not observed.", [["mitochondria", "ANATOMY", 41, 53], ["mitochondria", "CELLULAR_COMPONENT", 41, 53], ["obvious structural pathology of mitochondria", "PROBLEM", 9, 53], ["obvious", "OBSERVATION_MODIFIER", 9, 16], ["structural", "OBSERVATION_MODIFIER", 17, 27], ["pathology", "OBSERVATION", 28, 37]]], ["Thus, the absence of CLPP leads to abortion of spermatogenesis at an early stage before spermatid generation.", [["spermatid", "ANATOMY", 88, 97], ["CLPP", "GENE_OR_GENE_PRODUCT", 21, 25], ["spermatid", "CELLULAR_COMPONENT", 88, 97], ["CLPP", "PROTEIN", 21, 25], ["CLPP", "PROBLEM", 21, 25], ["spermatogenesis", "PROBLEM", 47, 62], ["CLPP", "OBSERVATION", 21, 25]]], ["Similarly, in Clpp 2/2 ovaries the follicular granulosa cell layers appeared reduced, with a higher amount of apoptotic bodies in comparison with matched controls (Fig. 3C) .", [["Clpp 2/2 ovaries", "ANATOMY", 14, 30], ["follicular granulosa cell layers", "ANATOMY", 35, 67], ["bodies", "ANATOMY", 120, 126], ["ovaries", "ORGAN", 23, 30], ["follicular granulosa cell layers", "TISSUE", 35, 67], ["Clpp", "TEST", 14, 18], ["the follicular granulosa cell layers", "TEST", 31, 67], ["Clpp", "ANATOMY_MODIFIER", 14, 18], ["2/2", "ANATOMY_MODIFIER", 19, 22], ["ovaries", "ANATOMY", 23, 30], ["follicular granulosa cell layers", "OBSERVATION", 35, 67], ["reduced", "OBSERVATION_MODIFIER", 77, 84], ["higher", "OBSERVATION_MODIFIER", 93, 99], ["amount", "OBSERVATION_MODIFIER", 100, 106], ["apoptotic bodies", "OBSERVATION", 110, 126]]], ["Overall, the size of ovaries and the ratio of corpora lutea versus follicles before rupture were reduced for Clpp 2/2 , suggesting impaired oogenesis and a disrupted ovarian cycle (Fig. 3D ).", [["ovaries", "ANATOMY", 21, 28], ["corpora lutea", "ANATOMY", 46, 59], ["follicles", "ANATOMY", 67, 76], ["ovarian", "ANATOMY", 166, 173], ["rupture", "DISEASE", 84, 91], ["ovaries", "ORGAN", 21, 28], ["corpora lutea", "MULTI-TISSUE_STRUCTURE", 46, 59], ["follicles", "MULTI-TISSUE_STRUCTURE", 67, 76], ["Clpp 2/2", "GENE_OR_GENE_PRODUCT", 109, 117], ["ovarian", "ORGAN", 166, 173], ["Clpp 2/2", "PROTEIN", 109, 117], ["corpora lutea", "PROBLEM", 46, 59], ["rupture", "PROBLEM", 84, 91], ["Clpp", "TEST", 109, 113], ["impaired oogenesis", "PROBLEM", 131, 149], ["a disrupted ovarian cycle", "PROBLEM", 154, 179], ["size", "OBSERVATION_MODIFIER", 13, 17], ["ovaries", "ANATOMY", 21, 28], ["corpora lutea", "ANATOMY", 46, 59], ["suggesting", "UNCERTAINTY", 120, 130], ["impaired oogenesis", "OBSERVATION", 131, 149], ["ovarian", "ANATOMY", 166, 173]]], ["These findings appeared to be a quite faithful model of human ovarian failure due to the recently discovered Clpp missense and splice site mutations (22) and provide mechanistic insights into the pathogenesis of this variant of human Perrault syndrome, where streak ovaries with few scattered follicles had previously been described (49, 50) .", [["ovarian", "ANATOMY", 62, 69], ["streak ovaries", "ANATOMY", 259, 273], ["follicles", "ANATOMY", 293, 302], ["ovarian failure", "DISEASE", 62, 77], ["Perrault syndrome", "DISEASE", 234, 251], ["human", "ORGANISM", 56, 61], ["ovarian", "ORGAN", 62, 69], ["Clpp", "GENE_OR_GENE_PRODUCT", 109, 113], ["human", "ORGANISM", 228, 233], ["streak ovaries", "ORGAN", 259, 273], ["follicles", "MULTI-TISSUE_STRUCTURE", 293, 302], ["Clpp missense", "DNA", 109, 122], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 228, 233], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 228, 233], ["human ovarian failure", "PROBLEM", 56, 77], ["the recently discovered Clpp missense", "PROBLEM", 85, 122], ["splice site mutations", "PROBLEM", 127, 148], ["human Perrault syndrome", "PROBLEM", 228, 251], ["streak ovaries", "PROBLEM", 259, 273], ["few scattered follicles", "PROBLEM", 279, 302], ["human ovarian failure", "OBSERVATION", 56, 77], ["Clpp missense", "OBSERVATION", 109, 122], ["splice site", "OBSERVATION", 127, 138], ["human Perrault syndrome", "OBSERVATION", 228, 251], ["streak", "OBSERVATION_MODIFIER", 259, 265], ["ovaries", "ANATOMY", 266, 273], ["few", "OBSERVATION_MODIFIER", 279, 282], ["scattered", "OBSERVATION_MODIFIER", 283, 292], ["follicles", "OBSERVATION", 293, 302]]], ["Our data suggest a selective vulnerability of spermatid and granulosa cell differentiation to CLPP deficiency.CLPP deficiency triggers ubiquitous induction of mitochondrial chaperones and of inflammatory factorsTo elucidate Clpp 2/2 effects on protein levels and mRNA expression in diverse tissues, other pathway components were studied systematically (Tables 1 and 2, Supplementary Material, Table S2 ).", [["spermatid", "ANATOMY", 46, 55], ["granulosa cell", "ANATOMY", 60, 74], ["mitochondrial", "ANATOMY", 159, 172], ["tissues", "ANATOMY", 290, 297], ["CLPP", "CHEMICAL", 110, 114], ["spermatid", "CELL", 46, 55], ["granulosa cell", "CELL", 60, 74], ["CLPP", "GENE_OR_GENE_PRODUCT", 94, 98], ["CLPP", "GENE_OR_GENE_PRODUCT", 110, 114], ["mitochondrial", "CELLULAR_COMPONENT", 159, 172], ["Clpp 2/2", "GENE_OR_GENE_PRODUCT", 224, 232], ["tissues", "TISSUE", 290, 297], ["CLPP", "PROTEIN", 110, 114], ["mitochondrial chaperones", "PROTEIN", 159, 183], ["inflammatory factors", "PROTEIN", 191, 211], ["Clpp 2/2", "PROTEIN", 224, 232], ["Our data", "TEST", 0, 8], ["spermatid and granulosa cell differentiation", "PROBLEM", 46, 90], ["CLPP deficiency", "PROBLEM", 94, 109], ["CLPP deficiency", "PROBLEM", 110, 125], ["mitochondrial chaperones", "TREATMENT", 159, 183], ["inflammatory factors", "PROBLEM", 191, 211], ["Clpp", "PROBLEM", 224, 228], ["protein levels", "TEST", 244, 258], ["mRNA expression in diverse tissues", "PROBLEM", 263, 297], ["other pathway components", "PROBLEM", 299, 323], ["selective", "OBSERVATION_MODIFIER", 19, 28], ["spermatid", "OBSERVATION", 46, 55], ["granulosa cell differentiation", "OBSERVATION", 60, 90], ["CLPP deficiency", "OBSERVATION", 94, 109], ["deficiency", "OBSERVATION", 115, 125], ["inflammatory", "OBSERVATION_MODIFIER", 191, 203], ["Clpp", "OBSERVATION", 224, 228], ["2/2 effects", "OBSERVATION_MODIFIER", 229, 240], ["diverse tissues", "ANATOMY", 282, 297]]], ["Densitometric analyses of immunoblots revealed Clpp 2/2 to cause ubiquitous accumulation not only of the chaperone CLPX, but also of the other mitochondrial matrix chaperones.", [["mitochondrial matrix", "ANATOMY", 143, 163], ["Clpp 2/2", "GENE_OR_GENE_PRODUCT", 47, 55], ["CLPX", "GENE_OR_GENE_PRODUCT", 115, 119], ["mitochondrial matrix", "CELLULAR_COMPONENT", 143, 163], ["Clpp 2/2", "PROTEIN", 47, 55], ["chaperone CLPX", "PROTEIN", 105, 119], ["mitochondrial matrix chaperones", "PROTEIN", 143, 174], ["Densitometric analyses", "TEST", 0, 22], ["immunoblots", "TEST", 26, 37], ["Clpp", "PROBLEM", 47, 51], ["ubiquitous accumulation", "PROBLEM", 65, 88], ["the chaperone CLPX", "PROBLEM", 101, 119], ["Clpp", "OBSERVATION", 47, 51], ["accumulation", "OBSERVATION", 76, 88], ["CLPX", "OBSERVATION", 115, 119]]], ["These effects reached significance for mtHSP75/HSPA9/mortalin, mtHSP10/HSPE1/chaperonin 10 and mtDNAJ/DNAJA3, but not for mtHSP60/HSPD1/chaperonin 60 (Table 1 ).CLPP deficiency triggers ubiquitous induction of mitochondrial chaperones and of inflammatory factorsIn contrast to the down-regulated Clpx transcript levels, the transcript levels of all other mitochondrial chaperones were increased in the more severely affected tissues testis and heart muscle ( Table 2) .", [["mitochondrial", "ANATOMY", 210, 223], ["mitochondrial", "ANATOMY", 355, 368], ["tissues testis", "ANATOMY", 425, 439], ["heart muscle", "ANATOMY", 444, 456], ["CLPP", "CHEMICAL", 161, 165], ["mtHSP75", "GENE_OR_GENE_PRODUCT", 39, 46], ["HSPA9", "GENE_OR_GENE_PRODUCT", 47, 52], ["mortalin", "GENE_OR_GENE_PRODUCT", 53, 61], ["mtHSP10", "GENE_OR_GENE_PRODUCT", 63, 70], ["HSPE1", "GENE_OR_GENE_PRODUCT", 71, 76], ["chaperonin 10", "GENE_OR_GENE_PRODUCT", 77, 90], ["mtDNAJ", "GENE_OR_GENE_PRODUCT", 95, 101], ["DNAJA3", "GENE_OR_GENE_PRODUCT", 102, 108], ["mtHSP60", "GENE_OR_GENE_PRODUCT", 122, 129], ["HSPD1", "GENE_OR_GENE_PRODUCT", 130, 135], ["chaperonin 60", "GENE_OR_GENE_PRODUCT", 136, 149], ["CLPP", "GENE_OR_GENE_PRODUCT", 161, 165], ["mitochondrial", "CELLULAR_COMPONENT", 210, 223], ["Clpx", "GENE_OR_GENE_PRODUCT", 296, 300], ["mitochondrial", "CELLULAR_COMPONENT", 355, 368], ["tissues testis", "TISSUE", 425, 439], ["heart muscle", "TISSUE", 444, 456], ["mtHSP75", "PROTEIN", 39, 46], ["HSPA9", "PROTEIN", 47, 52], ["mortalin", "PROTEIN", 53, 61], ["mtHSP10", "PROTEIN", 63, 70], ["HSPE1", "PROTEIN", 71, 76], ["chaperonin 10", "PROTEIN", 77, 90], ["mtDNAJ", "PROTEIN", 95, 101], ["DNAJA3", "PROTEIN", 102, 108], ["mtHSP60", "PROTEIN", 122, 129], ["HSPD1", "PROTEIN", 130, 135], ["chaperonin 60", "PROTEIN", 136, 149], ["Table 1", "PROTEIN", 151, 158], ["CLPP", "PROTEIN", 161, 165], ["mitochondrial chaperones", "PROTEIN", 210, 234], ["inflammatory factors", "PROTEIN", 242, 262], ["Clpx", "PROTEIN", 296, 300], ["mitochondrial chaperones", "PROTEIN", 355, 379], ["mtHSP75", "TEST", 39, 46], ["HSPA9", "TEST", 47, 52], ["mortalin", "TREATMENT", 53, 61], ["mtHSP10", "TEST", 63, 70], ["chaperonin", "TREATMENT", 77, 87], ["mtDNAJ/DNAJA3", "TREATMENT", 95, 108], ["CLPP deficiency", "PROBLEM", 161, 176], ["mitochondrial chaperones", "TREATMENT", 210, 234], ["inflammatory factors", "PROBLEM", 242, 262], ["the transcript levels", "TEST", 320, 341], ["all other mitochondrial chaperones", "PROBLEM", 345, 379], ["deficiency", "OBSERVATION", 166, 176], ["inflammatory", "OBSERVATION_MODIFIER", 242, 254], ["mitochondrial chaperones", "OBSERVATION", 355, 379], ["increased", "OBSERVATION_MODIFIER", 385, 394], ["severely", "OBSERVATION_MODIFIER", 407, 415], ["affected", "OBSERVATION", 416, 424], ["tissues testis", "OBSERVATION", 425, 439], ["heart muscle", "ANATOMY", 444, 456]]], ["Additional oligonucleotide-microarray-based profiling of mRNAs encoded by the nuclear genome in these tissues emphasized the severity of the transcriptional dysregulation in the testis (Supplementary Material, Table S2 ).", [["nuclear genome", "ANATOMY", 78, 92], ["tissues", "ANATOMY", 102, 109], ["testis", "ANATOMY", 178, 184], ["nuclear", "CELLULAR_COMPONENT", 78, 85], ["tissues", "TISSUE", 102, 109], ["testis", "ORGAN", 178, 184], ["mRNAs", "RNA", 57, 62], ["nuclear genome", "DNA", 78, 92], ["Additional oligonucleotide", "TEST", 0, 26], ["microarray", "TEST", 27, 37], ["the transcriptional dysregulation in the testis", "PROBLEM", 137, 184], ["nuclear genome", "OBSERVATION", 78, 92], ["transcriptional dysregulation", "OBSERVATION", 141, 170], ["testis", "ANATOMY", 178, 184]]], ["In total, this transcriptome study revealed 4266 down-and 7985 significant up-regulations in testis, in comparison with 340 downand 344 up-regulations in the heart, 418 down-and 310 up-regulations in the liver, 155 down-and 125 up-regulations in the brain at the medium adult age of 9-10 months.", [["testis", "ANATOMY", 93, 99], ["heart", "ANATOMY", 158, 163], ["liver", "ANATOMY", 204, 209], ["brain", "ANATOMY", 250, 255], ["testis", "ORGAN", 93, 99], ["heart", "ORGAN", 158, 163], ["liver", "ORGAN", 204, 209], ["brain", "ORGAN", 250, 255], ["this transcriptome study", "TEST", 10, 34], ["testis", "ANATOMY", 93, 99], ["heart", "ANATOMY", 158, 163], ["liver", "ANATOMY", 204, 209], ["brain", "ANATOMY", 250, 255]]], ["Only very few transcript dys-regulations affected all tissues consistently.", [["tissues", "ANATOMY", 54, 61], ["tissues", "TISSUE", 54, 61], ["very", "OBSERVATION_MODIFIER", 5, 9], ["few", "OBSERVATION_MODIFIER", 10, 13], ["transcript dys-regulations", "OBSERVATION", 14, 40], ["all tissues", "OBSERVATION_MODIFIER", 50, 61]]], ["Ubiquitous transcript inductions were observed for the protease Mmp14, for the antioxidants glutathione S-transferase alpha enzymes Gsta1/Gsta2 and for the iron-binding transcriptional coregulator Pir (Supplementary Material, Table S2 ).", [["glutathione", "CHEMICAL", 92, 103], ["glutathione", "CHEMICAL", 92, 103], ["S", "CHEMICAL", 104, 105], ["Mmp14", "GENE_OR_GENE_PRODUCT", 64, 69], ["glutathione S-transferase alpha", "GENE_OR_GENE_PRODUCT", 92, 123], ["Gsta1", "GENE_OR_GENE_PRODUCT", 132, 137], ["Gsta2", "GENE_OR_GENE_PRODUCT", 138, 143], ["protease Mmp14", "PROTEIN", 55, 69], ["antioxidants glutathione S-transferase alpha enzymes", "PROTEIN", 79, 131], ["Gsta1", "PROTEIN", 132, 137], ["Gsta2", "PROTEIN", 138, 143], ["iron-binding transcriptional coregulator", "PROTEIN", 156, 196], ["Pir", "PROTEIN", 197, 200], ["Supplementary Material, Table S2", "PROTEIN", 202, 234], ["Ubiquitous transcript inductions", "TREATMENT", 0, 32], ["the protease Mmp14", "TREATMENT", 51, 69], ["the antioxidants glutathione S", "TEST", 75, 105], ["alpha enzymes", "TEST", 118, 131], ["Gsta1/Gsta2", "TREATMENT", 132, 143], ["the iron-binding transcriptional coregulator Pir", "TREATMENT", 152, 200]]], ["Specifically in the testis, a high proportion of subunits of the extra-mitochondrial proteasome and of the ubiquitin-mediated proteolysis pathways showed dys-regulation (Supplementary Material, Fig. S5 ), providing evidence that nuclear-encoded factors of the cytosolic protein degradation machinery change their expression levels in response to the impaired mitochondrial degradation.", [["testis", "ANATOMY", 20, 26], ["nuclear", "ANATOMY", 229, 236], ["cytosolic", "ANATOMY", 260, 269], ["mitochondrial", "ANATOMY", 359, 372], ["testis", "ORGAN", 20, 26], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 107, 116], ["nuclear", "CELLULAR_COMPONENT", 229, 236], ["mitochondrial", "CELLULAR_COMPONENT", 359, 372], ["extra-mitochondrial proteasome", "PROTEIN", 65, 95], ["ubiquitin", "PROTEIN", 107, 116], ["nuclear-encoded factors", "PROTEIN", 229, 252], ["cytosolic protein", "PROTEIN", 260, 277], ["the extra-mitochondrial proteasome", "TREATMENT", 61, 95], ["dys-regulation", "PROBLEM", 154, 168], ["the cytosolic protein degradation machinery", "PROBLEM", 256, 299], ["the impaired mitochondrial degradation", "PROBLEM", 346, 384], ["testis", "ANATOMY", 20, 26], ["high", "OBSERVATION_MODIFIER", 30, 34], ["impaired", "OBSERVATION_MODIFIER", 350, 358], ["mitochondrial degradation", "OBSERVATION", 359, 384]]], ["Interestingly, several subunits of the immunoproteasome were induced there (Supplementary Material, Fig. S5 ).", [["immunoproteasome", "GENE_OR_GENE_PRODUCT", 39, 55], ["S5", "GENE_OR_GENE_PRODUCT", 105, 107], ["immunoproteasome", "PROTEIN", 39, 55], ["S5", "PROTEIN", 105, 107], ["the immunoproteasome", "TREATMENT", 35, 55]]], ["These testis expression data jointly suggest that the degradation pathology in the mitochondrial matrix is perceived by the eukaryotic cell, which triggers compensatory degradation efforts with induction of cytosolic proteases/proteasome subunits.CLPP deficiency triggers ubiquitous induction of mitochondrial chaperones and of inflammatory factorsSurprisingly, all other ubiquitous up-regulations concerned 20 oligonucleotide spots that represent transcripts of wellestablished or putative inflammatory and infection defense factors, namely Gbp3, Gbp6/Mpa2l, H2-Q6, Ifi27l1, Igtp, Irgm2, Lgals3bp, Oasl2, Rnf213, Rsad2, Rtp4, Stat1, Tgtp1/ Tgtp2, Trim30, Usp18 and Xaf1 (Supplementary Material, Table S2 ) (KEGG pathway alteration illustrated in Supplementary Material, Fig. S6 ).", [["testis", "ANATOMY", 6, 12], ["mitochondrial matrix", "ANATOMY", 83, 103], ["cell", "ANATOMY", 135, 139], ["cytosolic", "ANATOMY", 207, 216], ["mitochondrial", "ANATOMY", 296, 309], ["CLPP", "CHEMICAL", 247, 251], ["infection", "DISEASE", 508, 517], ["testis", "ORGAN", 6, 12], ["mitochondrial matrix", "CELLULAR_COMPONENT", 83, 103], ["cell", "CELL", 135, 139], ["cytosolic proteases/proteasome subunits", "GENE_OR_GENE_PRODUCT", 207, 246], ["CLPP", "GENE_OR_GENE_PRODUCT", 247, 251], ["mitochondrial", "CELLULAR_COMPONENT", 296, 309], ["Gbp3", "GENE_OR_GENE_PRODUCT", 542, 546], ["Gbp6", "GENE_OR_GENE_PRODUCT", 548, 552], ["Mpa2l", "GENE_OR_GENE_PRODUCT", 553, 558], ["H2-Q6", "GENE_OR_GENE_PRODUCT", 560, 565], ["Ifi27l1", "GENE_OR_GENE_PRODUCT", 567, 574], ["Igtp", "GENE_OR_GENE_PRODUCT", 576, 580], ["Irgm2", "GENE_OR_GENE_PRODUCT", 582, 587], ["Lgals3", "GENE_OR_GENE_PRODUCT", 589, 595], ["Oasl2", "GENE_OR_GENE_PRODUCT", 599, 604], ["Rnf213", "GENE_OR_GENE_PRODUCT", 606, 612], ["Rsad2", "GENE_OR_GENE_PRODUCT", 614, 619], ["Rtp4", "GENE_OR_GENE_PRODUCT", 621, 625], ["Stat1", "GENE_OR_GENE_PRODUCT", 627, 632], ["Tgtp1", "GENE_OR_GENE_PRODUCT", 634, 639], ["Tgtp2", "GENE_OR_GENE_PRODUCT", 641, 646], ["Trim30", "GENE_OR_GENE_PRODUCT", 648, 654], ["Usp18", "GENE_OR_GENE_PRODUCT", 656, 661], ["Xaf1", "GENE_OR_GENE_PRODUCT", 666, 670], ["S6", "GENE_OR_GENE_PRODUCT", 776, 778], ["eukaryotic cell", "CELL_TYPE", 124, 139], ["cytosolic proteases", "PROTEIN", 207, 226], ["proteasome subunits", "PROTEIN", 227, 246], ["CLPP", "PROTEIN", 247, 251], ["mitochondrial chaperones", "PROTEIN", 296, 320], ["inflammatory factors", "PROTEIN", 328, 348], ["inflammatory and infection defense factors", "PROTEIN", 491, 533], ["Gbp3", "PROTEIN", 542, 546], ["Gbp6", "PROTEIN", 548, 552], ["Mpa2l", "PROTEIN", 553, 558], ["H2", "PROTEIN", 560, 562], ["Q6", "PROTEIN", 563, 565], ["Ifi27l1", "PROTEIN", 567, 574], ["Igtp", "PROTEIN", 576, 580], ["Irgm2", "PROTEIN", 582, 587], ["Lgals3", "PROTEIN", 589, 595], ["Oasl2", "PROTEIN", 599, 604], ["Rnf213", "PROTEIN", 606, 612], ["Rsad2", "PROTEIN", 614, 619], ["Rtp4", "PROTEIN", 621, 625], ["Stat1", "PROTEIN", 627, 632], ["Tgtp1", "PROTEIN", 634, 639], ["Tgtp2", "PROTEIN", 641, 646], ["Trim30", "PROTEIN", 648, 654], ["Usp18", "PROTEIN", 656, 661], ["Xaf1", "PROTEIN", 666, 670], ["Supplementary Material, Table S2", "PROTEIN", 672, 704], ["S6", "PROTEIN", 776, 778], ["the degradation pathology in the mitochondrial matrix", "PROBLEM", 50, 103], ["compensatory degradation efforts", "PROBLEM", 156, 188], ["cytosolic proteases/proteasome subunits", "TREATMENT", 207, 246], ["CLPP deficiency", "PROBLEM", 247, 262], ["mitochondrial chaperones", "TREATMENT", 296, 320], ["inflammatory factors", "PROBLEM", 328, 348], ["20 oligonucleotide spots", "PROBLEM", 408, 432], ["putative inflammatory and infection defense factors", "PROBLEM", 482, 533], ["Gbp3", "TEST", 542, 546], ["Gbp6", "TEST", 548, 552], ["Mpa2l", "TEST", 553, 558], ["H2", "TEST", 560, 562], ["Ifi27l1", "TEST", 567, 574], ["Igtp", "TEST", 576, 580], ["Irgm2", "TEST", 582, 587], ["Lgals3", "TEST", 589, 595], ["bp", "TEST", 595, 597], ["Oasl2", "TEST", 599, 604], ["Rnf", "TEST", 606, 609], ["Rsad2", "TEST", 614, 619], ["Rtp4", "TEST", 621, 625], ["Stat1", "TEST", 627, 632], ["Tgtp1", "TEST", 634, 639], ["Tgtp2", "TEST", 641, 646], ["Trim30", "TEST", 648, 654], ["Xaf1", "TEST", 666, 670], ["mitochondrial matrix", "OBSERVATION", 83, 103], ["eukaryotic cell", "OBSERVATION", 124, 139], ["deficiency", "OBSERVATION", 252, 262], ["inflammatory", "OBSERVATION_MODIFIER", 328, 340], ["inflammatory", "OBSERVATION_MODIFIER", 491, 503], ["infection", "OBSERVATION", 508, 517]]], ["These findings indicate that the absence of CLPP in the mitochondrial matrix causes a strong nuclear response in all tissues, activating well-known mediators of inflammation and immunity.CLPP deficiency triggers ubiquitous induction of mitochondrial chaperones and of inflammatory factorsT-lymphocytes in the spleen of Clpp 2/2 mice are activatedCLPP deficiency triggers ubiquitous induction of mitochondrial chaperones and of inflammatory factorsTo document the immunity phenotype of Clpp 2/2 mice further, lymphocytes in the spleen were analyzed by multi-color (Fig. 4B, columns 1, 2, 3, 4, 9) expressing cells, but no differences in the frequencies of CD62L expressing cells (data not shown).", [["mitochondrial matrix", "ANATOMY", 56, 76], ["nuclear", "ANATOMY", 93, 100], ["tissues", "ANATOMY", 117, 124], ["mitochondrial", "ANATOMY", 236, 249], ["inflammatory factorsT-lymphocytes", "ANATOMY", 268, 301], ["spleen", "ANATOMY", 309, 315], ["mitochondrial", "ANATOMY", 395, 408], ["lymphocytes", "ANATOMY", 508, 519], ["spleen", "ANATOMY", 527, 533], ["cells", "ANATOMY", 607, 612], ["cells", "ANATOMY", 672, 677], ["inflammation", "DISEASE", 161, 173], ["CLPP", "CHEMICAL", 187, 191], ["CLPP", "GENE_OR_GENE_PRODUCT", 44, 48], ["mitochondrial matrix", "CELLULAR_COMPONENT", 56, 76], ["nuclear", "CELLULAR_COMPONENT", 93, 100], ["tissues", "TISSUE", 117, 124], ["CLPP", "GENE_OR_GENE_PRODUCT", 187, 191], ["mitochondrial", "CELLULAR_COMPONENT", 236, 249], ["factorsT", "GENE_OR_GENE_PRODUCT", 281, 289], ["spleen", "ORGAN", 309, 315], ["Clpp 2/2 mice", "ORGANISM", 319, 332], ["activatedCLPP", "GENE_OR_GENE_PRODUCT", 337, 350], ["mitochondrial", "CELLULAR_COMPONENT", 395, 408], ["Clpp 2/2 mice", "ORGANISM", 485, 498], ["lymphocytes", "CELL", 508, 519], ["spleen", "ORGAN", 527, 533], ["cells", "CELL", 607, 612], ["CD62L", "GENE_OR_GENE_PRODUCT", 655, 660], ["cells", "CELL", 672, 677], ["CLPP", "PROTEIN", 44, 48], ["CLPP", "PROTEIN", 187, 191], ["mitochondrial chaperones", "PROTEIN", 236, 260], ["inflammatory factorsT-lymphocytes", "CELL_TYPE", 268, 301], ["mitochondrial chaperones", "PROTEIN", 395, 419], ["inflammatory factors", "PROTEIN", 427, 447], ["lymphocytes", "CELL_TYPE", 508, 519], ["expressing cells", "CELL_TYPE", 596, 612], ["CD62L expressing cells", "CELL_TYPE", 655, 677], ["mice", "SPECIES", 328, 332], ["mice", "SPECIES", 494, 498], ["mice", "SPECIES", 328, 332], ["mice", "SPECIES", 494, 498], ["CLPP in the mitochondrial matrix", "PROBLEM", 44, 76], ["inflammation", "PROBLEM", 161, 173], ["CLPP deficiency", "PROBLEM", 187, 202], ["mitochondrial chaperones", "TREATMENT", 236, 260], ["inflammatory factorsT", "PROBLEM", 268, 289], ["lymphocytes", "PROBLEM", 290, 301], ["Clpp", "PROBLEM", 319, 323], ["activatedCLPP deficiency", "PROBLEM", 337, 361], ["mitochondrial chaperones", "TREATMENT", 395, 419], ["inflammatory factors", "PROBLEM", 427, 447], ["Clpp", "TEST", 485, 489], ["lymphocytes in the spleen", "PROBLEM", 508, 533], ["multi-color", "TEST", 551, 562], ["columns", "TEST", 573, 580], ["expressing cells", "PROBLEM", 596, 612], ["CLPP", "OBSERVATION", 44, 48], ["mitochondrial matrix", "ANATOMY", 56, 76], ["strong", "OBSERVATION_MODIFIER", 86, 92], ["nuclear response", "OBSERVATION", 93, 109], ["all tissues", "ANATOMY", 113, 124], ["inflammation", "OBSERVATION", 161, 173], ["deficiency", "OBSERVATION", 192, 202], ["inflammatory", "OBSERVATION_MODIFIER", 268, 280], ["lymphocytes", "OBSERVATION", 290, 301], ["spleen", "ANATOMY", 309, 315], ["activatedCLPP deficiency", "OBSERVATION", 337, 361], ["inflammatory", "OBSERVATION_MODIFIER", 427, 439], ["spleen", "ANATOMY", 527, 533], ["no", "UNCERTAINTY", 618, 620]]], ["Similar analyses for B cell subsets revealed no significant changes concerning the expression pattern of IgD/IgM/CD24 and MHC class II (data not shown).", [["B cell", "ANATOMY", 21, 27], ["B cell", "CELL", 21, 27], ["IgD", "GENE_OR_GENE_PRODUCT", 105, 108], ["IgM", "GENE_OR_GENE_PRODUCT", 109, 112], ["CD24", "GENE_OR_GENE_PRODUCT", 113, 117], ["MHC class II", "GENE_OR_GENE_PRODUCT", 122, 134], ["B cell subsets", "CELL_TYPE", 21, 35], ["IgD", "PROTEIN", 105, 108], ["IgM", "PROTEIN", 109, 112], ["CD24", "PROTEIN", 113, 117], ["MHC class II", "PROTEIN", 122, 134], ["Similar analyses", "TEST", 0, 16], ["B cell subsets", "TEST", 21, 35], ["significant changes", "PROBLEM", 48, 67], ["IgD", "TEST", 105, 108], ["IgM", "TEST", 109, 112], ["CD24", "PROBLEM", 113, 117], ["no", "UNCERTAINTY", 45, 47], ["significant", "OBSERVATION_MODIFIER", 48, 59]]], ["A parallel analysis of these biomarkers in a similarly aged mouse mutant with deficiency in the mitochondrial kinase PINK1 versus matched controls (51) revealed no significant changes of splenocyte subsets (data not shown).", [["mitochondrial", "ANATOMY", 96, 109], ["splenocyte", "ANATOMY", 187, 197], ["mouse", "ORGANISM", 60, 65], ["mitochondrial", "CELLULAR_COMPONENT", 96, 109], ["PINK1", "GENE_OR_GENE_PRODUCT", 117, 122], ["splenocyte", "CELL", 187, 197], ["mitochondrial kinase", "PROTEIN", 96, 116], ["PINK1", "PROTEIN", 117, 122], ["splenocyte subsets", "CELL_TYPE", 187, 205], ["mouse", "SPECIES", 60, 65], ["mouse", "SPECIES", 60, 65], ["A parallel analysis", "TEST", 0, 19], ["these biomarkers", "TEST", 23, 39], ["deficiency", "PROBLEM", 78, 88], ["the mitochondrial kinase PINK1", "TEST", 92, 122], ["significant changes of splenocyte subsets", "PROBLEM", 164, 205], ["mitochondrial kinase", "ANATOMY", 96, 116], ["no", "UNCERTAINTY", 161, 163], ["significant", "OBSERVATION_MODIFIER", 164, 175], ["splenocyte subsets", "OBSERVATION", 187, 205]]], ["This supports the assertion that CLPP deficiency is special among mitochondrial dysfunctions by triggering a strong activation of T-cells and adaptive immunity.CLPP deficiency triggers ubiquitous induction of mitochondrial chaperones and of inflammatory factorsCLPP deficiency leads to ubiquitous accumulation of mtDNA A known link between mitochondria and immunity exists: The innate immunity of eukaryotic cells is triggered by exposure to proteins with formyl modifications or to DNA with hypomethylated CpG groups that are typical for bacteria or mitochondria (52) (53) (54) (55) .", [["mitochondrial", "ANATOMY", 66, 79], ["T-cells", "ANATOMY", 130, 137], ["mitochondrial", "ANATOMY", 209, 222], ["mitochondria", "ANATOMY", 340, 352], ["cells", "ANATOMY", 408, 413], ["mitochondria", "ANATOMY", 551, 563], ["CLPP", "CHEMICAL", 33, 37], ["mitochondrial dysfunctions", "DISEASE", 66, 92], ["CLPP", "CHEMICAL", 160, 164], ["formyl", "CHEMICAL", 456, 462], ["CpG", "CHEMICAL", 507, 510], ["CLPP", "GENE_OR_GENE_PRODUCT", 33, 37], ["mitochondrial", "CELLULAR_COMPONENT", 66, 79], ["T-cells", "CELL", 130, 137], ["CLPP", "GENE_OR_GENE_PRODUCT", 160, 164], ["mitochondrial", "CELLULAR_COMPONENT", 209, 222], ["factorsCLPP", "GENE_OR_GENE_PRODUCT", 254, 265], ["mtDNA", "CELLULAR_COMPONENT", 313, 318], ["mitochondria", "CELLULAR_COMPONENT", 340, 352], ["eukaryotic cells", "CELL", 397, 413], ["DNA", "CELLULAR_COMPONENT", 483, 486], ["mitochondria", "CELLULAR_COMPONENT", 551, 563], ["T-cells", "CELL_TYPE", 130, 137], ["CLPP", "PROTEIN", 160, 164], ["mitochondrial chaperones", "PROTEIN", 209, 233], ["inflammatory factorsCLPP", "PROTEIN", 241, 265], ["eukaryotic cells", "CELL_TYPE", 397, 413], ["CLPP deficiency", "PROBLEM", 33, 48], ["special among mitochondrial dysfunctions", "PROBLEM", 52, 92], ["CLPP deficiency", "PROBLEM", 160, 175], ["mitochondrial chaperones", "TREATMENT", 209, 233], ["inflammatory factorsCLPP deficiency", "PROBLEM", 241, 276], ["ubiquitous accumulation of mtDNA", "PROBLEM", 286, 318], ["eukaryotic cells", "PROBLEM", 397, 413], ["formyl modifications", "TREATMENT", 456, 476], ["DNA with hypomethylated CpG groups", "TREATMENT", 483, 517], ["bacteria", "PROBLEM", 539, 547], ["mitochondria", "TEST", 551, 563], ["CLPP deficiency", "OBSERVATION", 33, 48], ["deficiency", "OBSERVATION", 165, 175], ["inflammatory", "OBSERVATION_MODIFIER", 241, 253], ["factorsCLPP deficiency", "OBSERVATION", 254, 276], ["eukaryotic cells", "OBSERVATION", 397, 413]]], ["Furthermore, the accumulation of CLPX levels in Clpp 2/2 tissues is also linked to mtDNA, since CLPX was recently shown to control the condensation and maintenance of mtDNA (56) .", [["Clpp 2/2 tissues", "ANATOMY", 48, 64], ["CLPX", "GENE_OR_GENE_PRODUCT", 33, 37], ["Clpp 2/2 tissues", "TISSUE", 48, 64], ["mtDNA", "CELLULAR_COMPONENT", 83, 88], ["CLPX", "GENE_OR_GENE_PRODUCT", 96, 100], ["mtDNA", "CELLULAR_COMPONENT", 167, 172], ["CLPX", "PROTEIN", 33, 37], ["CLPX", "PROTEIN", 96, 100], ["CLPX levels", "TEST", 33, 44], ["CLPX", "PROBLEM", 96, 100], ["accumulation", "OBSERVATION_MODIFIER", 17, 29], ["CLPX levels", "OBSERVATION", 33, 44], ["Clpp", "OBSERVATION_MODIFIER", 48, 52], ["2/2 tissues", "OBSERVATION", 53, 64]]], ["In this context, it was remarkable that our systematic expression analyses had uncovered a ubiquitous significant up-regulation of the transcript levels for the mitochondrially encoded Cox1, but not for other nuclear encoded subunits of the respiratory chain (Table 1 , Supplementary Material, Table S2 ).", [["nuclear", "ANATOMY", 209, 216], ["mitochondrially", "CELLULAR_COMPONENT", 161, 176], ["Cox1", "GENE_OR_GENE_PRODUCT", 185, 189], ["Cox1", "PROTEIN", 185, 189], ["nuclear encoded subunits", "PROTEIN", 209, 233], ["respiratory chain", "PROTEIN", 241, 258], ["Table 1 , Supplementary Material, Table S2", "PROTEIN", 260, 302], ["our systematic expression analyses", "TEST", 40, 74], ["the transcript levels", "TEST", 131, 152], ["respiratory chain", "ANATOMY", 241, 258]]], ["To test the hypothesis that abnormal amounts of mtDNA underlie the elevation of Cox1 transcripts, we quantified the DNA levels of another mitochondrially encoded complex IV subunit, Cox3, in comparison with the DNA levels of the nuclear encoded complex I subunit Ndufv1.", [["nuclear", "ANATOMY", 229, 236], ["mtDNA", "CELLULAR_COMPONENT", 48, 53], ["Cox1", "GENE_OR_GENE_PRODUCT", 80, 84], ["DNA", "CELLULAR_COMPONENT", 116, 119], ["mitochondrially encoded complex IV subunit", "GENE_OR_GENE_PRODUCT", 138, 180], ["Cox3", "GENE_OR_GENE_PRODUCT", 182, 186], ["DNA", "CELLULAR_COMPONENT", 211, 214], ["nuclear", "CELLULAR_COMPONENT", 229, 236], ["Ndufv1", "GENE_OR_GENE_PRODUCT", 263, 269], ["Cox1 transcripts", "RNA", 80, 96], ["mitochondrially encoded complex IV subunit", "PROTEIN", 138, 180], ["Cox3", "PROTEIN", 182, 186], ["nuclear encoded complex I subunit", "PROTEIN", 229, 262], ["Ndufv1", "PROTEIN", 263, 269], ["abnormal amounts of mtDNA", "PROBLEM", 28, 53], ["the elevation of Cox1 transcripts", "PROBLEM", 63, 96], ["the DNA levels", "TEST", 112, 126], ["the DNA levels", "TEST", 207, 221], ["elevation", "OBSERVATION_MODIFIER", 67, 76], ["Cox1 transcripts", "OBSERVATION", 80, 96]]], ["The quantitative real -time PCR (qPCR) results demonstrated several-fold accumulation of mtDNA in Clpp 2/2 compared to Clpp +/+ tissues, with high significance for the testis, ovary, heart and brain (Fig. 5) , and in excellent agreement with the fold-changes of Cox1 transcript levels in these Clpp 2/2 tissues (Table 2) .", [["Clpp 2/2", "ANATOMY", 98, 106], ["Clpp +/+ tissues", "ANATOMY", 119, 135], ["testis", "ANATOMY", 168, 174], ["ovary", "ANATOMY", 176, 181], ["heart", "ANATOMY", 183, 188], ["brain", "ANATOMY", 193, 198], ["Clpp 2/2 tissues", "ANATOMY", 294, 310], ["mtDNA", "CELLULAR_COMPONENT", 89, 94], ["Clpp 2/2", "GENE_OR_GENE_PRODUCT", 98, 106], ["Clpp", "GENE_OR_GENE_PRODUCT", 119, 123], ["testis", "ORGAN", 168, 174], ["ovary", "ORGAN", 176, 181], ["heart", "ORGAN", 183, 188], ["brain", "ORGAN", 193, 198], ["Cox1", "GENE_OR_GENE_PRODUCT", 262, 266], ["Clpp 2/2 tissues", "TISSUE", 294, 310], ["Clpp", "PROTEIN", 119, 123], ["Cox1 transcript", "RNA", 262, 277], ["The quantitative real -time PCR", "TEST", 0, 31], ["several-fold accumulation of mtDNA", "PROBLEM", 60, 94], ["Clpp", "TEST", 98, 102], ["Clpp", "TEST", 119, 123], ["Cox1 transcript levels", "TEST", 262, 284], ["several", "OBSERVATION_MODIFIER", 60, 67], ["-fold", "OBSERVATION_MODIFIER", 67, 72], ["accumulation of mtDNA", "OBSERVATION", 73, 94], ["+ tissues", "ANATOMY", 126, 135], ["testis", "ANATOMY", 168, 174], ["ovary", "ANATOMY", 176, 181], ["heart", "ANATOMY", 183, 188], ["brain", "ANATOMY", 193, 198]]], ["Thus, the absence of CLPP affects not only the degradation of proteins, but also the maintenance of mtDNA in the mitochondrial matrix in different tissues, with effects on transcript levels of mitochondrially encoded genes.DISCUSSIONMitochondria are bacterial endosymbionts that are tolerated in eukaryotic cells since they serve different functions.", [["mitochondrial matrix", "ANATOMY", 113, 133], ["tissues", "ANATOMY", 147, 154], ["cells", "ANATOMY", 307, 312], ["CLPP", "GENE_OR_GENE_PRODUCT", 21, 25], ["mtDNA", "CELLULAR_COMPONENT", 100, 105], ["mitochondrial matrix", "CELLULAR_COMPONENT", 113, 133], ["tissues", "TISSUE", 147, 154], ["cells", "CELL", 307, 312], ["CLPP", "PROTEIN", 21, 25], ["mitochondrially encoded genes", "DNA", 193, 222], ["eukaryotic cells", "CELL_TYPE", 296, 312], ["CLPP", "PROBLEM", 21, 25], ["the degradation of proteins", "PROBLEM", 43, 70], ["mtDNA in the mitochondrial matrix", "TREATMENT", 100, 133], ["transcript levels", "TEST", 172, 189], ["DISCUSSIONMitochondria", "TREATMENT", 223, 245], ["bacterial endosymbionts", "PROBLEM", 250, 273], ["eukaryotic cells", "TREATMENT", 296, 312], ["CLPP", "OBSERVATION", 21, 25], ["mtDNA", "OBSERVATION", 100, 105], ["mitochondrial matrix", "OBSERVATION", 113, 133], ["different tissues", "ANATOMY", 137, 154], ["bacterial endosymbionts", "OBSERVATION", 250, 273]]], ["However, impairment of mitochondrial functions contributes to aging and disease in mammalian organism (57, 58) .", [["mitochondrial", "ANATOMY", 23, 36], ["mitochondrial", "CELLULAR_COMPONENT", 23, 36], ["impairment of mitochondrial functions", "PROBLEM", 9, 46], ["disease in mammalian organism", "PROBLEM", 72, 101], ["mitochondrial functions", "OBSERVATION", 23, 46]]], ["A network of pathways keeps mitochondria functional over time and regulates their mass and dynamics (35) (36) (37) .", [["mitochondria", "ANATOMY", 28, 40], ["mitochondria", "CELLULAR_COMPONENT", 28, 40], ["mass", "OBSERVATION", 82, 86]]], ["Part of this network is the quality control of proteins by different mitochondrial proteases and chaperones, and the control of mtDNA.", [["mitochondrial", "ANATOMY", 69, 82], ["mitochondrial", "CELLULAR_COMPONENT", 69, 82], ["mtDNA", "CELLULAR_COMPONENT", 128, 133], ["mitochondrial proteases", "PROTEIN", 69, 92], ["chaperones", "PROTEIN", 97, 107], ["different mitochondrial proteases", "TREATMENT", 59, 92], ["chaperones", "TREATMENT", 97, 107]]], ["In the current study, we investigated the role of the macromolecular CLPXP protease complex located in the mitochondrial matrix by assessing two mouse lines with the deletion of Clpp.DISCUSSIONThe classical consequences of mitochondrial dysfunction such as apoptosis, respiratory failure combined with oxidative stress, impaired fusion/fission dynamics were not evident in most tissues.", [["mitochondrial matrix", "ANATOMY", 107, 127], ["mitochondrial", "ANATOMY", 223, 236], ["respiratory", "ANATOMY", 268, 279], ["tissues", "ANATOMY", 378, 385], ["mitochondrial dysfunction", "DISEASE", 223, 248], ["respiratory failure", "DISEASE", 268, 287], ["CLPXP protease", "GENE_OR_GENE_PRODUCT", 69, 83], ["mitochondrial matrix", "CELLULAR_COMPONENT", 107, 127], ["mouse", "ORGANISM", 145, 150], ["mitochondrial", "CELLULAR_COMPONENT", 223, 236], ["tissues", "TISSUE", 378, 385], ["macromolecular CLPXP protease complex", "PROTEIN", 54, 91], ["mouse lines", "CELL_LINE", 145, 156], ["mouse", "SPECIES", 145, 150], ["mouse", "SPECIES", 145, 150], ["the current study", "TEST", 3, 20], ["the macromolecular CLPXP protease complex", "TREATMENT", 50, 91], ["two mouse lines", "TREATMENT", 141, 156], ["mitochondrial dysfunction", "PROBLEM", 223, 248], ["apoptosis", "PROBLEM", 257, 266], ["respiratory failure", "PROBLEM", 268, 287], ["oxidative stress", "PROBLEM", 302, 318], ["impaired fusion/fission dynamics", "PROBLEM", 320, 352], ["mitochondrial matrix", "ANATOMY", 107, 127], ["mouse lines", "OBSERVATION", 145, 156], ["mitochondrial dysfunction", "OBSERVATION", 223, 248], ["respiratory failure", "OBSERVATION", 268, 287], ["impaired", "OBSERVATION_MODIFIER", 320, 328], ["fusion", "OBSERVATION", 329, 335], ["most tissues", "OBSERVATION_MODIFIER", 373, 385]]], ["However, strong and specific phenotypes were observed in CLPP null mice and can be linked credibly to mitochondrial pathology.", [["mitochondrial", "ANATOMY", 102, 115], ["CLPP", "GENE_OR_GENE_PRODUCT", 57, 61], ["mice", "ORGANISM", 67, 71], ["mitochondrial", "CELLULAR_COMPONENT", 102, 115], ["mice", "SPECIES", 67, 71], ["mice", "SPECIES", 67, 71], ["mitochondrial pathology", "PROBLEM", 102, 125], ["strong", "OBSERVATION_MODIFIER", 9, 15]]], ["The organism as a whole was found to have severe growth retardation, diminished spontaneous motor activity, a strong decrease in survival and a marginal respiratory deficit in several tissues.", [["respiratory", "ANATOMY", 153, 164], ["tissues", "ANATOMY", 184, 191], ["growth retardation", "DISEASE", 49, 67], ["respiratory deficit", "DISEASE", 153, 172], ["tissues", "TISSUE", 184, 191], ["severe growth retardation", "PROBLEM", 42, 67], ["diminished spontaneous motor activity", "PROBLEM", 69, 106], ["a strong decrease in survival", "PROBLEM", 108, 137], ["a marginal respiratory deficit in several tissues", "PROBLEM", 142, 191], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["growth", "OBSERVATION_MODIFIER", 49, 55], ["retardation", "OBSERVATION", 56, 67], ["diminished", "OBSERVATION_MODIFIER", 69, 79], ["spontaneous", "OBSERVATION_MODIFIER", 80, 91], ["motor activity", "OBSERVATION", 92, 106], ["strong", "OBSERVATION_MODIFIER", 110, 116], ["decrease", "OBSERVATION_MODIFIER", 117, 125], ["marginal", "OBSERVATION_MODIFIER", 144, 152], ["respiratory deficit", "OBSERVATION", 153, 172], ["several tissues", "OBSERVATION_MODIFIER", 176, 191]]], ["Similarly, mouse mutants of several other mitochondrial factors have manifested phenotypes of growth retardation and reduced survival, in particular due to light respiratory impairment, oxidative stress and mtDNA damage (59) (60) (61) (62) (63) (64) (65) (66) (67) (68) (69) (70) (71) (72) (73) (74) (75) .", [["mitochondrial", "ANATOMY", 42, 55], ["respiratory", "ANATOMY", 162, 173], ["growth retardation", "DISEASE", 94, 112], ["respiratory impairment", "DISEASE", 162, 184], ["mouse", "ORGANISM", 11, 16], ["mitochondrial", "CELLULAR_COMPONENT", 42, 55], ["mtDNA", "CELLULAR_COMPONENT", 207, 212], ["mitochondrial factors", "PROTEIN", 42, 63], ["mouse", "SPECIES", 11, 16], ["mouse", "SPECIES", 11, 16], ["several other mitochondrial factors", "PROBLEM", 28, 63], ["growth retardation", "PROBLEM", 94, 112], ["reduced survival", "PROBLEM", 117, 133], ["light respiratory impairment", "PROBLEM", 156, 184], ["oxidative stress", "PROBLEM", 186, 202], ["mtDNA damage", "TEST", 207, 219], ["growth retardation", "OBSERVATION", 94, 112]]], ["Prominently, Clpp deletion caused selective profound vulnerability of specific cells in testes and ovaries.", [["cells", "ANATOMY", 79, 84], ["testes", "ANATOMY", 88, 94], ["ovaries", "ANATOMY", 99, 106], ["Clpp", "GENE_OR_GENE_PRODUCT", 13, 17], ["cells", "CELL", 79, 84], ["testes", "ORGAN", 88, 94], ["ovaries", "ORGAN", 99, 106], ["Clpp deletion", "DNA", 13, 26], ["Clpp deletion", "PROBLEM", 13, 26], ["selective profound vulnerability of specific cells in testes and ovaries", "PROBLEM", 34, 106], ["Clpp deletion", "OBSERVATION", 13, 26], ["selective", "OBSERVATION_MODIFIER", 34, 43], ["profound", "OBSERVATION_MODIFIER", 44, 52], ["vulnerability", "OBSERVATION", 53, 66], ["specific cells", "OBSERVATION", 70, 84], ["testes", "ANATOMY", 88, 94], ["ovaries", "ANATOMY", 99, 106]]], ["This is also in agreement with several other mouse and fly mutants with mitochondrial dysfunction, which have shown a reduction of sperm number or motility or impaired spermatogenesis.", [["mitochondrial", "ANATOMY", 72, 85], ["sperm", "ANATOMY", 131, 136], ["mitochondrial dysfunction", "DISEASE", 72, 97], ["reduction of sperm number", "DISEASE", 118, 143], ["impaired spermatogenesis", "DISEASE", 159, 183], ["mouse", "ORGANISM", 45, 50], ["mitochondrial", "CELLULAR_COMPONENT", 72, 85], ["sperm", "ORGANISM_SUBSTANCE", 131, 136], ["sperm", "CELL_TYPE", 131, 136], ["mouse", "SPECIES", 45, 50], ["mouse", "SPECIES", 45, 50], ["mitochondrial dysfunction", "PROBLEM", 72, 97], ["impaired spermatogenesis", "PROBLEM", 159, 183], ["mitochondrial dysfunction", "OBSERVATION", 72, 97], ["reduction", "OBSERVATION_MODIFIER", 118, 127], ["impaired", "OBSERVATION_MODIFIER", 159, 167], ["spermatogenesis", "OBSERVATION", 168, 183]]], ["Deletions in mtDNA resulted in oligospermia, while deletions in the mitochondrial peptidase Immp2l resulted in male subfertility and female infertility due to defective folliculogenesis and ovulation (69, (76) (77) (78) (79) (80) (81) (82) (83) (84) (85) .DISCUSSIONOvarian failure and sensorineural deafness are the central symptoms of the autosomal recessive human Perrault syndrome, where mutations in the mitochondrial histidyl-tRNA-synthetase HARS2 (86) and in the steroid metabolism enzyme HSD17B4 (87) had previously been observed.", [["mitochondrial", "ANATOMY", 68, 81], ["mitochondrial", "ANATOMY", 409, 422], ["oligospermia", "DISEASE", 31, 43], ["subfertility", "DISEASE", 116, 128], ["infertility", "DISEASE", 140, 151], ["sensorineural deafness", "DISEASE", 286, 308], ["autosomal recessive", "DISEASE", 341, 360], ["Perrault syndrome", "DISEASE", 367, 384], ["steroid", "CHEMICAL", 470, 477], ["histidyl", "CHEMICAL", 423, 431], ["steroid", "CHEMICAL", 470, 477], ["mtDNA", "CELLULAR_COMPONENT", 13, 18], ["mitochondrial", "CELLULAR_COMPONENT", 68, 81], ["Immp2l", "GENE_OR_GENE_PRODUCT", 92, 98], ["human", "ORGANISM", 361, 366], ["mitochondrial", "CELLULAR_COMPONENT", 409, 422], ["histidyl-tRNA-synthetase HARS2 (86)", "GENE_OR_GENE_PRODUCT", 423, 458], ["HSD17B4", "GENE_OR_GENE_PRODUCT", 496, 503], ["mitochondrial peptidase", "PROTEIN", 68, 91], ["Immp2l", "PROTEIN", 92, 98], ["mitochondrial histidyl-tRNA-synthetase", "PROTEIN", 409, 447], ["HARS2", "PROTEIN", 448, 453], ["steroid metabolism enzyme", "PROTEIN", 470, 495], ["HSD17B4", "PROTEIN", 496, 503], ["human", "SPECIES", 361, 366], ["Deletions in mtDNA", "PROBLEM", 0, 18], ["oligospermia", "PROBLEM", 31, 43], ["the mitochondrial peptidase Immp2l", "TEST", 64, 98], ["male subfertility", "PROBLEM", 111, 128], ["female infertility", "PROBLEM", 133, 151], ["defective folliculogenesis", "PROBLEM", 159, 185], ["ovulation", "TEST", 190, 199], [".DISCUSSIONOvarian failure", "PROBLEM", 255, 281], ["sensorineural deafness", "PROBLEM", 286, 308], ["the central symptoms", "PROBLEM", 313, 333], ["the autosomal recessive human Perrault syndrome", "PROBLEM", 337, 384], ["the mitochondrial histidyl", "TEST", 405, 431], ["tRNA-synthetase HARS2", "TEST", 432, 453], ["the steroid metabolism enzyme HSD17B4", "TEST", 466, 503], ["oligospermia", "OBSERVATION", 31, 43], ["sensorineural deafness", "OBSERVATION", 286, 308], ["autosomal", "OBSERVATION_MODIFIER", 341, 350], ["recessive human Perrault syndrome", "OBSERVATION", 351, 384]]], ["A recent publication reported CLPP missense and splice site mutations (22) in Perrault syndrome, but CLPP mutations were not yet linked to male infertility and lack of sperm.", [["sperm", "ANATOMY", 168, 173], ["Perrault syndrome", "DISEASE", 78, 95], ["infertility", "DISEASE", 144, 155], ["CLPP", "GENE_OR_GENE_PRODUCT", 30, 34], ["CLPP", "GENE_OR_GENE_PRODUCT", 101, 105], ["sperm", "ORGANISM_SUBSTANCE", 168, 173], ["CLPP missense", "DNA", 30, 43], ["sperm", "CELL_TYPE", 168, 173], ["A recent publication", "PROBLEM", 0, 20], ["CLPP missense", "PROBLEM", 30, 43], ["splice site mutations", "PROBLEM", 48, 69], ["Perrault syndrome", "PROBLEM", 78, 95], ["CLPP mutations", "PROBLEM", 101, 115], ["male infertility", "PROBLEM", 139, 155], ["lack of sperm", "PROBLEM", 160, 173], ["CLPP missense", "OBSERVATION", 30, 43]]], ["Possibly the phenotype in Testis, heart, liver and brain protein levels documented by quantitative immunoblots with densitometry were analyzed with Student's t-test for significant differences, and the linear fold-change and the P-value were represented in this overview (n \u00bc 3 versus 3, mouse age 5 months).", [["Testis", "ANATOMY", 26, 32], ["heart", "ANATOMY", 34, 39], ["liver", "ANATOMY", 41, 46], ["brain", "ANATOMY", 51, 56], ["Testis", "ORGAN", 26, 32], ["heart", "ORGAN", 34, 39], ["liver", "ORGAN", 41, 46], ["brain", "ORGAN", 51, 56], ["mouse", "ORGANISM", 288, 293], ["P", "DNA", 229, 230], ["mouse", "SPECIES", 288, 293], ["the phenotype in Testis", "PROBLEM", 9, 32], ["brain protein levels", "TEST", 51, 71], ["quantitative immunoblots", "TEST", 86, 110], ["densitometry", "TEST", 116, 128], ["Student's t-test", "TEST", 148, 164], ["significant differences", "PROBLEM", 169, 192], ["the linear fold", "PROBLEM", 198, 213], ["the P-value", "TEST", 225, 236], ["phenotype", "OBSERVATION", 13, 22], ["Testis", "ANATOMY", 26, 32], ["heart", "ANATOMY", 34, 39], ["liver", "ANATOMY", 41, 46], ["brain", "ANATOMY", 51, 56]]], ["Significant up-regulations are highlighted in red, significant down-regulations in green. ns, non-significant; nd, non-detectable. mice varies from human, but it is also conceivable that the murine CLPP null mutation has a stronger fertility phenotype than the human CLPP missense/splice site mutations, which may cause only partial CLPP activity loss.", [["mice", "ORGANISM", 131, 135], ["human", "ORGANISM", 148, 153], ["murine", "ORGANISM", 191, 197], ["CLPP", "GENE_OR_GENE_PRODUCT", 198, 202], ["human", "ORGANISM", 261, 266], ["CLPP", "GENE_OR_GENE_PRODUCT", 267, 271], ["CLPP", "GENE_OR_GENE_PRODUCT", 333, 337], ["CLPP", "PROTEIN", 198, 202], ["human CLPP missense", "DNA", 261, 280], ["mice", "SPECIES", 131, 135], ["human", "SPECIES", 148, 153], ["murine", "SPECIES", 191, 197], ["human", "SPECIES", 261, 266], ["mice", "SPECIES", 131, 135], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 261, 266], ["Significant up-regulations", "PROBLEM", 0, 26], ["red", "PROBLEM", 46, 49], ["ns", "TREATMENT", 90, 92], ["nd", "PROBLEM", 111, 113], ["the murine CLPP null mutation", "PROBLEM", 187, 216], ["a stronger fertility phenotype", "PROBLEM", 221, 251], ["the human CLPP missense/splice site mutations", "PROBLEM", 257, 302], ["partial CLPP activity loss", "PROBLEM", 325, 351], ["significant", "OBSERVATION_MODIFIER", 51, 62], ["non-significant", "OBSERVATION_MODIFIER", 94, 109], ["nd", "OBSERVATION_MODIFIER", 111, 113], ["non-detectable", "OBSERVATION_MODIFIER", 115, 129], ["may cause", "UNCERTAINTY", 310, 319], ["partial", "OBSERVATION_MODIFIER", 325, 332], ["CLPP", "OBSERVATION", 333, 337], ["activity loss", "OBSERVATION", 338, 351]]], ["Thus, it will be important to screen male patients with a syndrome of azoospermia, short stature and neural dysfunction for CLPP mutations.", [["neural", "ANATOMY", 101, 107], ["azoospermia", "DISEASE", 70, 81], ["short stature", "DISEASE", 83, 96], ["neural dysfunction", "DISEASE", 101, 119], ["patients", "ORGANISM", 42, 50], ["CLPP", "GENE_OR_GENE_PRODUCT", 124, 128], ["patients", "SPECIES", 42, 50], ["a syndrome of azoospermia", "PROBLEM", 56, 81], ["short stature", "PROBLEM", 83, 96], ["neural dysfunction", "PROBLEM", 101, 119], ["CLPP mutations", "PROBLEM", 124, 138], ["azoospermia", "OBSERVATION", 70, 81], ["neural dysfunction", "OBSERVATION", 101, 119]]], ["Conversely, it will be important to conduct systematic screening of the auditory deficit in Clpp 2/2 mice assessing the affected tissue also with histology and molecular profiling.", [["tissue", "ANATOMY", 129, 135], ["auditory deficit", "DISEASE", 72, 88], ["mice", "ORGANISM", 101, 105], ["tissue", "TISSUE", 129, 135], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 101, 105], ["systematic screening", "TEST", 44, 64], ["the auditory deficit", "PROBLEM", 68, 88], ["Clpp", "TEST", 92, 96], ["the affected tissue", "PROBLEM", 116, 135], ["histology", "TEST", 146, 155]]], ["It is well known that auditory nerves are exceptionally sensitive to mitochondrial dysfunction, e.g. to altered import of mtRNA (88, 89) .", [["auditory nerves", "ANATOMY", 22, 37], ["mitochondrial", "ANATOMY", 69, 82], ["mitochondrial dysfunction", "DISEASE", 69, 94], ["auditory nerves", "MULTI-TISSUE_STRUCTURE", 22, 37], ["mitochondrial", "CELLULAR_COMPONENT", 69, 82], ["mtRNA", "GENE_OR_GENE_PRODUCT", 122, 127], ["mtRNA", "PROTEIN", 122, 127], ["mitochondrial dysfunction", "PROBLEM", 69, 94], ["auditory nerves", "ANATOMY", 22, 37]]], ["Beyond the severe gonad-and audition-specific pathologies, CLPP absence caused five marked effects that were ubiquitous.", [["gonad", "ANATOMY", 18, 23], ["gonad-and audition-specific pathologies", "DISEASE", 18, 57], ["gonad", "ANATOMICAL_SYSTEM", 18, 23], ["the severe gonad", "PROBLEM", 7, 23], ["audition-specific pathologies", "PROBLEM", 28, 57], ["CLPP absence", "PROBLEM", 59, 71], ["severe", "OBSERVATION_MODIFIER", 11, 17], ["gonad", "ANATOMY", 18, 23], ["marked", "OBSERVATION_MODIFIER", 84, 90]]], ["First, the accumulation of CLPX; second, the up-regulation of mitochondrial matrix chaperones; third, the elevated levels of mtDNA; fourth, the induction of an inflammatory signature and finally, the growth retardation affecting all tissues.", [["mitochondrial matrix", "ANATOMY", 62, 82], ["tissues", "ANATOMY", 233, 240], ["growth retardation", "DISEASE", 200, 218], ["CLPX", "GENE_OR_GENE_PRODUCT", 27, 31], ["mitochondrial matrix", "CELLULAR_COMPONENT", 62, 82], ["mtDNA", "CELLULAR_COMPONENT", 125, 130], ["tissues", "TISSUE", 233, 240], ["CLPX", "PROTEIN", 27, 31], ["mitochondrial matrix chaperones", "PROTEIN", 62, 93], ["the accumulation of CLPX", "PROBLEM", 7, 31], ["mitochondrial matrix chaperones", "TREATMENT", 62, 93], ["the elevated levels of mtDNA", "PROBLEM", 102, 130], ["an inflammatory signature", "PROBLEM", 157, 182], ["the growth retardation", "PROBLEM", 196, 218], ["accumulation", "OBSERVATION_MODIFIER", 11, 23], ["CLPX", "OBSERVATION", 27, 31], ["mitochondrial matrix", "OBSERVATION", 62, 82], ["elevated", "OBSERVATION_MODIFIER", 106, 114], ["inflammatory", "OBSERVATION", 160, 172]]], ["Our data show that the absence of CLPP leads to CLPX accumulation in spite of downregulated Clpx transcript levels.", [["CLPP", "GENE_OR_GENE_PRODUCT", 34, 38], ["CLPX", "GENE_OR_GENE_PRODUCT", 48, 52], ["Clpx", "GENE_OR_GENE_PRODUCT", 92, 96], ["CLPP", "PROTEIN", 34, 38], ["CLPX", "PROTEIN", 48, 52], ["Clpx", "PROTEIN", 92, 96], ["Our data", "TEST", 0, 8], ["CLPP", "PROBLEM", 34, 38], ["CLPX accumulation", "PROBLEM", 48, 65], ["downregulated Clpx transcript levels", "PROBLEM", 78, 114], ["CLPP", "OBSERVATION", 34, 38], ["CLPX accumulation", "OBSERVATION", 48, 65]]], ["The likeliest explanation is that CLPX degradation is reduced and depends on CLPP, and that the pathologically increased CLPX protein levels are insufficiently compensated by decreased transcript levels.", [["CLPX", "GENE_OR_GENE_PRODUCT", 34, 38], ["CLPP", "GENE_OR_GENE_PRODUCT", 77, 81], ["CLPX", "GENE_OR_GENE_PRODUCT", 121, 125], ["CLPX", "PROTEIN", 34, 38], ["CLPP", "PROTEIN", 77, 81], ["CLPX", "PROTEIN", 121, 125], ["CLPX degradation", "PROBLEM", 34, 50], ["CLPP", "TEST", 77, 81], ["the pathologically increased CLPX protein levels", "PROBLEM", 92, 140], ["decreased transcript levels", "PROBLEM", 175, 202], ["reduced", "OBSERVATION_MODIFIER", 54, 61], ["pathologically", "OBSERVATION_MODIFIER", 96, 110], ["increased", "OBSERVATION_MODIFIER", 111, 120], ["CLPX protein", "OBSERVATION", 121, 133], ["decreased", "OBSERVATION_MODIFIER", 175, 184], ["transcript levels", "OBSERVATION", 185, 202]]], ["In contrast, the elevated levels of other mitochondrial matrix chaperones through transcriptional up-regulation might constitute the crucial compensatory effort which prevents earlier pathology in tissues like the brain.", [["mitochondrial matrix", "ANATOMY", 42, 62], ["tissues", "ANATOMY", 197, 204], ["brain", "ANATOMY", 214, 219], ["mitochondrial", "CELLULAR_COMPONENT", 42, 55], ["matrix", "CELLULAR_COMPONENT", 56, 62], ["tissues", "TISSUE", 197, 204], ["brain", "ORGAN", 214, 219], ["mitochondrial matrix chaperones", "PROTEIN", 42, 73], ["the elevated levels", "PROBLEM", 13, 32], ["other mitochondrial matrix chaperones", "TREATMENT", 36, 73], ["earlier pathology in tissues like the brain", "PROBLEM", 176, 219], ["elevated", "OBSERVATION", 17, 25], ["compensatory effort", "OBSERVATION", 141, 160], ["brain", "ANATOMY", 214, 219]]], ["The elevated CLPX levels may be responsible for mtDNA accumulation, since a recent report showed CLPX to act not only as chaperone for unfolded proteins, but to be also important for the condensation of mtDNA, similar to TFAM (56).", [["CLPX", "GENE_OR_GENE_PRODUCT", 13, 17], ["mtDNA", "CELLULAR_COMPONENT", 48, 53], ["CLPX", "GENE_OR_GENE_PRODUCT", 97, 101], ["mtDNA", "CELLULAR_COMPONENT", 203, 208], ["TFAM", "GENE_OR_GENE_PRODUCT", 221, 225], ["CLPX", "PROTEIN", 13, 17], ["CLPX", "PROTEIN", 97, 101], ["unfolded proteins", "PROTEIN", 135, 152], ["TFAM", "PROTEIN", 221, 225], ["The elevated CLPX levels", "PROBLEM", 0, 24], ["mtDNA accumulation", "PROBLEM", 48, 66], ["CLPX", "PROBLEM", 97, 101], ["unfolded proteins", "PROBLEM", 135, 152], ["the condensation of mtDNA", "PROBLEM", 183, 208], ["elevated", "OBSERVATION_MODIFIER", 4, 12], ["CLPX", "OBSERVATION", 13, 17], ["may be responsible for", "UNCERTAINTY", 25, 47], ["mtDNA accumulation", "OBSERVATION", 48, 66]]], ["It is well established that the elimination of mitochondrial number as well as mtDNA reaches its physiological maximum during the maturation of germ cells.", [["mitochondrial", "ANATOMY", 47, 60], ["germ cells", "ANATOMY", 144, 154], ["mitochondrial", "CELLULAR_COMPONENT", 47, 60], ["mtDNA", "CELLULAR_COMPONENT", 79, 84], ["germ cells", "CELL", 144, 154], ["germ cells", "CELL_TYPE", 144, 154], ["germ cells", "PROBLEM", 144, 154], ["germ cells", "OBSERVATION", 144, 154]]], ["During spermatogenesis, the number of mtDNA nucleoids should be reduced from 10 000 or 1000 copies per cell to 100 copies per spermatozoon.", [["nucleoids", "ANATOMY", 44, 53], ["cell", "ANATOMY", 103, 107], ["spermatozoon", "ANATOMY", 126, 138], ["mtDNA", "CELLULAR_COMPONENT", 38, 43], ["nucleoids", "CELLULAR_COMPONENT", 44, 53], ["cell", "CELL", 103, 107], ["spermatozoon", "CELLULAR_COMPONENT", 126, 138], ["mtDNA nucleoids", "TREATMENT", 38, 53], ["mtDNA nucleoids", "OBSERVATION", 38, 53]]], ["During oogenesis, mitochondrial number would decrease while going through a quality control bottleneck, before expanding to 100 000 copies per oocyte (90, 91) .", [["mitochondrial", "ANATOMY", 18, 31], ["oocyte", "ANATOMY", 143, 149], ["mitochondrial", "CELLULAR_COMPONENT", 18, 31], ["mitochondrial number", "PROBLEM", 18, 38]]], ["Therefore the selective and strong testis and ovary pathology in the CLPP null mice might be due to the pathological accumulation of CLPX and mtDNA.", [["testis", "ANATOMY", 35, 41], ["ovary", "ANATOMY", 46, 51], ["testis", "ORGAN", 35, 41], ["ovary", "ORGAN", 46, 51], ["CLPP", "GENE_OR_GENE_PRODUCT", 69, 73], ["mice", "ORGANISM", 79, 83], ["CLPX", "GENE_OR_GENE_PRODUCT", 133, 137], ["mtDNA", "CELLULAR_COMPONENT", 142, 147], ["CLPX", "PROTEIN", 133, 137], ["mice", "SPECIES", 79, 83], ["ovary pathology", "TEST", 46, 61], ["the CLPP null", "TEST", 65, 78], ["the pathological accumulation of CLPX", "PROBLEM", 100, 137], ["selective", "OBSERVATION", 14, 23], ["ovary", "ANATOMY", 46, 51], ["pathology", "OBSERVATION", 52, 61], ["might be due to", "UNCERTAINTY", 84, 99], ["CLPX", "OBSERVATION", 133, 137]]], ["While depletion of mtDNA has been described as a consequence of mutations in numerous genes (92) , a strong accumulation as in CLPP null tissue has not been documented previously.", [["CLPP null tissue", "ANATOMY", 127, 143], ["mtDNA", "CELLULAR_COMPONENT", 19, 24], ["CLPP null tissue", "TISSUE", 127, 143], ["mtDNA", "PROBLEM", 19, 24], ["mutations in numerous genes", "PROBLEM", 64, 91], ["a strong accumulation", "PROBLEM", 99, 120], ["CLPP null tissue", "PROBLEM", 127, 143], ["mtDNA", "OBSERVATION", 19, 24], ["strong", "OBSERVATION_MODIFIER", 101, 107], ["accumulation", "OBSERVATION", 108, 120], ["null tissue", "OBSERVATION", 132, 143]]], ["Our data establish CLPP as a modifier factor for the reduction of mtDNA levels.DISCUSSIONThe CLPP effect on inflammation and infection defense factors could be interpreted in the light of two observations made in prokaryotes.", [["inflammation", "DISEASE", 108, 120], ["infection", "DISEASE", 125, 134], ["CLPP", "GENE_OR_GENE_PRODUCT", 19, 23], ["mtDNA", "CELLULAR_COMPONENT", 66, 71], ["CLPP", "PROTEIN", 19, 23], ["Our data", "TEST", 0, 8], ["CLPP", "PROBLEM", 19, 23], ["a modifier factor", "PROBLEM", 27, 44], ["mtDNA levels", "TEST", 66, 78], ["CLPP effect", "PROBLEM", 93, 104], ["inflammation", "PROBLEM", 108, 120], ["infection defense factors", "PROBLEM", 125, 150], ["CLPP", "OBSERVATION", 19, 23], ["mtDNA levels", "OBSERVATION", 66, 78], ["inflammation", "OBSERVATION", 108, 120], ["infection", "OBSERVATION", 125, 134]]], ["First, in E. coli CLPP was observed to influence the lysis-lysogeny decision during bacteriophage mu infections (11, 93) and second, a report in Staphylococcus aureus showed Clpp deletion to result in poor growth accompanied by prophage proteome accumulation and increased prophage release in some strains (94) .", [["infections", "DISEASE", 101, 111], ["Staphylococcus aureus", "DISEASE", 145, 166], ["E. coli", "ORGANISM", 10, 17], ["CLPP", "ORGANISM", 18, 22], ["Staphylococcus aureus", "ORGANISM", 145, 166], ["Clpp", "GENE_OR_GENE_PRODUCT", 174, 178], ["Clpp deletion", "DNA", 174, 187], ["E. coli", "SPECIES", 10, 17], ["Staphylococcus aureus", "SPECIES", 145, 166], ["E. coli", "SPECIES", 10, 17], ["Staphylococcus aureus", "SPECIES", 145, 166], ["E. coli CLPP", "PROBLEM", 10, 22], ["the lysis", "TREATMENT", 49, 58], ["bacteriophage mu infections", "PROBLEM", 84, 111], ["Staphylococcus aureus", "PROBLEM", 145, 166], ["Clpp deletion", "PROBLEM", 174, 187], ["poor growth", "PROBLEM", 201, 212], ["prophage proteome accumulation", "PROBLEM", 228, 258], ["increased prophage release", "PROBLEM", 263, 289], ["some strains", "PROBLEM", 293, 305], ["coli CLPP", "OBSERVATION", 13, 22], ["Staphylococcus aureus", "OBSERVATION", 145, 166], ["Clpp deletion", "OBSERVATION", 174, 187], ["poor growth", "OBSERVATION_MODIFIER", 201, 212], ["prophage proteome accumulation", "OBSERVATION", 228, 258], ["increased prophage", "OBSERVATION", 263, 281]]], ["Also in mammals the antiviral defense system and interferon induction are modulated crucially by mitochondria, through four known factors, namely Testis, heart, liver and brain transcript levels documented by quantitative real-time reverse transcriptase PCR (qPCR) through commercial Taqman assays were analyzed with the 2 2DDCt method.", [["mitochondria", "ANATOMY", 97, 109], ["Testis", "ANATOMY", 146, 152], ["heart", "ANATOMY", 154, 159], ["liver", "ANATOMY", 161, 166], ["brain", "ANATOMY", 171, 176], ["interferon", "GENE_OR_GENE_PRODUCT", 49, 59], ["mitochondria", "CELLULAR_COMPONENT", 97, 109], ["Testis", "ORGAN", 146, 152], ["heart", "ORGAN", 154, 159], ["liver", "ORGAN", 161, 166], ["brain", "ORGAN", 171, 176], ["interferon", "PROTEIN", 49, 59], ["reverse transcriptase", "PROTEIN", 232, 253], ["the antiviral defense system", "TREATMENT", 16, 44], ["interferon induction", "TREATMENT", 49, 69], ["brain transcript levels", "TEST", 171, 194], ["transcriptase PCR", "TEST", 240, 257], ["commercial Taqman assays", "TEST", 273, 297], ["the 2 2DDCt method", "TREATMENT", 317, 335], ["antiviral defense", "OBSERVATION", 20, 37], ["heart", "ANATOMY", 154, 159], ["liver", "ANATOMY", 161, 166], ["brain", "ANATOMY", 171, 176]]], ["The linear fold-change and the unpaired Student's-test P-value (significance threshold 0.05) were represented in this overview (n \u00bc 3 versus 3, mouse age 5 months).", [["mouse", "ORGANISM", 144, 149], ["mouse", "SPECIES", 144, 149], ["The linear fold-change", "PROBLEM", 0, 22], ["linear", "OBSERVATION_MODIFIER", 4, 10], ["fold", "OBSERVATION_MODIFIER", 11, 15], ["change", "OBSERVATION_MODIFIER", 16, 22]]], ["Significant up-regulations are highlighted in red, significant down-regulations in green. ns, non-significant.DISCUSSIONmatrix-localized NLRX1 and outer membrane-associated MAVS, ECSIT and STING (52, 53) .", [["outer membrane", "ANATOMY", 147, 161], ["NLRX1", "GENE_OR_GENE_PRODUCT", 137, 142], ["outer membrane", "CELLULAR_COMPONENT", 147, 161], ["MAVS", "GENE_OR_GENE_PRODUCT", 173, 177], ["STING", "GENE_OR_GENE_PRODUCT", 189, 194], ["DISCUSSIONmatrix-localized NLRX1", "PROTEIN", 110, 142], ["MAVS", "PROTEIN", 173, 177], ["ECSIT", "PROTEIN", 179, 184], ["STING", "PROTEIN", 189, 194], ["Significant up-regulations", "PROBLEM", 0, 26], ["red", "PROBLEM", 46, 49], ["ns", "TREATMENT", 90, 92], ["localized NLRX1 and outer membrane", "PROBLEM", 127, 161], ["STING", "TEST", 189, 194], ["significant", "OBSERVATION_MODIFIER", 51, 62], ["non-significant", "OBSERVATION_MODIFIER", 94, 109], ["outer membrane", "ANATOMY", 147, 161], ["MAVS", "OBSERVATION", 173, 177]]], ["Thus, in spite of the vast differences the bacterial and eukaryotic immune defense systems, CLPP deficiency might modulate antiviral defense.", [["CLPP", "CHEMICAL", 92, 96], ["CLPP", "GENE_OR_GENE_PRODUCT", 92, 96], ["the bacterial and eukaryotic immune defense systems", "PROBLEM", 39, 90], ["CLPP deficiency", "PROBLEM", 92, 107], ["bacterial", "OBSERVATION_MODIFIER", 43, 52], ["eukaryotic immune defense", "OBSERVATION", 57, 82], ["CLPP deficiency", "OBSERVATION", 92, 107], ["antiviral defense", "OBSERVATION", 123, 140]]], ["In this case, a novel functional parallel between the mitochondrial CLPXP machinery and the cytosolic proteasome would become apparent, since the latter is well known to respond to infections and inflammations via interferon-gamma exposure by adapting its composition and proteolysis pattern, thus serving as immunoproteasome (95) .", [["mitochondrial", "ANATOMY", 54, 67], ["cytosolic", "ANATOMY", 92, 101], ["infections", "DISEASE", 181, 191], ["inflammations", "DISEASE", 196, 209], ["mitochondrial", "CELLULAR_COMPONENT", 54, 67], ["CLPXP", "GENE_OR_GENE_PRODUCT", 68, 73], ["cytosolic", "CELLULAR_COMPONENT", 92, 101], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 214, 230], ["CLPXP", "PROTEIN", 68, 73], ["cytosolic proteasome", "PROTEIN", 92, 112], ["interferon", "PROTEIN", 214, 224], ["immunoproteasome", "PROTEIN", 309, 325], ["the mitochondrial CLPXP machinery", "TREATMENT", 50, 83], ["the cytosolic proteasome", "TREATMENT", 88, 112], ["infections", "PROBLEM", 181, 191], ["inflammations", "PROBLEM", 196, 209], ["interferon-gamma exposure", "TREATMENT", 214, 239], ["proteolysis pattern", "PROBLEM", 272, 291], ["infections", "OBSERVATION", 181, 191], ["inflammations", "OBSERVATION", 196, 209]]], ["Thus, although our mice were bred and aged in individually ventilated cages, with the absence of pathogenic infections being documented in regular health screens, we cannot exclude an undetected viral exposure of some mice that might explain our data partially.", [["infections", "DISEASE", 108, 118], ["mice", "ORGANISM", 19, 23], ["mice", "ORGANISM", 218, 222], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 218, 222], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 218, 222], ["ventilated cages", "TREATMENT", 59, 75], ["pathogenic infections", "PROBLEM", 97, 118], ["pathogenic", "OBSERVATION_MODIFIER", 97, 107], ["infections", "OBSERVATION", 108, 118]]], ["However, the transcriptome analyses documented a genotype-dependent elevation of immunity factors in every one of several mice and tissues, and the cellular analyses of splenocytes in independent animals confirmed this genotype-dependent effect.", [["tissues", "ANATOMY", 131, 138], ["cellular", "ANATOMY", 148, 156], ["splenocytes", "ANATOMY", 169, 180], ["mice", "ORGANISM", 122, 126], ["tissues", "TISSUE", 131, 138], ["cellular", "CELL", 148, 156], ["splenocytes", "CELL", 169, 180], ["immunity factors", "PROTEIN", 81, 97], ["splenocytes", "CELL_TYPE", 169, 180], ["mice", "SPECIES", 122, 126], ["mice", "SPECIES", 122, 126], ["the transcriptome analyses", "TEST", 9, 35], ["a genotype-dependent elevation of immunity factors", "PROBLEM", 47, 97], ["the cellular analyses", "TEST", 144, 165], ["this genotype-dependent effect", "PROBLEM", 214, 244], ["dependent", "OBSERVATION_MODIFIER", 58, 67], ["elevation", "OBSERVATION_MODIFIER", 68, 77], ["splenocytes", "ANATOMY", 169, 180]]], ["Furthermore, almost all mice in both Clpp 2/2 lines across their lifespan showed resistance against ulcerative dermatitis.", [["Clpp 2/2 lines", "ANATOMY", 37, 51], ["ulcerative", "ANATOMY", 100, 110], ["ulcerative dermatitis", "DISEASE", 100, 121], ["mice", "ORGANISM", 24, 28], ["Clpp 2/2 lines", "CELL", 37, 51], ["ulcerative dermatitis", "PATHOLOGICAL_FORMATION", 100, 121], ["Clpp 2/2 lines", "CELL_LINE", 37, 51], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 24, 28], ["ulcerative dermatitis", "PROBLEM", 100, 121], ["Clpp", "OBSERVATION_MODIFIER", 37, 41], ["2/2 lines", "OBSERVATION", 42, 51], ["resistance", "OBSERVATION_MODIFIER", 81, 91], ["ulcerative", "OBSERVATION_MODIFIER", 100, 110], ["dermatitis", "OBSERVATION", 111, 121]]], ["This skin condition is typical of murine C57BL/6 substrains during aging, does not respond to antibiotic or corticosteroid treatment, and is thought to arise from pruritus due to follicular dystrophy, with later bacterial superinfections by skin commensals (44, 96) .", [["skin", "ANATOMY", 5, 9], ["follicular", "ANATOMY", 179, 189], ["skin", "ANATOMY", 241, 245], ["pruritus", "DISEASE", 163, 171], ["follicular dystrophy", "DISEASE", 179, 199], ["superinfections", "DISEASE", 222, 237], ["skin", "ORGAN", 5, 9], ["murine", "ORGANISM", 34, 40], ["C57BL/6 substrains", "ORGANISM", 41, 59], ["corticosteroid", "SIMPLE_CHEMICAL", 108, 122], ["skin", "ORGAN", 241, 245], ["murine", "SPECIES", 34, 40], ["This skin condition", "PROBLEM", 0, 19], ["murine C57BL/6 substrains", "PROBLEM", 34, 59], ["antibiotic", "TREATMENT", 94, 104], ["corticosteroid treatment", "TREATMENT", 108, 132], ["pruritus", "PROBLEM", 163, 171], ["follicular dystrophy", "PROBLEM", 179, 199], ["later bacterial superinfections", "PROBLEM", 206, 237], ["skin", "ANATOMY", 5, 9], ["condition", "OBSERVATION", 10, 19], ["follicular dystrophy", "OBSERVATION", 179, 199], ["bacterial", "OBSERVATION_MODIFIER", 212, 221], ["superinfections", "OBSERVATION", 222, 237], ["skin", "ANATOMY", 241, 245]]], ["This general reduction of vulnerability of Clpp 2/2 animals toward an inflammatory disease is a strong argument that the CLPP effect on immunity occurs irrespective of infections.", [["infections", "DISEASE", 168, 178], ["Clpp 2/2 animals", "ORGANISM", 43, 59], ["CLPP", "CANCER", 121, 125], ["Clpp", "PROBLEM", 43, 47], ["an inflammatory disease", "PROBLEM", 67, 90], ["the CLPP effect", "PROBLEM", 117, 132], ["infections", "PROBLEM", 168, 178], ["reduction", "OBSERVATION_MODIFIER", 13, 22], ["vulnerability", "OBSERVATION_MODIFIER", 26, 39], ["Clpp", "OBSERVATION_MODIFIER", 43, 47], ["2/2 animals", "OBSERVATION_MODIFIER", 48, 59], ["inflammatory", "OBSERVATION_MODIFIER", 70, 82], ["disease", "OBSERVATION", 83, 90], ["CLPP", "OBSERVATION", 121, 125], ["infections", "OBSERVATION", 168, 178]]], ["Mitochondrial damage can by itself lead to inflammatory responses of the host cells.", [["Mitochondrial", "ANATOMY", 0, 13], ["cells", "ANATOMY", 78, 83], ["Mitochondrial damage", "DISEASE", 0, 20], ["Mitochondrial", "CELLULAR_COMPONENT", 0, 13], ["cells", "CELL", 78, 83], ["host cells", "CELL_TYPE", 73, 83], ["Mitochondrial damage", "PROBLEM", 0, 20], ["inflammatory responses of the host cells", "PROBLEM", 43, 83], ["damage", "OBSERVATION", 14, 20], ["inflammatory", "OBSERVATION", 43, 55], ["host cells", "OBSERVATION", 73, 83]]], ["Our data demonstrate that Clpp 2/2 deletion leads not only to the induction of mitochondrial chaperones, but also to transcriptional up-regulation of proteasome subunits and ubiquitin-mediated proteolysis factors, suggesting that non-degraded CLPP substrates are released from mitochondria to the eukaryotic cytosol.", [["mitochondrial", "ANATOMY", 79, 92], ["mitochondria", "ANATOMY", 277, 289], ["cytosol", "ANATOMY", 308, 315], ["Clpp 2/2", "GENE_OR_GENE_PRODUCT", 26, 34], ["mitochondrial", "CELLULAR_COMPONENT", 79, 92], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 174, 183], ["CLPP", "GENE_OR_GENE_PRODUCT", 243, 247], ["mitochondria", "CELLULAR_COMPONENT", 277, 289], ["cytosol", "CELLULAR_COMPONENT", 308, 315], ["Clpp 2/2 deletion", "DNA", 26, 43], ["mitochondrial chaperones", "PROTEIN", 79, 103], ["proteasome subunits", "PROTEIN", 150, 169], ["ubiquitin-mediated proteolysis factors", "PROTEIN", 174, 212], ["non-degraded CLPP substrates", "PROTEIN", 230, 258], ["Our data", "TEST", 0, 8], ["Clpp 2/2 deletion", "PROBLEM", 26, 43], ["mitochondrial chaperones", "TREATMENT", 79, 103], ["proteasome subunits", "TREATMENT", 150, 169], ["ubiquitin-mediated proteolysis factors", "TREATMENT", 174, 212], ["non-degraded CLPP substrates", "PROBLEM", 230, 258]]], ["This appears possible, since C. elegans CLPP was shown to modulate the peptide efflux from isolated mitochondria (18) and since retrograde export even of T cell subsets analyzed for their expression of CD25/CD44/CD62L/Ly6C also showed several significant changes.", [["mitochondria", "ANATOMY", 100, 112], ["T cell", "ANATOMY", 154, 160], ["C. elegans", "ORGANISM", 29, 39], ["CLPP", "ORGANISM", 40, 44], ["mitochondria", "CELLULAR_COMPONENT", 100, 112], ["T cell", "CELL", 154, 160], ["CD25", "GENE_OR_GENE_PRODUCT", 202, 206], ["CD44", "GENE_OR_GENE_PRODUCT", 207, 211], ["CD62L", "GENE_OR_GENE_PRODUCT", 212, 217], ["Ly6C", "GENE_OR_GENE_PRODUCT", 218, 222], ["T cell subsets", "CELL_TYPE", 154, 168], ["CD25", "PROTEIN", 202, 206], ["CD44", "PROTEIN", 207, 211], ["CD62L", "PROTEIN", 212, 217], ["Ly6C", "PROTEIN", 218, 222], ["C. elegans", "SPECIES", 29, 39], ["C. elegans", "SPECIES", 29, 39], ["C. elegans CLPP", "PROBLEM", 29, 44], ["T cell subsets", "TEST", 154, 168], ["CD25", "TEST", 202, 206], ["CD44", "TEST", 207, 211], ["CD62L", "TEST", 212, 217], ["several significant changes", "PROBLEM", 235, 262], ["appears possible", "UNCERTAINTY", 5, 21], ["Ly6C", "ANATOMY", 218, 222], ["several", "OBSERVATION_MODIFIER", 235, 242], ["significant", "OBSERVATION_MODIFIER", 243, 254], ["changes", "OBSERVATION", 255, 262]]], ["Statistical analysis was done by using SPICE (117) .", [["Statistical analysis", "TEST", 0, 20]]], ["Significance (alpha \u00bc 5%) in Student's t-test is indicated by +, significance in the Wilcoxon rank test by #. entire proteins across the mitochondrial membrane pore is possible (97) .", [["mitochondrial membrane pore", "ANATOMY", 137, 164], ["mitochondrial", "CELLULAR_COMPONENT", 137, 150], ["membrane pore", "CELLULAR_COMPONENT", 151, 164], ["Significance", "TEST", 0, 12], ["alpha", "TEST", 14, 19], ["Student's t-test", "TEST", 29, 45], ["mitochondrial membrane pore", "OBSERVATION", 137, 164]]], ["Eukaryotic cells recognize the appearance of microbial fragments by specific receptors for the typical formylated amino acids and hypomethylated CpG dinucleotides, eliciting responses of innate immunity against such PAMPs (pathogenassociated molecular patterns) (52) (53) (54) (55) .", [["cells", "ANATOMY", 11, 16], ["fragments", "ANATOMY", 55, 64], ["amino acids", "CHEMICAL", 114, 125], ["amino acids", "CHEMICAL", 114, 125], ["CpG dinucleotides", "CHEMICAL", 145, 162], ["Eukaryotic cells", "CELL", 0, 16], ["amino acids", "AMINO_ACID", 114, 125], ["PAMPs", "PROTEIN", 216, 221], ["Eukaryotic cells", "PROBLEM", 0, 16], ["microbial fragments", "PROBLEM", 45, 64], ["the typical formylated amino acids", "TREATMENT", 91, 125], ["hypomethylated CpG dinucleotides", "PROBLEM", 130, 162], ["such PAMPs", "TEST", 211, 221], ["microbial fragments", "OBSERVATION", 45, 64], ["amino acids", "OBSERVATION", 114, 125], ["CpG dinucleotides", "OBSERVATION", 145, 162]]], ["Similarly, LC3B-deficient mice with impaired autophagic degradation of dysfunctional mitochondria and subsequent accumulation of mtDNA in the cytosol were recently demonstrated to have significantly higher secretion of interleukins IL-1beta and IL-18 (98) .", [["autophagic", "ANATOMY", 45, 55], ["mitochondria", "ANATOMY", 85, 97], ["cytosol", "ANATOMY", 142, 149], ["LC3B", "GENE_OR_GENE_PRODUCT", 11, 15], ["mice", "ORGANISM", 26, 30], ["mitochondria", "CELLULAR_COMPONENT", 85, 97], ["mtDNA", "CELLULAR_COMPONENT", 129, 134], ["cytosol", "CELLULAR_COMPONENT", 142, 149], ["interleukins", "GENE_OR_GENE_PRODUCT", 219, 231], ["IL-1beta", "GENE_OR_GENE_PRODUCT", 232, 240], ["IL-18", "GENE_OR_GENE_PRODUCT", 245, 250], ["LC3B", "PROTEIN", 11, 15], ["interleukins", "PROTEIN", 219, 231], ["IL", "PROTEIN", 245, 247], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 26, 30], ["impaired autophagic degradation", "PROBLEM", 36, 67], ["dysfunctional mitochondria", "PROBLEM", 71, 97], ["subsequent accumulation of mtDNA in the cytosol", "PROBLEM", 102, 149], ["interleukins IL", "TREATMENT", 219, 234], ["IL", "TEST", 245, 247], ["impaired", "OBSERVATION_MODIFIER", 36, 44], ["autophagic degradation", "OBSERVATION", 45, 67], ["dysfunctional mitochondria", "OBSERVATION", 71, 97], ["accumulation of mtDNA", "OBSERVATION", 113, 134], ["cytosol", "ANATOMY", 142, 149], ["significantly", "OBSERVATION_MODIFIER", 185, 198], ["higher", "OBSERVATION_MODIFIER", 199, 205], ["secretion", "OBSERVATION_MODIFIER", 206, 215]]], ["Thus, we speculate that eukaryotic tolerance to mitochondria is challenged intrinsically in Clpp 2/2 animals by exposure to accumulating mtDNA and to the release of formylated amino acids.", [["mitochondria", "ANATOMY", 48, 60], ["amino acids", "CHEMICAL", 176, 187], ["amino acids", "CHEMICAL", 176, 187], ["mitochondria", "CELLULAR_COMPONENT", 48, 60], ["Clpp 2/2 animals", "ORGANISM", 92, 108], ["mtDNA", "CELLULAR_COMPONENT", 137, 142], ["formylated", "SIMPLE_CHEMICAL", 165, 175], ["amino acids", "AMINO_ACID", 176, 187], ["accumulating mtDNA", "PROBLEM", 124, 142], ["formylated amino acids", "TREATMENT", 165, 187], ["eukaryotic tolerance", "OBSERVATION", 24, 44], ["amino acids", "OBSERVATION", 176, 187]]], ["Throughout all tissues, our transcriptome findings define the molecular signature of inflammatory factors that appears to be triggered by mitochondrial failure.DISCUSSIONWe also believe that the sustained activation of inflammation constitutes a stress that contributes to the general growth failure of diverse tissues and cells, since organisms with altered immunocompetence are well known to present with phenotypes of growth retardation and reduced survival in mammals (99) (100) (101) .DISCUSSIONThus, CLPP is a strong suppressor of CLPX levels in different mouse tissues and plays a role in mtDNA turnover.", [["tissues", "ANATOMY", 15, 22], ["mitochondrial", "ANATOMY", 138, 151], ["tissues", "ANATOMY", 311, 318], ["cells", "ANATOMY", 323, 328], ["tissues", "ANATOMY", 568, 575], ["mitochondrial failure", "DISEASE", 138, 159], ["inflammation", "DISEASE", 219, 231], ["growth retardation", "DISEASE", 421, 439], ["tissues", "TISSUE", 15, 22], ["mitochondrial", "CELLULAR_COMPONENT", 138, 151], ["tissues", "TISSUE", 311, 318], ["cells", "CELL", 323, 328], ["CLPP", "GENE_OR_GENE_PRODUCT", 506, 510], ["CLPX", "GENE_OR_GENE_PRODUCT", 537, 541], ["mouse", "ORGANISM", 562, 567], ["tissues", "TISSUE", 568, 575], ["mtDNA", "CELLULAR_COMPONENT", 596, 601], ["inflammatory factors", "PROTEIN", 85, 105], ["CLPP", "PROTEIN", 506, 510], ["CLPX", "PROTEIN", 537, 541], ["mouse", "SPECIES", 562, 567], ["mouse", "SPECIES", 562, 567], ["inflammatory factors", "PROBLEM", 85, 105], ["mitochondrial failure", "PROBLEM", 138, 159], ["inflammation", "PROBLEM", 219, 231], ["a stress", "PROBLEM", 244, 252], ["the general growth failure of diverse tissues and cells", "PROBLEM", 273, 328], ["organisms", "PROBLEM", 336, 345], ["altered immunocompetence", "PROBLEM", 351, 375], ["growth retardation", "PROBLEM", 421, 439], ["reduced survival in mammals", "PROBLEM", 444, 471], ["a strong suppressor of CLPX levels", "TREATMENT", 514, 548], ["inflammatory", "OBSERVATION", 85, 97], ["appears to be", "UNCERTAINTY", 111, 124], ["mitochondrial failure", "OBSERVATION", 138, 159], ["inflammation", "OBSERVATION", 219, 231], ["growth", "OBSERVATION_MODIFIER", 285, 291], ["failure", "OBSERVATION", 292, 299], ["diverse tissues", "OBSERVATION", 303, 318], ["different mouse tissues", "OBSERVATION", 552, 575]]], ["Resulting mitochondrial dysfunction leads only to light bioenergetic deficits, is particularly well compensated for in brain, but is detectable in the muscle and the liver.", [["mitochondrial", "ANATOMY", 10, 23], ["brain", "ANATOMY", 119, 124], ["muscle", "ANATOMY", 151, 157], ["liver", "ANATOMY", 166, 171], ["mitochondrial dysfunction", "DISEASE", 10, 35], ["mitochondrial", "CELLULAR_COMPONENT", 10, 23], ["brain", "ORGAN", 119, 124], ["muscle", "ORGAN", 151, 157], ["liver", "ORGAN", 166, 171], ["mitochondrial dysfunction leads", "PROBLEM", 10, 41], ["light bioenergetic deficits", "PROBLEM", 50, 77], ["mitochondrial dysfunction", "OBSERVATION", 10, 35], ["bioenergetic deficits", "OBSERVATION", 56, 77], ["compensated", "OBSERVATION", 100, 111], ["brain", "ANATOMY", 119, 124], ["detectable", "OBSERVATION", 133, 143], ["muscle", "ANATOMY", 151, 157], ["liver", "ANATOMY", 166, 171]]], ["In contrast, Clpp deletion leads to marked ubiquitous up-regulations in the levels of several mitochondrial matrix chaperones and of various inflammatory factors.", [["mitochondrial matrix", "ANATOMY", 94, 114], ["Clpp", "GENE_OR_GENE_PRODUCT", 13, 17], ["mitochondrial matrix", "CELLULAR_COMPONENT", 94, 114], ["Clpp", "PROTEIN", 13, 17], ["mitochondrial matrix chaperones", "PROTEIN", 94, 125], ["inflammatory factors", "PROTEIN", 141, 161], ["Clpp deletion", "PROBLEM", 13, 26], ["several mitochondrial matrix chaperones", "TREATMENT", 86, 125], ["various inflammatory factors", "PROBLEM", 133, 161], ["Clpp deletion", "OBSERVATION", 13, 26], ["marked", "OBSERVATION_MODIFIER", 36, 42], ["ubiquitous", "OBSERVATION_MODIFIER", 43, 53], ["up-regulations", "OBSERVATION_MODIFIER", 54, 68], ["several", "OBSERVATION_MODIFIER", 86, 93], ["mitochondrial matrix chaperones", "OBSERVATION", 94, 125], ["various", "OBSERVATION_MODIFIER", 133, 140], ["inflammatory factors", "OBSERVATION", 141, 161]]], ["At the cellular level, T-cell activation is observed in the spleen, while selective apoptosis occurs among spermatids and follicular granulosa cells.", [["cellular", "ANATOMY", 7, 15], ["T-cell", "ANATOMY", 23, 29], ["spleen", "ANATOMY", 60, 66], ["spermatids", "ANATOMY", 107, 117], ["follicular granulosa cells", "ANATOMY", 122, 148], ["cellular", "CELL", 7, 15], ["T-cell", "CELL", 23, 29], ["spleen", "ORGAN", 60, 66], ["spermatids", "CELLULAR_COMPONENT", 107, 117], ["follicular granulosa cells", "CELL", 122, 148], ["spermatids", "CELL_TYPE", 107, 117], ["follicular granulosa cells", "CELL_TYPE", 122, 148], ["T-cell activation", "PROBLEM", 23, 40], ["selective apoptosis", "PROBLEM", 74, 93], ["spermatids and follicular granulosa cells", "PROBLEM", 107, 148], ["-cell activation", "OBSERVATION", 24, 40], ["spleen", "ANATOMY", 60, 66], ["selective", "OBSERVATION_MODIFIER", 74, 83], ["apoptosis", "OBSERVATION", 84, 93], ["follicular granulosa cells", "OBSERVATION", 122, 148]]], ["Histological findings were massive in the testis and the ovary with macroscopic tissue shrinkage.", [["testis", "ANATOMY", 42, 48], ["ovary", "ANATOMY", 57, 62], ["tissue", "ANATOMY", 80, 86], ["testis", "ORGAN", 42, 48], ["ovary", "ORGAN", 57, 62], ["tissue", "TISSUE", 80, 86], ["massive in the testis", "PROBLEM", 27, 48], ["macroscopic tissue shrinkage", "PROBLEM", 68, 96], ["massive", "OBSERVATION", 27, 34], ["testis", "ANATOMY", 42, 48], ["ovary", "ANATOMY", 57, 62], ["macroscopic tissue shrinkage", "OBSERVATION", 68, 96]]], ["At the organism level, the presence of CLPP is a prerequisite for female and male fertility, corroborating the recent implication of CLPP in human Perrault syndrome.", [["CLPP", "CHEMICAL", 133, 137], ["Perrault syndrome", "DISEASE", 147, 164], ["CLPP", "GENE_OR_GENE_PRODUCT", 39, 43], ["CLPP", "GENE_OR_GENE_PRODUCT", 133, 137], ["human", "ORGANISM", 141, 146], ["CLPP", "PROTEIN", 39, 43], ["CLPP", "PROTEIN", 133, 137], ["human", "SPECIES", 141, 146], ["human", "SPECIES", 141, 146], ["CLPP", "PROBLEM", 39, 43], ["CLPP in human Perrault syndrome", "PROBLEM", 133, 164], ["CLPP", "OBSERVATION", 39, 43], ["CLPP", "OBSERVATION", 133, 137], ["human Perrault syndrome", "OBSERVATION", 141, 164]]], ["Additional age-associated phenotypes are apparent with severe growth retardation, as well as reductions of spontaneous activity and survival, contrasting with resistance to ulcerative dermatitis.", [["ulcerative", "ANATOMY", 173, 183], ["growth retardation", "DISEASE", 62, 80], ["ulcerative dermatitis", "DISEASE", 173, 194], ["associated phenotypes", "PROBLEM", 15, 36], ["severe growth retardation", "PROBLEM", 55, 80], ["survival", "TREATMENT", 132, 140], ["ulcerative dermatitis", "PROBLEM", 173, 194], ["phenotypes", "OBSERVATION", 26, 36], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["growth", "OBSERVATION_MODIFIER", 62, 68], ["retardation", "OBSERVATION", 69, 80], ["spontaneous activity", "OBSERVATION", 107, 127], ["ulcerative dermatitis", "OBSERVATION", 173, 194]]], ["Overall, we speculate that the degradation impairment in Clpp deletion constitutes a challenge to eukaryotic tolerance versus mitochondria and that sustained inflammation underlies the growth impairment.", [["mitochondria", "ANATOMY", 126, 138], ["Clpp", "CHEMICAL", 57, 61], ["inflammation", "DISEASE", 158, 170], ["growth impairment", "DISEASE", 185, 202], ["Clpp", "GENE_OR_GENE_PRODUCT", 57, 61], ["mitochondria", "CELLULAR_COMPONENT", 126, 138], ["Clpp deletion", "DNA", 57, 70], ["the degradation impairment", "PROBLEM", 27, 53], ["Clpp deletion", "PROBLEM", 57, 70], ["mitochondria", "PROBLEM", 126, 138], ["sustained inflammation", "PROBLEM", 148, 170], ["the growth impairment", "PROBLEM", 181, 202], ["sustained", "OBSERVATION_MODIFIER", 148, 157], ["inflammation", "OBSERVATION", 158, 170], ["growth impairment", "OBSERVATION", 185, 202]]], ["The deficit in reduction of mtDNA and mitochondrial numbers may underlie the infertility in the CLPP-variant of the recessive Perrault syndrome.", [["mitochondrial", "ANATOMY", 38, 51], ["infertility", "DISEASE", 77, 88], ["Perrault syndrome", "DISEASE", 126, 143], ["mtDNA", "CELLULAR_COMPONENT", 28, 33], ["mitochondrial", "CELLULAR_COMPONENT", 38, 51], ["The deficit", "PROBLEM", 0, 11], ["mtDNA", "PROBLEM", 28, 33], ["mitochondrial numbers", "TEST", 38, 59], ["the infertility", "PROBLEM", 73, 88], ["the CLPP", "PROBLEM", 92, 100], ["the recessive Perrault syndrome", "PROBLEM", 112, 143], ["deficit", "OBSERVATION", 4, 11], ["reduction", "OBSERVATION_MODIFIER", 15, 24], ["mitochondrial numbers", "OBSERVATION", 38, 59], ["infertility", "OBSERVATION", 77, 88], ["recessive", "OBSERVATION_MODIFIER", 116, 125], ["Perrault syndrome", "OBSERVATION", 126, 143]]], ["We are convinced that the CLPP null mouse constitutes a reasonably faithful disease model and a valuable tool.Generation of Clpp 2/2 mice by TIGM with GeneTrap technologyClpp +/2 male and female mice from the two different founder lines IST11134F10 (line F) and IST13563G11 (line G) in the inbred C57bl/6 genetic background with the inactivating Gene-Trap insertions (102) in intron 1 and 2, respectively, were purchased from the TIGM and bred to obtain Clpp 2/2 mice (Fig. 1A) .Generation of Clpp 2/2 mice by TIGM with GeneTrap technologyThe mouse genotyping was carried out using polymerase chain reactions (PCR) on tail biopsy DNA with the following primers: Clpp74F 5 \u2032 -GCTCTGTTGTCTCGCCTTG and Clpp277R 5 \u2032 -TGAAAGGTCATCCTCCCTTG to detect the WT locus of line F, Clpp700F 5 \u2032 -TCCCAGGCTGGCCTT-GAACTC and Clpp920R 5 \u2032 -GAGGCCCTGGGAACCAGGAA to detect the WT locus of line G, any combination of the primers located in the Omnibank gene-trap vector V76F 5 \u2032 -CTTGC AAAATGGCGTTACTTAAGC or V76R 5 \u2032 -CCAATAAA CCCTCTTGCAGTTGC with primers in Clpp to detect the mutant locus.Mouse breeding and dissectionMutant mice and littermate WT controls were bred from heterozygous matings and were maintained in individually ventilated cages with 12 h light cycle with food and water ad libitum.", [["tail biopsy", "ANATOMY", 618, 629], ["CLPP", "GENE_OR_GENE_PRODUCT", 26, 30], ["mouse", "ORGANISM", 36, 41], ["Clpp 2/2", "ORGANISM", 124, 132], ["mice", "ORGANISM", 133, 137], ["Clpp", "GENE_OR_GENE_PRODUCT", 170, 174], ["female mice", "ORGANISM", 188, 199], ["IST11134F10", "CELL", 237, 248], ["line F", "CELL", 250, 256], ["IST13563G11", "CELL", 262, 273], ["line G", "CELL", 275, 281], ["C57bl/6", "ORGANISM", 297, 304], ["mice", "ORGANISM", 463, 467], ["Clpp 2/2", "ORGANISM", 493, 501], ["mice", "ORGANISM", 502, 506], ["mouse", "ORGANISM", 543, 548], ["DNA", "CELLULAR_COMPONENT", 630, 633], ["Clpp74F", "GENE_OR_GENE_PRODUCT", 662, 669], ["Clpp920R 5 \u2032 -GAGGCCCTGGGAACCAGGAA", "GENE_OR_GENE_PRODUCT", 809, 843], ["line G", "GENE_OR_GENE_PRODUCT", 870, 876], ["Clpp", "GENE_OR_GENE_PRODUCT", 1040, 1044], ["Mouse", "ORGANISM", 1072, 1077], ["dissectionMutant mice", "ORGANISM", 1091, 1112], ["littermate WT controls", "ORGANISM", 1117, 1139], ["CLPP null mouse", "CELL_LINE", 26, 41], ["inactivating Gene", "DNA", 333, 350], ["Trap insertions", "DNA", 351, 366], ["intron 1", "DNA", 376, 384], ["tail biopsy DNA", "DNA", 618, 633], ["Clpp74F 5 \u2032 -GCTCTGTTGTCTCGCCTTG and Clpp277R 5", "DNA", 662, 709], ["WT locus", "DNA", 748, 756], ["WT locus", "DNA", 858, 866], ["Omnibank gene-trap vector", "DNA", 924, 949], ["Clpp", "DNA", 1040, 1044], ["mutant locus", "DNA", 1059, 1071], ["mouse", "SPECIES", 36, 41], ["mice", "SPECIES", 133, 137], ["mice", "SPECIES", 195, 199], ["mice", "SPECIES", 463, 467], ["mice", "SPECIES", 502, 506], ["mouse", "SPECIES", 543, 548], ["Mouse", "SPECIES", 1072, 1077], ["mice", "SPECIES", 1108, 1112], ["mouse", "SPECIES", 36, 41], ["mice", "SPECIES", 133, 137], ["mice", "SPECIES", 195, 199], ["mice", "SPECIES", 502, 506], ["mouse", "SPECIES", 543, 548], ["Mouse", "SPECIES", 1072, 1077], ["mice", "SPECIES", 1108, 1112], ["the CLPP null mouse", "PROBLEM", 22, 41], ["Clpp", "TEST", 124, 128], ["GeneTrap technology", "TREATMENT", 151, 170], ["Clpp", "PROBLEM", 170, 174], ["the inbred C57bl/6 genetic background", "TREATMENT", 286, 323], ["the inactivating Gene-Trap insertions", "TREATMENT", 329, 366], ["Clpp", "TEST", 454, 458], ["Clpp", "TEST", 493, 497], ["GeneTrap technology", "TREATMENT", 520, 539], ["The mouse genotyping", "TREATMENT", 539, 559], ["polymerase chain reactions", "PROBLEM", 582, 608], ["tail biopsy DNA", "TEST", 618, 633], ["Clpp74F", "TEST", 662, 669], ["Clpp277R", "TEST", 699, 707], ["Clpp700F", "TEST", 768, 776], ["-TCCCAGGCTGGCCTT-GAACTC", "TEST", 781, 804], ["Clpp920R", "TEST", 809, 817], ["line G", "TREATMENT", 870, 876], ["the primers", "TREATMENT", 897, 908], ["AAAATGGCGTTACTTAAGC", "TEST", 966, 985], ["the mutant locus", "PROBLEM", 1055, 1071], ["Mouse breeding", "TREATMENT", 1072, 1086], ["dissectionMutant mice", "TREATMENT", 1091, 1112], ["littermate WT controls", "TREATMENT", 1117, 1139], ["heterozygous matings", "PROBLEM", 1155, 1175], ["ventilated cages", "TREATMENT", 1212, 1228], ["null mouse", "OBSERVATION", 31, 41], ["faithful disease", "OBSERVATION", 67, 83]]], ["Sentinel animals and regular health monitoring including blood tests for viral and parasite infections uncovered no pathology.", [["blood", "ANATOMY", 57, 62], ["viral and parasite infections", "DISEASE", 73, 102], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["Sentinel animals", "TEST", 0, 16], ["regular health monitoring", "TEST", 21, 46], ["blood tests", "TEST", 57, 68], ["viral and parasite infections", "PROBLEM", 73, 102], ["pathology", "PROBLEM", 116, 125], ["parasite infections", "OBSERVATION", 83, 102]]], ["After decapitation, the organs were removed and immediately frozen in liquid nitrogen or fixed for histological and ultrastructural analyses or processed for mitochondrial isolation.Quantitative real-time reverse transcription PCRIsolation of total RNA was performed with Trizol (Gibco), DNase treatment of RNA with DNAse Amplification Grade (Invitrogen) and reverse transcription with SuperScript III (Invitrogen), always following the instructions of the manufacturers.Quantitative real-time reverse transcription PCRqPCR was performed with Expression Assays (Applied Biosystems) in cDNA from 20 ng total RNA in 20 ml reactions with 2\u00d7 master mix from Roche in a StepOnePlus Real-Time PCR System (Applied Biosystems).", [["organs", "ANATOMY", 24, 30], ["mitochondrial", "ANATOMY", 158, 171], ["nitrogen", "CHEMICAL", 77, 85], ["organs", "ORGAN", 24, 30], ["mitochondrial", "CELLULAR_COMPONENT", 158, 171], ["DNase", "GENE_OR_GENE_PRODUCT", 288, 293], ["DNase", "PROTEIN", 288, 293], ["DNAse", "PROTEIN", 316, 321], ["SuperScript III", "DNA", 386, 401], ["cDNA", "DNA", 585, 589], ["liquid nitrogen", "TREATMENT", 70, 85], ["histological and ultrastructural analyses", "TEST", 99, 140], ["mitochondrial isolation", "TREATMENT", 158, 181], ["total RNA", "TREATMENT", 243, 252], ["Trizol (Gibco)", "TREATMENT", 272, 286], ["DNase treatment of RNA", "TREATMENT", 288, 310], ["DNAse Amplification Grade (Invitrogen)", "TREATMENT", 316, 354], ["SuperScript III (Invitrogen)", "TREATMENT", 386, 414], ["Expression Assays", "TEST", 543, 560], ["organs", "ANATOMY", 24, 30]]], ["The analysis of the data was carried out with the 2 2DDCT method (103).Quantitative real-time reverse transcription PCRReal-time PCR of two Clpp transcript assays and of Gapdh as housekeeping normalizer were performed, the products separated in 2% agarose gels and visualized with ethidium bromide, to assess the null mutation in brain tissue (Fig. 1B) .Quantitative immunoblotsFrozen tissues were homogenized on ice in a glass-Teflon douncer in RIPA buffer with 50 mM Tris -HCl (pH 8), 150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS and protease inhibitor cocktail (Roche).", [["brain tissue", "ANATOMY", 330, 342], ["Frozen tissues", "ANATOMY", 378, 392], ["ethidium bromide", "CHEMICAL", 281, 297], ["Tris -HCl", "CHEMICAL", 469, 478], ["NaCl", "CHEMICAL", 494, 498], ["NP-40", "CHEMICAL", 503, 508], ["Na-deoxycholate", "CHEMICAL", 515, 530], ["ethidium bromide", "CHEMICAL", 281, 297], ["Tris -HCl", "CHEMICAL", 469, 478], ["NaCl", "CHEMICAL", 494, 498], ["Na-deoxycholate", "CHEMICAL", 515, 530], ["SDS", "CHEMICAL", 537, 540], ["Clpp", "GENE_OR_GENE_PRODUCT", 140, 144], ["Gapdh", "GENE_OR_GENE_PRODUCT", 170, 175], ["ethidium bromide", "SIMPLE_CHEMICAL", 281, 297], ["brain tissue", "TISSUE", 330, 342], ["Frozen tissues", "TISSUE", 378, 392], ["Tris -HCl", "SIMPLE_CHEMICAL", 469, 478], ["NP-40", "SIMPLE_CHEMICAL", 503, 508], ["Na-deoxycholate", "SIMPLE_CHEMICAL", 515, 530], ["Gapdh", "PROTEIN", 170, 175], ["The analysis", "TEST", 0, 12], ["the data", "TEST", 16, 24], ["PCR", "TEST", 129, 132], ["two Clpp transcript assays", "TEST", 136, 162], ["Gapdh", "TEST", 170, 175], ["the products", "TREATMENT", 219, 231], ["2% agarose gels", "TREATMENT", 245, 260], ["ethidium bromide", "TREATMENT", 281, 297], ["the null mutation in brain tissue", "PROBLEM", 309, 342], ["Quantitative immunoblotsFrozen tissues", "PROBLEM", 354, 392], ["Teflon douncer in RIPA buffer", "TREATMENT", 428, 457], ["pH", "TEST", 480, 482], ["NaCl", "TEST", 494, 498], ["Na-deoxycholate", "TREATMENT", 515, 530], ["protease inhibitor cocktail", "TREATMENT", 545, 572], ["null mutation", "OBSERVATION", 313, 326], ["brain tissue", "ANATOMY", 330, 342], ["Frozen tissues", "OBSERVATION", 378, 392]]], ["Total lysates were briefly sonicated on ice, and cell debris was removed by centrifugation.", [["lysates", "ANATOMY", 6, 13], ["cell", "ANATOMY", 49, 53], ["lysates", "ORGANISM_SUBSTANCE", 6, 13], ["cell", "CELL", 49, 53], ["Total lysates", "TREATMENT", 0, 13], ["ice", "TREATMENT", 40, 43], ["cell debris", "PROBLEM", 49, 60], ["cell debris", "OBSERVATION", 49, 60]]], ["Protein concentration was determined according to the method of Bradford.", [["Protein concentration", "TEST", 0, 21]]], ["SDS -PAGE-separated proteins (20 mg/lane) were blotted onto a PVDF membrane (Bio-Rad) and probed with the specific primary antibodies (see Table 1 ) overnight followed by the incubation with the adequate secondary antibody (GE Healthcare UK Limited, anti-mouse IgG NA931V, antirabbit IgG NA934V) for 1 h.", [["PVDF membrane", "ANATOMY", 62, 75], ["PVDF", "CHEMICAL", 62, 66], ["membrane", "CELLULAR_COMPONENT", 67, 75], ["primary antibodies", "PROTEIN", 115, 133], ["secondary antibody", "PROTEIN", 204, 222], ["GE Healthcare UK Limited, anti-mouse IgG NA931V", "PROTEIN", 224, 271], ["antirabbit IgG NA934V", "PROTEIN", 273, 294], ["anti-mouse", "SPECIES", 250, 260], ["SDS", "TEST", 0, 3], ["a PVDF membrane", "TREATMENT", 60, 75], ["anti-mouse IgG NA931V", "TREATMENT", 250, 271], ["antirabbit IgG NA934V", "TREATMENT", 273, 294]]], ["OPA1 proteolytic processing was assessed by calculating the ratio of long isoforms L1 + L2 versus the short isoforms S3 + S4 + S5, using a previously published antibody (104) .Statistical analysisQuantitative fertility, motor behavior and gene dosage data were analyzed with the GraphPad software and illustrated in bar graphs, showing variance with standard error and P-values from Student's t-test ( * P , 0.05; * * P , 0.01; * * * P , 0.001).Genome-wide mRNA profilingFor expression profiling, 100 ng of total RNA was linearly amplified and biotinylated using the GeneChip HT 3 \u2032 IVT Express Kit (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's instructions.", [["OPA1", "GENE_OR_GENE_PRODUCT", 0, 4], ["OPA1", "PROTEIN", 0, 4], ["L1", "PROTEIN", 83, 85], ["L2", "PROTEIN", 88, 90], ["S3", "PROTEIN", 117, 119], ["S4", "PROTEIN", 122, 124], ["S5", "PROTEIN", 127, 129], ["OPA1 proteolytic processing", "PROBLEM", 0, 27], ["a previously published antibody", "TEST", 137, 168], ["Statistical analysisQuantitative fertility", "PROBLEM", 176, 218], ["gene dosage data", "TEST", 239, 255], ["the GraphPad software", "TEST", 275, 296], ["Student's t-test", "TEST", 383, 399], ["P", "TEST", 404, 405], ["P", "TEST", 418, 419], ["P", "TEST", 434, 435], ["expression profiling", "TEST", 475, 495], ["total RNA", "TREATMENT", 507, 516], ["the GeneChip HT", "TREATMENT", 563, 578], ["L2", "ANATOMY_MODIFIER", 88, 90], ["S4", "ANATOMY", 122, 124], ["S5", "ANATOMY", 127, 129]]], ["Fifteen micrograms of labeled and fragmented cRNA was hybridized onto GeneChip HT MG-430 PM Array Plates (Affymetrix).", [["Fifteen micrograms of labeled and fragmented cRNA", "TREATMENT", 0, 49], ["GeneChip HT MG", "TREATMENT", 70, 84], ["PM Array Plates (Affymetrix)", "TREATMENT", 89, 117]]], ["Hybridization, washing, staining and scanning were performed automatically in a GeneTitan instrument (Affymetrix).", [["Hybridization", "TREATMENT", 0, 13], ["scanning", "TEST", 37, 45], ["a GeneTitan instrument (Affymetrix", "TREATMENT", 78, 112]]], ["Scanned images were subjected to visual inspection to control for hybridization artifacts and proper grid alignment and analyzed with AGCC 3.0 (Affymetrix) to generate CEL files.Genome-wide mRNA profilingAll subsequent data analysis steps were performed on the software platform R 2.14.0 and Bioconductor 2.14.0 (105) .", [["AGCC 3.0", "DNA", 134, 142], ["Scanned images", "TEST", 0, 14], ["visual inspection", "TEST", 33, 50], ["hybridization artifacts", "PROBLEM", 66, 89], ["proper grid alignment", "TEST", 94, 115], ["AGCC", "TEST", 134, 138], ["All subsequent data analysis steps", "TEST", 204, 238], ["the software platform R", "TEST", 257, 280], ["Bioconductor", "TEST", 292, 304]]], ["Initially, the expression data from all chips were background corrected, quantile normalized and summarized with Robust Multichip Average (106) .", [["all chips", "TEST", 36, 45]]], ["Owing to the design of the experiment, two parameters (strain and tissue) have an impact on gene expression.", [["tissue", "ANATOMY", 66, 72], ["tissue", "TISSUE", 66, 72]]], ["Thus, a combined factor from both parameters was used to design a linear model that captures the influence on gene expression levels.", [["a linear model", "TREATMENT", 64, 78], ["gene expression levels", "TEST", 110, 132]]], ["Comparisons of CLPP homozygous null ( 2/2 ) and corresponding WT samples were defined as contrasts and the linear model coefficients were estimated.", [["samples", "ANATOMY", 65, 72], ["CLPP", "GENE_OR_GENE_PRODUCT", 15, 19], ["CLPP", "PROTEIN", 15, 19], ["CLPP homozygous null", "TEST", 15, 35], ["corresponding WT samples", "TEST", 48, 72], ["homozygous null", "OBSERVATION", 20, 35]]], ["A non-specific filter based on overall variance was applied to remove noninformative features before the fitting of the linear model was performed.", [["A non-specific filter", "TREATMENT", 0, 21], ["the linear model", "TEST", 116, 132], ["non-specific", "OBSERVATION_MODIFIER", 2, 14], ["filter", "OBSERVATION", 15, 21]]], ["Empirical Bayes shrinkage of the standard errors was used to calculate the moderated F-statistic (107) .", [["Empirical Bayes shrinkage", "TREATMENT", 0, 25], ["the standard errors", "TREATMENT", 29, 48]]], ["The resulting P-values were established and corrected for multiple testing with 'Benjamini-Hochberg' (108) .", [["P", "DNA", 14, 15], ["The resulting P-values", "TEST", 0, 22], ["multiple testing", "TEST", 58, 74]]], ["To attribute significant regulations to individual contrasts, a decision matrix was generated based on the function 'decide tests' within the limma package, where significant up-or down-regulations are represented by values of 1 or 21, respectively.", [["a decision matrix", "TREATMENT", 62, 79], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["significant", "OBSERVATION_MODIFIER", 163, 174]]], ["The lists of differentially regulated transcripts were analyzed for over-representation of gene ontology terms and KEGG pathways, respectively, using the hypergeometric test.Genome-wide mRNA profilingAll transcriptome data were deposited in a public database and are accessible at http://www.ncbi.nlm.nih.gov/geo/query/acc. cgi?acc=GSE40207, last accessed on 17 July 2013.Genome-wide mRNA profilingmtDNA quantification mtDNA and nuclear DNA copy number were determined by qPCR of the mitochondrial Cox3 gene and the nuclear Ndufv1 gene, respectively.", [["nuclear", "ANATOMY", 429, 436], ["mitochondrial", "ANATOMY", 484, 497], ["nuclear", "ANATOMY", 516, 523], ["mtDNA", "CELLULAR_COMPONENT", 419, 424], ["nuclear", "CELLULAR_COMPONENT", 429, 436], ["DNA", "CELLULAR_COMPONENT", 437, 440], ["mitochondrial", "CELLULAR_COMPONENT", 484, 497], ["Cox3", "GENE_OR_GENE_PRODUCT", 498, 502], ["nuclear", "CELLULAR_COMPONENT", 516, 523], ["Ndufv1", "GENE_OR_GENE_PRODUCT", 524, 530], ["mitochondrial Cox3 gene", "DNA", 484, 507], ["nuclear Ndufv1 gene", "DNA", 516, 535], ["the hypergeometric test", "TEST", 150, 173], ["nuclear DNA copy number", "TEST", 429, 452]]], ["For amplification of the mitochondrial Cox3 fragment, we used the following primers: Cox3-fwd 5 \u2032 -TTTGCAGGATTCTTCTGAGC and Cox3-rev 5 \u2032 -TGAG CTCATGTAATTGAAACACC.", [["mitochondrial", "ANATOMY", 25, 38], ["mitochondrial", "CELLULAR_COMPONENT", 25, 38], ["Cox3", "GENE_OR_GENE_PRODUCT", 39, 43], ["mitochondrial Cox3 fragment", "DNA", 25, 52], ["Cox3-rev 5 \u2032 -TGAG CTCATGTAATTGAAACACC", "DNA", 124, 162], ["the mitochondrial Cox3 fragment", "PROBLEM", 21, 52], ["Cox3-", "TEST", 85, 90], ["TTTGCAGGATTCTTCTGAGC", "TEST", 99, 119], ["Cox3-rev", "TEST", 124, 132], ["mitochondrial", "OBSERVATION", 25, 38], ["Cox3 fragment", "OBSERVATION", 39, 52]]], ["Primer pairs for Ndufv1 were according to a previous publication (109) .", [["Ndufv1", "GENE_OR_GENE_PRODUCT", 17, 23], ["Primer pairs", "DNA", 0, 12], ["Ndufv1", "DNA", 17, 23], ["Ndufv1", "PROBLEM", 17, 23]]], ["The qPCR reaction was initiated by 508C for 2 min and then 948C for 10 min, followed by 40 cycles of 958C for 10 s, 608C for 60 s, and a final melting curve ranging from 858C to 658C was done.", [["508C", "CHEMICAL", 35, 39], ["948C", "CHEMICAL", 59, 63], ["958C", "CHEMICAL", 101, 105], ["608C", "CHEMICAL", 116, 120], ["The qPCR reaction", "TEST", 0, 17], ["a final melting curve", "TEST", 135, 156]]], ["All reactions were run in quadruplicates using a StepOnePlus real-time PCR equipment (Applied Biosystems) and SYBR Green technology.", [["All reactions", "PROBLEM", 0, 13], ["a StepOnePlus real-time PCR equipment", "TREATMENT", 47, 84]]], ["The relative amount of mtDNA to nuclear genome was calculated using the 2 2DDCt method (103).Survival curveAge at natural death was documented for each animal.", [["nuclear genome", "ANATOMY", 32, 46], ["death", "DISEASE", 122, 127], ["mtDNA", "CELLULAR_COMPONENT", 23, 28], ["nuclear", "CELLULAR_COMPONENT", 32, 39], ["nuclear genome", "DNA", 32, 46], ["the 2 2DDCt method", "TREATMENT", 68, 86], ["Survival curveAge at natural death", "PROBLEM", 93, 127], ["amount", "OBSERVATION_MODIFIER", 13, 19], ["mtDNA", "OBSERVATION_MODIFIER", 23, 28], ["nuclear genome", "OBSERVATION", 32, 46]]], ["The number of mice analyzed was 69 for WT and 79 for Clpp 2/2 (both lines together).", [["mice", "ORGANISM", 14, 18], ["Clpp 2/2", "GENE_OR_GENE_PRODUCT", 53, 61], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["WT", "TEST", 39, 41], ["Clpp", "TEST", 53, 57]]], ["For statistical analysis, the IBM SPSS Statistics software package (19.0.0.) was used and Kaplan-Meier survival estimates generated, taking into account that currently a large number of mice is still alive.", [["mice", "ORGANISM", 186, 190], ["mice", "SPECIES", 186, 190], ["mice", "SPECIES", 186, 190], ["statistical analysis", "TEST", 4, 24], ["large", "OBSERVATION_MODIFIER", 170, 175]]], ["Significance was determined with pairwise comparisons (Log rank, Breslow and Tarone-Ware).Body weight and lengthMutant animals and matched controls were weighed at regular intervals.", [["Body", "ANATOMY", 90, 94], ["Body", "ORGANISM_SUBDIVISION", 90, 94], ["Body weight", "TEST", 90, 101], ["lengthMutant animals", "TREATMENT", 106, 126]]], ["The body length was recorded in parallel for matched pairs in manually immobilized and extended animals from the nose to the anus.Motor activityAcoustic startle Maximal amplitude (V max ) of locomotor responses within a time lag window (50 -110 ms) after burst tones interrupting white noise at varying time intervals, ranging in loudness between 90 and 120 dB were recorded by accelerometer within an SR-Lab Startle Reflex System (San Diego Instruments) as previously published (51) .Open fieldSpontaneous motor activity of naive mice was automatically recorded in equipment with Versamax monitors from Accuscan (Columbus) over 5 min sessions.RotarodInduced motor activity of naive mice was studied on Accelerod equipment (Ugo Basile) over 10 min, recording the latency until falling/jumping off or the latency until two consecutive rides around hanging onto the beam (110) .MEFsGeneration, culture, mitochondrial dynamics: mouse embryonic fibroblasts (MEFs) were prepared from individual embryos at 14.5 days post-coitus following intercrosses of Clpp +/2 mice.", [["body", "ANATOMY", 4, 8], ["nose", "ANATOMY", 113, 117], ["anus", "ANATOMY", 125, 129], ["mitochondrial", "ANATOMY", 901, 914], ["embryonic fibroblasts", "ANATOMY", 931, 952], ["MEFs", "ANATOMY", 954, 958], ["embryos", "ANATOMY", 990, 997], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["nose", "ORGANISM_SUBDIVISION", 113, 117], ["anus", "ORGAN", 125, 129], ["mice", "ORGANISM", 531, 535], ["mice", "ORGANISM", 683, 687], ["mitochondrial", "CELLULAR_COMPONENT", 901, 914], ["mouse", "ORGANISM", 925, 930], ["embryonic fibroblasts", "CELL", 931, 952], ["MEFs", "CELL", 954, 958], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 990, 997], ["mice", "ORGANISM", 1058, 1062], ["mouse embryonic fibroblasts", "CELL_TYPE", 925, 952], ["MEFs", "CELL_TYPE", 954, 958], ["mice", "SPECIES", 531, 535], ["mice", "SPECIES", 683, 687], ["mouse", "SPECIES", 925, 930], ["mice", "SPECIES", 1058, 1062], ["mice", "SPECIES", 531, 535], ["mice", "SPECIES", 683, 687], ["mouse", "SPECIES", 925, 930], ["The body length", "TEST", 0, 15], ["Acoustic startle", "TEST", 144, 160], ["locomotor responses", "TEST", 191, 210], ["lag window", "TEST", 225, 235], ["burst tones interrupting white noise", "PROBLEM", 255, 291], ["Versamax monitors", "TREATMENT", 581, 598], ["the latency", "PROBLEM", 800, 811], ["MEFsGeneration", "TEST", 876, 890], ["culture", "TEST", 892, 899], ["mouse embryonic fibroblasts", "PROBLEM", 925, 952], ["Clpp", "TEST", 1049, 1053], ["body", "OBSERVATION_MODIFIER", 4, 8], ["length", "OBSERVATION_MODIFIER", 9, 15], ["nose", "ANATOMY", 113, 117], ["anus", "ANATOMY", 125, 129], ["field", "OBSERVATION_MODIFIER", 490, 495], ["Spontaneous", "OBSERVATION_MODIFIER", 495, 506], ["motor activity", "OBSERVATION", 507, 521], ["embryonic fibroblasts", "OBSERVATION", 931, 952]]], ["MEFs were maintained in Dulbecco's minimal essential medium 4.5 g/l glucose (Invitrogen, Karlsruhe) supplemented with 15% bovine growth serum (BGS, Thermo Scientific, Schwerte, Germany), l% glutamine, 1% penicillin and streptomycin (all Invitrogen, Karlsruhe) at 378C and 5% CO 2 in a humidified incubator.Growth curveThree WT MEF lines and three Clpp 2/2 MEF lines were cultivated as described above in flasks coated with 0.2% gelatin at 378C.", [["MEFs", "ANATOMY", 0, 4], ["serum", "ANATOMY", 136, 141], ["MEF lines", "ANATOMY", 327, 336], ["MEF lines", "ANATOMY", 356, 365], ["glucose", "CHEMICAL", 68, 75], ["glutamine", "CHEMICAL", 190, 199], ["penicillin", "CHEMICAL", 204, 214], ["streptomycin", "CHEMICAL", 219, 231], ["378C", "CHEMICAL", 439, 443], ["glucose", "CHEMICAL", 68, 75], ["glutamine", "CHEMICAL", 190, 199], ["penicillin", "CHEMICAL", 204, 214], ["streptomycin", "CHEMICAL", 219, 231], ["CO 2", "CHEMICAL", 275, 279], ["MEFs", "CELL", 0, 4], ["glucose", "SIMPLE_CHEMICAL", 68, 75], ["bovine", "ORGANISM", 122, 128], ["serum", "ORGANISM_SUBSTANCE", 136, 141], ["glutamine", "SIMPLE_CHEMICAL", 190, 199], ["penicillin", "SIMPLE_CHEMICAL", 204, 214], ["streptomycin", "SIMPLE_CHEMICAL", 219, 231], ["MEF lines", "CELL", 327, 336], ["Clpp 2/2 MEF lines", "CELL", 347, 365], ["gelatin", "SIMPLE_CHEMICAL", 428, 435], ["curveThree WT MEF lines", "CELL_LINE", 313, 336], ["Clpp 2/2 MEF lines", "CELL_LINE", 347, 365], ["bovine", "SPECIES", 122, 128], ["bovine", "SPECIES", 122, 128], ["MEFs", "TEST", 0, 4], ["Dulbecco", "TEST", 24, 32], ["glucose (Invitrogen, Karlsruhe)", "TREATMENT", 68, 99], ["BGS", "TEST", 143, 146], ["l% glutamine", "TREATMENT", 187, 199], ["1% penicillin", "TREATMENT", 201, 214], ["streptomycin", "TREATMENT", 219, 231], ["a humidified incubator", "TREATMENT", 283, 305], ["Growth curveThree WT MEF lines", "TREATMENT", 306, 336], ["three Clpp 2/2 MEF lines", "TREATMENT", 341, 365], ["0.2% gelatin", "TREATMENT", 423, 435], ["MEF lines", "OBSERVATION", 327, 336], ["MEF lines", "OBSERVATION", 356, 365]]], ["Population densities (PDs) were determined by the following equation: PD \u00bc 3.32 \u00d7 (log10 UCY 2 log10 I) + X (where UCY is the number of cells at the end of the passage; I is the number of cells that were seeded at the beginning of the passage and X the previous PD number.Growth curveMitochondrial morphology was analyzed by Mitotracker Red CMX ROS staining (MTR, Invitrogen).", [["cells", "ANATOMY", 136, 141], ["cells", "ANATOMY", 188, 193], ["cells", "CELL", 136, 141], ["cells", "CELL", 188, 193], ["Mitotracker Red CMX", "SIMPLE_CHEMICAL", 325, 344], ["ROS", "SIMPLE_CHEMICAL", 345, 348], ["MTR", "SIMPLE_CHEMICAL", 359, 362], ["MTR", "PROTEIN", 359, 362], ["Population densities (PDs)", "PROBLEM", 0, 26], ["PD", "TEST", 70, 72], ["UCY", "TEST", 89, 92], ["UCY", "TEST", 115, 118], ["Growth curveMitochondrial morphology", "TEST", 272, 308], ["Red CMX ROS staining", "TEST", 337, 357], ["MTR", "TEST", 359, 362], ["Invitrogen", "TEST", 364, 374], ["densities", "OBSERVATION", 11, 20]]], ["150 000 cells were seeded onto 24 mm cover slips coated with 0.2% gelatin.", [["cells", "ANATOMY", 8, 13], ["gelatin", "CHEMICAL", 66, 73], ["cells", "CELL", 8, 13], ["0.2% gelatin", "TREATMENT", 61, 73]]], ["After 24 h or 48 h the cells were incubated for 1 h with MTR (final concentration 50 nM).", [["cells", "ANATOMY", 23, 28], ["MTR", "CHEMICAL", 57, 60], ["cells", "CELL", 23, 28], ["MTR", "SIMPLE_CHEMICAL", 57, 60]]], ["Cells were then fixed with 4% paraformaldehyde and embedded in Dako Fluorescent Mounting Medium.", [["Cells", "ANATOMY", 0, 5], ["paraformaldehyde", "CHEMICAL", 30, 46], ["Cells", "CELL", 0, 5], ["paraformaldehyde", "SIMPLE_CHEMICAL", 30, 46], ["4% paraformaldehyde", "TREATMENT", 27, 46]]], ["Mitochondria were visualized by using a Leica TCS SP5 confocal laser scanning microscope at the appropriate spectral settings and equipped with an HCX PL APO lambda blue 63.0\u00d7, 1.40 OIL UV objective that was controlled by the LAS AF scan software (version 1.8.2, Leica).Light microscopyAfter removal of skeletal muscle and testis, tissue samples were immediately frozen in liquid nitrogen.", [["Mitochondria", "ANATOMY", 0, 12], ["skeletal muscle", "ANATOMY", 303, 318], ["testis", "ANATOMY", 323, 329], ["tissue samples", "ANATOMY", 331, 345], ["nitrogen", "CHEMICAL", 380, 388], ["Mitochondria", "CELLULAR_COMPONENT", 0, 12], ["skeletal muscle", "TISSUE", 303, 318], ["testis", "ORGAN", 323, 329], ["tissue samples", "TISSUE", 331, 345], ["a Leica TCS", "TEST", 38, 49], ["an HCX PL APO lambda blue", "TEST", 144, 169], ["OIL UV objective", "TEST", 182, 198], ["the LAS AF scan software", "TEST", 222, 246], ["version", "TEST", 248, 255], ["Light microscopyAfter removal", "TREATMENT", 270, 299], ["tissue samples", "TEST", 331, 345], ["liquid nitrogen", "TREATMENT", 373, 388], ["skeletal muscle", "ANATOMY", 303, 318], ["testis", "ANATOMY", 323, 329]]], ["Sections of 10 mm thickness were cut using a microtome and mounted on Super Frost Plus slides (Microm International, Walldorf, Germany).", [["a microtome", "TREATMENT", 43, 54], ["10 mm", "OBSERVATION_MODIFIER", 12, 17]]], ["Sections were dried and stained for H and E, NADH, COX and SDH according to standard protocols.", [["NADH", "CHEMICAL", 45, 49], ["E", "SIMPLE_CHEMICAL", 42, 43], ["NADH", "SIMPLE_CHEMICAL", 45, 49], ["COX", "GENE_OR_GENE_PRODUCT", 51, 54], ["SDH", "SIMPLE_CHEMICAL", 59, 62], ["NADH", "PROTEIN", 45, 49], ["COX", "PROTEIN", 51, 54], ["SDH", "PROTEIN", 59, 62], ["NADH", "PROBLEM", 45, 49], ["COX", "PROBLEM", 51, 54], ["SDH", "PROBLEM", 59, 62], ["standard protocols", "TREATMENT", 76, 94]]], ["Additionally, heart and skeletal muscles, testes and ovaries were fixed in buffered formalin (4% formaldehyde; pH 7.4), embedded in paraffin, cut at 4 mm and stained for H and E.Electron microscopySkeletal muscle and testis tissue samples were fixed for 2 h using 2.5% glutaraldehyde buffered in cacodylate buffer.", [["heart", "ANATOMY", 14, 19], ["skeletal muscles", "ANATOMY", 24, 40], ["testes", "ANATOMY", 42, 48], ["ovaries", "ANATOMY", 53, 60], ["Skeletal muscle", "ANATOMY", 197, 212], ["testis tissue samples", "ANATOMY", 217, 238], ["formalin", "CHEMICAL", 84, 92], ["formaldehyde", "CHEMICAL", 97, 109], ["glutaraldehyde", "CHEMICAL", 269, 283], ["formalin", "CHEMICAL", 84, 92], ["formaldehyde", "CHEMICAL", 97, 109], ["paraffin", "CHEMICAL", 132, 140], ["glutaraldehyde", "CHEMICAL", 269, 283], ["cacodylate", "CHEMICAL", 296, 306], ["heart", "ORGAN", 14, 19], ["skeletal muscles", "TISSUE", 24, 40], ["testes", "ORGAN", 42, 48], ["ovaries", "ORGAN", 53, 60], ["formalin", "SIMPLE_CHEMICAL", 84, 92], ["formaldehyde", "SIMPLE_CHEMICAL", 97, 109], ["Skeletal muscle", "TISSUE", 197, 212], ["testis tissue samples", "TISSUE", 217, 238], ["glutaraldehyde", "SIMPLE_CHEMICAL", 269, 283], ["pH", "TEST", 111, 113], ["E.Electron microscopy", "TEST", 176, 197], ["2.5% glutaraldehyde buffered in cacodylate buffer", "TREATMENT", 264, 313], ["heart", "ANATOMY", 14, 19], ["skeletal muscles", "ANATOMY", 24, 40], ["testes", "ANATOMY", 42, 48], ["ovaries", "ANATOMY", 53, 60], ["muscle", "ANATOMY", 206, 212], ["testis", "ANATOMY", 217, 223]]], ["The embedding procedure comprised fixation in 1% osmium tetroxide, dehydration in a graded ethanol series intermingled by an incubation step with uranyl acetate (between the 50 and 90% ethanol step) and finally rinsing in propylene oxide.", [["osmium tetroxide", "CHEMICAL", 49, 65], ["dehydration", "DISEASE", 67, 78], ["ethanol", "CHEMICAL", 91, 98], ["uranyl acetate", "CHEMICAL", 146, 160], ["ethanol", "CHEMICAL", 185, 192], ["propylene oxide", "CHEMICAL", 222, 237], ["osmium tetroxide", "CHEMICAL", 49, 65], ["ethanol", "CHEMICAL", 91, 98], ["uranyl acetate", "CHEMICAL", 146, 160], ["ethanol", "CHEMICAL", 185, 192], ["propylene oxide", "CHEMICAL", 222, 237], ["osmium tetroxide", "SIMPLE_CHEMICAL", 49, 65], ["ethanol", "SIMPLE_CHEMICAL", 91, 98], ["uranyl acetate", "SIMPLE_CHEMICAL", 146, 160], ["ethanol", "SIMPLE_CHEMICAL", 185, 192], ["propylene oxide", "SIMPLE_CHEMICAL", 222, 237], ["The embedding procedure", "TREATMENT", 0, 23], ["fixation", "TREATMENT", 34, 42], ["1% osmium tetroxide", "TREATMENT", 46, 65], ["dehydration", "PROBLEM", 67, 78], ["a graded ethanol series", "TREATMENT", 82, 105], ["uranyl acetate", "TREATMENT", 146, 160], ["finally rinsing in propylene oxide", "TREATMENT", 203, 237]]], ["The specimens were then embedded in epoxy resins that polymerized for 16 h at 608C.", [["specimens", "ANATOMY", 4, 13], ["epoxy", "CHEMICAL", 36, 41], ["specimens", "CELL", 4, 13], ["epoxy resins", "TREATMENT", 36, 48], ["epoxy resins", "OBSERVATION", 36, 48]]], ["After embedding, first semithin sections (0.5 mm) were cut using an ultramicrotome (Leica Ultracut UCT, Deerfield, IL, USA) with a diamond knife.", [["sections", "ANATOMY", 32, 40], ["semithin sections", "MULTI-TISSUE_STRUCTURE", 23, 40], ["first semithin sections", "TREATMENT", 17, 40], ["a diamond knife", "TREATMENT", 129, 144]]], ["Sections were stained with toluidine blue, placed on glass slides and examined by light microscopy to select appropriate areas for ultrathin preparation.", [["toluidine blue", "CHEMICAL", 27, 41], ["toluidine blue", "CHEMICAL", 27, 41], ["toluidine blue", "SIMPLE_CHEMICAL", 27, 41], ["toluidine blue", "TREATMENT", 27, 41], ["light microscopy", "TEST", 82, 98], ["ultrathin preparation", "TREATMENT", 131, 152]]], ["Ultrathin sections (50 -70 nm) were cut again using an ultramicrotome.", [["sections", "ANATOMY", 10, 18], ["Ultrathin sections", "TEST", 0, 18], ["an ultramicrotome", "TREATMENT", 52, 69]]], ["Sections were mounted on copper grids and contrasted with uranyl acetate for 2 -3 h at 428C and lead citrate for 20 min at room temperature.", [["copper", "CHEMICAL", 25, 31], ["uranyl acetate", "CHEMICAL", 58, 72], ["citrate", "CHEMICAL", 101, 108], ["copper", "CHEMICAL", 25, 31], ["uranyl acetate", "CHEMICAL", 58, 72], ["citrate", "CHEMICAL", 101, 108], ["uranyl acetate", "SIMPLE_CHEMICAL", 58, 72], ["428C", "SIMPLE_CHEMICAL", 87, 91], ["citrate", "SIMPLE_CHEMICAL", 101, 108], ["copper grids", "TEST", 25, 37], ["uranyl acetate", "TREATMENT", 58, 72], ["lead citrate", "TREATMENT", 96, 108]]], ["These samples were imaged and digital pictures were taken with a FEI Tecnai G2 Spirit Biotwin TEM (Hillsboro, OR, USA) at an operating voltage of 120 kV.Preparation of mitochondriaMouse heart mitochondria (MHM) and mouse liver mitochondria (MLM) were isolated following the protocol developed for rat heart mitochondria (111) with the modification that all buffer volumes and the trypsin and trypsin inhibitor quantities were halved.", [["samples", "ANATOMY", 6, 13], ["heart mitochondria", "ANATOMY", 186, 204], ["MHM", "ANATOMY", 206, 209], ["liver mitochondria", "ANATOMY", 221, 239], ["heart mitochondria", "ANATOMY", 301, 319], ["heart mitochondria", "MULTI-TISSUE_STRUCTURE", 186, 204], ["MHM", "MULTI-TISSUE_STRUCTURE", 206, 209], ["mouse", "ORGANISM", 215, 220], ["liver mitochondria", "MULTI-TISSUE_STRUCTURE", 221, 239], ["rat", "ORGANISM", 297, 300], ["heart mitochondria", "MULTI-TISSUE_STRUCTURE", 301, 319], ["trypsin", "GENE_OR_GENE_PRODUCT", 380, 387], ["trypsin", "GENE_OR_GENE_PRODUCT", 392, 399], ["trypsin", "PROTEIN", 380, 387], ["trypsin", "PROTEIN", 392, 399], ["mouse", "SPECIES", 215, 220], ["rat", "SPECIES", 297, 300], ["mouse", "SPECIES", 215, 220], ["rat", "SPECIES", 297, 300], ["These samples", "TEST", 0, 13], ["digital pictures", "TEST", 30, 46], ["an operating voltage", "TEST", 122, 142], ["mitochondriaMouse heart mitochondria", "PROBLEM", 168, 204], ["mouse liver mitochondria", "PROBLEM", 215, 239], ["the protocol", "TREATMENT", 270, 282], ["rat heart mitochondria", "PROBLEM", 297, 319], ["all buffer volumes", "TREATMENT", 353, 371], ["the trypsin and trypsin inhibitor quantities", "TREATMENT", 376, 420], ["heart", "ANATOMY", 186, 191], ["liver", "ANATOMY", 221, 226], ["heart", "ANATOMY", 301, 306]]], ["Mouse brain mitochondria (MBM) were isolated as described previously (112) .", [["brain mitochondria", "ANATOMY", 6, 24], ["MBM", "ANATOMY", 26, 29], ["Mouse", "ORGANISM", 0, 5], ["brain mitochondria", "MULTI-TISSUE_STRUCTURE", 6, 24], ["MBM", "MULTI-TISSUE_STRUCTURE", 26, 29], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse brain mitochondria (MBM", "PROBLEM", 0, 29], ["brain", "ANATOMY", 6, 11]]], ["For the isolation of mitochondria from mouse skeletal muscle (MSMM), both rear hind limbs were dissected out and rinsed in ice-cold washing buffer (100 mM sucrose, 100 mM Tris -HCl, 9 mM EDTA, 1 mM EGTA, 46 mM KCl, pH 7.4).", [["mitochondria", "ANATOMY", 21, 33], ["skeletal muscle", "ANATOMY", 45, 60], ["MSMM", "ANATOMY", 62, 66], ["hind limbs", "ANATOMY", 79, 89], ["sucrose", "CHEMICAL", 155, 162], ["Tris -HCl", "CHEMICAL", 171, 180], ["EGTA", "CHEMICAL", 198, 202], ["KCl", "CHEMICAL", 210, 213], ["sucrose", "CHEMICAL", 155, 162], ["Tris -HCl", "CHEMICAL", 171, 180], ["EDTA", "CHEMICAL", 187, 191], ["EGTA", "CHEMICAL", 198, 202], ["KCl", "CHEMICAL", 210, 213], ["mitochondria", "CELLULAR_COMPONENT", 21, 33], ["mouse", "ORGANISM", 39, 44], ["skeletal muscle", "TISSUE", 45, 60], ["MSMM", "MULTI-TISSUE_STRUCTURE", 62, 66], ["hind limbs", "ORGANISM_SUBDIVISION", 79, 89], ["Tris -HCl", "SIMPLE_CHEMICAL", 171, 180], ["EDTA", "SIMPLE_CHEMICAL", 187, 191], ["EGTA", "SIMPLE_CHEMICAL", 198, 202], ["mouse", "SPECIES", 39, 44], ["mouse", "SPECIES", 39, 44], ["Tris", "TEST", 171, 175], ["EDTA", "TEST", 187, 191], ["1 mM EGTA", "TREATMENT", 193, 202], ["46 mM KCl", "TREATMENT", 204, 213], ["pH", "TEST", 215, 217], ["skeletal muscle", "ANATOMY", 45, 60], ["hind limbs", "ANATOMY", 79, 89]]], ["The muscle tissue was cut into small pieces, whereas bone pieces and the connective tissue were removed as far as possible.", [["muscle tissue", "ANATOMY", 4, 17], ["pieces", "ANATOMY", 37, 43], ["bone pieces", "ANATOMY", 53, 64], ["connective tissue", "ANATOMY", 73, 90], ["muscle tissue", "TISSUE", 4, 17], ["bone", "TISSUE", 53, 57], ["connective tissue", "TISSUE", 73, 90], ["bone pieces", "TREATMENT", 53, 64], ["the connective tissue", "PROBLEM", 69, 90], ["muscle tissue", "ANATOMY", 4, 17], ["small", "OBSERVATION_MODIFIER", 31, 36], ["pieces", "OBSERVATION_MODIFIER", 37, 43], ["bone pieces", "OBSERVATION", 53, 64], ["connective tissue", "ANATOMY", 73, 90]]], ["The dissected muscle tissue was dissolved in 10 ml washing buffer and stirred for 15 min in the presence of 1.25 mg trypsin (dissolved in 1 mM HCl).", [["muscle tissue", "ANATOMY", 14, 27], ["HCl", "CHEMICAL", 143, 146], ["HCl", "CHEMICAL", 143, 146], ["muscle tissue", "TISSUE", 14, 27], ["trypsin", "SIMPLE_CHEMICAL", 116, 123], ["1.25 mg trypsin", "TREATMENT", 108, 123], ["dissected", "ANATOMY_MODIFIER", 4, 13], ["muscle", "ANATOMY", 14, 20], ["tissue", "OBSERVATION", 21, 27], ["dissolved", "OBSERVATION_MODIFIER", 32, 41]]], ["During incubation, the tissue was homogenized twice in a glass/teflon potter at 500 rpm for 1 min.", [["tissue", "ANATOMY", 23, 29], ["tissue", "TISSUE", 23, 29], ["a glass/teflon potter", "TREATMENT", 55, 76], ["tissue", "ANATOMY", 23, 29]]], ["Trypsinization was finally stopped by the addition of 6.5 mg trypsin inhibitor (from soy beans).", [["trypsin", "GENE_OR_GENE_PRODUCT", 61, 68], ["beans", "ORGANISM_SUBDIVISION", 89, 94], ["Trypsinization", "TREATMENT", 0, 14], ["6.5 mg trypsin inhibitor", "TREATMENT", 54, 78]]], ["The solution was filtered through polyamide filter cloth (pore size 210 mm, A. Hartenstein, W\u00fcrzburg) and the remnants of this filtration were transferred into 20 ml isolation buffer (100 mM sucrose, 100 mM Tris -HCl, 9 mM EDTA, 1 mM EGTA, 46 mM KCl, pH 7.4 + 1 mg/ml BSA fatty acid free) and homogenized once more at 500 rpm for 1 min.", [["sucrose", "CHEMICAL", 191, 198], ["Tris -HCl", "CHEMICAL", 207, 216], ["EGTA", "CHEMICAL", 234, 238], ["KCl", "CHEMICAL", 246, 249], ["fatty acid", "CHEMICAL", 272, 282], ["polyamide", "CHEMICAL", 34, 43], ["sucrose", "CHEMICAL", 191, 198], ["Tris -HCl", "CHEMICAL", 207, 216], ["EDTA", "CHEMICAL", 223, 227], ["EGTA", "CHEMICAL", 234, 238], ["KCl", "CHEMICAL", 246, 249], ["fatty acid", "CHEMICAL", 272, 282], ["Tris -HCl", "SIMPLE_CHEMICAL", 207, 216], ["EDTA", "SIMPLE_CHEMICAL", 223, 227], ["EGTA", "SIMPLE_CHEMICAL", 234, 238], ["BSA fatty acid", "SIMPLE_CHEMICAL", 268, 282], ["The solution", "TREATMENT", 0, 12], ["polyamide filter cloth (pore size", "TREATMENT", 34, 67], ["A. Hartenstein, W\u00fcrzburg", "TREATMENT", 76, 100], ["this filtration", "TREATMENT", 122, 137], ["EDTA", "TEST", 223, 227], ["1 mM EGTA", "TREATMENT", 229, 238], ["46 mM KCl", "TREATMENT", 240, 249], ["pH", "TEST", 251, 253], ["BSA fatty acid", "TEST", 268, 282], ["polyamide filter", "OBSERVATION", 34, 50]]], ["This solution was also filtered through the polyamide filter cloth and the two filtrates were combined.", [["polyamide", "CHEMICAL", 44, 53], ["This solution", "TREATMENT", 0, 13], ["the polyamide filter cloth", "TREATMENT", 40, 66], ["the two filtrates", "TREATMENT", 71, 88], ["polyamide filter cloth", "OBSERVATION", 44, 66], ["two", "OBSERVATION_MODIFIER", 75, 78], ["filtrates", "OBSERVATION", 79, 88]]], ["The combined solution was centrifuged for 15 min at 600g, and the supernatant was transferred into a new centrifugation tube.", [["supernatant", "ANATOMY", 66, 77], ["tube", "TISSUE", 120, 124], ["The combined solution", "TREATMENT", 0, 21], ["a new centrifugation tube", "TREATMENT", 99, 124], ["new", "OBSERVATION_MODIFIER", 101, 104], ["centrifugation tube", "OBSERVATION", 105, 124]]], ["Mitochondria were collected by a high-speed centrifugation step (10 min at 5.700g) and re-dissolved in 20 ml isolation buffer.", [["Mitochondria", "ANATOMY", 0, 12], ["Mitochondria", "CELL", 0, 12], ["a high-speed centrifugation step", "TREATMENT", 31, 63]]], ["After a second round of low-speed (15 min at 600g) and high-speed centrifugation (10 min at 5700g) the mitochondrial pellet was finally dissolved in 1 ml isolation buffer.Measurement of mitochondrial respirationThe rate of mitochondrial respiration was monitored at 258C using an Oxygraph-2k system (Oroboros, Innsbruck) equipped with two chambers and DatLab software version 4.3.", [["mitochondrial pellet", "ANATOMY", 103, 123], ["mitochondrial", "ANATOMY", 186, 199], ["mitochondrial", "ANATOMY", 223, 236], ["mitochondrial", "CELLULAR_COMPONENT", 103, 116], ["mitochondrial", "CELLULAR_COMPONENT", 186, 199], ["mitochondrial", "CELLULAR_COMPONENT", 223, 236], ["high-speed centrifugation", "TREATMENT", 55, 80], ["the mitochondrial pellet", "TREATMENT", 99, 123], ["mitochondrial respiration", "TEST", 186, 211], ["mitochondrial respiration", "TEST", 223, 248], ["an Oxygraph-2k system", "TREATMENT", 277, 298], ["DatLab software version", "TEST", 352, 375], ["mitochondrial respiration", "OBSERVATION", 186, 211]]], ["MHM (between 90 and 140 mg protein), MBM (between 280 and 410 mg protein) or MSMM (between 90 and 120 mg protein) were added to 2 ml of a buffer containing 200 mM sucrose, 10 mM potassium phosphate (pH 7.0), 10 mM Tris-HCl, 10 mM MgSO 4 and 2 mM EDTA.", [["MHM", "CHEMICAL", 0, 3], ["MSMM", "CHEMICAL", 77, 81], ["sucrose", "CHEMICAL", 163, 170], ["potassium phosphate", "CHEMICAL", 178, 197], ["Tris-HCl", "CHEMICAL", 214, 222], ["MgSO", "CHEMICAL", 230, 234], ["sucrose", "CHEMICAL", 163, 170], ["potassium phosphate", "CHEMICAL", 178, 197], ["Tris-HCl", "CHEMICAL", 214, 222], ["MgSO", "CHEMICAL", 230, 234], ["EDTA", "CHEMICAL", 246, 250], ["MHM", "SIMPLE_CHEMICAL", 0, 3], ["sucrose", "SIMPLE_CHEMICAL", 163, 170], ["potassium phosphate", "SIMPLE_CHEMICAL", 178, 197], ["Tris-HCl", "SIMPLE_CHEMICAL", 214, 222], ["EDTA", "SIMPLE_CHEMICAL", 246, 250], ["MHM", "TEST", 0, 3], ["MBM", "TEST", 37, 40], ["MSMM", "TEST", 77, 81], ["a buffer", "TREATMENT", 136, 144], ["potassium phosphate", "TEST", 178, 197], ["pH", "TEST", 199, 201], ["Tris", "TEST", 214, 218]]], ["MHM and MBM were fueled by 5 mM malate/5 mM pyruvate, whereas MSMM was fueled by 4.8 mM malate/5.6 mM glutamate.", [["MHM", "CHEMICAL", 0, 3], ["malate", "CHEMICAL", 32, 38], ["pyruvate", "CHEMICAL", 44, 52], ["MSMM", "CHEMICAL", 62, 66], ["malate", "CHEMICAL", 88, 94], ["glutamate", "CHEMICAL", 102, 111], ["malate", "CHEMICAL", 32, 38], ["pyruvate", "CHEMICAL", 44, 52], ["MSMM", "CHEMICAL", 62, 66], ["malate", "CHEMICAL", 88, 94], ["glutamate", "CHEMICAL", 102, 111], ["MHM", "SIMPLE_CHEMICAL", 0, 3], ["MBM", "SIMPLE_CHEMICAL", 8, 11], ["malate", "SIMPLE_CHEMICAL", 32, 38], ["pyruvate", "SIMPLE_CHEMICAL", 44, 52], ["MSMM", "SIMPLE_CHEMICAL", 62, 66], ["malate", "SIMPLE_CHEMICAL", 88, 94], ["glutamate", "SIMPLE_CHEMICAL", 102, 111], ["MSMM", "TEST", 62, 66]]], ["The respiratory control factor was determined as the ratio between state 3 and state 2 [following the revised nomenclature of (113)] respiration after the addition of 2 mM ADP.", [["respiratory", "ANATOMY", 4, 15], ["ADP", "CHEMICAL", 172, 175], ["ADP", "CHEMICAL", 172, 175], ["ADP", "SIMPLE_CHEMICAL", 172, 175], ["respiratory control factor", "PROTEIN", 4, 30], ["The respiratory control factor", "TEST", 0, 30], ["2 mM ADP", "TREATMENT", 167, 175]]], ["Subsequently, complex I was inhibited by adding rotenone (5 mM) and the complex II-dependent respiration was measured after adding succinate (5 mM).", [["rotenone", "CHEMICAL", 48, 56], ["succinate", "CHEMICAL", 131, 140], ["rotenone", "CHEMICAL", 48, 56], ["succinate", "CHEMICAL", 131, 140], ["complex I", "GENE_OR_GENE_PRODUCT", 14, 23], ["rotenone", "SIMPLE_CHEMICAL", 48, 56], ["succinate", "SIMPLE_CHEMICAL", 131, 140], ["complex I", "PROTEIN", 14, 23], ["complex II", "PROTEIN", 72, 82], ["rotenone", "TREATMENT", 48, 56], ["succinate", "TREATMENT", 131, 140], ["dependent", "OBSERVATION_MODIFIER", 83, 92], ["respiration", "OBSERVATION", 93, 104]]], ["Finally, KCN (2 mM) was added to determine the mitochondria-independent oxygen consumption that was (if present) subtracted from all rates of the respective measurement.Blue native gel analysis of respiratory complexesSolubilization of mitochondria and 1-D BNE (blue native electrophoresis) was performed as described (114) .", [["mitochondria", "ANATOMY", 47, 59], ["mitochondria", "ANATOMY", 236, 248], ["KCN", "CHEMICAL", 9, 12], ["oxygen", "CHEMICAL", 72, 78], ["1-D BNE", "CHEMICAL", 253, 260], ["KCN", "CHEMICAL", 9, 12], ["oxygen", "CHEMICAL", 72, 78], ["KCN", "SIMPLE_CHEMICAL", 9, 12], ["mitochondria", "CELLULAR_COMPONENT", 47, 59], ["oxygen", "SIMPLE_CHEMICAL", 72, 78], ["mitochondria", "CELLULAR_COMPONENT", 236, 248], ["1-D BNE", "SIMPLE_CHEMICAL", 253, 260], ["respiratory complexes", "PROTEIN", 197, 218], ["KCN (2 mM)", "TREATMENT", 9, 19], ["independent oxygen consumption", "TREATMENT", 60, 90], ["the respective measurement", "TEST", 142, 168], ["Blue native gel analysis", "TEST", 169, 193], ["mitochondria", "TEST", 236, 248], ["1-D BNE (blue native electrophoresis", "TREATMENT", 253, 289], ["respiratory complexes", "OBSERVATION", 197, 218]]], ["Briefly isolated mitochondria from MHM, MBM and MLM were solubilized with 6 g/g digitonin/protein in solubilization buffer (50 mM NaCl, 50 mM imidazole/HCl, 2 mM 6-aminohexanoic acid, 1 mM EDTA, pH 7.0).", [["mitochondria", "ANATOMY", 17, 29], ["MHM", "ANATOMY", 35, 38], ["digitonin", "CHEMICAL", 80, 89], ["NaCl", "CHEMICAL", 130, 134], ["imidazole", "CHEMICAL", 142, 151], ["HCl", "CHEMICAL", 152, 155], ["6-aminohexanoic acid", "CHEMICAL", 162, 182], ["digitonin", "CHEMICAL", 80, 89], ["NaCl", "CHEMICAL", 130, 134], ["imidazole", "CHEMICAL", 142, 151], ["HCl", "CHEMICAL", 152, 155], ["6-aminohexanoic acid", "CHEMICAL", 162, 182], ["EDTA", "CHEMICAL", 189, 193], ["mitochondria", "CELLULAR_COMPONENT", 17, 29], ["MHM", "SIMPLE_CHEMICAL", 35, 38], ["digitonin", "SIMPLE_CHEMICAL", 80, 89], ["imidazole", "SIMPLE_CHEMICAL", 142, 151], ["HCl", "SIMPLE_CHEMICAL", 152, 155], ["6-aminohexanoic acid", "SIMPLE_CHEMICAL", 162, 182], ["EDTA", "SIMPLE_CHEMICAL", 189, 193], ["6 g/g digitonin/protein in solubilization buffer", "TREATMENT", 74, 122], ["NaCl", "TREATMENT", 130, 134], ["HCl", "TREATMENT", 152, 155], ["aminohexanoic acid", "TREATMENT", 164, 182], ["pH", "TEST", 195, 197]]], ["Following 20 min centrifugation at 22 000g, supernatants were supplemented with Coomassie Brilliant Blue G-250 suspension in 500 mM 6-aminohexanoic acid, and each sample was loaded three times onto a 3 -13% acrylamide gradient gel with a 3% sample gel on top.", [["supernatants", "ANATOMY", 44, 56], ["sample", "ANATOMY", 163, 169], ["Coomassie Brilliant Blue G-250", "CHEMICAL", 80, 110], ["6-aminohexanoic acid", "CHEMICAL", 132, 152], ["acrylamide", "CHEMICAL", 207, 217], ["G-250", "CHEMICAL", 105, 110], ["6-aminohexanoic acid", "CHEMICAL", 132, 152], ["acrylamide", "CHEMICAL", 207, 217], ["Coomassie Brilliant Blue G-250", "SIMPLE_CHEMICAL", 80, 110], ["6-aminohexanoic acid", "SIMPLE_CHEMICAL", 132, 152], ["acrylamide", "SIMPLE_CHEMICAL", 207, 217], ["Coomassie Brilliant Blue G-250", "SPECIES", 80, 110], ["Coomassie Brilliant Blue G", "TREATMENT", 80, 106], ["aminohexanoic acid", "TREATMENT", 134, 152], ["a 3 -13% acrylamide gradient gel", "TREATMENT", 198, 230], ["a 3% sample gel", "TREATMENT", 236, 251]]], ["One-dimensional gels were stained with Coomassie Brilliant Blue G-250 or by an in gel complex I activity assay (NADH:NBT reductase activity) or a complex IV heme stain as described in Zerbetto et al. (115) with some modifications (116) .", [["Brilliant Blue G-250", "CHEMICAL", 49, 69], ["NADH", "CHEMICAL", 112, 116], ["G-250", "CHEMICAL", 64, 69], ["NADH", "CHEMICAL", 112, 116], ["NBT", "CHEMICAL", 117, 120], ["heme", "CHEMICAL", 157, 161], ["Coomassie Brilliant Blue G-250", "SIMPLE_CHEMICAL", 39, 69], ["NADH", "SIMPLE_CHEMICAL", 112, 116], ["NBT reductase", "GENE_OR_GENE_PRODUCT", 117, 130], ["NADH:NBT reductase", "PROTEIN", 112, 130], ["Coomassie Brilliant Blue G-250", "SPECIES", 39, 69], ["One-dimensional gels", "TREATMENT", 0, 20], ["Coomassie Brilliant Blue G", "TREATMENT", 39, 65], ["NBT reductase activity", "TREATMENT", 117, 139], ["a complex IV heme stain", "TREATMENT", 144, 167]]], ["The Bio-Rad ChemiDoc XRS system was used for densitometric quantification.Flow cytometric analysis of splenocytesThe flow cytometric analysis of lymphocyte populations in the spleen was based on two 10-parameter antibody panels, covering markers for T-cells (CD3, CD4, CD8 and gdTCR) and further subsets (CD44, CD62L, CD25 and Ly6C), and for B-cells (CD19 and B220) and further subsets (CD24, IgD, IgM and MHC class II).", [["splenocytes", "ANATOMY", 102, 113], ["lymphocyte", "ANATOMY", 145, 155], ["spleen", "ANATOMY", 175, 181], ["T-cells", "ANATOMY", 250, 257], ["CD4", "ANATOMY", 264, 267], ["B-cells", "ANATOMY", 342, 349], ["splenocytes", "ORGANISM", 102, 113], ["lymphocyte populations", "CELL", 145, 167], ["spleen", "ORGAN", 175, 181], ["T-cells", "CELL", 250, 257], ["CD3", "GENE_OR_GENE_PRODUCT", 259, 262], ["CD4", "GENE_OR_GENE_PRODUCT", 264, 267], ["CD8", "GENE_OR_GENE_PRODUCT", 269, 272], ["gdTCR", "GENE_OR_GENE_PRODUCT", 277, 282], ["CD44", "GENE_OR_GENE_PRODUCT", 305, 309], ["CD62L", "GENE_OR_GENE_PRODUCT", 311, 316], ["CD25", "GENE_OR_GENE_PRODUCT", 318, 322], ["Ly6C", "GENE_OR_GENE_PRODUCT", 327, 331], ["B-cells", "CELL", 342, 349], ["CD19", "GENE_OR_GENE_PRODUCT", 351, 355], ["B220", "GENE_OR_GENE_PRODUCT", 360, 364], ["CD24", "GENE_OR_GENE_PRODUCT", 387, 391], ["IgD", "GENE_OR_GENE_PRODUCT", 393, 396], ["IgM", "GENE_OR_GENE_PRODUCT", 398, 401], ["MHC class II", "GENE_OR_GENE_PRODUCT", 406, 418], ["splenocytes", "CELL_TYPE", 102, 113], ["lymphocyte populations", "CELL_TYPE", 145, 167], ["T-cells", "CELL_TYPE", 250, 257], ["CD3", "PROTEIN", 259, 262], ["CD4", "PROTEIN", 264, 267], ["CD8", "PROTEIN", 269, 272], ["gdTCR", "PROTEIN", 277, 282], ["CD44", "PROTEIN", 305, 309], ["CD62L", "PROTEIN", 311, 316], ["CD25", "PROTEIN", 318, 322], ["Ly6C", "PROTEIN", 327, 331], ["B-cells", "CELL_TYPE", 342, 349], ["CD19", "PROTEIN", 351, 355], ["B220", "PROTEIN", 360, 364], ["CD24", "PROTEIN", 387, 391], ["IgD", "PROTEIN", 393, 396], ["IgM", "PROTEIN", 398, 401], ["MHC class II", "PROTEIN", 406, 418], ["The Bio-Rad ChemiDoc XRS system", "TEST", 0, 31], ["densitometric quantification", "TEST", 45, 73], ["Flow cytometric analysis", "TEST", 74, 98], ["splenocytes", "PROBLEM", 102, 113], ["The flow cytometric analysis", "TEST", 113, 141], ["lymphocyte populations", "TEST", 145, 167], ["parameter antibody panels", "TEST", 202, 227], ["covering markers", "TEST", 229, 245], ["T-cells", "TEST", 250, 257], ["CD3", "TEST", 259, 262], ["CD4", "TEST", 264, 267], ["CD8", "TEST", 269, 272], ["gdTCR", "TEST", 277, 282], ["further subsets", "TEST", 288, 303], ["CD44", "TEST", 305, 309], ["CD62L", "TEST", 311, 316], ["CD25", "TEST", 318, 322], ["B-cells", "TEST", 342, 349], ["CD19", "TEST", 351, 355], ["further subsets", "TEST", 370, 385], ["CD24", "TEST", 387, 391], ["IgD", "TEST", 393, 396], ["IgM", "TEST", 398, 401], ["splenocytes", "ANATOMY", 102, 113], ["flow cytometric", "OBSERVATION", 117, 132], ["lymphocyte populations", "OBSERVATION", 145, 167], ["spleen", "ANATOMY", 175, 181], ["Ly6C", "ANATOMY", 327, 331]]], ["In short, after organ collection, the complete organ was stored at 48C in 2 -3 ml of RPMI/2% FCS.", [["organ", "ANATOMY", 16, 21], ["organ", "ANATOMY", 47, 52], ["organ", "ORGAN", 16, 21], ["organ", "ORGAN", 47, 52], ["organ collection", "TEST", 16, 32], ["RPMI", "TREATMENT", 85, 89], ["2% FCS", "TREATMENT", 90, 96], ["short", "OBSERVATION_MODIFIER", 3, 8], ["organ", "ANATOMY", 16, 21], ["collection", "OBSERVATION", 22, 32]]], ["For further preparation, a part of each spleen was transferred into a cocktail of collagenase II (Serlabo Technologies SARL, Entraigues sur la Sorgue, France) and DNase I (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) within RPMI/2% FCS and dissociated using GentleMACS C tubes (Miltenyi Biotec, Bergisch Gladbach, Germany) and the GentleMACS tissue dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany).", [["spleen", "ANATOMY", 40, 46], ["tissue", "ANATOMY", 346, 352], ["spleen", "ORGAN", 40, 46], ["collagenase II", "GENE_OR_GENE_PRODUCT", 82, 96], ["DNase I", "GENE_OR_GENE_PRODUCT", 163, 170], ["tissue", "TISSUE", 346, 352], ["collagenase II", "PROTEIN", 82, 96], ["DNase I", "PROTEIN", 163, 170], ["Miltenyi Biotec", "PROTEIN", 282, 297], ["Bergisch Gladbach", "PROTEIN", 299, 316], ["GentleMACS tissue dissociator", "PROTEIN", 335, 364], ["Miltenyi Biotec", "PROTEIN", 366, 381], ["Bergisch Gladbach", "PROTEIN", 383, 400], ["collagenase II", "TREATMENT", 82, 96], ["GentleMACS C tubes (Miltenyi Biotec", "TREATMENT", 262, 297], ["Bergisch Gladbach", "TREATMENT", 299, 316], ["the GentleMACS tissue dissociator", "TREATMENT", 331, 364], ["spleen", "ANATOMY", 40, 46], ["GentleMACS tissue", "ANATOMY", 335, 352]]], ["Collagenase digestion at room temperature over 20 min was stopped with a 0.1 M EDTA-PBS solution.", [["EDTA", "CHEMICAL", 79, 83], ["Collagenase", "GENE_OR_GENE_PRODUCT", 0, 11], ["EDTA", "SIMPLE_CHEMICAL", 79, 83], ["Collagenase digestion", "TREATMENT", 0, 21], ["a 0.1 M EDTA-PBS solution", "TREATMENT", 71, 96]]], ["Then red blood cell lysis was performed with RBC lysis solution (eBioscience, Inc., San Diego, USA), cells were washed in PBS buffer (PBS, 0.5% BSA, 0.02% sodium azide, pH 7.45), then incubated with Fc block (anti-mouse CD16/32), fluorescence-conjugated antibodies (BD Biosciences, Heidelberg, Germany), propidium iodide (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) and washed.", [["red blood cell", "ANATOMY", 5, 19], ["RBC", "ANATOMY", 45, 48], ["cells", "ANATOMY", 101, 106], ["BSA", "CHEMICAL", 144, 147], ["sodium azide", "CHEMICAL", 155, 167], ["propidium iodide", "CHEMICAL", 304, 320], ["sodium azide", "CHEMICAL", 155, 167], ["propidium iodide", "CHEMICAL", 304, 320], ["blood cell", "CELL", 9, 19], ["cells", "CELL", 101, 106], ["BSA", "SIMPLE_CHEMICAL", 144, 147], ["sodium azide", "SIMPLE_CHEMICAL", 155, 167], ["CD16", "GENE_OR_GENE_PRODUCT", 220, 224], ["propidium iodide", "SIMPLE_CHEMICAL", 304, 320], ["Fc block", "PROTEIN", 199, 207], ["CD16", "PROTEIN", 220, 224], ["fluorescence-conjugated antibodies", "PROTEIN", 230, 264], ["red blood cell lysis", "TEST", 5, 25], ["RBC lysis solution", "TREATMENT", 45, 63], ["PBS", "TEST", 134, 137], ["BSA", "TEST", 144, 147], ["0.02% sodium azide", "TREATMENT", 149, 167], ["pH", "TEST", 169, 171], ["Fc block", "TREATMENT", 199, 207], ["anti-mouse CD16", "TEST", 209, 224], ["fluorescence", "TEST", 230, 242], ["propidium iodide", "TREATMENT", 304, 320], ["blood cell lysis", "OBSERVATION", 9, 25]]], ["Cells had been plated on a 96-well plate, and the cells were acquired with a HyperCyt plate loader in combination with a Gallios flow cytometer (Beckman Coulter Germany, Krefeld).", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 50, 55], ["Cells", "CELL", 0, 5], ["cells", "CELL", 50, 55], ["a HyperCyt plate loader", "TREATMENT", 75, 98], ["a Gallios flow cytometer", "TREATMENT", 119, 143]]], ["Analysis was done with FlowJo (Tree Star, Inc., Oregon USA); dead cells were eliminated on the basis of their propidium iodide signal and subpopulations gated for corresponding leukocyte markers.", [["cells", "ANATOMY", 66, 71], ["leukocyte", "ANATOMY", 177, 186], ["propidium iodide", "CHEMICAL", 110, 126], ["propidium iodide", "CHEMICAL", 110, 126], ["cells", "CELL", 66, 71], ["propidium iodide", "SIMPLE_CHEMICAL", 110, 126], ["leukocyte", "CELL", 177, 186], ["dead cells", "CELL_TYPE", 61, 71], ["leukocyte markers", "PROTEIN", 177, 194], ["Analysis", "TEST", 0, 8], ["FlowJo", "TEST", 23, 29], ["dead cells", "PROBLEM", 61, 71], ["their propidium iodide signal", "TEST", 104, 133], ["corresponding leukocyte markers", "TEST", 163, 194]]]], "6007f2b19b6b433de7a7af42ff531f37f98cd706": [["It can be used to perform the Br\u00fcckner test and Hirschberg test, to check the pupillary reflex, and to examine the fundus.", [["fundus", "ANATOMY", 115, 121], ["fundus", "MULTI-TISSUE_STRUCTURE", 115, 121], ["the Br\u00fcckner test", "TEST", 26, 43], ["Hirschberg test", "TEST", 48, 63], ["the pupillary reflex", "TEST", 74, 94], ["pupillary reflex", "ANATOMY", 78, 94], ["fundus", "ANATOMY", 115, 121]]], ["However, the ophthalmologist's face is prone to exposure to a patient's sneeze or cough.", [["sneeze", "DISEASE", 72, 78], ["cough", "DISEASE", 82, 87], ["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69], ["a patient's sneeze", "PROBLEM", 60, 78], ["cough", "PROBLEM", 82, 87], ["cough", "OBSERVATION", 82, 87]]], ["The emergence of the coronavirus disease (COVID-19) has challenged the current healthcare system.", [["coronavirus disease", "DISEASE", 21, 40], ["coronavirus", "ORGANISM", 21, 32], ["coronavirus", "SPECIES", 21, 32], ["the coronavirus disease", "PROBLEM", 17, 40], ["COVID", "TEST", 42, 47], ["coronavirus disease", "OBSERVATION", 21, 40]]], ["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be transmitted through virus-containing droplets from infected patients, regardless of whether the patient is symptomatic.", [["acute respiratory syndrome coronavirus", "DISEASE", 7, 45], ["Severe acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 47], ["SARS-CoV-2", "ORGANISM", 49, 59], ["patients", "ORGANISM", 128, 136], ["patient", "ORGANISM", 164, 171], ["patients", "SPECIES", 128, 136], ["patient", "SPECIES", 164, 171], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 0, 45], ["SARS-CoV-2", "SPECIES", 49, 59], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 0, 45], ["SARS-CoV", "TEST", 49, 57], ["transmitted through virus", "PROBLEM", 68, 93], ["symptomatic", "PROBLEM", 175, 186], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33], ["symptomatic", "OBSERVATION", 175, 186]]], ["1 The viruscontaining respiratory droplets propelled toward physicians and other examiners expose them to the infection, even if those patients are wearing a mask; furthermore, it is especially difficult for young children and some patients with special needs to wear masks.", [["respiratory droplets", "ANATOMY", 22, 42], ["infection", "DISEASE", 110, 119], ["patients", "ORGANISM", 135, 143], ["children", "ORGANISM", 214, 222], ["patients", "ORGANISM", 232, 240], ["patients", "SPECIES", 135, 143], ["children", "SPECIES", 214, 222], ["patients", "SPECIES", 232, 240], ["The viruscontaining respiratory droplets", "TREATMENT", 2, 42], ["the infection", "PROBLEM", 106, 119], ["a mask", "TREATMENT", 156, 162], ["masks", "TREATMENT", 268, 273], ["respiratory droplets", "OBSERVATION", 22, 42], ["infection", "OBSERVATION", 110, 119]]], ["2 During the COVID-19 pandemic, proper protection during practice is highly recommended.", [["the COVID", "TEST", 9, 18]]], ["3 In Taiwan, no severe outbreak has occurred; however, strict triage is being performed at the entrance of the hospital before any medical treatment is administered.", [["severe outbreak", "PROBLEM", 16, 31], ["any medical treatment", "TREATMENT", 127, 148], ["no", "UNCERTAINTY", 13, 15], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["outbreak", "OBSERVATION", 23, 31]]], ["In some countries, non-essential services have been temporarily closed.", [["non-essential services", "TREATMENT", 19, 41]]], ["However, ophthalmologists are still in close contact with high-risk patients.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76]]], ["4 We propose a simple and lowcost protective shield for the ophthalmoscope to prevent the spray of droplets from reaching the examiner's face.", [["a simple and lowcost protective shield", "TREATMENT", 13, 51], ["the ophthalmoscope", "TREATMENT", 56, 74], ["the spray of droplets", "TREATMENT", 86, 107]]], ["An overhead transparency (size A4), stapler, staples, hook and loop fasteners (Velcro), scissors, and a box cutter are required to create this shield.", [["An overhead transparency (size A4)", "TREATMENT", 0, 34], ["stapler", "TREATMENT", 36, 43], ["staples", "TREATMENT", 45, 52], ["hook and loop fasteners (Velcro)", "TREATMENT", 54, 86], ["scissors", "TREATMENT", 88, 96], ["a box cutter", "TREATMENT", 102, 114], ["overhead transparency", "OBSERVATION", 3, 24], ["size", "OBSERVATION_MODIFIER", 26, 30], ["stapler", "OBSERVATION_MODIFIER", 36, 43], ["staples", "OBSERVATION", 45, 52], ["hook", "OBSERVATION_MODIFIER", 54, 58], ["loop fasteners", "OBSERVATION", 63, 77]]], ["The basic construction of the shield is shown in Figure 1 it should not be large enough to allow droplets pass through it.", [["large", "OBSERVATION", 75, 80]]], ["Using a tape to seal the gap between the ophthalmoscope and shield is recommended.", [["a tape", "TREATMENT", 6, 12]]], ["We sincerely hope this small and useful invention could protect our colleagues from exposure to droplets and infections.Dear Editor,F I G U R E 1 Drawings showing the basic structure of a shield comprising an overhead transparency, fixation straps (hook and loop fastener to hold and fixate the ophthalmoscope), A, and a rectangular hole (optional) as the viewing window, B. The completed protective shield for the ophthalmoscope, C", [["infections", "DISEASE", 109, 119], ["infections", "PROBLEM", 109, 119], ["an overhead transparency", "TREATMENT", 206, 230], ["fixation straps (hook and loop fastener", "TREATMENT", 232, 271], ["a rectangular hole (optional)", "TREATMENT", 319, 348], ["the ophthalmoscope", "TEST", 411, 429], ["small", "OBSERVATION_MODIFIER", 23, 28], ["infections", "OBSERVATION", 109, 119], ["overhead transparency", "OBSERVATION", 209, 230], ["fixation straps", "OBSERVATION", 232, 247]]]]}